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ABSTRACT 
 
The inappropriate use of antibiotics poses a risk to individual health, is a waste of 
health resources, and triggers antibiotic resistance, a global health problem. Despite 
strategies promoted internationally to address antibiotic misuse and resistance (AMR), 
few low and middle-income countries have fully incorporated them into their national 
health policies. There is scarce research on the factors that affect the development of 
AMR policies at the national level. The present study addresses this gap by applying a 
policy-analysis approach to understand agenda setting, policy inaction and policy 
change with regard to AMR, focusing on the case of Mexico. 
 
This study is designed as a longitudinal case-study, looking at events between 2001 
and 2012 in Mexico, which cover two periods of government. The study used Kingdon’s 
multiple streams (MS) theory of agenda-setting to guide the analysis, explaining both 
when the issue of AMR was denied a position on the agenda (first period studied) and 
when the issue gained agenda status and a policy change occurred (second period 
studied). The methods used were semi-structured interviews with key social actors, 
document analysis and media analysis. 
 
The following factors hindered AMR inclusion in the health policy agenda during the 
2000-2006 administration: a) low problem visibility and a narrow definition that pulled 
AMR away from the scope of public policies; b) lack of clarity on the policy alternatives 
and their feasibility; c) absence of policy entrepreneurs promoting these policies; d) 
within the health-reform context, improving medicine stocks was the priority. During the 
2006-2012 administration, the problem of self-medication with antibiotics gained 
visibility when it was related to the 2009 influenza pandemic; a group of specialists 
acted as policy entrepreneurs supporting AMR policies. The national health crisis and a 
previous designation of an institutional body to control medicine sales favoured agenda 
placement and the development of a narrow-focused regulation, but hindered the 
formation of a comprehensive national policy on AMR. 
 
The usefulness of Kingdon’s theory in examining AMR agenda-setting, in the context of 
Mexico, is explained. The research findings are discussed in light of other studies to 
draw lessons for Mexico and other countries aiming to develop AMR policies.  
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1. INTRODUCTION 
 
 
1.1 Setting the problem 
 
It has been estimated, that, globally, half of all medicines are inappropriately prescribed 
and dispensed, and that half of all patients do not adhere to prescribed treatment 
(WHO, 2004). In developing and transitional countries, in primary care less than 40% of 
patients in the public sector and 30% of patients in the private sector are treated in 
accordance with standard treatment guidelines; two thirds of all antibiotics are sold 
without prescription, favouring inadequate self-medication (Holloway and van Dijk, 
2011: 1); up to 75% of antibiotics are prescribed inappropriately, even in teaching 
hospitals, worldwide (Wiedenmayer, 2004: 141). The inadequate use of medicines1 
poses a risk to individual health, because of treatment failures and adverse reactions, 
and poses an economic burden to health systems and households. However, the 
inappropriate use of antibiotics is of particular concern because it triggers the spread of 
antimicrobial resistance2, which reduces the effectiveness of these medicines to cure 
infectious diseases, leading in turn to increased morbidity, mortality, and health care 
expenditure (Smith and Coast, 2002; WHO, 2001a). 
 
Since more than two decades ago, antimicrobial resistance has been recognized, in its 
own, as a major threat to global public health, a “worldwide calamity” (Kunin, 1993). 
Despite this recognition, the declining effectiveness of antibiotics in treating common 
infections has hastened in recent years (Laxminarayan, et al., 2013). In 2012, Doctor 
Margaret Chan, Director-General of the World Health Organization (WHO), underlined 
the severity of the problem envisaging a bleak panorama: “A post-antibiotic era means, 
in effect, an end to modern medicine as we know it. Things as common as strep throat 
or a child’s scratched knee could once again kill”3. More recently, the World Economic 
                                                             
1
 The terms “irrational use” and “inappropriate use” are used interchangeably in the literature. 
These terms include the overuse of antibiotics (frequent use for minor self-limiting infections), 
misuse (incorrect choice of medicine, dose and treatment schedule), and underuse (not using 
antibiotics when needed, not completing the treatment course) (WHO, 2001b). In the present 
document, I will use the terms “irrational use”, “inappropriate use” and “misuse” interchangeably. 
2
 In the literature, the terms “antibiotics” and “antibiotic resistance” are often used 
interchangeably with “antimicrobials” and “antimicrobial resistance”. However, while antibiotics 
tend to refer only to medicines against bacteria, antimicrobials also encompass medicines to 
treat viral, fungal or protozoal diseases, including medicines against tuberculosis, malaria or 
HIV, which are not the focus of this study. The focus of this study is placed on the use of 
antibiotics and on bacterial resistance against antibiotics. However, the terms antibiotic 
resistance and antimicrobial resistance are used interchangeably. 
3
 Chan, M. “Antimicrobial Resistance in the European Union and the World”. World Health 
Organization, March 14
th
 2012, 
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Forum (WEF, 2013: 28) declared that antibiotic-resistant bacteria constitute one of the 
main risks to human health. 
 
Antimicrobial resistance is a consequence of naturally-occurring mutations in microbes 
and selection pressure from antibiotic use that provides a competitive advantage for 
mutated strains; mutated strains then spread in health-care facilities and communities. 
Every dose of antibiotics creates selection pressure for resistance; however, 
inadequate antibiotic use (which includes suboptimal doses, as well as overuse, such 
as their frequent use to treat minor ailments) helps to trigger the selection of resistance 
(Laxminarayan, et al., 2013). In fact, it has been clearly established that high levels of 
antibiotic consumption correlate with high levels of resistance to antibiotics (Diekema, 
et al., 2000; Goossens, et al., 2005).4 
 
Strategies aiming to contain antimicrobial resistance can be directed to avoid the 
emergence of new resistance, or to prevent the transmission of existing resistance. But 
as transmission of resistance can only occur once resistance has emerged, the primary 
goal is avoiding the emergence of resistance (Smith and Coast, 2002: 127); and to 
attain this goal, improving antibiotic use is crucial (Leung, et al., 2011). Until recently, 
new antibiotics have been developed to replace ineffective ones. However, 
antimicrobial resistance may be outpacing human innovation: the development pipeline 
of novel antibiotics is running dry. Consequently, maintaining the effectiveness of 
currently available antibiotics, by preventing their inadequate use, is of utmost 
importance (WEF, 2013; WHO, 2001a). This brings us again to the problem initially 
discussed here, the misuse of antibiotics. As these two problems are strongly related, 
in the present study I examine both as a single problem: antibiotic misuse and 
resistance (AMR). 
 
AMR is no longer considered a mere medical issue; it is increasingly being considered 
a societal issue: individual decisions (by patients, prescribers or dispensers) can have 
repercussions in the rest of the population (WHO, 2001a: 2).5 The burden of AMR is 
heavier in low and middle-income countries, where infectious diseases are more 
                                                                                                                                                                                  
http://www.who.int/dg/speeches/2012/amr_20120314/en/index.html (accessed on August 24
th
, 
2013). 
4
 The use of antibiotics in animals (such as growth promoters in livestock, or in veterinary 
medicine) and its potential effect on antimicrobial resistance in pathogens affecting humans has 
also being a matter of concern. Despite the relevance of the human-animal interface in 
antimicrobial resistance, this study focuses solely on the use of antibiotics in humans.  
5
 In economics, this is understood as a negative externality. The containment of resistance may 
also be defined as a global public good, since it is impossible to exclude people from benefiting 
from it; this stresses the need for international coordinated action on AMR (Smith and Coast, 
2002). 
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frequent, a large proportion of the total medicines budget is dedicated to medicines 
(including antibiotics) and patients often have to pay out-of-pocket for them, 
aggravating existing poverty and inequities. In this sense, the reasons to promote the 
rational use of antibiotics and contain resistance involve health, ethics and economics 
(Madrid, et al., 1998). 
 
Concerned about the rapid emergence and spread of human pathogens resistant to 
available antibiotics, the 1998 World Health Assembly (WHA)6 urged Member States to 
improve practices to prevent the spread of infection and thereby the spread of resistant 
pathogens; as well as to promote appropriate antibiotic use in health care facilities and 
in the community. In 2001, the WHO published a review of interventions and strategies 
to improve the use of antimicrobials in developing countries (WHO, 2001c), and 
launched the Global Strategy for Containment of Antimicrobial Resistance (WHO, 
2001a). The Global Strategy proposed a series of educational, managerial and 
regulatory interventions (more than 60), directed to policymakers, prescribers, 
dispensers, patients and relevant stakeholders (such as pharmaceutical industry and 
professional associations). These recommendations aimed at enabling countries to 
define and implement national policies on AMR, under the umbrella of national health 
policies. Over the years, a number of international, regional and national organizations 
and initiatives added to the call of improving antibiotic use and contain resistance, and 
have sought to promote policy action at the country level.7 
 
Despite some important advances on the adoption AMR policies at the national level, 
mainly in developing countries, the WHO has recognized that, overall, the progress has 
been slow. Specialists on antimicrobial resistance have also pointed out to the 
“vagueness of the international response and the failure to translate existing knowledge 
into concrete action” (Cars and Nordberg, 2005: 103), underlining the breach between 
                                                             
6
 Fifty-first World Health Assembly, 16 May 1998. Emerging and other communicable diseases: 
antimicrobial resistance, available at: 
http://apps.who.int/medicinedocs/index/assoc/s16334e/s16334e.pdf?ua=1 
7
 In Europe, regional initiatives seek to promote AMR policies and national campaigns 
(European Centre for Disease Prevention and Control, available at: 
http://ecdc.europa.eu/en/eaad/Pages/Home.aspx). Global networks also seek to trigger action 
on antibiotic resistance. Examples of these networks, conformed mostly by health professionals 
are: APUA-Alliance for the Prudent Use of antibiotics, available at: 
http://www.tufts.edu/med/apua/; ReAct - Action on Antibiotic Resistance, available at: 
http://www.reactgroup.org/; WAAR - World Alliance against Antibiotic Resistance available at: 
http://www.infectiologie.com/site/waaar.php; the Antimicrobial Stewardship Working Group, 
available at: http://www.ischemo.org/index.php/sections/isc-antimicrobial-stewardship; and the 
Global Antibiotic Resistance Partnership-GARP, available at: http://cddep.org, which seeks to 
develop policy recommendations relevant to low- and middle-income countries. The 
International Network for Rational use of Drugs –INRUD, available at: http://www.inrud.org/  
(and the International Conferences for Improving the Use of Medicines- ICIUM held in 1997, 
2004 and 2011) also seeks to improve the use of antibiotics.  
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strategies promoted by the global society and their acceptance by national policy 
makers (Cars, et al., 2008). The 2005 WHA called again for the rational use of 
antibiotics by providers and consumers, and requested the Director General to 
strengthen WHO’s leadership role in AMR and to provide more technical support.8 
However, over the years, it became clear that actions on AMR have been frequently 
taken forward by individual programmes and institutions, but the effort is often 
fragmented and not comprehensive. Above all, AMR has not been prioritized by 
national governments (Leung, et al., 2011). On World Heath Day 2011, dedicated to 
raising awareness about antimicrobial resistance, WHO urged countries to commit to a 
comprehensive financed national plan on AMR, emphasizing: “Not action today, no 
cure tomorrow”. That day, WHO introduced a six-point policy package, aiming to 
reframe and clarify the critical actions to be taken by governments in order to stimulate 
action by all stakeholders (Leung, et al., 2011). This long-existing gap between 
international and national policy recommendations on AMR and policy action by 
national governments was what sparked the interest to conduct the present study. 
 
Given the global nature of antimicrobial resistance, international collective action is 
essential; however, the responsibility for health and health policies (where AMR are 
embedded) remains predominantly national (Smith and Coast, 2002). Therefore, a 
disparity arises between the problems and solutions related to AMR and the institutions 
and mechanisms that are available to address them. This disparity reflects a common 
problem in international agencies that have been raised up in other aspects of 
pharmaceutical policies: developing global recommendations for policies that require 
national implementation (Reich, 1987: 49). While the WHO serves a coordinating and 
catalytic role in medicines and in AMR policies, advocating for action, shaping 
collaborations and facilitating evidence based guidance, it is not an  enforcing or 
regulatory agency (Reich, 1987). As such, it is still national policy makers who must 
take policy decisions constrained by social, economic and political local contexts. 
 
Political will and political commitment have been identified as critical prerequisites to 
bring about action on AMR, to develop comprehensive policies, organize health 
systems and legislation as required, and translate recommendations into practice 
(Leung, et al., 2011: 391; WHO, 2001a: 10). Besides other factors such as poverty or 
weak health systems, the lack of political will has often been pointed out as a major 
                                                             
8
 Fifty-eighth World Health Assembly, 16-25 May 2005. Improving the containment of 
antimicrobial resistance available at: http://apps.who.int/gb/ebwha/pdf_files/WHA58-
REC1/english/A58_2005_REC1-en.pdf 
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reason for political inaction on AMR. As two leading specialists and activists on 
antimicrobial resistance bluntly put it: 
 
How do we prevent the same pattern from continuously repeating itself: one in which 
medical experts meet and compare escalating figures of resistant bacteria from different 
parts of the world, discuss worst-case scenarios but fail to reach out successfully either 
to politicians or to society as a whole? Obviously, current efforts are not enough to 
make the problem of antibiotic resistance a national political priority in any country; 
therefore, other ways must be explored. Politicians are predictable. They will certainly 
remain inactive as long as political passivity outweighs the will to initiate action on this 
issue. (Cars and Nordberg, 2005: 110). 
 
The Lancet Infectious Diseases Commission publication “Antibiotic resistance—the 
need for global solutions”, authored by a group of infectious disease experts from 
around the world (Laxminarayan, et al., 2013), also stresses the relevance of political 
commitment at the national level. Along the document, the need for “visionary 
governments with adequate funding” (p. 5), “enlightened national and global 
leadership” (p.8), and “serious commitment of many stakeholders, including 
government authorities, policy makers” (p. 9) are pointed to as requisites to getting out 
of the current impasse concerning policy action on AMR. Similarly, a recent WHO 
publication (2012: 92) examining the experiences with implementing international 
recommendations on AMR concludes that “mobilizing the necessary expertise and 
resources to mount a concerted effort to prevent and control AMR will depend on the 
commitment of policy decision-makers across the world.” 
 
However, how does political commitment on AMR come about? The aforementioned 
publications provide only few hints.  Sharing positive experiences among countries, 
fostering collaboration between disciplines and sectors, generating reliable and up-to-
date information on AMR –including its contribution to excess mortality and costs- and 
strengthening the engagement of academics, community leaders and civil society 
organizations, have been enumerated as relevant to raise governmental awareness, 
generate political will, and trigger governmental action (Laxminarayan, et al., 2013; 
WHO, 2012). Despite these and similar factors being raised up by diverse scholars and 
organizations, there is scarce empirical evidence on how these factors come into play 
to generate (or not) political action on AMR. The present study addresses this gap by 
empirically examining the factors that influence policy inaction and policy change on 
AMR with a case-study at the national level. 
 
The present study underlines the fact that AMR policies imply changes in health and 
pharmaceutical policies; and that policy reform in such areas involve highly political 
processes (Reich, 1994, 1995b, 2002; WHO, 2001b). Thus, the focus on political will, 
13 
 
which has frequently being stressed with regard to action on AMR, has a number of 
limitations to understand the process of policy reform9; as political scientist Michael R. 
Reich (2002:138) explains, the concept political will emphasises individual agency (“the 
leader makes decision and makes it happen”), disregarding the role of other factors, 
such as the influence of other stakeholders or institutional capacity, and ignoring 
political constraints and the political risks that reform implies. But besides these 
important influences on policymaking, political leaders do need to exercise their will-
power and skills to attain policy reform. With this regard, policy advocates can create 
incentives for political leaders to enact reforms. To do this, policy advocates benefit 
from assessing the power, intentions and actions of stakeholders involved (political or 
stakeholder analysis); and using political strategies to improve the political feasibility of 
policy change (Reich, 2002: 139). These approaches have been applied to assess and 
to manage the political dimension of pharmaceutical policy reform (WHO, 1997); 
however, to the extent of my knowledge, have not been applied specifically to AMR 
policies. 
 
On the other hand, before policymakers undertake policy action (i.e. enact policies) 
upon any given issue, firstly, they have to ‘decide to decide’ upon it. And for this to 
happen, the issue in question has to be in the policy agenda. Political theorist John 
Kingdon (1995: 3) defines the policy agenda as “the list of subjects or problems to 
which governmental officials, and people outside of government closely associated with 
those officials, are paying some serious attention at any given time”. But how and why 
certain issues become agenda items? Or as Kingdon puts it, “what makes people in 
and around government attend, at any given moment to some subjects, and not 
others?” In order to answer this question, John Kingdon provides a policy-analysis 
theory, known as ‘Multiple Streams’, to understand the agenda-setting process. This 
theory proposes that agendas are the product of the flow and interaction between three 
processes or ‘streams’ operating independently of each other: problems (public matters 
requiring attention), policies (generation of policy alternatives), and politics (the context 
and flow of political events). An issue is most likely to achieve public agenda status 
when these streams intersect; this is, a ‘policy window’ opens. Despite the diversity of 
factors involved and the ‘fluidity’ implicit in the model, Kingdon shows that there are 
patterns to policy intersection; policy windows are not random. 
 
                                                             
9
 With this regard, political scientists Grindle and Thomas (1991: 123) assert that “lack of 
political will becomes a catch-all culprit, even though the term has little analytic content and its 
very vagueness express the lack of knowledge of specific detail”. 
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Hence, Kingdon’s theory diverges from views in which agendas result from the mere 
addition of a number of factors; nor they are the product on only one circumstance, 
such as ‘political will’ or ‘evidence’. Therefore, this theory provides insight to 
understand the complexity of the processes of agenda setting for AMR. This 
understanding on policy windows is important for advocates of policy proposals, as 
they can seize opportunities and take advantage of them (Kingdon, 1995: 175). And, as 
Reich (2002: 140) suggests, the political strategies adopted by policy advocates within 
each of the streams can make a critical difference for policy change to succeed. 
However, there is a dearth of studies on AMR agenda setting and policy adoption; and, 
to the best of my knowledge, Kingdon’s theory has not been used before to analyse the 
problem of AMR agenda-setting at the national level. 
 
Therefore, the main argument in the present thesis is that policy action (and inaction) 
on AMR can be understood –at least in part– by understanding whether AMR is on the 
policy agenda and the factors that affect AMR agenda-setting. Based on this idea, the 
present study initially sought to gain insight on policy inaction on AMR (i.e. lack of 
adoption of specific governmental policies to address AMR) by analysing the case of 
Mexico. This middle-income country, as many others, does not have an explicit 
national policy on AMR, despite the fact that problems related to antibiotic misuse 
(including inadequate prescribing, self-medication) and resistance have been 
documented. As such, the case study in Mexico sought to shed light on the factors 
related to lack of agenda placement and policy inaction on AMR at the national level. 
Originally, the present study only covered the 2000-2006 Mexican presidential 
administration. During this administration, a large health system reform was introduced 
and a national pharmaceutical policy proposal developed, which disregarded the issue 
of AMR. The main research interest here was on the factors that prevented AMR from 
reaching the health policy agenda. However, while analysing data collected, 
unexpectedly, in 2009 a policy to enforce the regulation of antibiotic sales only with 
medical prescription was announced, and enacted in 2010. Given the opportunity that 
this circumstance offered to examine policy action on AMR, the study was extended to 
cover the 2006-2012 presidential administration as well. The main research interest 
here was on the factors that allowed AMR to gain agenda status and triggered a policy 
change.  
 
As a result, the present longitudinal case study comprises the analysis of agenda-
setting for AMR in Mexico during 12 years, covering two presidential terms: one 
characterized by stability and policy inaction on AMR; and a second one when a policy 
change occurred.  
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1.2 Aim of the study, research questions and objectives 
 
Aim of the study 
The aim of this study is to explain the process of agenda-setting for the appropriate use 
of antibiotics and containment of antimicrobial resistance (AMR) in Mexico, and how 
that affected the adoption of related policies. 
 
Research questions 
The overall research question of this study is:  
How did the issue of antibiotic misuse and resistance (AMR) come on to the national 
health policy agenda in Mexico and how that affected the adoption of AMR policies? 
 
There are two main sub-questions guiding this thesis: 
 Why did AMR not reach the health policy agenda during the 2000-2006 
administration in Mexico, and how that affected the adoption of related 
policies?? 
 Why did AMR reach the health policy agenda during the 2006-2012 
administration in Mexico, and how that affected the adoption of related policies? 
In order to answer these questions, it is necessary to understand the problem of AMR, 
and to analyse the content of health policy documents in its relationship with that 
problem; to identify the role of different social actors –within and outside government–in 
health and pharmaceutical policymaking; to understand how the problem of AMR and 
its possible solutions were perceived by these actors; to elucidate the processes of 
policymaking for health and pharmaceutical policies; and to comprehend the context in 
which these actors interact.  These queries are the focus of policy analysis (Parsons, 
1995), and specifically agenda-setting analysis, which provides the theoretical and 
conceptual background for the present study. 
 
Specific Objectives 
 
1. To analyse the factors related to AMR agenda placement in Mexico during the 
2001-2006 administration and the adoption of related policies, by focusing on 
problem definition and recognition, the political context, the development and 
perception of policy alternatives, and the role of policy entrepreneurs. 
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2. To analyse the factors related to AMR agenda placement in Mexico during the 
2007-2012 administration and the adoption of related policies,   by focusing on 
problem definition and recognition, the political context, the development and 
perception of policy alternatives, and the role of policy entrepreneurs. 
 
1.3 Structure of the thesis 
 
The present document is organized as follows: 
 
Chapter 2 provides background information for this study. It begins with overview of 
pharmaceutical policies, in which specific policies to improve antibiotic use are 
embedded, and describes some of the challenges that countries face in developing 
such policies as documented in the literature. Subsequently, a review of the situation 
regarding antibiotic misuse and resistance in Mexico is presented. Finally, contextual 
information regarding Mexico’s political system, as well as health and pharmaceutical 
policies is provided.   
 
Chapter 3 reviews relevant theoretical approaches of policy analysis, discussing the 
concepts of public and health policies, and examining different approaches to 
understanding the process of public policy-making. The chapter goes on describing 
theories on agenda-setting (which provide the theoretical propositions for this thesis) 
and lastly presents the conceptual framework of the study. 
 
Chapter 4 then presents the methodological approach, the study design and methods 
used to address the research questions posed. The case study design is described and 
its utilization for this study is justified. The chapter goes on to describe the two main 
sources of data for the study (documents and interviews with stakeholders), as well as 
the document analysis, thematic analysis of interviews, and media content analysis 
undertaken. 
 
There are two results chapters. Chapter 5 presents findings pertaining to the first 
studied period (the 2000-2006 Mexican presidential administration), based principally in 
interviews with stakeholders and the analysis of official documents. Chapter 6 presents 
findings concerning the second studied period (the 2006-2012 administration), based in 
interviews with stakeholders, the analysis of official documents, and results of a media 
content analysis covering that period. 
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Chapter 7 summarize and compare findings pertaining to the two studied periods, and 
discusses as well results of this study in the light of other studies on agenda- setting 
and policy development for antibiotic use and resistance. The chapter finishes 
discussing some lessons, derived from the study, for Mexico and for other countries 
seeking to develop AMR policies. Finally, a summary and conclusion of this study is 
provided. 
 
1.4 Role of the candidate 
 
I was supported in the conduction of this doctoral research by the National Council for 
Science and Technology of Mexico (CONACYT, scholarship number 167955). While 
conducting the present study, I was firstly invited as a visiting researcher at the 
Mexican National Institute of Health, INSP (from October 2005 to November 2006). 
From 2008, I am a full time researcher in that Institution. As I mentioned in the 
Statement concerning conjoint work, I confirm that the work presented here is my own. 
However, my affiliation at INSP implied the collaboration with other researchers, which 
contributed, to a minor degree, to the work presented here, as described in the 
Statement. Additionally, two persons, Patricia Solís and Evelyn Aaron revised English 
grammar use in some sections of this document. 
 
Information obtained from the literature review, interviews, as well as document and 
media analysis –undertaken as part of the present thesis– has been incorporated in a 
number of publications and conference presentations, which are enlisted in Appendix 
1. 
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2. LITERATURE REVIEW 
 
 
The present investigation is concerned with the development policies directed to 
improve antibiotic use and contain antibiotic resistance at the national level, analysing 
the case of Mexico. In this chapter, I provide background information for that analysis. 
The chapter begins with an overview of pharmaceutical policies, in which specific 
policies to improve antibiotic use are embedded, and describes some of the challenges 
that countries face in developing such policies. The second section presents a review 
of the problem of antibiotic misuse and resistance in Mexico.1 The third section 
provides contextual information concerning the health system and pharmaceutical 
policies in this country.2 Lastly, the fourth section describes the political system and the 
policy-making process in Mexico, focussing particularly on the 2000- 2006 and 2006-
2012 presidential administrations. 
 
 
2.1 Pharmaceutical policies and rational use of antibiotics 
 
2.1.1 Pharmaceutical policies 
 
Besides their unquestionable economic value –the pharmaceutical industry being 
amongst the most powerful in the world’s economy– the importance of medicines is 
crucial in health care and public health. In this sense, medicines are not simply 
commodities like any other: they are fundamental for medical care, and affect morbidity 
and mortality; account for a large share of the total health budget, and out-of-pocket 
expenses by patients; often legitimise health services and the role of health 
professionals, and are closely related with patient satisfaction. As such, medicines are 
at the core of discussions about equity, health, and health system performance 
throughout the world (Anderson and Huss, 2004: 12; Roberts and Reich, 2011; WHO, 
2001b: 3). 
 
Despite the key relevance of medicines, globally, problems related to insufficient 
access, poor quality, irrational use and waste prevail; this situation hinders the full 
potential that medicines have to improve the population’s health. Reasons behind 
                                                             
1
 The information presented in this chapter summarizes and updates the findings of a published 
review by Dreser, et al., (2008). 
2
 Some of the information presented in this section has been published in Dreser, et al., (2011b) 
and Wirtz, et al., (2012). 
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these problems are complex as a wide array of interdependent factors are involved, 
including socio-economic circumstances, characteristics of the medicines market, 
legislation and functioning of health systems, as well as behaviours of prescribers, 
dispensers and consumers (WHO, 2001b: 3). But, overall, it is public policy which 
largely influences the pharmaceutical system and their potential to improve the 
population’s health: medicines supply in public health care facilities, product 
registration and quality monitoring, licensing of health professionals and facilities, are 
all subject of governmental decision making (Roberts and Reich, 2011). 
 
Public policy choices with regard to medicines and the pharmaceutical system, are 
known as pharmaceutical policies.3 The pharmaceutical system is composed by a 
number of other complex subsystems, including: medicines research and development, 
registration and quality assurance, manufacturing, procurement and importation, supply 
chains, selection in health services, dispensing and sales, prescription and medicines 
use by patients (Anderson and Huss, 2004: 12; Roberts and Reich, 2011; WHO, 
2001b). According to Roberts and Reich (2011), pharmaceutical policy is “the 
conscious efforts of national governments to influence the functioning of these 
subsystems”. This influence includes public sector and private sector performance, as 
well as the actions of citizens in using medicines (Roberts and Reich, 2002: 4). The 
World Health Organization (WHO) explains a national drug policy4 as a “commitment to 
a goal and a guide for action”. As such, it expresses and prioritizes the goals set by the 
government for the pharmaceutical sector, as well as the main strategies for attaining 
them. It provides a framework within which the activities of both the public and the 
private sector, and main actors in the pharmaceutical field can be coordinated (WHO, 
2001b: 4). 
 
This complexity of the pharmaceutical system, calls for a common framework to 
understand –and act upon– interrelated problems; different approaches can be used.5 
For the present study, I use the framework proposed by the WHO that focuses on the 
integration of a national pharmaceutical policy (NPP) addressing three key objectives 
(WHO, 2001b: 6): 
                                                             
3
 Many components of pharmaceutical policies overlap with health policies, and are within the 
realm of action of the health care sector. Nevertheless, other components overlap with policies 
in other sectors, such as industrial and property rights policies. Medicines utilization (which are 
focus of the present study) is both discussed within health policies (quality of healthcare), but it 
is also a key objective of pharmaceutical policies. 
4
 Drugs policy, medicines policy, and pharmaceutical policy are terms often used 
interchangeably. 
5
 A common approach is to use an economic perspective focusing on the demand and supply of 
pharmaceuticals, paying attention to cost-containment, efficiency, quality and equity as 
objectives in pharmaceutical policy (Jacobzone, 2000; Mossialos and Oliver, 2005). 
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 Access: equitable availability and affordability of essential medicines6, i.e., 
those that satisfy the health care needs of the majority of the population.  
 Quality: the quality, safety and efficacy of all medicines 
 Rational use: the promotion of therapeutically sound and cost- effective use of 
medicines by health professionals (prescribers, dispensers) and consumers. 
Policies directed to improve the use of antibiotics and contain antimicrobial 
resistance are included within this objective. 
 
This approach has been widely used by academics due to the long experience of WHO 
in research on medicines, and providing advice to countries, dealing with the many 
medicines issues in a systematic way (Anderson and Huss, 2004: 13). Furthermore, 
given its emphasis in the rational use of medicines, it is particularly relevant for this 
study. 
 
2.1.2 Rational use of medicines 
 
Medicine use is considered rational (appropriate, proper, correct) when patients receive 
the appropriate medicines for their clinical condition, in doses that meet their own 
individual requirements, for an adequate period of time, and at the lowest cost both to 
them and the community. Medicines use is considered irrational (inappropriate, 
improper, incorrect, inadequate) if one or more of these conditions is not met. Irrational 
use may take many different forms, for example, polypharmacy, over-use of antibiotics, 
failure to prescribe in accordance with clinical guidelines and inappropriate self-
medication (Holloway and van Dijk, 2011: 2; WHO, 2001b). The WHO World Health 
Medicines Situation report (2004), estimated that over half of all medicines were 
prescribed, dispensed or sold inappropriately. The World Medicines Situation report of 
2011 (Holloway and van Dijk, 2011: 2) concluded, despite this global problem few 
countries are monitoring medicines use or taking sufficient action to correct the 
situation. 
 
                                                             
6
 Essential medicines are selected in compliance with public health relevance, evidence on 
efficacy and safety, and comparative cost-effectiveness. The essential drugs concept is central 
within a national medicines policy, as it promotes equity and helps to set priorities for the health 
care system. The rationales is that the use of a limited number of carefully selected medicines 
based on agreed clinical guidelines leads to a better supply of drugs, to more rational 
prescribing and to lower costs (WHO, 2001b). 
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The irrational use of medicines is wasteful and can be harmful for both the individual 
and the population. At the individual level, it can cause treatment failures and adverse 
medicines events; these, in turn cause significant morbidity and mortality. The overuse 
and misuse of antibiotics is a particularly serious global problem, as it triggers the 
development of antimicrobial resistance, which affects the population as a whole. 
 
The use of antibiotics and other medicines is influenced by a complex interplay of 
cultural predilections, beliefs, knowledge, expectations and interactions of health-care 
providers and patients, economic incentives, as well as characteristics of health 
systems, pharmaceutical markets and the regulatory environment (Avorn and Solomon, 
2000; Radyowijati and Haak, 2003; Wiedenmayer, 2004). Simplistic interventions to 
improve medicine use (such as disseminating printed information) have proven 
ineffective (Laing, et al., 2001). Given this complexity on factors related to medicines 
use, it has been recommended that countries develop a coordinated national approach 
to promoting rational use of medicines and containing antimicrobial resistance 
(Holloway and van Dijk, 2011: 16; WHO, 2001a, 2012). 
 
Worldwide, interventional research on improving the use of medicines and particularly 
antibiotics has been amply conducted gathering evidence to inform the development of 
policies. The WHO has had an important role in synthetizing and disseminating such 
evidence into policy recommendations, both directed to improving medicines in general 
and antibiotics in particular. These policy recommendations include educational, 
managerial and regulatory interventions, and are briefly described in Box 2.1. 
Additionally, in 2001, WHO published specific recommendations on antimicrobial 
resistance, the ‘Global Strategy for Containment of Antimicrobial Resistance’ (WHO, 
2001a). These recommendations were updated in 2011 in a simpler six-point policy 
package (Leung, et al., 2011). The contents of such documents are described in Box 
2.2 and 2.3. At was mentioned before, the WHO has recommended these strategies to 
be developed as a coordinated national approach promoting rational use of medicines 
and containing antimicrobial resistance, and as a part of health and pharmaceutical 
policies. The need to establish a national intersectoral body to guide actions by several 
stakeholders under the overall stewardship of government has been stressed 
repetitively (Leung, et al., 2011).   
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Box 2.1 Recommended strategies to promote rational use of antibiotics and to contain 
antimicrobial resistance 
 
Macro level: Advocacy and regulatory interventions 
 Multidisciplinary national body to coordinate medicine use policies 
 Create a national intersectoral force on antimicrobial resistance with sufficient 
resources, and develop indicators to monitor and evaluate interventions 
 Appropriate and enforced regulation:  
o Medicines licensing (allowing only registration of antibiotics meeting 
international standards, avoid irrational drug combinations) 
o Prescription and dispensing (enforce prescription-only status of antibiotics, or 
dispensing by professionals)  
o Licensure requirements prescribers / dispensers 
o Medicines promotion and advertising 
 Avoidance of perverse financial incentives that encourage inappropriate use 
 
Meso level: Managerial interventions 
 Development and use of standard treatment guidelines (STG) linked to an essential 
medicines list (EML) to guide medicines procurement and prescription. Involvement 
of professional groups  
 Medicine and therapeutics committees in districts and hospitals. Antibiotic use / 
antibiotic resistance policies and surveillance in health-care settings 
 Supervision, audit, and feedback of prescribing practices 
 
Micro level: Educational interventions 
 Undergraduate and continuing in-service education on medicines use for health care 
professionals, based on STG and EML and local patterns of antimicrobial resistance 
 Independent information on medicines (bulletins, formularies) 
 Public education on medicines, involvement of consumers groups  
 
Sources: (Laing, et al., 2001; WHO, 2001a, 2001c, 2002b) 
 
 
Box 2.2 List of 2001 WHO Global Strategy for Containment of Antimicrobial Resistance 
recommendations 
 
1. Patients and the general community 
 Education 
2. Prescribers and dispensers 
 Education 
 Management, guidelines and formularies 
 Regulation 
3. Hospitals 
 Management 
 Diagnostic laboratories 
 Interactions with the pharmaceutical industry 
4. Use of antimicrobials in food-producing animals 
5. National governments and health systems 
 Advocacy and intersectoral action 
 Regulations 
 Policies and guidelines 
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 Education 
 Surveillance of resistance, antimicrobial usage and disease burden 
6. Drug and vaccine development 
7. Pharmaceutical promotion 
8. International aspects of containing antimicrobial resistance 
 
Source: (WHO, 2001a, 2012) 
 
 
 
Box 2.3 The WHO policy package to combat antimicrobial resistance, 2011 
 
1. Commit to a comprehensive, financed national plan with accountability and civil 
society engagement 
a. Provide stewardship and coordination; establish a national inter-sectoral steering 
committee 
b. Cost plans, mobilize and earmark resources 
c. Build partnerships with civil society; build strong public awareness and set up an 
accountability framework 
 
2. Strengthen surveillance and laboratory capacity 
a. Establish AMR surveillance and monitoring systems 
b. Build laboratory capacity for rapid and reliable diagnostic testing 
c. Engage in regional and global surveillance networks 
 
3. Ensure uninterrupted access to essential medicines of assured quality 
a. Reinforce the system for supply of essential medicines 
b. Assure the quality of drugs according to international standards 
 
4. Regulate and promote rational use of medicines, including in animal husbandry, and 
ensure proper patient care 
a. Promote and enforce standard treatment guidelines 
b. Enforce prescription-only use of antimicrobials 
c. Promote education on antimicrobial medicines and their use 
d. Reduce antimicrobial use in food-producing animals  
e. Work to reduce financial incentives that encourage irrational use of medicines 
 
5. Enhance infection prevention and control (IPC) 
a. Ensure availability of IPC programmes across the spectrum of health care, that 
include core elements 
b. Foster basic IPC standards in congregate settings 
c. Promote standards IPC measures and provide education on IPC in the community 
setting 
 
6. Foster innovations and research and development for new tools 
a. Improve the use of current diagnostics and antimicrobials 
b. Create incentives for new product development 
c. Enable rapid regulatory processes for new tools and equitable access 
 
Source: (Leung, et al., 2011; WHO, 2012: 115) 
 
 
2.1.3 Experience at the country level 
 
The WHO World Health Medicines Situation report of 2004 concluded that few 
countries have fully incorporated the afore mentioned recommendations into their 
24 
 
national pharmaceutical policies; and even when they have, regulatory gaps are 
common, with the private and informal sectors for medicines supply often neglected, or 
lack mechanisms to enforce the implementation of regulations (WHO, 2004). 
 
A comparative analysis of pharmaceutical policies in 12 countries (WHO, 1997) 
concludes that in most countries improving the availability of medicines in the public 
sector has been given priority above other NPP components; improving rational 
medicine use has been given much less priority. Similarly, a multi country study 
regarding the regulation of medicines concluded that prescribing practice is the least 
widely regulated activity (WHO, 2002a). 
 
In formulating and implementing medicines policies, countries have been restrained by 
diverse social, political and economic factors. Box 2.4 summarizes the factors affecting 
the development of pharmaceutical policies and rational use policies at the country 
level that have been reported in the literature. Economic and political ideologies (Kanji, 
1992: ix); and the relationship between the public and the private sectors (Reich, 1987) 
have been pointed out as a key issues affecting the achievement of the objectives of 
pharmaceutical policies.  
 
 
Box 2.4 Factors affecting the development  (adoption and implementation) of 
pharmaceutical policies and rational use policies at the country level 
 
Impeding factors 
 Ignore problem of inappropriate use and consequences, ignore NPP and WHO 
recommendations 
 Competing issues in the agenda: prioritising availability in public services 
 Providing medicines has more political appeal that rationalizing their use 
 Lack of resources to implement strategies 
 Funding: only 5% of the total pharmaceutical sector lending by the World Bank lending 
is committed to policy work and rational use of medicines 
 Opposition of the pharmaceutical industry: threat to monetary profit 
 Opposition by medical associations: threat to prescribing freedom 
 Difficulties in implementing components of the policy that involve changes in behaviour 
 Difficulties in implementing components of the policy that involve inter-ministerial  
collaboration and the private sector 
 Priorities on NPP depend on type of actors involved (e.g. technicians and 
pharmacologists favour quality assurance; economists focus on access) 
 
Enabling factors 
 Favourable political conditions: climate of economic and/or social reform 
 Involvement and support of key stakeholders; public involvement 
 Political skills and commitment at the highest level 
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 Adequate and scientifically sound data 
 Evidence on economic consequences, need for cost-containment 
 Conducing continuous policy analysis through policy formulation and implementation 
 Political strategies such as coordination, bargaining and formation of alliances 
 
Sources: (Falkenberg and Tomson, 2000; Kanji, 1992; LSHTM/KIT, 1989; Reich, 1987, 1994, 
1995b; Summers, 2004; WHO, 1988, 1997) 
 
The WHO World Health Medicines Situation report of 2011 concluded that there has 
little improvement: Less than half of all countries are implementing many of the basic 
policies needed to ensure appropriate use of medicines, such as regular monitoring of 
use, regular updating of clinical guidelines and having therapeutics committees in most 
of their hospitals or regions (Holloway and van Dijk, 2011). This report underlines that a 
major reason for the failure to adopt a coordinated approach in promoting the rational 
use of medicines and containing antimicrobial resistance is that these aspects have not 
been “institutionalized” within health systems (Holloway and van Dijk, 2011: 16). While 
many rich nations have adapted their health systems with focus on the rational use of 
medicines by setting up national systems for medicines selection, prescription 
monitoring and obligatory continuing medical education, this has not been the case for 
the majority of low- and middle-income countries (Holloway and van Dijk, 2011: 16). 
 
Another WHO report (WHO, 2012: 92) examining the experiences with implementing 
international recommendations on the containment of antimicrobial resistance, reached 
similar conclusions: although some specific interventions have been undertaken, very 
few countries have nationally funded and coordinated comprehensive activities on 
antimicrobial resistance. These are mostly high-income countries with stronger 
management and infrastructure capabilities. Australia provides a good example of 
success in developing a coordinated national approach promoting rational use of 
medicines and containing antimicrobial resistance. This country has an extensive 
National Medicines Policy; one of its main objectives, taken up in a national 
programme, is “Quality Use of Medicines”. The country has  implemented as well a 
National Prescribing Service (NPS), and has developed numerous campaigns to 
promote the rational use of antibiotics, directed to practitioners, pharmacists and the 
general public (Holloway and van Dijk, 2011: 17). 
 
However, there are also some successful experiences in low- and middle income 
countries. Thailand developed an “Antibiotics Smart Use” programme (Sumpradit, et 
al., 2012). In South Korea, antibiotic overuse has been addressed by separating 
prescribing by physicians and dispensing by pharmacists, and by introducing a new 
payment system instead of the prevailing fee-for-service system (Park, et al., 2005; 
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Kwon and Reich, 2005). More recently, in South Korea, antibiotic overuse has been 
addressed by publicly disclosing information on antibiotic prescribing rates of all health 
care providers (Choi and Reich, 2011). Advocacy and capacity building on 
interventions to contain antimicrobial resistance has been undertaken in some African 
countries (Joshi, et al., 2011). However, it is important to note that most studies on 
AMR policies focus on the content policy outputs and their impact, and not in the policy 
process which led to policy adoption. With a few exceptions –for example the study on 
health care and pharmaceutical reform in South Korea by Kwon and Reich (2005) – 
little is known about the processes of agenda setting and policy formation for AMR at 
the national level.  Other relevant country level experiences (the cases of Chile, India, 
Brazil and Peru) are described in the discussion chapter.  
 
 
2.2 The problem: antibiotic misuse and resistance in Mexico 
 
A systematic literature review on published research (1990-2004) concerning access 
and use of medicines in Mexico (Wirtz, et al., 2008) concluded that the majority of 
studies (81 out of 108) focussed on the use of medicines. Of these, 52 studies showed 
that prescribing practices for hospitalized and ambulatory patients were often 
inappropriate, did not follow treatment guidelines, and implied unnecessary costs to 
patients; however, half of these studies were conducted before 1996. Far fewer studies 
were concerned with the dispensation of medicines or their utilization by patients. The 
majority of studies were descriptive, largely regarding the prescription of antibiotics in 
primary care settings; only 7 were interventional studies (Wirtz, et al., 2008). The 
results of a more detailed analysis of those studies concerned specifically with 
problems related to antibiotic use (Dreser, et al., 2008) are described below. With 
regard to the levels and trends of antibiotic consumption in the country from 1997 to 
2007, concluded that Mexico had the highest level of consumption in the region, 
although it showed a decreasing trend during that period. However, consumption of 
broad-spectrum antibiotics (such as quinolones and new macrolides) rose sharply, as 
in other countries in the region. This high level of consumption was related to both self-
prescription (antibiotics obtained without medical prescription in private pharmacies) 
and medical over-prescription (Wirtz, et al., 2010). 
 
Antibiotic prescription. Diverse studies shown that, both in private and public health 
care settings, between 70 and 80% of all patients with acute respiratory infections 
(ARI) and diarrhoeal diseases (DD) received antibiotics, while their use is justified in 
less than 15% of the cases (Bojalil, et al., 1998; Gutiérrez, et al., 1994; Pelaez-
27 
 
Ballestas, et al., 2003; Perez-Cuevas, et al., 1996; Reyes Morales, et al., 1997).  
Inadequate prescription of antibiotics for surgical antibiotic prophylaxis has also been 
reported (Mendez Lopez, et al., 2005). 
 
Some of the factors that have been related to an inadequate prescription of medicines 
in Mexico are deficient undergraduate and post graduate medical education, reliance 
on information on medicines distributed by the pharmaceutical industry, the perception 
of patient’s expectation to receive medicines, and the prevalence of deficient but 
institutionalised treatment patterns (Corral-Terrazas, et al., 2002; Guiscafre, et al., 
1998; Vilar-Puig, 2000). Interventions to improve the use of antibiotics in Mexico have 
largely been educational and directed to prescribers in the public sector, particularly 
IMSS (Guiscafre, et al., 1995; Guiscafre, et al., 1988; Guiscafre, et al., 1998; Gutiérrez, 
et al., 1994; Perez-Cuevas, et al., 1996). Although successfully evaluated, there have 
been scarce  efforts for scaling up these interventions at the national level. 
 
Antibiotic dispensing and self-medication.  Antibiotics have been among the most 
common type of medicines bought in private drugstores (almost a third of all sales) 
(Calva and Bojalil, 1996; Leyva-Flores, 2002), mainly for the treatment of ARI and DD– 
where they are hardly needed. Although current legislation requires antibiotics to be 
sold only with prescription, this regulation has not been enforced: between 40-60% of 
antibiotics are sold over the counter (Calva and Bojalil, 1996; Leyva-Flores, 2002; SSA-
COFEPRIS, 2005; Wirtz, et al., 2007). Among those who self-medicate, 90% of 
antibiotic purchases were inadequate regarding the type, dose or duration of treatment; 
this factor was pointed to contribute to the development of antibiotic resistance (Bojalil 
and Calva, 1994).  In Mexico, it is not required for most pharmacies to have a full-time 
pharmacist; so under-trained clerks dispense most medicines. Between 70 and 80% of 
the treatment recommendations given by pharmacy clerks for DD, ARI and urinary tract 
infections (mostly involving antibiotics) were incorrect (Kroeger, et al., 2001; Leyva-
Flores, et al., 2000; Turner, et al., 2003). 
 
Another important issue to consider with regard to the use of antibiotics is the 
information available for the public. In Mexico, the large majority of pharmaceutical 
products (including antibiotics) do not include a patient information leaflet. Not only is 
consumer-directed information lacking, but also for medical professionals and 
pharmacy personnel there is no national formulary to provide independent information 
on medicines. Instead, the most commonly used written information on medicines is a 
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non-exhaustive commercial formulary7 published yearly by the pharmaceutical industry. 
In this sense, some consumers associations (HAI-Mexico, 2000) and professional 
associations (CTFM, 1999) have demanded the government to provide patients and 
prescribers with practical and reliable information on medicines. 
 
With regard to patient’s knowledge on medicines, there are few studies available. A 
study with drugstores customers concluded that the overall majority of customers did 
not know that medicines they bought could produce adverse reactions. This was 
particularly alarming because they frequently bought prescription-only-medicines 
(including antibiotics) without consulting a physician (Wirtz, et al., 2009). Another study 
explored specifically knowledge on antibiotics among patients seeking care for ARI at 
IMSS. The study found that self-treatment with and misperceptions about antibiotics 
were common. Many participants believed that common non-antibiotic treatments 
(such as aspirin and paracetamol) were antibiotics (Gonzales, et al., 2012). 
 
Consequences of antibiotic misuse. There is no systematic data collection and 
reporting on adverse medicine events and medication errors in Mexico. Consequently, 
it is not possible to understand the magnitude and severity of the consequences of 
inadequate antibiotic prescription and self-medication in terms of health expenditure 
and health outcomes (such therapeutic failure and adverse drug reactions) (Dreser, et 
al., 2008: S843). One of the few studies published exploring costs related to 
inappropriate antibiotic use concluded that the waste of antibiotics due to the unjustified 
prescription and abandoned treatments for ARI and DD represented 11% of annual 
expenditure on medicines at that institution (Reyes Morales, et al., 1997). A study in 
pharmacies concluded that inappropriate prescribing represented, with respect to 
standard treatments, an additional cost per patient of $ 3.57 and $ 8.37 for ARI and for 
DD (Flores, et al., 2003), which was equivalent to 0.8 and 1.9 of the daily minimum in 
Mexico. Finally, another study at IMSS concluded that the majority (38%) of the 
adverse reactions reported in that health care institution were related to anti-infective 
medicines, particularly antibiotics (Hernández-Santillán, et al., 2005). Similarly, a study 
conducted in a private hospital concluded that 40% of the adverse reactions reported 
were related to antibiotics (Zavaleta Bustos and Rosete Reyes, 2007). 
 
Antibiotic resistance. In Mexico, there are diverse national and international networks 
which collect information on antibiotic resistance; some of them focus specific 
                                                             
7
 Diccionario de Especialidades Farmacéuticas, PLM Publisher. Other Latin American countries 
such as Argentina and Venezuela are a step ahead from Mexico regarding this aspect, 
publishing regularly a National Therapeutic Formulary as part of their national strategy to 
promote the rational use of medicines. 
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pathogens. For example, the SENTRY network (Gales, et al., 2012) is oriented to intra-
hospital infections,) and the SIREVA network, organized by the Pan American Health 
Organization is oriented to pneumonia-related pathogens (Castañeda, et al., 2009). 
While results of these networks originate an ample number of scientific publications 
and conference presentations, there is not a mechanism in place to systematise this 
information and communicate it to prescribers and policy-makers (Dreser, et al., 2008). 
A study analysing antibiotic resistance in Streptococcus pneumoniae in ten Latin 
American countries, with data collected from 2000 to 2005, concluded that Mexico had 
the highest prevalence of resistant bacteria (Castañeda, et al., 2009). This could be 
related to the fact that, during the same period, Mexico had the largest level of 
antibiotic consumption, when compared with other Latin American countries (Wirtz, et 
al., 2010). 
 
A system of hospital surveillance has documented antibiotic-resistant pathogens 
related with high mortality in hospital-settings; researchers have warned that these 
multi-resistant bacterial strains could spread quickly through the population (Silva, et 
al., 1999; Silva, et al., 1998; Silva, et al., 2001). Increasing antibiotic resistance has 
also been documented for pathogens causing common community acquired infections 
such as common ARI and DD (Miranda, et al., 1997; Nys, et al., 2004; Solórzano and 
Miranda, 1998). 
 
 
2.3 The context: Health system and pharmaceutical policies in 
Mexico 
 
2.3.1 Mexico country profile 
 
Mexico is an upper middle-income country, with more than 112 million inhabitants 
according to the 2010 national census.8 Life expectancy is 74 years, and 33% of the 
population is young (economically active population is 52 million).9 Mexico is 
undergoing epidemiological transition where cardiovascular diseases and diabetes are 
the leading causes of death; nevertheless, acute respiratory infections and diarrhoeal 
                                                             
8
 Officially, 112,336,538 inhabitants in 2010; 106.6 and 103 million in 2008 and 2006, 
respectively. See: Instituto Nacional de Estadística y Geografía (INEGI), the Mexican 
statististics agency, http://www.inegi.org.mx.  
9
 See UNPD, http://www.mx.undp.org/content/mexico/es/home/countryinfo/  
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diseases are still among the main causes of general morbidity and under-five mortality, 
especially among the poorest sectors of the population (Gómez-Dantés, et al., 2011).10 
 
With a GDP of current US$1.261 trillion in 2013, Mexico is the second largest economy 
in Latin America and the fifteenth economy in the world.11  Although Mexico is the only 
Latin American member of the Organization for Economic Cooperation and 
Development (OECD), it is a very diverse country with the highest income inequality 
among such group (OECD, 2011). Mexican gross national income per capita is nearly 
US$ 10 thousand (above Latin America average of 9.5 thousand),12 but the GINI index 
(48.1 in 2012) reveals the important unequal income distribution.13 According to the 
United Nations Development Programme and CONEVAL,14 in 2012, 43.3 million (46% 
of the Mexican households) lived in poverty, of which 11.5 million (9.8%) lived in 
extreme poverty. The country ranks 61 in the Human Development Index (0.775), out 
of 187 countries and territories. 
 
2.3.2 Mexico’s health system 
 
Since its origins, the Mexican health system has been organized around a segmented 
model: health services have been divided in those for people employed in the formal 
sector and their families (the insured population); and health services for people in the 
informal or agricultural sectors (the uninsured population). Formal sector employees 
are enrolled in social security schemes: the most important is the Mexican Institute of 
Social Security (IMSS, by its Spanish initials) which provides services to private sector 
workers, followed by the Social Security Institute for Government Employees (ISSSTE). 
Social security schemes provide a broad package of prepaid interventions, services, 
and medicines included in the institutional formularies.  
 
As of 2000, before the 2003 health system reform, IMSS covered about 40% of the 
nearly 100 million inhabitants of Mexico on that time. ISSSTE covered an additional 
7%, and private insurance accounted for around 3% of the population. Thus, about 
                                                             
10
 INEGI http://www.inegi.org.mx. 
11
 It is ranked twelfth using GDP 2013, PPP. World Bank http://datacatalog.worldbank.org/  
12
 World bank, http://data.worldbank.org/country/mexico.  
13
 “Gini index measures the extent to which the distribution of income or consumption 
expenditure among individuals or households within an economy deviates from a perfectly equal 
distribution. […] a Gini index of 0 represents perfect equality, while an index of 100 implies 
perfect inequality” World Bank, http://data.worldbank.org/indicator/SI.POV.GINI. In such index 
Mexico stands slightly higher than Bolivia (46.6) and Argentina (43.3 in 2011), but lower than 
Colombia (53.5), Brazil (52.7) Chile (50.8 in 2011). East and South east Asian countries are 
better situated; Indonesia (38.1 in 2011) and Thailand (39.4 in 2010). 
14
 CONEVAL is the Spanish initials for National Council to Evaluate social Development Policy, 
see: http://www.coneval.gob.mx. 
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50% of the population was left without access to any form of prepaid health insurance 
(Frenk, et al., 2006). The uninsured population could seek care in private facilities or in 
public health care facilities in exchange for a user fee which, despite being subsidised, 
still contributed to out-of-pocket expenses. Medicines shortages were common in 
public services (Gómez-Dantés, et al., 2001), and this was the most frequent reason 
reported for not returning to use public health care services (Ramírez-Sánchez, et al., 
1998). As such, many patients attending public health care services had to pay for 
medicines in the private sector. In fact, medicines expenses accounted for two-thirds of 
household catastrophic health expenditures on the poorest sector of the population 
(Nigenda, et al., 2003). Additionally, self-medication has been a common practice in 
Mexico (Leyva-Flores, et al., 2001; Pagán, et al., 2006); consequently, private 
pharmacies have played an important role in health care (Ángeles-Chimal, et al., 1992; 
Molina Salazar and Rivas-Vilchis, 1998). 
 
Accumulated evidence on the reliance on out-of-pocket payments that led to further 
impoverishment and deeper inequity (Leyva-Flores, et al., 1998; Nigenda, et al., 2003; 
Pérez-Rico, et al., 2005) contributed to the 2003 reform, under the leadership of Health 
Minister Julio Frenk, which established the System of Social Protection in Health. This 
system, implemented from January 1, 2004, includes a subsidised insurance scheme, 
the Seguro Popular (Popular Health Insurance). It offers free access at the point of 
delivery to an explicit set of health-care interventions and medicines (Frenk, et al., 
2006). Official data collected by the Mexican Ministry of Health, suggested that, by 
2012 the Seguro Popular provided insurance to 52.6% of the population (the majority of 
the previously uninsured population), and, therefore, universal health coverage has 
been attained (Knaul, et al., 2012). However, the 2012 National Health and Nutrition 
Survey, revealed otherwise: the Seguro Popular covered 38.5% of the population; as 
such, only 78.6% of the population has access to pre-paid health insurance (Gutiérrez, 
et al., 2012). 
 
Despite this important advancement in the provision and financing of health services in 
Mexico, total health spending (6.2% of GDP in 2012) is still lower than the average in 
Latin America, and among the lowest shares of OECD countries (OECD, 2014). In 
2007, private expenditures in health concentrated 54.6% of the total health 
expenditures (including health services and medicines), of which around 93% were out-
of-pocket expenditures. Thus, Mexico still presents one of the highest rates of out-of-
pocket expenditures in the region (Gómez-Dantés, et al., 2011). It has been estimated 
that expenditures in medicines accounts for 24% of the total health expenditure (1.4% 
of GDP). Most expenditures in medicines are private (79%), predominantly out-of-
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pocket. Higher out-of-pocket expenses in medicines in relation to other out-of pocket 
expenses related to health is more prevalent amongst the poorest sector of the 
population (González Pier and Barraza Lloréns, 2011: 54-55) 
 
By 2004, nearly 83% of available medical facilities were private; from those, the 
majority (87%) was ambulatory care units consisting of independent doctor offices or 
small clinics owned by the same doctors in most cases.15 Apart from the private health 
services, in Mexico there are 23,858 health units (2007), of which 4,354 are hospitals 
and the rest are ambulatory units. From the total of hospitals, 1,182 are public and 
3,172 are private. Hospital certification by the General Health Council (since 1999) has 
been sluggishly accomplished. By 2009, only 256 health care facilities had valid 
certificates. The national ratio of doctors per 1,000 habitants is 1.85, which is lower 
than that of the OECD countries. There are around 80 Medical schools and faculties; 
only 44 are certified by the Mexican Council for Medical Education Certification 
(Gómez-Dantés, et al., 2011). 
 
There are around 23,500 private pharmacies in the country. A decade ago, most of the 
pharmacies were independent (neighbourhood) pharmacies; however, these are being 
increasingly substituted by large pharmacy chains and pharmacies in supermarkets 
Pharmacy chains account now for 48% of sales, while independent pharmacies only 
21%. Some of the largest pharmacy chains and supermarkets have partnered with 
pharmaceutical laboratories to commercialize their own branded generics (González 
Pier and Barraza Lloréns, 2011: 52). As, by law, only those pharmacies that sell 
controlled medicines (narcotic drugs and psychotropic substances), which are the 
minority, require a professional pharmacist to be present, the large majority of 
pharmacy personnel are sales clerks, who receive only a very brief training (Dreser, et 
al., 2011b). It has been estimated that between 43% and 59% of prescription-only 
medicines, including antibiotics, were sold without a prescription (Altagracia, et al., 
2003; Wirtz, et al., 2006; Wirtz, et al., 2009). According to a Ministry of Health (MOH) 
policy proposal (SSA-COFEPRIS, 2005: 47), and as health officials confirmed in the 
interviews (see chapter 5) the prescription-only requirement of most medicines 
(including antibiotics) has not been enforced in order to favour the access to medicines. 
 
                                                             
15
 “Síntesis ejecutiva 17. El componente privado del sistema de salud: producción, 
establecimientos y personal ocupado” [“Executive summary 17. The private component of the 
health system; production, facilities and personnel”], National System of Health Information 
2007, Ministry of Health, available at: 
http://sinais.salud.gob.mx/descargas/pdf/SE17_ComponentePrivado.pdf (accessed on February 
5
th
, 2013). 
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Despite the increasing coverage of public health insurance provided by the Seguro 
Popular, utilization of private services is still high and has increased, accounting for 
nearly 40% of national ambulatory medical consultations in 2012. Up to 31% of those 
insured choose to use private health facilities for ambulatory care, because of shorter 
waiting times and perception of quality of these services. Since a decade ago, a new 
form of private premises began to function: the medical clinics adjacent to private 
pharmacies,16 which offer cheap consultations. In 2012, these clinics accounted for 
40% of private ambulatory consultations, and 16% of all ambulatory consultations 
(Gutiérrez, et al., 2012; Pérez-Cuevas, et al., 2014). The majority of users on these 
clinics (65%) were affiliated to a pre-paid public health insurance (social security and 
Seguro Popular). Despite favouring access to medical services, questions have been 
raised with regard to the impact of these clinics in the overall function of the health 
system, and out-of-pocket expenses that derivate from their utilization; as well as the 
potential conflict of interest (resulting from the linkage of prescribing and dispensing) 
which could derivate in adequate prescribing (Chu and García-Cuellar, 2011; Pérez-
Cuevas, et al., 2014).17 
 
2.3.3 Pharmaceutical market 
 
As of 2003, Mexico was the ninth largest pharmaceutical market in the world; the 
largest proportion of the market, by value, corresponded to alimentary and metabolic 
drugs (18.6%) and systemic anti-infectives (15.2%), including antibiotics (IMS-Health, 
2003).18 Anti-infectives represented a largest share of the market when compared with 
other large markets (e.g. in Brazil, antibiotics accounted for 6.7% of the market, while in 
the UK, only 3.5%) (IMS-Health, 2003). Despite a slowing growth rate, as of 2009, the 
Mexican pharmaceutical market was still among the 15 largest in the world, and the 
second largest in Latin America; systemic anti-infectives were still the second most 
important groups of medicines, with a 12.5% of the total value market (González Pier 
and Barraza Lloréns, 2011). 
                                                             
16
 The forerunner was a commercial chain targeting the low-income segments of the population 
called Farmacias Similares, oriented to the sale of generic medicines. Since the first pharmacies 
began to operate in 1997, their number has grown exponentially; by 2005, Similares was the 
largest drugstore chain in Latin America. Its founder, Víctor González Torres, declared himself a 
candidate for the Mexican 2006 Presidential elections; one of his campaign slogan was 
“vitamins + sports = health” (Chu and García-Cuellar, 2011). 
17
 It is important to notice that current regulations for private pharmacies literally forbid their 
“direct communication, through windows, doors or aisles, with other businesses, such as 
doctor’s offices (…)”. However, doctor’s offices have been opened besides or even within 
pharmacies (Dreser, et al., 2011b; Pérez-Cuevas, et al., 2014).  
18
 Antibiotics have been top-seller medicines in the country since decades ago. In 1984, 
systemic antibiotics were the most widely medicines sold, accounting for 19% of total market 
sales; ampicillin was the best-seller medicine, commercialised in 68 trademarks (WHO, 1988). 
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By value of the total sales, the pharmaceutical market is almost 80% private, and 20% 
public; whereas by volume, 65% of all commercialized units are sold in the private 
sector, and 35% are sold to the public sector (González Pier and Barraza Lloréns, 
2011:15,54).  In 2008, about 86% of medicines that were consumed in Mexico were 
produced locally and the rest was imported (Gómez-Dantés, et al., 2011). However, 
65% of the pharmaceutical market value is concentrated in the national branches of 15 
transnational pharmaceutical corporations19; the Mexican pharmaceutical industry has 
a smaller share of the market value, and has been oriented largely to the production of 
generics. With regard to the market composition, the commercialization of generics has 
increased considerably during the last decade, attaining 54% of the total market by 
volume, and almost 30% by value (González Pier and Barraza Lloréns, 2011: 45-48). 
Despite this increase in generic sales, studies have shown that, when adjusted for 
income, medicines (including generic versions) in Mexico are far more expensive than 
in other countries (Danzon and Furukawa, 2003). 
 
Although more than 40,000 medicines have been registered in Mexico, around 7,000 
are commercially available (SSA-COFEPRIS, 2005: 47). A Mexican pharmacopoeia 
and a quality assurance system are in place to assure that all registered medicines are 
of good quality (e.g. purity or bioavailability). However it has been documented that 
between 10-15% of the medicines commercially available are unsafe, prohibited or 
restricted in other countries (CTFM, 1999; Vicencio Acevedo, et al., 1995). 
Furthermore, the commercialization of antibiotics in irrational combinations20 has been 
reported such as antibiotics together with cold and cough preparations (Arenas-
Garduza, 2002; Calva and Bojalil, 1996; CTFM, 1999; Leyva-Flores, 2002), leading to 
an increased risk of adverse effects, inappropriate use, and the development of 
antibiotic resistance (PAHO, 1999; Valsecia, et al., 1997; Wirtz, et al., 2013b).21 
 
The pharmaceutical industry in Mexico is organized since 1946 in the National 
Chamber of the Pharmaceutical Industry (CANIFARMA, by its acronym in Spanish) 
congregating 97 laboratories. Besides this large chamber, the industry is organized in 
                                                             
19 Pfizer/Wyeth, MSD/Schering Plough, Sanofi-Aventis, Bayer and Novartis have the largest 
market share (González Pier and Barraza Lloréns, 2011:49). 
20
 Irrational combinations are those fixed-dose medicine combinations that do not show an 
increased efficacy when compared with the separate components, have a low therapeutic value, 
and their use represents more risk that benefit. Their commercialisation is indicator of the poor 
quality of medicines and the scarce regulation over the licensing of medicines (Capella and 
Laporte, 1993; DURG-LA, 1997). 
21
 Although the consumption of antibiotics in irrational fixed combinations is decreasing in Latin 
America, it is worth mentioning that the majority of these antibiotics in combination have an 
approved indication for cough- and cold related symptoms or for diarrhoea, conditions for which 
antibiotics generally are not indicated (Wirtz, et al., 2013b). 
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other associations, according to the interests of the producers. The largest one is 
AMIIF, which groups 30 transnational pharmaceutical corporations, and dominates the 
sector economically and politically; its main aim is to promote the protection of 
intellectual property rights. The longstanding ANAFAM groups 20 laboratories, many of 
them domestic, but more recently incorporated also transnational companies 
specialized in generic medicines. Its main interest is to promote the development of the 
national industry, as well as market entry to generic medicines. Newer associations are 
AMELAF, grouping more than 50 Mexican laboratories, which aims to promote national 
industry and access to national generics; AMEGI, which congregates both national and 
foreign producers of generic medicines. With regard to the distributors of medicines, 
the largest companies are represented by DIPROFAR. Finally, independent 
pharmacies are represented mainly by the National Association of Pharmacies of 
Mexico (ANAFARMEX) and the National Union of Pharmacy Entrepreneurs 
(UNEFARM). On the other hand, large chain pharmacies and their own distributors are 
represented by the association ANADIM, while supermarket pharmacies are grouped in 
the association of supermarkets ANTAD. Smaller pharmacy chains are represented by 
the associations ANEFAR and PROFARMEX (González Pier and Barraza Lloréns, 
2011: 48-52; Shadlen, 2009: 51). 
 
 
2.3.4 Pharmaceutical policy and legislation in Mexico 
 
Although some elements of a national pharmaceutical policy (NPP) were developed 
since the 1950’s and 1960’s –e.g. a national essential medicines list (EML) or ‘Cuadro 
básico’– the development of the first comprehensive Mexican NPP was triggered by 
the 1982 economic crisis, which resulted in a severe shortage of medicines (Gasman, 
1995). The objectives of the first NPP –enacted within the General Law of Health 
document in 1984– were: 1) To make good quality essential medicines available to the 
population at a reasonable price; 2) To promote self-sufficiency and the development of 
the national pharmaceutical industry; and 3) To promote the rational use of medicines 
(WHO, 1988). However, the 1984 policy received strong opposition and pressure from 
transnational corporations, mainly directed against the use of generic names and the 
elimination of medicines from the register; the Mexican Government had to revise and 
change some of these regulations (Gasman, 1995; WHO, 1988: 90). The 1984 NPP 
brought important advances, namely the improvement of the medicines coverage, the 
development of the national pharmaceutical industry and of a quality assurance 
system. The promotion of rational use of medicines was the weakest part of the policy 
(Gasman, 1995; WHO, 1988). Although most of the elements for a sound and rational 
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NPP were in place, the time allowed for its implementation was too short. As in many 
countries, towards the end of the 80’s Mexico experimented a shift on its economic 
policy, characterized by a general trend to de-regularisation within the health and 
pharmaceutical sectors (Madrid, et al., 1998). When Mexico joined the North American 
Free Trade Agreement in 1994, pharmaceutical issues were negotiated mainly from the 
industrial and commercial perspective, but without explicit concern for public health 
issues (such as equitable access and rational use). The NPP had to be revised once 
again, was replaced by a de facto policy (Gasman, 1995) for which no public document 
set out explicit national targets regarding access, quality and use of medicines. 
 
Hitherto, Mexico does not have an official and explicit pharmaceutical policy document; 
additionally, the regulatory framework for medicines is complex and dispersed in many 
different documents.  Some elements are present on the General Health Law; others, 
in specific regulations pertaining health care services, health care products, the 
essential medicines list, and specific regulations for social security institutions (such as 
IMSS and recently the Seguro Popular), all of which are weakly connected (Dreser, et 
al., 2011b; Wirtz, et al., 2012). Within the General Health Law (the main juridical 
instrument for health policy), one of its 18 chapters is dedicated to the control of a wide 
variety of products and services: food, drugs, pesticides, tobacco, medicines, 
pharmaceutical manufacturing and pharmacies. Within this chapter, legislation on 
medicines and pharmacies (that could be relevant for policies on rational use of 
medicines) is heavily loaded toward the regulation of narcotics and psychotropic 
substances. While there are 23 articles dedicated to narcotic and psychotropic drugs, 
there are only 14 dedicated the rest of the medicines (which include scheduling 
medicines in prescription-only and over-the-counter), and only two devoted to 
pharmacies. Confusingly, this Law assigns responsibility on pharmacies regulation to a 
special commission within the Pharmacopoeia Committee (in charge principally of 
assuring the quality and safety of medicines). Consequently, this regulation diverts  the 
functioning of pharmacies (central for ensuring adequate dispensing and promoting the 
rational use of medicines) from other regulations and policies related to quality of care 
(Dreser, et al., 2011b). 
 
In the course of the following years, medicines policies in Mexico were addressed from 
two divergent perspectives: health, and industrial development, with no link between 
the two. In general these policies have not arisen from a detailed analysis of priorities 
and alternatives; rather, they have been developed to respond to specific conjunctures, 
or stakeholders’ interests (González Pier and Barraza Lloréns, 2011; Wirtz, et al., 
2012). Although in Mexico there has been for decades a list of generic preparations 
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forming the EML, it has been used almost solely to organize medicines procurement in 
the public sector, and not to promote the rational use of medicines. The concept of 
‘essential medicines’ has been rarely incorporated in the university curricula; there has 
not been a strategy to promote this concept the private sector (Gasman, 1995). 
 
By the end of 2005, the Mexican Ministry of Health published a NPP policy proposal: 
“Towards a comprehensive pharmaceutical policy for Mexico” (SSA, 2005). The 
process, by which this document was developed, as well as its content with relation to 
medicines use and AMR, is described in Chapter 5. Here, it is important to say that this 
proposal did not include rational use of medicines as an objective, nor specific 
strategies on AMR. The policy proposal did not materialize in an official NPP, although 
some of the proposed actions were indeed implemented. 
 
Since 2005, diverse medicines-related initiatives have been developed and regulations 
have been enacted; various elements related to a NPP are dispersed in a fragmented 
legal framework and the national health programmes published with each new 
administration. In addition, there is lack of clarity about what government agencies 
have the responsibility to draft, monitoring and evaluating pharmaceutical policies. The 
lack of a national pharmaceutical policy document, the fragmented legislation, the 
multiplicity of policy initiatives, and the absence of a clear institutional responsibility on 
pharmaceutical policy creates a very confusing policy arena (Wirtz, et al., 2012). 
 
As was described before, the pharmaceutical industry in Mexico is well organized in a 
national commercial chamber (CANIFARMA), and several other associations. These 
organizations have facilitated the industry participation –both by formal and informal 
means–, in the formulation and implementation of pharmaceutical policies in Mexico. 
The influence of the organized pharmaceutical industry in Mexico is illustrated by an 
analysis comparing the politics of patents on medicines in Brazil and Mexico (Shadlen, 
2009). After the introduction of the trade agreement TRIPS in the mid 1990’s, 22 Brazil 
adjusted the intellectual property rights system to serve public-health purposes, i.e. to 
ameliorate the effects that medicines patents can have on prices and access. In 
contrast, Mexico introduced few adjustments, and these tended to reinforce the effects 
of drug patents; as such, prices of patented drugs remained higher in Mexico. The 
author argues that these differences cannot be explained only by the fact that Mexico 
                                                             
22
 The World Trade Organization’s Agreement on Trade-related Aspects of Intellectual Property 
Rights (TRIPS) as well as the intellectual property rights provisions of the North American Free 
Trade Agreement (NAFTA) prohibit countries from declaring pharmaceutical non-patentable, 
and require countries to provide patent holders with strong rights of exclusion, all of which can 
raise medicines prices and deter access (Shadlen, 2009:41). 
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signed the NAFTA, or by the political orientation of governments. Rather, a political 
economy perspective focusing on the role of actors and coalitional formation provides 
an explanation for these divergent trajectories (2009: 41-42). In Brazil, there was a 
compelling governmental response and wide social mobilization to face the HIV/AIDS 
epidemic which triggered changes to patent law in favour of access to medicines.  
Even if the Brazilian reforms of patents system were state-led, they were feasible 
because the government could elicit the support, as coalition partners, of the local 
pharmaceutical industry interested in promoting national made generic medicines. 
Despite the opposition of the transnational pharmaceutical sector to reforms, the 
national industry had strong economic and political assets, and was crucial in not 
blocking, and indeed supporting, the reforms (Shadlen, 2009). 
According the study by Shadlen (2009), the policy process for patents system reforms 
in Mexico was different in many aspects. While Mexico had a less compelling response 
to HIV/AIDS epidemic, the economic crises of 1994, the escalating prices of 
pharmaceuticals, and the insufficient coverage of social security systems put access to 
medicines on the political agenda.  In fact, the idea of reforming the patent system for 
public health purposes was based on the Brazilian experience and underpinned a 
legislative initiative in Mexico in 2002. This initiative, which was against of TRIPS and 
NAFTA requirements, was proposed by a member of the Chamber of Deputies of the 
Green Party, who was relative to the owner of the pharmacy chain Similares, seller of 
national generic medicines. The proposal drew a sharp reaction from the transnational 
pharmaceutical industry, well organized the association AMIIF, interested on protecting 
medicines patents. AMIIF mobilized resources to gain the support of decision-makers, 
law firms and even foreign embassies. This association launched a counterproposal to 
reform the patent system which was supported by President Fox government.  A new 
version of the initiative (which increased patent protection) was drafted and passed in 
the legislative, and the signed into law by President Fox in 2004. On the other hand, 
the national industry interested in producing national generic medicines, organized in 
the association ANAFARM, did not provide support for the original initiative, nor 
opposed the revised and unfavourable version. ANEFARM was neither economically 
strong nor politically independent vis-à-vis the transnational industry. Both associations 
(AMIIF-the transnational sector and ANEFARM- the national sector) are part of the 
chamber CANIFARMA. Furthermore, ANEFARM was suffering a decline in its 
membership was undergoing trans-nationalization of its own, with international generic 
firms purchasing long-established Mexican firms; additionally it was not and ally of the 
pharmacy chain Similares (Shadlen, 2009: 49-50). The author concluded that even 
though the idea of reforming the patent system for public health purposes was able to 
39 
 
reach the policy agenda in Mexico, the policy was not developed. This was a result of 
the strong opposition of well-organized and powerful patent-holding firms, and the 
scarce support of national manufacturers of generic medicines: “[t]he nature of 
Mexico’s transnationalized pharmaceutical sector meant that [health minister] Frenk 
could not, and therefore would not, attempt to go down the Brazilian path” (Shadlen, 
2009: 53). 
As the study previously described explains, the strongly organized pharmaceutical 
industry in Mexico has been able to mobilize resources to influence decision-making. 
Additionally, recent evidence points out to collusive practices of the pharmaceutical 
industry in Mexico, affecting the implementation of public procurement of medicines 
(Bohórquez and Devrim, 2012). In 2010, six pharmaceutical companies were 
sanctioned for bid-rigging on IMSS auctions of different medicines. The involved 
pharmaceutical companies maintained contact through the pharmaceutical commercial 
chamber establishing agreements to winning and losing bids, which resulted in 
unusually high contract prices (Bohórquez and Devrim, 2012: 106). 
 
2.4 Political system and the process of policy-making in Mexico 
 
2.4.1 Political system: The authoritarian legacy and the transition towards 
democracy.  
 
Mexico is federal republic composed of 31 states and a Federal District; government 
has the usual three branches of power (executive, legislative and judicial). The chief 
executive of the Federal Government is the President, who is elected for a six-year 
term. A bicameral National Congress, comprised of the Chamber of Representatives 
and the Senate, represents the federal legislative branch. Since 1986, the National 
Health Council (Consejo Nacional de Salud) is the collegiate board from the executive 
branch of government where Mexican health policies are formulated, and where 
coordinating mechanisms are established among federal and state level to oversee the 
implementation of the National Health Programmes. The Council is chaired by the 
Minister of Health, and is integrated by 32 state-level health ministers, as well as the 
directors of the main national health and social security institutions. With regard to the 
legislative branch, both cameras of the National Congress have permanent Health 
Commissions which decide upon health legislation. 
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For most of the twentieth century, Mexican political system has been considered an 
authoritarian regime, under the hegemonic rule of the centre-right political party Partido 
de la Revolución Institucional (PRI, by its Spanish initials). The 71 years long PRI’s rule 
(1929-2000) was characterized by presidentialism, corruption, corporatism, informal 
arrangements, cronyism, and clientelism (Cadena, 2004; Lehoucq, et al., 2005; Morris, 
1999; Teichman, 1992). Under the PRI unified government, nearly all legislators and 
governors belonged to the same party. Although elections were held every 6 years, the 
outgoing president was the one who designated the PRI candidate that became, 
invariably, the new president. Clientelistic23 practices and labour corporatism 
(particularly the inextricable relationship between large labour unions confederations, 
government and PRI) were central features that ensured political stability and PRI 
permanence (Hagene 2015). 
 
Under the PRI heydays, policy-making was state-centred, vertical and exclusionary. 
Given the concentration of power in the executive, it was the president and a small 
group of close collaborators (appointed by the president) who initiated policies and 
decided policy formulation. The president had “meta-constitutional” powers; i.e., 
although not formally established in the Federal Constitution, the president enjoyed a 
superlative power and the Congress systemically approved presidential initiatives with 
scarce opposition (Díez, 2006; Lehoucq, et al., 2005). Additionally, the role of the 
Mexican Congress was constrained by financial and technical limitations, and a strong 
party discipline. Advisory commissions in the Congress (such as the health 
commissions) played only a secondary role in decision-making. Given that by law 
members of the Congress couldn’t be re-elected, they had scarce experience and 
incentives to be actively involved in policy-making. Furthermore, given the non-re-
election clause, congressmen tended to court the favour of the president or the party to 
seek appointments after the completion of their terms, and were less responsive to 
public demands    (Cabrero, 2000; Díez, 2006; Starr, 2002; Trostle, et al., 1999).  
 
Notwithstanding the low permeability of the system that hindered participation in the 
policy process, the institutional design facilitated the participation and influence of 
certain actors. Among these were businessman and manufacturers (‘empresarios’); 
these were organized on industrial and commercial chambers (or ‘cámaras’). One of 
these chambers is the CANIFARMA which organizes the pharmaceutical industry in 
México. These economically powerful chambers have been, by law, instruments of 
                                                             
23 Political clientelism refers to a long term relationship involving the exchange of goods and 
services (including benefits from public programmes and employment in the public sector) for 
electoral support (Hagene 2015).  
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consultation of the State regarding national industrial and commercial needs. In the 
political reality, these cámaras have been used by businessman to protect their 
interests and to influence public policy-making (González-Casanova, 1985: 66). In 
contrast to these well-organized groups, other societal groups not belonging to the 
corporatist structure lacked the political instruments –as well as the political culture– to 
participate as citizens in public decision-making. In this way, participation was much 
restricted to intermediation and personal relationships (Cabrero, 2000; González-
Casanova, 1985: 156).  
 
The exclusionary nature of agenda setting and policy formulation was aided by a print 
media uncritical of the regime’s policies (Díez, 2006; Lawson, 2002). Once policy was 
formulated, the minister responsible would start a process of negotiation thorough his 
ministry’s bureaucracy, which was largely unprofessional. The implementation of policy 
was carried out through the corporatist structure and clientelistic relationships. 
Bureaucrats became the de facto interpreters and brokers of policies. As practices 
were mostly discretional and unsystematic, this caused the traditional gap that exists in 
Mexico between the adoption of policies (“legal formalism”) and their implementation 
(Díez, 2006; Lehoucq, et al., 2005). 
 
Between 1983 and 1997, politics in Mexico experienced a transitional period. Fraud 
and disputed elections, economic crisis, growing discontent with the regime and social 
mobilization led to a series of electoral system reforms. These reforms fuelled the 
development of a three-party system and eventually, functional elections. Until 1982, 
Mexican social policy was sustained by a welfare State regime; however, during the 
technocratic presidential administrations of 1988-1994 and 1994-2000 structural 
adjustment policies were introduced consolidating a neo-liberal tendency. Other 
relevant institutional changes brought by these administrations were  decentralization 
program that transferred responsibilities to the state and municipal levels, liberalization 
of trade (including joining the North American Free Trade agreement), and the 
privatization of some state companies (Camp, 2012; Lehoucq, et al., 2005). However, 
the 1988 electoral fraud scandal, and the 1994 guerrilla movement and economic crisis 
triggered social mobilization, fractured the relationships with the business community, 
and ultimately eroded PRI’s legitimacy. During this transitional period, oppositional 
parties began to make electoral gains, and in 1997, PRI lost its absolute majority in the 
Congress Chamber of deputies. This marked the beginning of a new period of policy-
making under a divided government, in which presidentialism weakened, and the 
Congress began to play a more active role in policy formulation (Díez, 2006; Lehoucq, 
et al., 2005). Despite these changes, the public’s opportunities to influence decision-
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making remained minimal (Cabrero, 2000). This gave place to political system that 
Cabrero (2000: 197) defined as “semi-open system, fragmented and in chaos”.  
 
In 2000, after 71 years of PRI’s continuous rule, the general election brought party 
alternation to the executive:  Mr. Vicente Fox, candidate of the opposing conservative 
centre-right National Action Party (PAN), became president for the 2000-2006 
administration. Mexico’s political context, the protracted political transition and the 
characteristics of the policy-making process after the 2000 election (which is the period 
under investigation in this thesis) are described below. 
 
2.4.2 The political system during the 2000-2006 and the 2006-2012 presidential 
administrations.  
 
Party alternation after the 2000 general election is often regarded as the most 
important turning point in Mexico’s democratic transition, or even more, the moment of 
instauration of democracy. Undoubtedly, political representation had a major shift after 
2000: there were functional elections, and the people of Mexico were represented by a 
plurality of political parties. Under the new divided government, no longer was the PRI 
the absolute majority in Congress, and there were governors from all parties. 
Metaconstitutional practice ceased to exist, and Congress attained a growing role in 
initiating new legislation. Nevertheless, as many political experts underline, “democratic 
transition” is a highly contested term, because democracy in Mexico was –and still is– 
far away from being consolidated (Camp, 2012; Cansino, 2004; Cansino 2012).  
 
President Vicente Fox administration. During the 2000-2006 administration, 
Mexico’s political transition advanced unevenly across policy areas and levels.  Despite 
the increasing role of the legislative in policy-making and the strengthening of the 
judiciary, equilibrium between powers was not fully attained: decision-making in the 
executive branch kept a strong role (Díez, 2006). However, as the PAN (the ruling 
party) did not have a majority of seats in the Mexican Congress, a number of 
presidential initiatives failed to pass in Congress. As part of his fiscal reform, early in 
his administration President Fox proposed to expand the valued-added tax to 
medicines (among other items). This proposal was strongly opposed by the public, by 
the PRI and PRD (arguing that the tax was too regressive), and even by the PAN, who 
raised concerns about the political cost of such measure (Starr, 2002). This proposal 
was not approved (which reveals the increasing Congress veto power); however, the 
public discussion that the proposal sparked underlines the relevance of access to 
medicines as a political issue in that moment. Nevertheless, as is explained in other 
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sections, under President Fox administration and the leadership of the Minister of 
Health Dr. Frenk other policy proposals prospered, namely  a new health insurance 
scheme (Seguro Popular), and number of health policies related to medicines (see 
sections 2.2.2 and 5.1).  
President Fox’s administration was characterized by being overtly related to business 
groups:  businessmen participated in his electoral campaign and many actors from the 
private sector –highly qualified, but without political experience– were appointed in his 
initial cabinet (Camp, 2012; Díez, 2006; Starr, 2002). Actually, for Thacker (2012) the 
willingness of the private sector to participate in party politics has been regarded as 
one of the most important changes in the Mexican political system, especially after 
2000. President Vicente Fox himself was largely an “outsider” to Mexican politics, who 
emerged from the private sector (he was formerly a chief executive in Coca-Cola 
Company). During this administration, a large number of business candidates won 
offices on the executive. Moreover, there was an important increase of business 
association members in the legislature. The private sector lobbied, directly and 
indirectly, through the Congress, and as a result and the legislative agenda was 
influenced by powerful stakeholders (Díez, 2006:10-11; Thacker, 2012:319-320; 
Shadlen, 2009). This is exemplified by the effective mobilization of the organized 
transnational pharmaceutical industry (backed by President Fox) against a patent 
system reform initiative (Shadlen 2009) as has been described before. On the other 
hand, private foundations were encouraged to finance the implementation of some 
governmental health programmes (Mills, 2006). Finally, President Fox favoured the 
creation of a new administrative agency of the Ministry of Economy, the Federal 
Commission for Regulatory Improvement (COFEMER, by its initials in Spanish), in 
order to promote the development of cost-effective regulations, and to reduce the 
burden on business. In practice, the Commission opened a new door to business 
companies to lobby and to influence the drafting of regulations guarding their interests 
(Díez, 2006). 
 
Vicente Fox has been regarded as a weak president, which was not able to exert 
presidential leadership, was not supported by his party, faced opposition in the 
legislature, and lacked the political ability to move forward his agenda (Méndez, 2013). 
Although his electoral triumph fed hopes for major changes in the political and 
economic spheres, these did not happen. There was policy confusion and inefficiency, 
related to the cabinet lacking government experience.  President Fox political capacity 
and public approval ratings declined in the following years (Méndez, 2013; Starr, 2002). 
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President Felipe Calderón administration. The subsequent presidential election, in 
2006, was highly controversial. There was a close party competition among PAN, PRI 
and the left-wing Party of the Democratic Revolution (PRD, by its Spanish initials). The 
final vote count gave the victory to Mr. Felipe Calderón, the candidate of the ruling 
party PAN, but only with a narrow margin of less than one percentage of the vote 
above the leftist PRD candidate. PRD alleged irregularities, there were street protests, 
and ballot boxes had to be recounted. Finally, the Electoral Tribunal ratified Mr. 
Calderón’s triumph, but he came to power rather delegitimized. The 2006 elections 
caused a generalized lack of credibility in the political parties and an institutional crisis 
of the electoral system (Cansino, 2012).  
 
President Calderón had the support of only a few PAN Governors, and PAN did not 
have majority in the Congress. Quite differently from President Fox, he cared a lot for 
the presidential reputation, followed protocols strictly and had a tight control on his 
cabinet (Méndez, 2013). From the first days of his administration he made clear that 
the central issue of his agenda would be the “war” against drug cartels. Firstly, this 
initiative was supported by the public, and the Congress approved a constitutional 
reform on public security that included deploying the army in some cities. However, the 
war on drugs soon backfired. From 2008 on, violent crime and organized-crime related 
deaths increased dramatically. The insecurity crisis brought important social and 
economic costs, as well as further dissatisfaction with the government. As President 
Calderón’s political capital eroded, approval ratings for his administration declined. 
Overall, President Calderón did not exert presidential leadership, and his level of 
achievement was low: although he accomplished some minor reforms, public security 
was a major failure (Méndez, 2013).  In 2012, PRI returned to the presidency –and re-
gained the majority of seats in Congress– after another controversial election in which 
there were allegations of media bias and vote buying in favour of PRI (Cansino, 2012; 
Hagene 2015). 
 
Policy-making under a divided government. Two presidential administrations (2000-
2006, and 2006-2012) after the historic party alternation, there is no evidence of a 
dramatic change towards democracy. Corruption, informal agreements, impunity and a 
discredited political class are still features of the political culture (Cansino, 2004; 
Espinoza Valle, 2006). Overall, public accountability has been much less common that 
accountability to political parties or political cliques (Cabrero, 2000). Because of these 
characteristics, the Mexican political system remains in a grey area between 
authoritarianism and democracy, and there is much debate among political science 
specialists on how to classify it. For Robert Ai Camp (2012) Mexico has remained a 
45 
 
“semi-authoritarian political model” that can be best described as in the “process of 
democratic consolidation”. Besides the shift to a democratic model in the electoral 
arena, he explains, other conditions remain to be met in order to fully attain democracy: 
transparency, respect for human rights and a strong legal system. Furthermore, the 
media still has to fulfil its democratic potential (Camp, 2012).  
 
Cansino (2012) asserts that, even it if has not progressed as a continuous process and 
has had setbacks, there is evidence that a political transition has indeed taken place. 
However, the political system during the 2000-2012 period was characterized by a 
“failed establishment of democracy”.  According to this author, the main reason behind 
this failure is that party alternation in Mexico has not been accompanied by 
constitutional integral reforms that could actualise –in a democratic perspective– the 
normative and institutional legacies of the past regime (Cansino, 2004, 2012).  
Coinciding with Casino (2012), other authors have also underscored the role of 
institutions24 in Mexico’s political transition to explain patterns in policy formulation. 
policy outputs and outcomes (Cabrero, 2000; Camp, 2012; Díez, 2006; Hagene 2015; 
Lehoucq, et al., 2005). As Camp (2012:17) asserts, in Mexico “[…] many patterns of 
political behaviour among politicians are determined by informal rather than institutional 
or structural influences and therefore are much more impervious to change and more 
difficult to ascertain.[…] Informal characteristics can have a significant impact on 
institutional patterns of behaviour or internal processes […].”  The role of the 
legislature, bureaucracy, and informal instututions as part of the political system during 
the 2000-2012 period is explained below.   
The separation of powers boosted the role of the Congress in law making during this 
period. Actually, the legislative branch has played a central role in the democratic 
transition (Camp, 2012).  At the same time, the loss of the metaconstitutional powers 
revealed the institutional weakness of the figure of the President, who consequenly, 
loss the ability to change the status quo (Lehoucq, et al., 2005). Despite the important 
change in the role of the legislature, the non-re-election clause for members of the 
                                                             
24 Institutions are the rules of the game within a society that structure human interaction by 
constraining and enabling actor’s behaviours.  They encompass formal constraints 
(constitutions, laws, regulations) and informal constraints (conventions, norms of behaviour) and 
their enforcement characteristics (North, 1990). Other authors have further explained formal 
institutions as those that are legal or official, encompassing state institutions (e.g. legislatures, 
bureaucracies) and state-enforced rules  (e.g. laws, regulations), as well as the official rules that 
govern organizations. On the contrary, informal institutions are shared rules, usually unwritten, 
created and enforced outside official channels (Helmke and Levitsky 2004:727). Informal 
institutions (such as clientelism or corruption) emerge as a complement or substitute for the 
state when formal institutions are too cumbersome or ineffective, or when they exist on paper, 
but not in practice (Helmke and Levitsky 2004).   
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Congress remained unchanged, which hinders congressmen to adquire legislative 
experience. Furthermore, because Mexican legislators cannot be reelected, they are 
not susceptible to public opinion; legislators are accountable to their party, not to the 
electorate (Cabrero, 2000; Díez, 2003; Starr, 2002). On the other hand, business 
chambers (cámaras) still participate on Congress comissions, both formally and 
informally  (Díez, 2006). Business groups are in advantegeous position to lobby 
Congress given their resources in comparison with the weak structure and experience 
among nonrepeating congressmen (Thacker 2012). 
After the 2000 general elections, labour corporatism –i.e. the influence of organized 
labour in policy-making– declined. However, political clientelism in Mexico remained as 
a resilient phenomenon enduring macro-political changes. Political clientelism is 
profoundly integrated in relations of power in Mexico, has cultural components, and is 
not necessarily perceived as illegitimate. Furthermore, this phenomenon is fueled by 
prevailing poverty and inequity  (Díez, 2006:25; Hagene 2015). Clientelistic practices 
still have a major influence hampering the implementation of existing programmes 
(Lehoucq, et al., 2005). 
Legal dualism –law that appears to be an ideal on paper, but is not implemented as 
originally devised or not implemented at all– is still prevalent in Mexico. This has been 
related to the characteristic low level of voluntary compliance with the law in the 
country, the persistent lack of resources and a largely non-professional bureaucracy, 
weak institutional capacity, as well as to the opposition of powerful interests and 
prevailing clientelistic practices (Camp, 2012; Díez, 2006; Lehoucq, et al., 2005). 
However, Lehoucq et al. (2005) explain that policy implementation has become less 
coherent and less coordinated under the divided government because of the increasing 
aperture of the policy-making process that includes more and new policy players. 
Furthermore, the process of decentralization in Mexico has had important implications 
for policy-making and outcomes, particularly in education and health services25 
(Lehoucq, et al., 2005:12: Mills, 2006).  
 
                                                             
25 Decentralization involves the devolution of responsibility, but not necessarily power, to lower 
levels of government. This reordering is negotiated and contested, as social actors strive to 
appropriate space. As responsibility for policy development and implementation shifts to the 
states, the strenghtening of veto players in the system has increased, a characteristic that is 
status quo preserving (Lehoucq, et al., 2005:12: Mills, 2006:490) In Mexico, along the 1980’s 
and 1990’s the federal government initiated and progressed unevenly in the decentralization of 
health care services.  Implementation resulted in in greater inequity in health services provision 
in some states. During the late 1980’s, this process of decentralization had to be stopped as a 
result of opposition by trade unions and state governments, and had to be reconfigured, before 
being reactivated again (Mills, 2006: 490). 
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Finally, it has been argued that with the end of the corporatist system and the advent of 
the divided government in Mexico, many of the vested interests have actually 
increased rather than decreased their influence in policy-making (Camp, 2012; 
Thacker, 2012). Indeed, as the political system opened up, non-state actors gained 
access to the policy process. Such was the case of the active participation of 
international non-governmental organizations (NGOs) as in maternal health policy 
(Mills, 2006) and environmental policy (Díez, 2006). However, this opening of the 
political system also meant that business groups gained more access points into the 
political system, and were able to compete with other interest groups from a more 
favourable position, i.e. with greater resources and more extensive experience in 
lobbying. As such, even if the political transition introduced changes that affected the 
private sector, “[…] through the use of concentrated market power, legal maneuvering, 
political participation and access, and effective deployment of its material resources, 
big business has succeeded in protecting itself from democratic incursions while 
maximizing its own freedom to maneuver” (Thacker 2006:331). The empirical study by 
Díez (2006) pointed to the differential access that business had (vis-à-vis NGOs) to the 
policy process, using non-transparent mechanism of access, but also facilitated by the 
establishment of institutional mechanisms (e.g. COFEMER). As a result of the greater 
involvement of the private sector, and the authoritarian legacy in the exercise of power 
encouraged by the permanence of pre-democratic rules of the game in policy-making, 
Díez argues, the concentration of power in Mexico has been equally excessive before 
and after the alternation of 2000. In this context, policy initiatives that threaten the 
legitimization of political elites have been neglected (Cansino, 2012). 
 
2.4.3 The process of public policy agenda setting and policy formulation, and the 
role of research.  
 
What are the characteristics of the processes of public policy agenda-setting and policy 
formulation within the context of political transition and unattained democracy? Cabrero 
(2000) explains that, in the earlier moments of political transition in Mexico, public 
policy-making followed largely a state-centred and enclosed process, deriving from a 
tradition of governmental intensity during the PRI authoritarian regime. Even in the 
context of democratic transition, the structures were not designed to be permeable, nor 
have the actors been oriented to openness and participation. The government 
dominated all the phases of policy-making, more by means of sectorial political cliques 
(´camarillismo’) and inter-personal relations than by professional policy communities.  
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The definition of public problems and agenda-setting kept as government-centred, 
endogenous processes; government specialists within each political area defined social 
problems and solutions. It was not uncommon that internally created governmental 
agenda led (through the media, labour unions or business groups) to the public 
agenda, which posteriorly was transformed to the official governmental agenda26 
(Cabrero, 2000: 201). Undoubtedly, there were moments in which a consensus with 
other groups were needed, but the general the trend –the non-formally established rule 
of the game– for agenda setting was dominantly endogenous (Cabrero, 2000: 203).  
 
According to this author, policy formulation was an even more enclosed process, left 
often exclusively to autonomous groups of governmental specialists, and sometimes 
also to private consultants hired by the government. Indirect dialogue, underground 
negotiations, personal relations and informal networks were more important in policy-
making than direct and open dialogue.  In contrast with countries with a longer 
democratic tradition, in Mexico the creation of formal experts groups of different sectors 
(involving, for example diverse governmental ministries, academics and NGOs) in 
order to discuss policy options was uncommon. Academic institutions and NGOs were 
sometimes invited to opine about a finished document or even about an already 
operating plan. The exclusion of the public from this process, together with the use of 
highly technical language, caused public policies to be perceived by the public as a 
technocratic ambit alien to citizen demands (Cabrero, 2000: 204). 
 
What has been the role of research in policy-making in Mexico?  In an empirical study 
of four vertical health programmes in Mexico, Trostle, et al. (1999) pointed to the 
longstanding scarcity of well-defined channels of communication between research and 
decision-makers. The excessive state centralization, the hierarchical management of 
information, the drastic changes in top-level management and priorities within 
governmental ministries with each sexennial change of president, along with a ‘political 
culture’ of decision-making based on experience and immediate pressures (including 
“yellow journalism”) were identified as factors that deterred the uptake of research in 
policy decision-making. Furthermore, the particular agendas of non-academic interest 
groups (particularly, the private industry) were frequent causes of conflict and hindered 
research uptake for decision-making; on the contrary, research results that that did not 
pose conflict with other governmental sectors or the private industry were preferred for 
decision-making (Trostle, et al 1999:108-109).  These factors had hindered legislators 
or members of the executive to receive advice about specific health policy problems 
                                                             
26 This process is reflected on the sexennial plans, which allegedly emerge from citizen polls, 
such as the National Development Plan, and the National Health Programme. 
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and solutions. On the other hand, the existence of good personal relationships between 
researchers and policy makers and the need for prompt solutions to urgent health 
problems were identified as key factors that facilitated research uptake in health policy-
making. Quantitative studies were given preference over qualitative ones. The political 
stability provided by the long term PRI rule (in which researchers rotated in and out of 
government) and well as the scarce opposition by the legislature also favoured 
research informed decision-making. According to this study, the WHO had an important 
normative force to inform national policies; however, the role of foreign donors has 
been characterized as minor in informing health policy initiatives (Trostle, et al., 1999). 
 
As discussed previously in this section, newer studies (Barquera et al., 2013; Díez, 
2006; Mills, 2006; Shadlen 2009) show some changes regarding the actors and 
processes of policy-making in Mexico from what was described by Cabrero and Trostle 
et al. (op. cit.). The stronger role of the legislative, and the incursion of non-state actors 
in policy-making during the 2000-2012 period point out to increasing pluralism. The role 
of international initiatives, foreign donors and NGOs according to these studies is also 
manifest, as it is described below. 
 
Mills (2006) explain that international NGOs facilitated –by funding both policy research 
and advocacy organizations– the creation of networks oriented to maternal health in 
Mexico,  involving NGOs and governments at the national and sub-national level (state 
and municipal local level). Linkages between actors and the creation of “spaces of 
engagement” for maternal health policies at the sub-national level were favoured by the 
decentralization of health services provision. Additionally, the United Nations 
Millennium Development Goals also boosted interest of the federal government in this 
policy area. Similarly, Díez (2006) found that, in the case of environmental policies, 
international links were very relevant for national NGOs to obtain funding, training and 
expertise to allow them to participate in policy-making and advance their demands. 
Furthermore, during the 1994-2000 period, environmental policy-making was greatly 
aided by a reformist Minister of Environment. This Minister was not linked to any 
political clique; instead, she came from an academic background and included a tight 
group of researchers in her cabinet. Furthermore, this Minister was able to steer the 
environmental policy agenda by working closely with standing committees of the 
Mexican Congress. These findings underline policy-making beyond political cliques or 
camarillismo, greater involvement of academic groups, as well as the increasing role of 
formal institutions (i.e. the Congress) in policy-making. However, Díez concludes that 
agenda status and the move towards greater participation in environmental policy-
making during 1994-2000 were not sustained after 2000 elections. This was related, in 
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part, to the privileged access and influence in decision-making that powerful business 
groups kept and even increased during President Fox administration27. But 
environmental policy-making also was affected by the weakening of national NGO’s (as 
the most important environmentalist were recruited to work in the government) and to 
the decreasing funding from international donors. Some international funding sources 
considered that, since Mexico had become a stable democracy (after party alternation), 
they could shift their attention to other countries (2006:163). 
 
Finally, a more recent account of health policy-making in Mexico is provided by 
Barquera et al. (2013), describing the development of the National Agreement for 
Healthy Nutrition (ANSA, by its Spanish initials) in Mexico in 2010. The dramatic 
increase of obesity and overweight (particularly in children), as well as its relation with 
the consumption of caloric beverages was documented by researchers with data of the 
2006 National Health Survey. This research evidence, together with the support of the 
WHO Global Strategy on this matter, brought obesity to the policy agenda in Mexico 
during the 2006-2012 administration. An inter-sectorial expert panel was integrated, 
which drafted a series of policy recommendations grouped in the ANSA28. This 
agreement was signed by numerous actors, including the ministers of health and 
education, with the President of Mexico, Mr. Calderón, as witness. However, policy 
recommendations were soon strongly opposed by the beverage and food industries, as 
well as by milk and sugar producers, using the media to discredit the pertinence of 
such policies, and stressing economic losses. A public hearing for the regulation of 
foods in schools was opened in COFEMER. The majority of the comments received 
were in favour of the regulation and only one third –mainly by the food industry– was 
against it. Despite this support, COFEMER made a preliminary ruling rejecting the 
original proposal. This led to a re-negotiation of the policy with the industry, which 
resulted in changes that, ultimately, allowed some energy dense foods and beverages 
(originally forbidden) to be sold at schools (2013:74). Furthermore, according to the 
authors, the strong influence of the food and beverages industries has successfully 
prevented other of the recommended policies to be developed.  
 
                                                             
27 Díez (2006) argue that the close relationship between President Fox’s cabinet and business 
groups resulted in pressure from the President’s office to influence –and even block– 
environmental policies. The most notable example was a controversy over a policy addressing 
dirty beaches in 2003. The Minister of Environment released research results that indicated the 
high levels of pollution in some Mexican beaches. This announcement was strongly opposed by 
hoteliers, the National Hotel Chamber, governors of touristic states, and even by the President; 
it ultimately resulted in the dismissal of the Minister of Environment. 
28 Among these, were: banning energy dense food and sugar-sweetened beverages from 
schools, implementing a new food labelling system, regulating of marketing directed to children, 
and introducing a tax to soda beverages.  
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At the same time, a consortium of more than 20 health related NGOs and academic 
groups was formed: The Mexican Alliance for Health Nutrition, which received funding 
from Bloomberg Philanthropy. The Alliance launched an innovative media campaign to 
support the ANSA policy recommendations and to counteract the industry’s arguments. 
According to Barquera et al. (2013:77) substantial backing by effective civil society 
organizations, along with the support of key political leaders, was very relevant to move 
forward the enactment and the implementation of some of the recommended policies. 
However, the ANSA recommendations still face strong challenges to be implemented. 
These challenges are the strong opposition of powerful industries, as well as 
government limitations, including poor planning capacity, lack of accountability and 
insufficient resources to assess implementation. Overall, the authors conclude, “[i]n 
some cases unwillingness to protect the public interest from [economic] influences that 
oppose health policies has been a factor in the failure to enact some policies” 
(2013:77). 
 
Taken together, the studies described here allow identifying some important 
characteristics of the political system and the policy-making process during the 2000-
2012 period in Mexico. Firstly, following a longstanding authoritarian regime, policy-
making kept largely as an enclosed, executive centred governmental process. In 
contrast to the scarcity of well-defined channels of communication between 
researchers and decision-makers, personal relationships have had an important role in 
research uptake. Secondly, the political transition has given place to an increasing 
participation of other actors. In addition to the relevant role of international 
organizations informing national policies (such as WHO), networks involving decision-
makers, researchers and national and international NGO’s have had an increasing role 
supporting policy development. The legislative has exhibited a stronger role in policy-
making; however, this role is stalled by the institutional design that does not favour 
experience and accountability to the electorate, but facilitates the participation of 
business groups above, for example, researchers.   On the other hand, with the 
opening of the political system, business groups have gained more access to the 
policy-making process. Given their longstanding lobbying experience and strong 
organization (such as in the commercial chambers) and their relation to political elites, 
business groups had been able to block the enactment of policies that affect their 
interests. In the case of health and pharmaceutical policies, this is illustrated by 
opposition of the transnational pharmaceutical industry to the 2002 initiative for patent 
system reform, and the resistance of the food industry (reflected as well in the official 
COFEMER) to the 2010 healthy nutrition agreement. These characteristics are relevant 
to understand the context in which AMR policies would be developed in Mexico. 
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2.5 Summary and conclusion 
 
International organizations, especially WHO, have provided ample guidance on 
strategies and interventions to improve the use of medicines, address irrational 
antibiotic use, and contain antimicrobial resistance. These recommendations imply 
changes in health and pharmaceutical policies at the national level. While there are 
successful experiences in some countries, a number of barriers have been identified to 
fully incorporate these recommendations in national policies. Therefore, it is necessary 
to recognize the complexities of AMR problems and policies, as well as to understand 
the local contexts in which AMR policies would be adopted and implemented. 
 
In Mexico, problems related to the inadequate use of antibiotics have been reported in 
the literature: inadequate prescribing, lax regulation of pharmacies that facilitate self-
medication with antibiotics, and scarce information on medicines use for prescribers 
and patients. The consequences of inadequate use of antibiotics, in terms of costs and 
adverse reactions, have also been documented. Nevertheless, there is no systematic 
collection on any of this data. Similarly, despite a number of networks generating data 
on antimicrobial resistance, there are not mechanisms in place to systematise this 
information and communicate it to prescribers and policy-makers. The response to the 
problem of AMR has been mainly in the form of educational and managerial 
interventions directed to physicians in public health services, as well as epidemiological 
surveillance of antimicrobial resistance. However, there is a paucity of research and 
interventions on AMR focused on patients, pharmacies, and the private sector. Above 
all, there is not a national policy on AMR; promoting the rational use of medicines and 
addressing AMR have been largely disregarded by health policies in Mexico. 
 
The information described in this chapter provides insights on some relevant contextual 
factors to consider when analysing health and pharmaceutical policies and policy-
making in Mexico. Despite important improvements in strengthening the public health 
sector, the country is still marked by inequity in access to health care and medicines.   
The private sector is an important actor in health care, by the provision of medical 
services and medicines. Anti-infective medicines (including antibiotics) account for a 
substantial share of the large medicines market. The transnational pharmaceutical 
sector is well-organized and has experience in policy lobbying.  Even if the democratic 
transition is, slowly, bringing some changes about the political system in Mexico, 
policymaking is still very much state-centred. Whereas the institutional design 
facilitates the participation of some interest groups (particularly business groups) in 
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policy-making, the opportunities of participation for other groups (researchers, 
professional associations, NGOs) remain limited, although slowly increasing. While the 
gradual incursion of new non-state actors in policymaking could enable policy change, 
the system has been regarded as largely status quo preserving. This is related to the 
enduring powerful elites, decentralization of governmental responsibilities, and 
persistent informal institutions. Longstanding practices of political clientelism, and 
corruption, as well as a non-professional-bureaucracy and a discredited political class 
prevail as features of the political system in Mexico.  The normative role of the WHO to 
inform health policies is recognized; nevertheless, the influence of powerful business 
groups (including pharmaceutical industry and commerce, and the food industry) in 
health policy is patent, as these groups had been able to block the enactment of health 
policies, These are important contextual factors to take into consideration when 
analysing the process of agenda-setting for AMR in Mexico.  
54 
 
3. CONCEPTUAL AND THEORETICAL BACKGROUND 
 
 
The present investigation is concerned with how and why health and pharmaceutical 
policies in Mexico have dealt (or not) with the issue of inappropriate use of antibiotics 
and antibiotic resistance (AMR). These questions are addressed from the disciplinary 
perspective of policy analysis, focusing on the difficulties and opportunities to place 
AMR on the governmental health-policy agenda. Therefore, I begin this chapter by 
presenting a theoretical review of policy analysis, discussing the concepts of public and 
health policies, and examining different approaches to understanding the process of 
public policy-making. The chapter goes on describing theories on agenda-setting that 
provide the theoretical propositions on which this thesis is based. Finally, I present the 
conceptual framework of the study. 
 
 
3.1 Public policy and health policy  
 
Overall policy, public policy and health policy are much contested concepts. Policy has 
been defined as “a relatively stable, purposive course of action or inaction followed by 
an actor or set of actors in dealing with a problem or matter of concern” (Anderson, 
2011: 6). However, a policy can also be a course of action that is not intended, but is 
nonetheless carried out (Parsons, 1995: 13). Furthermore, a policy can refer to what is 
not being done (Leichter, 1979: 6-7). Public policy, in turn, focuses on the public and its 
problems. It is concerned with problems in those spheres which are designated as 
public, or held in common, as opposed to those domains of life that are private, or 
individual. As such, public policy has been regarded as requiring governmental or 
social intervention (Parsons, 1995: 3). The concept of public policy is generally 
understood as governmental decisions or choices regarding courses of action (which 
involve, firstly, defining public problems and solution alternatives). These decisions and 
courses of action are undertaken by the administrative executive branches including 
ministries or departments such as those of health, education, defence, and transport. 
However, recognising that policy decisions are fluid and not confined to one level or 
stage (Gilliat, 1984: 345), the concept of public policy is also concerned with the 
process that leads to any given course of action. In this process, a large number of 
actors participate individually or as groups including governmental agencies, interest 
groups, researchers and journalists. Furthermore, each actor has different ideas and 
interests regarding the policy problems and solutions (Sabatier, 2007: 3). The process 
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of public policy frequently involves negotiation and bargaining among competing 
interests and groups aiming to influence decision-making in favour of their interests and 
ideas. Moreover, the fora or institutions where these political interactions occur can 
influence public policy-making and its outputs. Finally, the wider social, political and 
economic context is relevant as well to understand the issues, actors, and processes 
involved in policy-making1 (Leichter, 1979). 
 
Regarding health policy, this concept has been frequently defined featuring the policy 
content; for example, the World Health Organization defines health policy as 
“decisions, plans, and actions that are undertaken to achieve specific health-care goals 
within a society”2. The technical orientation in the definition of health policies and its 
implicit consensual environment has been challenged by many scholars (Walt and 
Gilson, 1994). The health-policy environment is fluid, frequently uncertain and 
conflictual given, among others, the following characteristics: 
 Besides involving technical issues, health policy takes on a political dimension 
(determined by the values and interests of the participants involved), as well as 
an ethical dimension3 (Roberts and Reich, 2002). 
 Whereas health policies are often considered ‘low politics’, they usually have a 
high profile and demand public responses (Walt, 1994; Walt, et al., 2008). This 
is especially true for pharmaceutical policies, given that medicines are a 
tangible part of health care, provide a visible output of state policy, and often 
legitimise health services and the role of the doctors (Reich, 1995b). 
 Whereas some health policies are likely to be considered only by a single 
government department (likely the Ministry of Health, MOH), and to be dealt 
with by the bureaucracy using standard operative procedures, others involve 
the increasing participation of a wide array of actors; these include other 
                                                             
1
 For example, at the national level, the political system affects the extent to which people and 
interest groups can participate in public policy-making. In addition, the political culture (i.e., 
people’s beliefs, expectations and attitudes towards politics) influences participation. Besides 
these structural factors, Leichter (1979) distinguishes other contextual factors that can influence 
policy-making: situational factors (e.g., disease outbreaks and economic crises), cultural factors 
(e.g., religion and values within society) and international factors (e.g., globalisation and the role 
of multilateral organisations). 
2
 World Health Organization: “Health Policy”, at: http://www.who.int/topics/health_policy/en/ 
(accessed on November 28, 2014). Health policies have diverse branches or categories, 
including health-care financing, health-care delivery, public health, and pharmaceutical policy. 
AMR policies fall within the larger scope of health policies, although, given the emphasis on 
medicine utilization, it is frequently discussed specifically as part of pharmaceutical policies.  
3
 The goals that guide policy makers can favour, for example, cost-effective interventions 
(utilitarian perspective, based on the consequences of policy) above those directed to improve 
social equity (communitarian perspective, emphasising the character and virtue of the policy) or 
patient choice (libertarian position, giving priority to individual rights) (Roberts and Reich, 2002). 
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governmental departments, professional associations, international and 
multilateral organisations, and several interest groups (Walt, 1994). The 
tobacco, food, and pharmaceutical industries are powerful interest groups that 
seek to influence the health policy process (Brownell and Warner, 2009; Reich, 
1995b). Furthermore, health policy is increasingly shaped by complex cross-
border and inter-organisational relationships and global decisions, in addition to 
actions at the national level (Walt, et al., 2008). 
 Distributive and redistributive health and pharmaceutical policies, such as 
medicine provision and taxation, are highly confrontational. Most 
pharmaceutical policies are regulatory (WHO, 2002a)4 (impose restrictions on 
the actions of individuals or groups in the provision of goods and services) and, 
as such, are also contentious; there is frequently tension between attaining self-
regulatory or regulatory policies.5 
 In low- and middle-income countries, the health-policy environment is more 
uncertain given weaker regulation and monitoring systems, reliance on donor 
funds, and more patronage in political systems, among other issues (Walt, et 
al., 2008). 
 
Incorporating the concepts related to public policies and health policies discussed 
above, Gill Walt (1994) provides a different definition of health policies, underscoring 
that health policy is about process and power:  
 
Health policy embraces courses of action that affect the set of institutions, 
organizations, services, and funding arrangements of the health care system. It goes 
beyond health services, however, and includes actions or intended actions by public, 
private and voluntary organizations that have an impact on health (Walt, 1994: 41). 
 
Consequent to this understanding of health policy, a number of scholars have made 
the case of transiting research from a mere technical-content orientation to an analysis 
of health-policy processes and their determinants (Bernier and Clavier, 2011; Oliver, 
2006; Reich, 1995b, 2002; Walt and Gilson, 1994). These authors have underlined that 
prescriptions for health policy abound; for example, policy recommendations on what 
strategies should be implemented to improve medicine use and contain antimicrobial 
resistance. Conversely, much less information is available as to why these policies are 
                                                             
4
 Policies directed towards AMR and medicine utilization are largely regulatory; for example, 
they establish rules for medicine licensing and promotion, licensure requirements for health 
providers, regulate prescription according to a narrow medicine list, and regulate medicine 
dispensing as OTCs or prescription-only drugs (WHO, 2002). 
5
 For example, the Codes of Marketing Practices and Good Manufacturing Practices (GMP) 
agreed by pharmaceutical companies allow them to skip direct regulation as well as to promote 
their marketing procedures as ethical and their products as of good quality. 
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successfully developed or not. There is scarce advice on how to draw the attention of 
decision makers to these issues, and how to effectively formulate and implement 
recommended policies. Here, policy analysis plays an important role not only in 
understanding past policy failures and successes but also in planning for future policy 
development (Walt, et al., 2008), which is the focus of the present study. 
 
Some arguments have been exposed, though, against policy analysis, underscoring its 
limits in attaining generalisation. It has been argued that policy is unique in time and 
place; that given the complexity of the policy process, it is impossible to fully 
understand it; that information becomes quickly out-dated; and that, because policy 
analysis theory is based on developed countries, it is not applicable to other contexts. 
However, other scholars disagree with these arguments and underline the relevance of 
policy analysis for advancing the health policy agenda and influencing policy outputs 
and outcomes in both developed and developing countries (Grindle and Thomas, 1991: 
141; Walt and Gilson, 1994: 366).  
 
Considering the complexity of the health policy environment, relevant elements have 
been highlighted in conducting policy analysis. Grounded in a political-economy 
perspective, Walt and Gilson (1994) propose the ‘policy triangle’ analysis framework for 
health policies, which incorporates the analytical categories of policy content, actors, 
context, and processes, and considers how these elements interact to shape health 
policy-making. Similarly, the interaction between institutions, interests and ideas in the 
policy process has been emphasised with regard to health policies (Walt, et al., 2008: 
308). The present study is based on this understanding of health policy. While the 
government is considered at the centre of health policy and is the main focus of the 
study, the actions, ideas and interests of non-state actors as well as the role of some 
relevant contextual factors are also taken into account. These elements of policy-
making are further discussed in the next sections. 
 
 
3.2 Policy-making and policy analysis 
 
The process of public policy-making is complex. It often involves very technical, 
scientific legal issues disputes regarding public problems and solutions, as well as 
hundreds of different social actors (from inside and outside the government, with 
deeply held values and interests) interacting over periods of a decade or more. Policy-
making process comprises the way in which problems are conceptualised and brought 
into the government agenda for solution; the manner in which governmental institutions 
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formulate and select policy alternatives as solutions; and how those solutions are 
implemented, evaluated and revised. As such, when attempting to understand policy-
making, it is simply not possible to look for, and see everything. Analysts have thus 
developed diverse models, conceptual frameworks and theories, which involve an 
interrelated set of propositions, to understand and explain general sets of phenomena 
related to policy-making (Sabatier, 2007: 3-4). Frameworks, such as the ‘stages 
heuristic’ described below, identify the critical elements or variables of policy-making 
and their interrelationships. Theories, on the other hand, deepen our understanding of 
the relationship between these elements, and can be applied or tested empirically to 
shed light on the causality of the policy process (Walt, et al., 2008). Kingdon’s Multiple 
Streams theory, described further on this chapter, provides the theoretical propositions 
for the present study. 
 
The classic ‘stages heuristic’ framework divides the policy-making process into a series 
of five broad subsequent stages6 (Anderson, 2011:3-5): 
1. Problem definition and agenda-setting: The identification and specification of 
issues as public problems, and the generation of public policy attention to those 
problems. 
2. Policy formulation: The creation or borrowing of policy alternatives for dealing 
with a problem, from which a choice is to be made. Involves setting the policy 
objectives and the means to achieve them. 
3. Policy adoption or decision-making: Involves making a discrete choice from 
among two or more policy alternatives (including taking no action); and the 
authoritative enactment of the chosen alternative (policy outputs in the form of 
legislation, regulation or programmes, for example). 
4. Policy implementation: The carrying out of adopted policies. 
5. Policy monitoring, evaluation and revision: Activities intended to determine what 
a policy is accomplishing (outcomes). 
 
However, this framework has been subject to several criticisms, mainly because it 
inaccurately assumes clear-cut stages rather than a continuous process where the 
different activities in each stage influence each other; furthermore, success in one of 
the stages does not necessarily imply success in others (Kingdon, 1995: 3; Sabatier 
2007). Furthermore, although this framework identifies important elements of the 
policy-making process within each stage, it does not offer propositions on causality. 
Nonetheless, it is useful to dissect and simplify the analysis of a rather complex 
                                                             
6 Different authors number and name these stages differently. For example, Sabatier (2007) 
portrays policy formulation and legitimation as a single stage.  Zahariadis (2007) make 
reference to the term policy formation, comprising the processes of agenda setting, formulation 
of policy alternatives, and decision making among those alternatives. Anderson (2010) 
differentiates between policy formation (agenda setting and policy formulation), and policy 
adoption (decision-making). 
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process involving many interacting elements over long periods of time (John, 2002; 
Sabatier, 2007), with each stage providing a context in which different approaches and 
frameworks for analysis can be deployed (Parsons, 1995: 80). 
 
The present study, concerned with health policy-making directed to the problem of 
AMR, focuses on the early stages of the policy process, often referred to as policy 
formation. The main focus of this thesis is on agenda-setting, and secondarily on how 
agenda status affected the adoption of related policies. It seeks to comprehend 
perceptions regarding AMR as a public problem and the responsibility on it; placement 
on the governmental agenda, the development of policy alternatives to deal with the 
problem of AMR; and the formulation, content and adoption of a specific policy -or the 
lack of it. These processes are discussed with more detail in section 3.4; but, firstly, it is 
important to discuss the scope of policy analysis and the different approaches involved. 
 
Policy analysis as a form of inquiry can follow a range of different objectives and 
relations with regard to the policy process. However, two broad purposes are 
distinguished (Gordon, et al., 1997):  
 
 Analysis of policy. This analysis is used retrospectively to provide descriptions 
and explanations of policy. It encompasses analysis of policy determination, 
concerned mainly with examining how and why policy is made. It also includes 
analysis of policy content, which refers to aspects such as the operation of 
specific policies, and describes a policy either in relation to other policies or 
based on a theoretical or value framework (Gordon, et al., 1997; Parsons, 1995: 
55). 
 Analysis for policy. It is used prospectively, pursuing ‘prescriptions’ for policy. It 
includes policy advocacy, and information to aid decision-making. 
 
The present study deals with analysis of policy. Its main interest is policy determination, 
which emphasises “the inputs and transformational processes operating upon the 
construction of public policy” (Gordon, et al., 1997: 6). It aims to understand how the 
machinery of the state and political actors interact to produce public actions (John, 
2002: 1), or not producing them. The main focus of the present study is on the 
construction (or formation) of AMR policies in Mexico. The study also involves the 
analysis of policy content, in an effort to determine the extent to which  Mexican health 
and pharmaceutical policies included elements recommended internationally for 
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addressing AMR when the study began; and if  policy changes occurred during the two 
studied periods. 
 
Peter John (2002: 12) maintains that, when analysing public policy-making there are 
two main sets of phenomena that researchers seek to explain: One is policy variation 
including differences in policy construction between sectors such as education and 
health, and differences in policy-making between countries. The other relevant 
phenomenon is policy change (also named policy dynamics), which involves policy 
stability or change overtime. According to (Capano, 2009:14) policy change can be 
understood in many ways, including changes in the policy processes, or in terms of the 
policy content (e.g strategies, instruments), or even in terms of implementation 
outcomes. Likewise, policy can change in different degrees: while some policies are 
new or innovative (radical change), others are only incremental refinements of earlier 
policies and involve a marginal shift of the status quo (incremental change). For the 
present study, policy change is understood as the adoption of national policies 
specifically targeting the problem of AMR, either as a radical or incremental change. 
 
The determinants of policy change (how and why policies change- or not) are complex. 
Gordon et al. (1997: 7-9) underscore that attempts to analyse the determination of 
public policy are unavoidably based upon models and assumptions of the policy 
process. For example, researchers can assume that policy-making is in essence a 
rational and controlled process tending to consensus and centred in decision-making. 
Under this rational model perspective, policy makers are able to identify particular 
problems, assess their relevance, establish clear goals, and meticulously consider 
each alternative to deal with a problem. On the other hand, researchers can assume 
that public policy-making is an “inescapably political activity”, in which the perceptions 
and interests of different actors play a key role through all policy stages (1997: 7). As 
such, conflict rather than consensus predominates. This last perspective has been 
emphasised in studies related to pharmaceutical policy, given that medicines are of 
utmost importance for the functioning of health systems, are a pressing demand of the 
population, and involve powerful interest groups. For example, analysing three cases of 
national pharmaceutical policy in developing countries, Reich (1995b) explains that 
pharmaceutical-policy reform is highly political because it has distributional 
consequences of valued goods in society and, as such, can bear important implications 
for a regime’s political stability. Opposing to rationalistic approaches to understand the 
determinants of policy making, the incrementalist approach argues that policy makers 
are generally pragmatic and conservative in decision-making, tending to choose those 
options that differ only slightly from existing policies; as such policy-making is much a 
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matter of “muddling through” (Lindblom, 1980).On the other hand, analysts can argue, 
following  a ‘path-dependency’ approach, that there are  culturally embedded 
preferences, generally in the form of norms, conventions and other informal 
constraints, which lead to incremental rather than drastic policy changes (Bennett and 
Howlett, 1992). Finally, other authors have pointed out that that politics and policy is 
not only about conflict and power, but also about knowledge, uncertainty and decision-
making (Heclo, 1974, cited in Bennett and Howlett, 1992), 
In summary, alternative views of rationality in the policy process (including the Multiple 
Streams theory, described below) recognize that policy-making and policy change 
occurs under conditions of ambiguity (often involving highly technical issues) and 
encompass the interests of different actors, whose behaviour is constrained by formal 
and informal rules.   
 
No unified paradigm has emerged to organise research on public policy, and there are 
now many approaches that often overlap, complement and supplement each other 
(John, 2002: 8-9; Parsons, 1995: 88; Sabatier, 2007; Walt, et al., 2008). Sabatier 
(2007) advises researchers to be aware of and capable of applying different theoretical 
perspectives when conducting policy analysis; this, in order to clarify differences in 
assumptions across frameworks, to encourage the development of multiple 
hypotheses, and to explain the choice of perspective. In this regard, I provide below a 
brief account of approaches to understanding policy-making, and the ways they feed 
into the present study on the policy determination of AMR policies. 
 
3.3 Approaches to understanding policy determination 
 
The following elements have been traditionally deemed important in public policy-
making: conflicting values and interests, ideas and information flows, institutional 
arrangements, and variation in the socioeconomic environment (Sabatier, 2007: 8). 
Emphasis on each of these elements has given place to particular approaches to 
understanding policy-making. Peter John (2002: 168) proposes that the diverse 
approaches can be linked together by distinguishing between constraints and causes 
of political action; processes involved in each of these approaches interact with the 
others over time:  
 
[I]nstitutions, patterns of interest-group and networked relationships and socio-economic 
structures are limits to human action though sometimes they change autonomously. 
Individual actors are the drivers for change and the foundations for human action. Ideas, 
on the other hand, give human agents purpose and are the way they express their 
interests (John, 2002: 168). 
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The following is a description of some approaches that are relevant for analysing the 
early stages of policy-making; I provide some examples with regard to health and 
pharmaceutical policies, identifying elements that could be involved in AMR policies. 
Following John’s (2002) classification, I begin with those approaches related to causes 
and constraints of action. Then provide a brief account to what John (2002), Sabatier 
(2007) and Parsons (1995) define as “synthetic” or more comprehensive approaches to 
policy-making. 
 
Socioeconomic approaches. These approaches assert that public policy results from 
the structure of economic and social power in nation-states and is driven by the interest 
of the most powerful.  Elitist and Marxist accounts, as well as analysis of the 
dimensions of power exerted by interest groups (Bachrach and Baratz, 1962; Dahl, 
1957; Lukes, 1974) sum up to this approach. With regard to health and pharmaceutical 
policies, medical professionals7 and the pharmaceutical industry have been traditionally 
regarded as powerful interest groups that seek to influence policy. Their dominant and 
exclusive position to do so derives from their specialised knowledge, their legitimate 
access to the policy process, and their relation to the provision of valued goods that 
could determine life and death (Osman, 2002; Reich, 1995b; Walt, et al., 2008: 309). 
One example is policies that aim to increase access to essential medicines by 
regulating market entry as well as controlling prices and promoting the use of generics. 
These policies have been seen by the pharmaceutical industry as instruments used by 
politicians against the economic interests of the industry (Reekie and Weber, 1979); in 
this sense, AMR policies directed to limit or rationalise antibiotic use may involve 
similar interests. With regard to political agenda-setting, the lobbying activities of the 
pharmaceutical industry aiming to put forward their own interests in health policies 
have been documented. For example, Beder at al. (2003) analysed how the 
pharmaceutical industry has deployed sophisticated public-relation techniques and 
effective advocacy coalitions in order to shape the mental-health agenda seeking to 
increase the sale of their products. These resources are unlikely to be deployed by 
other groups such as public-health specialists or academics in order to set the agenda 
for health or pharmaceutical policies.  
 
Rational-Choice theory. This model proposes that individual choice is the main driver 
of political action and inaction. Policy decisions are the result of bargains between 
                                                             
7
 Whereas this is particularly true in the United Stated and Europe, medical professionals in low- 
and middle-income countries (such as India and those in Latin America) appear to have much 
less power in the policy-making process. This has been related to their weaker organisation in 
these settings and to the fact that, in these countries, policy-making is highly centralised and 
state-centred (Walt, et al. 2008: 103; Osman, 2002). 
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actors motivated by material self-interest seeking to maximise their utility. A major 
critique to this theory is that not all behaviour can be reduced to the preferences of the 
individuals, and the relevance of structures in shaping decisions is denied. 
 
Institutional approaches. While the preceding approaches for policy-making 
emphasise power and the behaviour of social actors, the institutional perspective 
underlines that behaviour occurs in the context of institutions, and can only so be 
understood (Immergut, 1998: 6). Institutions such as the parliament, legal systems and 
bureaucracies structure policy decisions and constrain how decision makers behave. 
The school of thought of new institutionalism extends the definition of institutions to 
formal and informal procedures, norms, routines, and codes of conduct reflecting 
cultural antecedents that are capable to favour some groups and demobilise others, 
rendering some policy outputs possible, and others unlikely (Béland, 2005; Immergut, 
1998; North, 1990). Historical institutionalism explains that institutions not only mediate 
political struggles, but also determine subsequent development of institutions and 
policies, taking into account the role of previous choices and political forces (Oliver and 
Mossialos, 2005; see also Thelen and Steinmo, 1992). This school of thought is useful 
to explain how politicians will be reluctant or unable to make a policy change when the 
prevalent policy path is tied with the expectations of the general public, or has 
institutionally-advantaged actors with vested interests in its maintenance (Oliver and 
Mossialos, 2005)8 . 
 
Group and network approaches. These approaches assert that formal and informal 
relationships between the participants of the policy process, both within and outside 
political organisations, shape policy decisions. Originally, groups approaches centred 
on the influence of ‘iron triangles’ ‒executive agencies, congressional committees and 
‘producer groups’ (which include medical and pharmaceutical industry associations). 
However, this approach has been replaced by networks approaches: not only the 
presence of an organization affects policy-making, but also the relationships (networks) 
between different actors involved in policy-making (John, 2002: 78). Networks vary in 
complexity and scale, ranging from clusters of actors collaborating in closely connected 
policy or discourse communities, or clusters loosely structured in which actors engage 
in collective action around a particular issue (issue networks) (Marsh and Rhodes, 
1992). Issue networks may include politicians, interest group lobbyists, experts, and 
                                                             
8
 For example, a study of the politics of health-care reform in France, Switzerland and Sweden 
shows that the structure of the Swiss federal system reinforces the political influence of medical 
professionals, such that they can oppose reform more easily that their colleagues in other 
countries (Immergut, 1992). The institutional approach has been scarcely applied in health-
policy studies referring to low- and middle-income countries (Walt, et al. 2008). 
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policy analysts who share the same values and policy goals around certain issue 
(Heclo, 1978). In network approaches, understanding the power, resources and 
strategies deployed by actors is important to understand policy determination. Policy 
networks have been regarded to constrain the policy agenda because these 
regularized relationships exclude some groups of exercising power and participating in 
the policy process (John, 2002: 84); however, policy networks had been pointed as 
having a central role in defining health policy–such as in defining smoking policies 
(Read, 1992). There is controversy among scholars over the explanatory value of 
network as a concept, or if it is merely descriptive (Walt, et al., 2008). 
 
Ideas-based approaches. Apart from interests and institutions shaping policy-making, 
ideas-based approaches appraise actors’ believes and conceptions about policy 
problems and solutions on influencing political action. As Stone affirms (1989), it is 
ideas what is created, changed and fought over in politics. John (2002: 144) explains 
that “Ideas can be statements of value of worth; they can specify causal relationships; 
they can be solutions to problems; they can be symbols and images which express 
private and public identities; and ideas can be world systems and ideologies”. Social 
actors9 advocate trying to influence decision-making on the basis of what they believe 
is a right course of action, articulate narratives, images and symbols to advance their 
ideas (Stone, 1989); this is particularly relevant for problem definition and agenda-
setting, as described in the next section. Sociological approaches of policy-making 
focus on the role of ideas in the social construction of problems; as such, language and 
discourse, debate and argument, all have a decisive role in policymaking (Majone, 
1989). Elite theorists such as Edelman (1977) focus on the role of language structuring 
reality so as to marginalize certain ideas and certain groups. But scientific research and 
public opinion are also important to define a problem; furthermore, the role of the media 
in labelling, amplifying and sensitising is central to the construction of problems and 
agenda setting (Baumgartner and Jones, 1993; Henshel, 1990; Nelson, 1984). 
Critiques to ideational approaches are that they underplay the importance of interests 
(John, 2002). 
 
Competing moral outlooks and ideologies can also influence the policy process 
especially in the discussion on policy alternatives. For example, policies directed to 
rationalise the use of medicines as a means of avoiding health hazards for the 
                                                             
9
 Kingdon (1995), and Baumgartner and Jones (1993) theories on agenda –setting emphasise 
the role of policy entrepreneurs for an idea to be successful in reaching the policy agenda. 
These entrepreneurs –people who invest time and energy in pushing a proposal or a problem 
for a policy change– can be politicians, bureaucrats, analysts, experts, journalists, academics 
and interest-group lobbyists. 
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population and costs related to unnecessary consumption can be seen as being in 
favour of communitarian or utilitarian value systems and opposed to libertarian ideas 
(Reich, 1995b). They are thus likely to be rejected by doctors who perceive them as a 
threat to their freedom in prescribing. Finally, another ideas-based approach is that of 
‘policy transfer’, which implies examining the positive and negative experiences in one 
country in order to develop it in another. This concept is discussed later on in this 
chapter with regard to the process of adopting global initiatives on AMR at the country 
level. 
 
It is clear that these approaches by themselves only provide a partial account of the 
complex process of policy-making: some of them focus on policy variation, others on 
policy change, and yet others on policy stability. However, according to John (2002), 
both policy change and variation are better explained by the interaction of the elements 
and processes mentioned above; for example, ideas become more relevant when they 
interplay with interests. As such, this author emphasises the relevance of integrating 
approaches, and distinguishes the work of three scholars as synthetic approaches to 
the policy process. These synthetic or integrative approaches that consider the  
interaction of institutions, interests, socioeconomic factors, individual choices and ideas 
are Sabatier’s Policy-Advocacy Coalition, John Kingdon’s Multiple Streams theory 
(Kingdon, 1995), Baumgartner and Jones’ (1993) Punctuated-Equilibrium theory, and 
what this author proposes as Evolutionary Theory (drawing on the preceding 
approaches). The synthetic approaches Multiple Streams and Punctuated-Equilibrium 
theories are of most relevance for my study because they are particularly useful in 
explaining both policy change and stability, and because they focus on problem 
definition and agenda-setting, as described in the next section. Both theories were 
developed involving health-policy case studies, and have been subsequently applied to 
health-policy research and global-health agendas (Walt, et al., 2008).  
In this regard, I present an account of research on agenda-setting, particularly of John 
Kingdon’s Multiple Streams theory, which provides the theoretical propositions  for the 
present study, as well as other relevant notions of agenda-setting which feed into the 
conceptual framework of this study. 
 
3.4 Analysing agenda-setting 
 
In its seminal article “Up and Down with Ecology –the Issue-Attention Cycle”, Anthony 
Down (1972:38) discusses how any one domestic issue “suddenly leaps into 
prominence, remain there for a short time, and then – though still largely unresolved – 
gradually fade from the center of public attention.”   Subsequent to this piece of work, 
66 
 
several authors had aimed to explain how and why issues gain (or fail to gain) a high 
priority among the public and the government concerns, i.e. get or not on the agenda. 
The term agenda has many uses. For example, it has been used to describe both the 
concerns of the public requiring governmental action, and the problems and policies 
under consideration by governmental bodies. The former is usually called public or 
systemic agenda, and is a product of the interaction between public opinion and issue 
salience on the media, with the latter often called policy or formal agenda10 (Cobb and 
Howard-Ross, 1997: 7; Soroka, 2002: 7-8). John Kingdon (1995: 3) refers to this last 
concept as “the list of subjects or problems to which governmental officials, and people 
outside of government closely associated with those officials, are paying some serious 
attention at any given time”. John Kingdon further distinguishes between the 
governmental agenda (subjects getting attention by government) and the decision 
agenda (issues that are up for an active decision). Furthermore, there are diverse 
specialized agendas within the government, such as the health or education agendas.  
 
The present study is concerned with the health policy agenda; this is, with those issues 
that obtain –or are denied– serious consideration by health-related governmental 
bodies (including both governmental and decisional agendas, following Kingdon’s 
definitions). 
 
Various models try to explain the factors whereby some issues reach the policy agenda 
while others do not. Concentrating attention on the role of governments as agenda 
setters and using a rational and prescriptive approach, Hogwood and Gunn (1984) 
described the steps that governments should follow to search for issues, establish if 
they are problems and decide if they should be included in the policy agenda. Other 
authors recognise that non-governmental actors influence the agenda as well. For 
example, Hall and colleagues (1975) allude to support (i.e., the position of different 
interest groups regarding a specific problem and policy) together with legitimacy and 
feasibility as necessary conditions for an issue to reach the agenda. Furthermore, other 
scholars recognise the conflict involved in defining issues as problems,11 and describe 
agenda-setting as “the politics of selecting issues for active consideration”. As such, 
                                                             
10
 The public and the governmental agendas are autonomous, but might be related: they can 
overlap, or one might precede and influence the other. This relation is further studied by 
Baumgartner and Jones (1993) as it is discussed later on. 
11
 Not all private or social conditions generate policy action; firstly, they have to be recognized 
as public problems (i.e. linked to human or governmental causes or amenable to such 
solutions). This is what Deborah Stone (1989) names ‘problem definition’. This aspect is 
addressed by John Kingdon (1995) (regarding the problem recognition ‘stream’) and by 
Baumgartner and Jones (1993) (regarding policy images), as it is described in the following 
sections. For example, analysing a case of environmental contamination, Reich (1983) 
described how the issue transited from being a private trouble, to a public issue, to a political 
controversy issue. 
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agendas are not just about what issues government chooses to act on; “they are also 
about competing interpretations of political problems and the alternative worldviews 
that underlie them” (Cobb and Howard-Ross, 1997: 3-4). 
 
Studies on policy agendas try to shed light as well on the dynamics of agenda-setting. 
Cobb and Howard-Ross (1997: 9) distinguish between inside access-agendas (which 
contain issues that originate within a narrow governmental group and are then placed 
in the formal agenda with or without attention from the public) and outside initiative 
models (which focus on the efforts of nongovernmental sources to place issues on the 
agenda). Cobb and Elder (1972) argue that agenda-setting occurs as a result of the 
expansion of an issue from a specifically concerned attention group to a wider 
interested or attentive public. The dynamics of this expansion depends in the first 
instance on the characteristics of the issue (i.e., degree of specificity, scope of social 
significance, temporal relevance, and degree of complexity) as well as on the 
strategies of issue containment deployed by opposing groups (such as discrediting the 
issue or the groups promoting it). 
 
Although these approaches are useful to understand some elements of agenda-setting, 
they do not provide an all-encompassing perspective on what makes people in and 
around governments to attend some subjects, and not others, at any given time. This 
integrative approach is provided by Baumgartner and Jones’ (1993) Punctuated-
Equilibrium theory and John Kingdon’s Multiple Streams theory (1995), described 
below. 
 
Baumgartner and Jones (1993) postulate that in a policy sector there are periods of 
stability with minimal or incremental policy change disrupted (‘punctuated’) by bursts of 
public interest, media scrutiny and rapid policy change. Policy stability and change are 
explained by the interaction of two forces: policy images (how policy problems and 
solutions are understood and discussed); and policy venues (institutions and groups in 
society that have the authority to make decisions concerning an issue) (1993: 25-38). 
The authors propose that policy images may predominate for a long period of time; but 
this can be challenged by new understandings of the problems and its solutions. On 
the other hand, a set of actors may hold policy monopolies (by means of a definable 
institutional structure and shared policy ideas and political values) for a long period, 
which limits access to the policy process. However, this monopoly is challenged as 
new actors with alternative policy images gain prominence.  
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Baumgartner and Jones emphasize the rapidity by which long periods of stability are 
replaced by periods of instability and public action. Central to this rapid change is issue 
expansion and the positive feedback that occurs in the interaction between policy 
entrepreneurs, the media, and public opinion. As issues expand, media coverage tends 
to shift from low and positive coverage in specialist sections, to high amounts of 
negative coverage in the front pages. Adopting a social constructivist perspective, this 
theory highlights the role of policy entrepreneurs and the media in constructing policy 
images and setting the agenda. The relevance of the media in framing policy issues 
and setting the agenda is further discussed in the next sections. 
 
The Punctuated-Equilibrium theory asserts that the nature of the policy problem and 
solutions has an influence in the interaction between policy images, policy venues and 
public debate. For example, for a new or very complex problem there might not be a 
clear institutional authority to deal with it. Furthermore, for highly complex issues, and 
those involving policies with dispersed costs and benefits (or those involving self-
regulatory policy types) the mobilization of constituencies is unlikely, and they are likely 
to remain out of the public agenda. On the contrary, issues with less technical 
complexity, and those which involve policies with concentrated costs and benefits 
(such as distributive and redistributive types) are more likely to generate public 
controversy and become politicized (Baumgartner and Jones, 1993: 33-41). These 
concepts are discussed later on this chapter with regard to Kingdon’s Multiple Streams 
theory, and are crucial to  the present study with regard to AMR policies: what is the 
perceived complexity of the problem and policy solutions,  and what are the institutional 
locations where authoritative decisions on AMR and on medicines utilization are made. 
 
Criticisms to Punctuated-Equilibrium theory this theory point out that they are based on 
the United States policy process, and question their applicability in non-liberal 
democracies (John, 2002). Regarding its application to health policy issues, elements 
of this theory were incorporated in a study of global health policy agendas, analysing 
the emergence of disease control priorities (Shiffman, et al., 2002).  
  
3.4.1 Kingdon’s Multiple Streams (MS) theory 
 
Kingdon’s Multiple Streams (MS) theory is considered as a synthetic or integrative 
approach of the public policy process (Parsons, 1995; John, 2002; Sabatier; 2007), 
which provides a comprehensive cognitive approach of policy change (Capano, 2009). 
MS examines the political system as a whole, embracing all the elements that are 
deemed important to explain policy determination and policy change: individual agency, 
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policy ideas, strategic interests, political institutions and external processes. 
Furthermore, this approach stresses that policies are made under conditions of 
ambiguity, i.e. uncertain problem definitions and goals (Zahariadis 2007:65). Rather 
than assuming that agendas are the automatic reflection of the power of the 
participants in the policy process, Kingdon argues that agendas are set based as much 
on chance as on intention (John, 2002: 173-174).   
 
In his book Agendas, Alternatives and Public Policies, first published 1984, John 
Kingdon (1995) proposes that agendas are the product of the flow and interaction 
between three processes or ‘streams’ running separately: problems (public matters 
requiring attention), policies (generation of policy alternatives), and politics (political 
processes and context, such as elections or the governmental structure). Social and 
political actors mobilize through these streams in order to promote specific issues or 
policy options. Visible participants –such as the president, high-level appointees and 
the media– have a prominent role on getting attention to problems and setting the 
governmental agenda. On the contrary, the role of hidden participants –including 
researchers, academics and bureaucrats– is generating policy alternatives. Interest 
groups (such as business, industry and professional associations) can affect both 
governmental agendas and the alternatives considered by policy makers, either 
positively (promoting new courses of action), or negatively (seeking to avoid public 
policy change) (Kingdon, 1995: 49). However, the role of policy entrepreneurs 
(politicians, bureaucrats, analysts, experts, journalists, academics, interest group 
lobbyists or any other person willing to invest time and energy advocating for their 
conception of problems and their ‘pet’ policy alternatives) is decisive to mobilize opinion 
and couple these streams at critical points (‘open windows’) in time, seeking to place 
an issue on the agenda and ensuring that it does not fall off it. MS embraces a non-
linear logic of policy making: contrary to the stages heuristic framework, Kingdon 
argues that the generation of policy alternatives, i.e. policy formulation, can precede 
agenda-setting. These are two distinct processes and involve different participants. 
 
According to Kingdon’s MS theory (1995: 15-18), two categories of factors affect 
agenda-setting and the specification of policy alternatives: active participants, and 
processes pertaining to each of the streams: problem recognition, generation of policy 
proposals, and political events. Each of these processes can act as an impetus or as a 
constraint for an issue to gain agenda status. When two streams converge, an issue 
can reach the governmental agenda. However, for an issue to reach the decision 
agenda, the three streams need to converge in a single package:  a pressing problem 
is recognized and demands attention; a policy proposal is developed, made available 
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and coupled to the problem as its solution; and developments in the political sphere 
favour the consideration of that problem and that policy proposal. Coupling is facilitated 
by policy entrepreneurs, whose major qualities are expertise, political connections, 
negotiating skills and persistence. If policy entrepreneurs are successful on bringing 
the three streams together, policy change can occur. However, it is important to note 
that processes on the policy stream by themselves will not open a window of 
opportunity to place any given subject on the decision agenda. This situation is more 
likely to happen when a ‘window of opportunity’ opens by events in either the problems 
or the political streams: a compelling problem appears, or a new administration in 
power facilitates to push some ideas forward.12 Open windows are an opportunity for 
policy entrepreneurs to promote their ideas. Open windows call for different borrowings 
from the policy stream, depending on what opened the window in the first place. If 
policy makers become convinced that a problem is pressing (i.e. a ‘problem window’ 
was opened) they reach into the policy stream for an alternative that could serve as an 
adequate solution; alternatives that are politically acceptable have more chances to 
advance as solutions. On the other hand, if policy makers decide to advance a topic 
that will serve their administration (i.e. a ‘political window’) they reach into the policy 
stream for proposals, and a problem is attached to it (Kingdon, 1995: 173-175).  
 
In sum, according to Kingdon’s MS theory, the governmental agenda is set in the 
problems or politics streams (happenings in these streams open problem or political 
windows). Policy alternatives are generated in the policy stream. A policy window 
opens to bring an issue to the decision agenda, and an opportunity for policy change 
occurs when the three streams converge, aided by skilful policy entrepreneurs. Policy 
windows sometimes open in a cyclical and to a certain extent, predictable manner, for 
example, after changes in the administration. However, windows are often 
unpredictable: separate happenings on the three streams coincide in time and favour 
their coupling (1995:188-195). Regardless of how they open, policy windows are 
scarce and do not stay open long. This calls for quick action, before the issue at hand 
falls in the issue-attention cycle (Downs, 1972). Therefore, it is very important that the 
policy stream produce viable alternatives well in advance a problem or political window 
opens. Otherwise, it is very likely that the subject will fade away from the decision 
agenda.  
 
                                                             
12
 For example, with regard to pharmaceutical policies, an economic crisis can focus attention 
on the elevated cost or shortages of medicines, and provide the impetus for introducing an 
essential drugs policy; according to Gasman (1995) this was the case of the inclusion of 
pharmaceutical policies in the development of the 1984 Mexican General Health Law. Reich 
(1995b) describes how in Bangladesh pharmaceutical policies have been tried to be introduced 
for years, but reform only succeeded when a military dictator came into power. 
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Many of the elements on MS theory coincide with Baumgartner and Jones’ Punctuated 
Equilibrium theory: problems and policies streams relate to policy images; and politics 
streams (particularly interest group mobilization and governmental jurisdictions) relate 
to policy venues (in which policy entrepreneurs can push their proposals). These two 
theories coincide on stressing the important role of policy entrepreneurs, and assert 
that both, agency and structure determine agenda setting. Kingdon recognizes that 
agenda-setting appears to follow a punctuated equilibrium fashion: attention to public 
problems proceeds ‘in jumps', and the agenda changes suddenly after a window 
opens. However, Kingdon (1995:226-227).stresses that continuity is also a 
characteristic of agenda-setting: policy alternatives are developed gradually, combining 
old and new proposals; happenings in the problems as politics stream flow 
independently along the time. Policy change arises from the continuous interplay of the 
three streams. 
 
With regard to the present study, Kingdon’s MS theory provides an indication as to why 
policy recommendations promoted internationally to address AMR might not by 
themselves place AMR as a policy problem on national agendas and prompt policy 
formulation and adoption. This theory suggests that favourable factors in each of these 
streams are needed, as well as an event (either in the problems or politics stream) to 
facilitate a window of opportunity to be open. Furthermore, the three streams have to 
converge in time, a process that is facilitated by a skilful policy entrepreneur.  The 
structural elements of Kingdon’s MS theory are further described in Box 3.1. These 
elements are incorporated for the present study conceptual framework (see Figure 
3.1). 
 
 
Box 3.1 Structural elements John Kingdon’s Multiple Streams theory 
 
a) Problem stream. Conditions become defined as problems when it is believed that 
something has to be done about them. The chances for a problem to rise on the agenda 
increase if statistical indicators, crisis or other ‘focusing events’, or feedback from 
previous policies raise it, and if a solution is attached to it.  
 Underlines the role of ideas and external processes. 
 
b) Policy stream. The generation of policy alternatives occurs in a process analogous to 
biological natural selection. Policy proposals are debated and refined within communities 
of specialists; many ideas ‘float’ around, recombining new with already-familiar elements, 
in a policy ‘primeval soup’. Those policy proposals that are technically feasible, congruent 
with current values, and anticipate future constraints for implementation (such as budget 
constraint and public acceptability), have more chances to be selected for serious 
consideration. Policy entrepreneurs ‘soften-up’ both policy communities and the public, 
getting them used to new ideas. 
 Underlines the role of ideas and institutions. 
72 
 
 
c) Politics stream. The flow of political events is a powerful agenda setter. It includes the 
prevailing national mood (e.g. pro or against governmental intervention); interests groups 
configurations; and changes in the administration (elections, turnover of key personnel, 
governmental jurisdictional boundaries). Policy change is aided by a constituency in 
favour of it, and hindered by the lack of it. Administration shifts affect agendas 
substantially. On the contrary, potential agenda items could be neglected when they are 
perceived to be handled elsewhere in government, or not to be within a specific 
governmental jurisdiction. 
 Underlines interest groups dynamics and institutions. 
 
d) Policy entrepreneurs. Favour the convergence of the three streams. Their role is critical 
on the softening up process of policy alternatives that must precede high agenda status 
and enactment; as well as on seizing opportunities (open windows) to negotiate and push 
for their proposals. 
 Underlines the relationship between individual agents, policy ideas, strategic 
interests, and political institutions*  
 
Policy windows. Happenings on the problems or politics streams can open windows of 
opportunity to place an issue on the governmental agenda. However, the probability of an 
issue rising on the decision agenda (and thus that a policy change occurs) increases sharply 
when the three streams are joined. 
 
 
Sources: KIngdon, 1995; John, 2002; Zahariadis, 2007:71. * See footnote 14 
 
Since its publication, Kingdon’s MS theory has been extensively applied to explain how 
policies are made by national governments in a wide variety of policy arenas. 
Regarding health policy, MS this theory has been applied to study agenda-setting and 
policy change at the national level for a range of issues, including tobacco control 
(Schwartz and Johnson, 2010), pesticides (Pralle, 2006), child health promotion 
(Guldbrandsson and Fossum, 2009) a public health crisis (Schwartz and McConnell, 
2009), and health sector reform (Mannheimer, et al. 2007; Shroff, et al., 2015). 
Furthermore, this theory has been successfully adapted for analysing the international 
or global health policy agendas13 (Ogden, et al., 2003; Reich, 1995a; Hafner and 
Shiffman, 2012). To my best knowledge, Kingdon’s MS theory has not been applied 
before on an empirical study on AMR agenda-setting; in this sense, the present study 
contributes to the literature.   
 
Given the integrative approach (involves all elements relevant to explain policy 
determination) and its focus on national governments, it provides the main theoretical 
framework for the present study. Furthermore, this approach is particularly suited form 
                                                             
13
 With regard to international health, Reich (1995a) critiques the simplistic concept of ‘political 
will’, and underlines the politics of agenda setting, identifying additional elements that feed into 
Kingdon’s politics stream (organizational, symbolic, economic, scientific and politician politics). 
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the present study, because it explains how policies are made under conditions of 
ambiguity, i.e. multiple and conflicting problem definitions and uncertain policy goals  
 (Zahariadis 2007). This is the case of health policies and particularly, AMR policies, 
studied in the present thesis. 
 
Some of the critiques of Kingdon’s MS theory are with regard to the independence of 
the streams. Given the efforts of people to seek solutions to problems, and given the 
fact that some policies are preferred over others because of developments in the 
political stream, the three streams might be more closely related, as Paul Sabatier’s 
advocacy coalition framework suggest. From a historical institutionalist perspective, 
Béland (2005: 7) explains that problems in policy agendas are largely constructed 
through a social learning process. In this sense, the three streams are only partially 
autonomous,14 because earlier policies can affect the definition of problems streams at 
a later time, by establishing some groups (and not others) as authoritative voices. With 
this regard, Kingdon (1995: 228) acknowledges that there are some links between the 
streams as well as the relevance of institutions, but asserts that still the streams are 
largely independent, involving different people and processes. Critiques also point to 
the fact that the overall importance of institutions is downplayed in the MS theory. 
Formal institutions (or veto points) has the ability to block the adoption of administrative 
and legislative policy proposals (Sparkes, et al., 2015). With this regard, Kingdon 
recognises that institutions (such as governmental forms and procedures) are 
important constraints to policy-making, rendering some outputs possible, while others 
unlikely (1995:230); however, this aspect is not sufficiently integrated within MS theory 
(Hewlett, et al. 2013).  
 
Finally the applicability of this theory in political contexts different than that of the 
United States has been questioned. This is an issue that is of much relevance for the 
present study, based in Mexico, a country undergoing an incipient democratic 
transition; this aspect is further addressed below. Because MS was developed on the 
basis of the US political system, it neglects the role of institutional variation from 
country to country to explain why some types of actor have more influence in agenda 
setting in some contexts than others (Béland, 2015:229). Because of this, the 
explanatory power of MS with regard to policy variation is weak (John, 2002:202). 
 
                                                             
14
 In order to succeed, policy ideas need the support of powerful actors that have an interest in 
promoting them; formal political institutions largely determine which actors are in a strong 
position to campaign for a policy alternative. And policy entrepreneurs promote their policy ideas 
by framing issues using cultural symbols acceptable in their society (Béland, 2005: 10). 
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3.4.2 Merits and limitations of using Kingdon’s MS theory to study agenda 
setting and policy change in the present study 
 
The present study aims to explain the process of agenda-setting for the appropriate 
use of antibiotics and containment of antimicrobial resistance (AMR) in Mexico, and 
how that affected the adoption of related policies.  The study applies Kingdon’s MS 
theory of agenda-setting to guide the analysis. On the following paragraphs, the 
merits and limitations of using theory are discussed, in relation to a) Its capacity to 
explain both when issues gain and fail to gain agenda placement; b) Its capacity to 
explain policy change and policy adoption; and c) Its capacity to be used in political 
contexts different from the United States, as it is the case of Mexico.. 
 
With regard to the first point, it has been pointed out that while the explanatory power 
of MS on policy change is strong, MS is less effective in explaining policy stability 
(John, 2002:202). Probably because of this, most empiric research on health policy 
using MS theory explains how a window did open to put an issue on the agenda, and 
not the contrary.  However, Kingdon’s affirms that MS theory can be used to explain 
both why some issues, at a given time, rise on governmental agendas; and why some 
issues, at a given time, are neglected. Processes and actors operating within each 
stream, and coupling opportunities act as an impetus or a as constraint for agenda-
setting (Kingdon 1995: 197). In this sense, in the present longitudinal case study, 
Kingdon’s theory streams are used as independent variables to explain both when the 
issue of AMR was denied a position on the agenda (first period studied) and when the 
issue gained agenda status and a policy change occurred (second period studied). 
 
With regard to the link between agenda setting and policy adoption (policy change) the 
present study begins with the ‘puzzle’ of policy action on AMR at the national level, i.e. 
why and how countries adopt policies directed to address the problem of AMR. It 
argues that policy action (and inaction) on AMR can be understood –at least in part– by 
understanding AMR agenda-setting. In this argument I state ‘at least in part’ because 
even if agenda placement is necessary for a policy being adopted, agenda placement 
does not automatically assure policy enactment, or the type of policy that will be 
enacted. It has been argued that the explanatory power of MS on policy change is 
strong, the opening of a policy window significantly increases the chance of a policy 
proposal to be seriously considered and adopted (Kingdon 1995; John, 2002). 
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However, the link between agenda change and policy change has been focus of much 
debate15, part of which is described below. 
 
In his seminal book, Kingdon argues that MS is not about how governmental 
authoritative figures make their final decision on policy adoption; rather, it focusses in 
two ‘pre-decision’ processes: agenda setting and alternative specification. Kingdon 
explains that open policy window act as ‘magnets’ for people concerned with particular 
problems and advocates of particular proposals; as a result, many problems and 
solutions cluster, overloading the system. In this scenario, the outputs16 (i.e. the 
specific policy or policies that will be adopted as a result of agenda placement), can be 
unpredictable (1995: 176-177). As such, “enacted proposals don’t always respond 
exactly to the perceived problems or to the contents of political events” (1995:217).  
Nevertheless, a relation or coincidence between agenda setting and policy adoption do 
exist, because the process of alternative specification, and the active role of policy 
entrepreneurs, narrows the ample set of possible alternatives to a limited set from 
which choices are made (1995:177, 196). In further editions of his book, Kingdon 
follows up some case studies, and points out that MS is useful in understanding policy 
formation as a whole (1995:209).  
 
Developing on Kingdon’s MS, other authors argue that MS has the capacity to explain 
policy formation as a whole: agenda setting and decision making, i.e. explaining why 
policymakers adopt some policies and not others (Zahariadis, 2007:65; Sabatier, 2007: 
297). Zahariadis incorporates the concept of policy outputs into MS theory (2007:71). In 
order to explain why a certain policy is adopted (and no others) this author explains 
that, using MS theory,  the answer relies on the persistence and ability of policy 
entrepreneurs to couple streams, as well as their resources and their strategies to 
focus attention and bias choice (2007:79). Similarly, Barzelay argues that agenda-
events can influence decision-making through two causal channels: first, problem 
definition influence the assignment of issues to distinct venues for policy formulation. 
Second, the prospect of policy change spurs the efforts of participants in alternative 
specification processes, whether they are entrepreneurs pushing for innovative 
policies, or protectors of the status quo (Barzelay, 2006:253-254). On the other hand, 
                                                             
15
 MS theory and Punctuated Equilibrium theory assume that that policy change is a product of 
changes of the governmental agenda. Nevertheless, some authors affirm that agenda status is 
not sufficient for policy change (negative aspect of decision making) . And even more, it has 
been argued that policy change can occur through cumulative incremental steps, which do not 
rely on agenda mobilization.  Agenda-Setting and Policy Change. European Consortium for 
Political Research. At: https://ecpr.eu/Events/PanelDetails.aspx?PanelID=914&EventID=5.   
16
 Kingdon uses the term ‘outcome’ here. However, other theorists developing on Kingdon’s 
work, have substituted this word for ‘outputs’ (Zahariadis, 2007: 71). 
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other authors are critical of these views that connect the capacity to bring an issue to 
the agenda to particular policy options, underlining that this assumption is forced and 
was not put forward by Kingdon;  therefore, new models are needed to extend MS 
theory to decision-making (Hewlett, et al. 2013). Following in this discussion, Capano 
affirms that even if MS does account for policy change, it does not distinguish among 
the different types of policy change (including a radical or an incremental change). At 
such, MS it provides scholars with ample room for manoeuvre for defining what will be 
considered policy change when formulating their analyses (Capano, 2009:21). In this 
sense, Kingdon’s theory has been used before in empirical studies to explain both 
agenda setting and policy adoption related to health sector reforms (Shroff, et al., 
2015).  In sum, in the present thesis, I primarily aim to explain the process of AMR 
agenda-setting using Kingdon’s MS theory; and secondarily, I aim to explore how 
agenda placement affected the adoption of related policies. However, I am aware that 
MS can only provide a partial explanation of policy outputs.  
 
Finally, as was mentioned above, the applicability of this theory in political contexts 
different than liberal democracy of the United States has been questioned (John, 
2002). Critiques underline that the nature of political instututions in each country 
determine the influence of actors and their opportunity to participation in the policy 
process, and thus the range of policy proposals that can reach the agenda and are 
adopted 17 (Sparkes, et al., 2015; Béland, 2015:229). However, it is important to 
underline that , by applying partial corrections, Kingdon’s  theory has been successfully 
applied to empirical studies in different contexts, including the European Union (John, 
2002; Sabatier, 2007) and even in an African low income country (Ridde, 2009). For 
example, when applying MS theory to analyse agenda setting and policy adoption of a 
national health insurance in India, Shroff, et al. (2015) modifies MS structural elements 
by adding a fourth stream: economic influences. In the case of Mexico, the state-
centered and exclusionary nature of policymaking; the strong role of the executive 
branch in decision-making; the opportunities of participation for business groups; and 
the prevalence of informal arrangements and corruption, are contextual factors that 
cannot be neglected when examining the determination of public policy. In the present 
thesis, findings of the case study are discussed in the light of these contextual 
characteristics. In this sense, the present study contributes to the literature, by applying 
Kingdon’s MS theory in an empirical research focusing on health policy in a middle-
income country undergoing a democratic transition. 
                                                             
17 For example, in the US, non-state actors have an important role in the production of policy 
proposals; while in France, state bureaucrats have more clout (Béland, 2015:229. 
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3.4.3 Policy inaction 
 
The present study is concerned with both policy inaction and policy change regarding 
AMR in Mexico. It seeks to explain which factors prevented AMR from reaching the 
health policy agenda during the first studied period; and what factors facilitated agenda 
setting and a policy being adopted during the second period. There are diverse 
approaches to analyse the lack of political action, i.e. policies are not enacted or 
adopted to deal with a public issue. This lack of political action can originate from: a) 
policy problems not reaching the policy agenda (policy ‘non-actions’); and b) when 
issues do reach the governmental agenda, and decision makers decide not to act upon 
them (the output is a negative policy or policy ‘inaction’) (Anderson, 2011).. In the 
present study, I refer to policy action on AMR as the adoption of public policies to deal 
with AMR; on the contrary, I use policy inaction referring to the lack of adoption of AMR 
policies (including both as a consequence of issues not being considered on agendas; 
as well as a negative policy resulting from decision-making). 
 
Cobb and Howard-Ross (1997: 7) suggests that in order to analyse why problems do 
not get attention in the policy agenda, three aspects should be considered. First, there 
must be some objective evidence that the problem exists. Second, for many issues, it 
is important to know if they were on the public agenda. Third, it has to be considered if 
the issue at hand is already on the formal agendas of countries with similar social 
systems. If the answer is yes, then there is a case of asking why the issue has not yet 
reached the formal agenda, as it was the case of the first period analysed in the 
present study regarding AMR in Mexico. 
 
Based on views that stress the role of structure, economic and social power on policy 
determination, diverse authors have emphasized that certain issues remain ‘latent’ and 
fail to enter the decision-making processes because they are against the interest of 
those in power, or because they contradict the dominant values and as such are 
deliberately suppressed from agendas (Bachrach and Baratz, 1962; Cobb and Howard-
Ross, 1997; Walt, 1994: 60). For these authors, non-decision-making (or agenda 
denial) involve the exercise of power to maintain a dominant set of beliefs, values, and 
institutional processes that privilege the vested interests of some groups in relation to 
others, restricting the scope of decision-making to those relatively ‘innocuous’ issues. 
According to Cobb and Howard-Ross (1997: xi) the major reason that issues are 
excluded from the agenda is the active effort of those whose interest would be affected 
if a particular issue is considered. Groups that oppose a new issue coming into the 
agenda use both material and symbolic resources and strategies such as avoidance, 
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attack and problem redefinition to keep an issue off the agenda18 (Cobb and Howard-
Ross, 1997: 25-41). However, Crenson (1971) underlines that active participation is not 
the only way to exert influence on agenda:19 “The mere reputation for power, 
unsupported by acts of power” can suffice to restrict the scope of decision-making and 
lead to instances of “political enforced neglect” (Crenson, 1971).For example, with 
regard to health policies, policy-makers could anticipate opposition of powerful groups 
(such as medical associations, or labour unions) and thus keep off the agenda policy 
issues that might be against the interests of these groups. 
 
Departing from the perspective of deliberate agenda denial, Kingdon's MS theory offers 
a more comprehensive view to understand why some issues are excluded from the 
policy agenda, and, consequently, policies are not adopted. One set of explanations is 
related to the processes operating within each stream; e.g. regarding problems, the 
conditions are not highlighted by indicators; regarding policies, a feasible alternative is 
not available to address the problem at hand. The second set of explanations derives 
from limits on the streams coupling opportunities: two streams might converge, but not 
the third, or there is not a policy entrepreneur coupling problems and solutions. Third, 
there are various constraints on the system intrinsic to the politics stream: political 
cycles and timing affect issues reaching and falling from the policy agenda.20 Once an 
issue is being act upon (symbolically or seriously) it falls from the agenda. Issues 
already on the policy agenda tends to deter other issues reaching it: a country can only 
consider a limited number of major problems at a time (Roberts, et al., 2004b). 
Consequently, believes about what are the most pressing problems must be taken into 
account on the study of policy agendas (Béland, 2005: 7). All these aspects are 
explored in the present study. Kingdon’s theory is used to explain both the lack of 
agenda placement (and subsequent policy inaction); and agenda setting (and 
subsequent policy action or policy adoption).  
 
                                                             
18
 Opponents –who may be bureaucrats, politicians, or organized groups outside the 
government– may use different strategies to keep an issue off the agenda. . Opponents can 
avoid the problem simply by not recognizing it (the ‘non-issue’ status of a problem, as Reich 
(1983) terms it, invoke reasons that a particular issue is inappropriate for consideration, and 
deny that the problem exists, or state that it is only an isolated incident. Other series of 
strategies involve attacking proponents of a policy: discredit the issue stance of the group and 
the groups itself, what can be done showing symbolic concern in dealing with a problem, or 
stating that the issue is not a legitimate concern and ought be resolved privately. Other 
strategies are to link the policy proponents with negative stereotypes, the use of deception, and 
even violence. Finally, the problem can be redefined in order to deal only with those parts of the 
problem that opponents prefer (Cobb and Howard-Ross, 1997). 
19
 Here, Lukes’ (1974) Dimensions of power are useful to explain how power in non-decision 
making is exerted. 
20
 This is also known as issue-attention cycle, described by Down (1972). 
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3.5 Problem definition and media framing 
Why do some problems gain the attention of governmental officials why others do not? 
According to Kingdon, the answer lies in how these officials learn about problems (e.g. 
indicators, or focus events), and how these conditions are defined as problems, i.e. the 
perceptual or interpretive element of problems (1995:110,197).  
 
For Rochefort and Cobb (1994: vii), ‘problem definition’ is concerned with what 
becomes to be identified as a public issue. Understanding how a problem is defined is 
central to understand its rise or decline on the governmental agendas, and the kind of 
solutions that governments devise. This view, shared by other scholars, blurs the line 
between agenda-setting and problem definition (Dery, 2000). While other authors 
recognize the relevance of problem definition to set the agendas, they draw a clear 
distinction between the two processes. For Weiss (1989: 118) problem definition has to 
do with the organization of a set of facts, beliefs and perceptions about issues (how 
people think and talk about any given issue), while agenda-setting is the process by 
which some problems come to public attention. Similarly, Kingdon stresses that 
problems and solutions run in different streams. However, once a problem is 
recognized as important, and defined in a particular way, whole classes of policy 
alternatives are favoured over others, affecting significantly the outcomes of agenda-
setting (1995:198). For this reason, policy entrepreneurs invest resources in pushing 
for their definition of problems and their policy alternatives to address them. The role of 
policy entrepreneurs is critical, because   the definition of problems tends to become 
‘frozen’ in the position of bureaucratic agencies and resist change (Reich, 1983: 309). 
As such, as Baumgartner and Jones affirm, “definition is at the heart of the political 
battle” (1983: 29). Therefore, for the present study, when exploring processes within 
the MS theory ‘problems stream’, special attention is paid to how AMR is understood 
by diverse social actors, and if AMR is defined as a problem. Relevant concepts related 
to problem definition are described below. 
 
Besides the nature21 of difficulties (e.g. severity, novelty, proximity, effects, problem 
populations), the use of symbolic language (e.g. causal ideas, metaphors, frames) is 
important to explain how difficult conditions come to be seen as problems (Kingdon, 
1995; Rochefort and Cobb, 1994; Stone, 1989). Furthermore, is through language that 
symbols are used to lend legitimacy to one definition, and undermine another, or to 
                                                             
21 
The intrinsic characteristics of medicines probably add complexity to the recognition of 
problems related to them:  while tobacco is now perceived to a great extent as prejudicial, 
medicines (and particularly antibiotics, ‘the miracle cure’) are perceived generally as beneficial.  
Furthermore, the low visibility of the consequences of antibiotic misuse (particularly antibiotic 
resistance) may hinder the identification of victims, and the recognition of it as a problem. 
80 
 
heighten participation of certain actors in the policy-making process, and restrict others. 
For example, the use of highly specialized or technical may narrow problem definition 
to procedural aspects, and group participation to closed elite. On the contrary, issues 
framed using broad social themes, such as justice or liberty, heighten other actor’s 
participation (Elder and Cobb, 1983; Rochefort and Cobb, 1994: 5, 9). 
 
Taking a social constructionist view of policy problems, Stone (1989) proposes that 
causal ideas are central to the transformation of difficulties into political problems. The 
author proposes that problem definition is “a process of image making, where the 
images have to do fundamentally with attributing cause, blame and responsibility” 
(Stone, 1989: 282). In this way, political actors deliberately use narrative story lines and 
symbolic devices focussing on the causality of events in order to define a condition as 
a problem or not, according to their own interests. This author proposes a typology of 
‘causal theories’. This typology distinguishes between conditions of accidental cause, 
and conditions derived from purposeful actions, where governmental intervention to 
stop the harm (e.g. prohibition, regulation, compensation or education) can be claimed.  
Causal politics is concerned with political actors pushing interpretations of a situation 
between the realm of accident and the realms of control (Stone, 1989: 284). A similar 
distinction has also been applied to disease and disease prevention paradigms (Tesh, 
1988) and can be applied to AMR. There are different understandings of AMR; some 
emphasize antibiotic resistance as the inescapable consequence of the inevitable use 
of these medicines (Bayer HealthCare, 2004); others underline the lack of individual 
awareness and education on the use of antibiotics; and others point out to the influence 
of a free-market healthcare environment (Baquero, et al., 2002: 34), economic interests 
of the industry (Price, 1989), and lack of governmental commitment (WHO, 2001a). 
These different understandings move AMR from the ‘accidental’, to the ‘inadvertent’ or 
even to the ‘intentional’ realms of Stone typology, calling for very different solutions.22 
 
Consequently, with regard to the present study, it was deemed important to gain insight 
in how stakeholders learn about AMR (for example which indicators are available), and 
also how they frame AMR.  The competing and prevalent causal stories related to AMR 
among diverse social actors in Mexico were studied, along with public discussions in 
                                                             
22
 For example, some actors from the pharmaceutical industry emphasize the need for 
development and commercialisation of newer antibiotics, and educational interventions to 
improve their use. From their perspective, governmental regulatory actions (such as imposing 
limits to antibiotics licensing and prescribing) have a detrimental effect on the development of 
new antibiotics, which in turn favour resistance (Bayer Healthcare, 2004). Understandings that 
underline individual behaviour on the use of medicines, call for educational interventions 
similarly to the problems of tobacco and unhealthy food. On the contrary, other views 
emphasize the influence of pervasive environments in which individuals live (and consume 
tobacco, unhealthy food or antibiotics), calling for supportive policies. 
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the media), in order to understand AMR problem definition and how this could influence 
agenda-setting. 
 
3.5.1 Role of the media and media framing 
 
Important elements related to problem definition are the role of the media, and media 
framing. As it was mentioned before, there is a multidirectional relation between the 
public agenda (the focus of public attention, commonly assessed by public opinion 
polls), the mass media, and the policy agenda. The role of the media in defining 
problems, amplifying issues or even ‘producing’ new problems has been raised by 
diverse scholars (Parsons, 1995: 107-110); thus, media has been deemed an 
influential agenda setter. According with Baumgartner and Jones’ theory (1993) mass 
media has central role in expanding issues and influencing public and governmental 
agendas. As such, media coverage indicators correspond to official concerns and can 
be used to describe the degree to which an issue is placed on the broad policy agenda. 
However, while Kingdon (1995) recognises that the media do report what is going on in 
government, he asserts that the effect of the media on governmental policy agendas is 
much less than what others authors indicate. Nevertheless, this author affirms that the 
media is still important in agenda-setting by acting as communicator within policy 
communities; it is relevant as well in shaping and magnifying movements that have 
started elsewhere; and, by affecting public opinion, it may influence the attention and  
position of participants in the policy process (1995: 57-60). 
 
One manner in which the media can shape the public agenda is by ‘framing’ or 
emphasizing issues in particular ways. There are various definitions of framing, but the 
most widely used is provided by Robert Entman (1993): 
 
Framing essentially involves selection and salience. To frame is to select some aspects 
of a perceived reality and make them more salient in a communicating text, in such a 
way as to promote a particular problem definition, causal interpretation, moral 
evaluation, and/or treatment recommendation for the item described (Entman, 1993: 52, 
italics in the original). 
 
As such, frames define problems (for example in terms of cost and benefit) and 
attribute causality, and suggest treatments or solutions to problems (Entman, 1993: 
52), all of which are aspects related to policy agenda-setting, as was described before. 
According to Entman, ‘salience’ means making a piece of information more noticeable, 
by placement, by repetition, or by associating it with culturally familiar symbols; while 
selection is related to highlighting some features of a given issue, while omitting others. 
Frames are manifested by the presence or absence of certain keywords, phrases and 
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sources of information (among others) within texts; these indicate the views or 
perspectives by which issues are discussed (Entman, 1993: 52-53). 
 
The way in which issues are framed in the media reflects journalistic conventions; the 
interaction among journalists and elite constituents, social movements, and scientific 
bodies; as well as a frame’s resonance with broader political values (Carragee and 
Roefs, 2004; de Vreese, 2005). De Vreese (2005) distinguishes between “issue 
specific” frames and “generic” frames which are not related to a specific topic or a 
specific cultural or historical context. Examples of generic frames are:  ‘episodic 
framing’ (in which social issues and public affairs are portrayed as limited to events 
only); ‘conflict’ (making reference to winners and losers, as well as ‘powerlessness’, 
‘human impact’ and ‘economic consequences’ (such as in reference to distressed 
groups). Social actors use these frames to draw attention to issues of concern implying 
that certain types of solutions are called for (Schön and Rein, 1994). Elite stakeholders 
have significant resources for shaping journalistic frames to serve their specific 
interests (Carragee and Roefs, 2004); but the media can also give voice to less 
powerful stakeholders to provide a new direction to a policy debate. (Esmail 2010) 
 
As Entman (1993: 55) explains, frames reveal the “imprint of power”, by reflecting the 
identity of actors and interests that compete to dominate news texts. Because framing 
emphasizes one aspect of a problem at the expense of others, it can restrict public 
debate on policies in the range of problems and policy alternatives considered (Schön 
and Rein, 1994), and thus potentially influence agenda setting (Esmail, et al., 2010).  
 
With regard to the present study, the role of the media and media framing were 
explored in relation to the policy process which led to the regulation of antibiotics sales 
during the second studied period. The interest was twofold: First, to gain insight in the 
participation of diverse stakeholders and their position vis-à-vis the policy development 
(as it was portrayed in media coverage); second, to shed light on the potential effects 
of media framing on AMR problem definition and the overall policy process. 
 
3.6 Research up take and policy transfer 
 
According to Kingdon, it is ideas, not only interests, what shapes agendas. Kingdon 
asserts that, after interest groups, the most important non-governmental actors 
influencing agendas are academics and researchers (1995:53) . Ideas from the 
academic literature are used when discussing policy problems and solution. Thus, 
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understanding the role of research uptake is important when analysing agendas, which 
is discussed below. 
According to Kingdon’s MS theory, the development of policy proposals and their 
coupling with a pressing problem or with a key political event is a critical element to 
agenda setting. Many policy proposals are generated and debated in specialized policy 
communities, but not all are considered by decision-makers. Thus, policy 
entrepreneurs push for the consideration of their views of problems and pet proposal in 
many ways, including the recombination of ideas within policy communities and 
decision-makers. This long process of softening-up is critical for policy change 
(Kingdon, 1995:201). Kingdon considers that in the formulation of policy alternatives, 
ideas can come from anywhere (1995:72); however, other authors underline the 
relevance of understanding the origins of policy ideas (Béland, 2015). For example, 
learning approaches hold that countries can learn from their own past experiences 
(Bennett and Howlett, 1992), and that leaning in turn can influence alternative 
specification and agenda setting.   
Previously, when discussing ideas-based approaches to understand policy-
determination, the role of scientific research (especially the uptake of evidence by 
policy makers), and the utilization of experiences on policy development in other 
settings (policy transfer) were mentioned. These concepts are related to the recognition 
and definition of policy problems and generation of policy alternatives, following 
Kingdon’s MS. thus, it is worthwhile describing them further and clarifying the extent to 
which they are considered in the present study. 
 
Understanding the uptake of research results in policy-making presents numerous 
aspects. Weiss (1979) has described different models to explain the range of uses of 
research in guiding decision-making. In the ‘interactive model’, direct interaction 
between researchers and policy makers influences both research and the policy 
process. The ‘strategic’ approach conceives research as a means that policy makers 
have to support predetermined solutions or to postpone decisions. A third approach, of 
‘enlightenment’ or diffusion, suggests that research plays a role in sensitising policy 
makers to the presence of problems and their proposed solutions. 
 
For T.R. Oliver (2006: 198) the primary influence of public health research on policy-
making is through its role in ‘documenting’ a problem: statistical information on disease 
burden, health care cost and quality can bring attention to a problem and facilitate its 
recognition. However, as it has been discussed before, even if indicators or evidence 
can be used for ‘enlightenment’ about a problem, they are not sufficient to bring an 
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issue into the governmental agenda. The definition of the problem with regard to its 
causes and which are the affected populations also influence governmental priorities.23 
 
Despite the range of possible uses of research for policy-making, the gap between 
research and policy has been frequently flagged as a problem. Some factors that have 
been pointed to influence the relationship between research and policy are ideology 
and interests (Rochefort and Cobb, 1994: 160) and scientific uncertainty24 (Reich, 
1983). A number of factors acting as barriers and as facilitators of the use of research 
evidence by policy makers have been identified in systematic reviews (Innvær, et al., 
2002; Oliver, et al., 2014). Personal contact and collaboration between researchers 
and policy-makers, timely relevance and clear policy recommendations were frequently 
reported as facilitating evidence uptake. On the contrary, absence of personal contact, 
lack of timely research output, power and budget struggles, and poor access to good 
quality relevant research were frequently reported barriers. Specifically in Mexico, the 
existence of good relationships between researchers and policy makers, the quality of 
research, the concreteness and cost-effectiveness of research recommendations, and 
the presence of urgent health problems were identified as key factors that facilitate 
research uptake in health policy-making. On the other hand, particular agendas 
brought up by the media or interest groups like the private industry, along with the 
desire of policy makers to maintain their public image, have been described as 
important impediments for the research-health policy connect (Trostle, et al., 1999). 
Interestingly, both the systematic reviews and the study in Mexico identify the 
collaboration and personal relations between researchers and policy makers among 
the most common factors that favour research uptake, an aspect that is explored in the 
present study. 
 
Concerning the present study, I was interested to learn about research and 
researchers on AMR in Mexico and their relation with policy-makers, in order to bring 
further understanding on problem recognition, development of policy alternatives and 
AMR agenda placement in this country. These issues were explored in the interviews 
with researchers and health officials (as part of the problems and policies streams in 
the conceptual framework); however, this relationship was not the main objective of the 
study, and not specific framework was applied to it. 
 
                                                             
23
 An example provided by Oliver (2006: 198) is bioterrorism, which draws attention 
disproportionate to its epidemiological impact. 
24
 Analysing a case of environmental contamination, Reich (1983) concludes that the 
uncertainties of epidemiological studies pose a dilemma for regulation and affect conflicting 
interests in society. This aspect may also be relevant when analysing AMR agenda-setting. 
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When generating political priority for health issues, not only domestic advocacy is 
relevant (including the role of policy entrepreneurs, researchers or the media, as was 
discussed before): transnational influence, both by shaping norms and providing 
resources, also play a key role (Shiffman, 2007). This aspect is particularly relevant as 
increasing globalisation is influencing the patterns of health and disease, calling for 
global solutions to shared health problems. This implies a new health policy 
environment, in which the role of international organisations (such as the WHO) and 
the global civil society is enhanced; new cross-border and inter-organisational 
relationships take increasing relevance (Walt, et al., 2008: 309). Additionally, countries 
can learn from the positive or negative experience of others; this is known as ‘policy 
transfer’,  the process by which political actors borrow policies developed in one setting 
to develop programmes and policies within another (also referred to as lesson-drawing 
or policy convergence) (Dolowitz and Marsh, 1996). 
 
AMR is a perfect example of ‘global health’: besides resistant pathogens, antibiotics, 
and antibiotic use behaviours crossing borders, efforts to improve antibiotic use and 
contain resistance do intend to cross borders as well. Initiatives such as the WHO 
Global Strategy for Containment of Antimicrobial Resistance (WHO, 2001a) seek to 
influence health policy development at the national level.25 In the present study, I was 
interested in understanding the role of international recommendations, and particularly 
the WHO Global Strategy, on the development of AMR in Mexico (in relation to the 
recognition and definition of AMR problems and the development of policy 
alternatives); this aspect was explored in the interviews. Additionally, interviews also 
explored knowledge of the case of AMR policy adopted in Chile. However, in the 
present study policy transfer was not analysed in-depth. 
 
3.7 Study conceptual framework 
 
The present study is an analysis of policy (or policy determination) examining policy 
dynamics (policy stability and change) in a longitudinal case study in Mexico, covering 
two administrative periods. Its overall aim is to explain the process of agenda-setting 
for the appropriate use of antibiotics and containment of antimicrobial resistance (AMR) 
in Mexico, and how that affected the adoption of related policies. 
 
                                                             
25
 Furthermore, regional initiatives also seek to promote AMR policies and national campaigns, 
such as the European Antibiotic Awareness Day, promoted by the European Centre for Disease 
Prevention and Control, (http://ecdc.europa.eu/en/eaad/Pages/Home.aspx). Other global AMR 
networks, conformed mostly by health professionals in both developed and developing 
countries are referred to in Chapter 1.   
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As it has been argued before on this chapter, policy change is complex social 
phenomena. In order to understand it, social inquiry implies abstracting aspects of the 
phenomena under study as a set of explanatory and dependant variables, which are 
specified by a given theory. Posteriorly, units to apply those variables are identified; 
and observations of those variables on the units are made (King, Gary and Keohane 
2001:218). In the present study, the structural elements of Kingdon’s MS theory 
provide the set if variables to be observed in the case of agenda setting for AMR in 
Mexico. I looked at the three streams of Kingdon MS -‘problems’, ‘policies’ ‘politics’- 
and ‘policy entrepreneurs’ as independent variables to explain the success or failure of 
AMR agenda-setting (dependent variable).  Furthermore, the study explores how 
agenda-setting affected the adoption of AMR polices.  
 
The study uses Kingdon’s MS theory of agenda-setting to guide the analysis, to 
answer the two main research sub-questions. MS theory was used to explain 
both when the issue of AMR was denied a position on the agenda (first period 
studied) and when the issue gained agenda status and a policy change occurred 
(second period studied).  
 
The ideas or assumptions implicit in Kingdon’s MS guided data collection and analysis. 
The key issues that were explored within each of Kingdon’s MS structural elements are 
the following: 
 
1) Problems stream 
 How did stakeholders in the governmental and non-governmental sectors 
identify and define the issue or problem of AMR?  
 How did the media frame the issue of AMR and the regulation of antibiotic 
sales? (second studied period) 
 
2) Policy stream  
 How did stakeholders perceive policy alternatives for AMR (feasibility and 
acceptability) 
 Did WHO recommendations and national research on AMR aid stakeholders in 
recognizing AMR as a problem, or in devising policy solutions? 
 Did specific policy proposals were developed by policy communities? 
 
3) Politics stream 
 What were the health policy priorities during each administration?  
 Which governmental institutional bodies had responsibilities in promoting the 
rational use of antibiotics?  
 How were interest groups involved in AMP policies? 
 
4) Policy entrepreneurs 
 Were there policy entrepreneurs promoting AMR policy proposals? How did 
they push for their policy proposals?  
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Policy window opening and policy change 
 Did a policy window opened to place AMR on the decision agenda?  
 Did a policy addressing AMR was adopted? 
 
Based on the structural elements of Kingdon’s MS theory, I propose a conceptual 
framework to analyse the favouring and impeding factors affecting AMR agenda-setting 
in Mexico (Figure 3.1). Starting on the emphasis of the role of ideas in policymaking 
implicit in Kingdon’s MS theory (Béland, 2015), I added some additional concepts. 
Within the ‘problems’ stream, I incorporated the concept of causal ideas, proposed by 
Deborah Stone) and media framing. Within the ‘problems’ and ‘policies’ streams, I 
consider the concepts of research uptake and policy transfer.  
 
The present study mainly followed a deductive approach. Informed by Kingdon’s 
theory, a number assumptions or presuppositions were put forward regarding the 
factors related to AMR agenda setting. These assumptions were confronted with data 
collection; conclusions were drawn about the case itself, and also regarding the 
helpfulness of Kingdon’s theory to explain the case in question. The research design 
and methods used in this thesis are explained on the following chapter. 
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 Adoption of national policies addressing AMR 
 
AGENDA-SETTING FOR AMR   
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Figure 3.1 Study conceptual framework for analysing AMR agenda-setting.   
Based on Kingdon’s Multiple Streams theory (Kingdon, 1995; Zahariadis, 2007) 
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4. METHODS 
 
 
As I explained in the previous chapter, this thesis is situated in a public policy analysis 
field, and is particularly oriented towards the analysis of a health policy process. It is 
concerned with the definition of a problem and the relationship of public policies to that 
problem.  It is also concerned with the content of public health policies and the 
processes involved in their development, including what policy makers and other 
stakeholders do – and do not do, as well as with the context in which these processes 
occur. Thus, Ritchie (2003: 24) explains, the remit of research in public policies “like 
the policy process itself, is multifaceted and extensive”. 
 
This chapter presents the methodological approach and the study design and methods 
used to address the research questions posed; the chapter also describes the role of 
Kingdon’s theory in the overall methodological framework for this study. First of all, the 
research paradigms in policy analysis and the relevance of qualitative methodology are 
discussed. Then, the case study design is described and its utilization for this study is 
justified. The chapter goes on to describe the qualitative data collection (documentary 
sources) and data generation methods (individual interviews) that were used, together 
with an account of the content and thematic analysis carried out. The last sections 
address the researcher’s position in this study, and the study’s ethical aspects. 
 
 
4.1 Methodological approach 
 
Policy analysis as a field of study is composed of a wide array of disciplines, theories 
and models; while public policies and problems are a common focus of social science, 
diverse disciplines can be involved, including political sciences, economics, psychology 
and sociology (Parsons, 1995: 29). Additionally, several qualitative and quantitative 
methods are commonly used when researching this complex phenomenon. Wildavsky 
(2007(1979): 15) argues that there is not a single definition of policy analysis; thus, its 
content “cannot be determined by disciplinary boundaries but by whatever appears 
appropriate to the circumstances of the time and the nature of the problem” In this 
sense, before considering the relevant methods used in the present study, it is useful to 
first discuss the theories or paradigms of knowledge –epistemology– related to the field 
of policy analysis, the purpose of the research (related to the kind research questions 
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involved and to the functions of the research product itself), as well as the nature of the 
phenomenon under study. 
 
4.1.1 Research paradigms in policy analysis 
 
The methodology that informs policy analysis is rooted and has traditionally drawn 
upon positivist assumptions about the nature of knowledge and scientific investigation 
(Hawkesworth, 1991; Parsons, 1995; Yanow, 2000). Assumptions regarding the 
existence of a ‘reality’ driven by laws of cause and effect which researchers can 
observe and measure, the hypothetic-deductive method of scientific analysis and the 
stress on empiricism and value-free inquiry of this epistemological tradition, have 
largely shaped the methods of policy inquiry1 (Hawkesworth, 1991: 296). However, 
other theorists have criticized the underpinnings of positivist-informed policy analysis. 
The post-positivist critique challenges the validity of the ‘fact/value dichotomy’ 
(Hawkesworth, 1991) and the assumptions that science and scientific knowledge are 
detached from society and subjective views. While still assuming that there is a reality 
‘out there’, the post-positivist perspective holds that it can only be known imperfectly: 
there is a multiplicity of causes and effects, and observers can be influenced by what 
they observe. And while still adhering to a deductive –hypothesis testing– rationale, 
more emphasis is placed on context. This paradigm of inquiry seeks objectivity, but as 
an inherently social phenomenon, it stresses the need to use triangulation across 
multiple fallible perspectives and embraces both quantitative and qualitative methods. 
 
Another source of criticism to the positivist view of policy analysis comes from the 
constructivist approach to social problems. Exponents of this view argue that reality is 
socially constructed; related theories stress the need to analyse politics and policies as 
‘modes of discourse which structure reality’ (Parsons, 1995: 70). An additional shift 
away from the positivist presuppositions in policy analysis comes from interpretative 
approaches that emphasise human behaviour: instead of focusing on the ‘reality’ of the 
world, they centre on people’s interpretations of it (Green and Thorogood, 2004: 12). 
Interpretative policy analysis argues for the centrality of subjective meaning and local 
knowledge held by a variety of policy-relevant actors, including decision makers, 
implementers and those likely to be affected by the policy (Yanow, 2000). Rather than 
questioning policy costs and benefits or measuring performance, interpretative policy 
                                                             
1
 The early growth of policy sciences was focused on how decisions come to be made, and 
particularly on how decision-making could be improved. The positivist philosophy is clearly 
reflected in the prospective uses of policy analysis (analysis for policy) based on a quantitative 
comparison of policy costs and benefits in order to evaluate alternative courses of action and 
make recommendations. 
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analysis questions policy meanings. This approach builds from the premise that policy 
implications are not transparent and easily evident, and that the assumptions of policy 
makers and constituencies should be understood. In order to ascertain these 
perspectives, the ‘policy artefacts’ (consisting of symbolic language, objects, and 
actions) have to be identified to determine how a policy, is framed or understood 
(Yanow, 2000). Interpretative policy analysis draws deeply on qualitative methods. 
However, differently from a deductive or an inductive rationale, it does not have a 
single starting point; it begins with a ‘puzzle’, typically arising from the juxtaposition of 
expectations (deriving from a priori knowledge) with field observations and experiences 
(Yanow, 2000: 143). 
 
From this account, it is clear that there are many schools of thought in public policy 
analysis. Parsons2 explains that no one theory or model is enough to explain the 
complex processes of policy activity; therefore, researchers “must accept the pluralistic 
nature of the inquiry, both in terms of the interdisciplinary quality of investigation and 
the need for a hermeneutic tolerance of diversity” (1995: 73). The present study draws 
from post-positivist and interpretative approaches to policy analysis.3 It includes a 
diversity of research techniques and social actors’ perspectives, and pays particular 
attention to the framing of problems and policies –an important dimension of agenda-
setting research, as was described in the preceding chapter. 
 
Despite the fact that the present study is informed by Kingdon’s ideas, following what is 
customary in qualitative research, no formal hypotheses were formulated to be tested 
through data collection. As Lewis (2003: 49) explains, a fixed theoretical position in 
qualitative research is unhelpful; researchers need to remain open to emergent 
concepts and themes. Following a deductive approach, the present study used 
Kingdon’s structural elements as intervening variables to analyse the determinants of 
AMR agenda setting and policy change in Mexico. But at the same time, it was open to 
unexpected clues that could indicate the presence of variables not considered initially; 
furthermore, this study reflects on the application of Kingdon’s theory on this particular 
case. 
 
                                                             
2
 For some authors, given that positivist, post-positivist and interpretative research paradigms 
are ‘incommensurable’, researchers should decide upon and make explicit their epistemological 
orientation. However, Parsons alludes to the complexity of inquiry in public policies to draw both 
on post-positivist and constructionist conceptions of policy analysis (1995: 73). 
3
 Given that post-positivism has been regarded as emphasising a deductive approach and 
interpretative systems as emphasising an inductive approach, drawing on both approaches may 
seem contradictory. However, both deduction and induction can be involved at different stages 
of the qualitative research (Snape and Spencer, 2003). 
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4.1.2 Methodology 
 
With regard to the chosen methodological approach, a distinction is usually made 
between two kinds of research questions that a study seeks to answer with regard to its 
purpose. While questions about ´how many´ or ‘how much´ are related to quantitative 
research, qualitative studies seek to answer questions about the ‘what’, ‘how’ or ‘why’ 
of a determined phenomenon (Green and Thorogood, 2004: 5). Accordingly, the main 
methodological approach for this investigation is qualitative research; more than 
quantify a phenomenon, this study aims to explore and explain it; it aspires to answer 
queries related to what are the policies, who are the actors, how does a policy process 
occur, and why do issues reach or  not reach the policy agenda. 
 
A qualitative approach is chosen when the major purpose of the research is related to 
understanding context or processes (Ritchie, 2003: 32); both are focal points of the 
present study. As such, a qualitative approach allows us to focus on naturally occurring 
events in natural settings and to provide ‘thick descriptions’ nested in a real context, 
with a strong potential for revealing complexity (Miles and Huberman, 1994: 10).  
Moreover, in the present study, understanding the perceptions and actions of different 
social actors regarding AMR is of utmost relevance; consequently, a qualitative 
approach for this study is extremely useful because it emphasizes people’s ‘lived 
experiences’ and the meaning they attach to their social world (Bowling, 2002: 352). In 
this sense, I have chosen a qualitative approach due to the flexibility it offers to explore 
and connect the broad macro social context in which policy-making takes place, with 
the insights that different stakeholders have regarding this process (Bronfman, et al., 
2003: 13-16). 
 
Another determinant in the use of qualitative research is related to the nature of the 
phenomenon being studied (Ritchie, 2003: 33), especially when it:  
 
a) Is ‘ill-defined’ or not well understood: as is the case of AMR policies as newly 
occurring social phenomena, together with the perceptions and roles of diverse 
social actors 
b) Is complex: involving technical matters, or exploring cognitive processes, 
such as policy decisions on AMR in the present study; and 
c) When the data is collected from individuals that have highly specialised roles 
in society, as is the case of governmental health officials and researchers in the 
present study. 
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Finally, the flexibility of qualitative research – which allows for the identification of 
informants, data collection and analysis to be developed as iterative processes and 
each feeding into the others –is necessary in policy analysis, where the issues are 
complex and involve a wide range of actors (Varvasovszky and Brugha, 2000: 341). 
 
The uses and roles of the diverse research methods are related to the research 
questions that arise in any specific social study. Although a distinction is usually made 
between theoretical research (aiming to generate new theories or testing existing ones) 
and applied research (aiming to contribute directly to the understanding or resolution of 
a contemporary issue), in social sciences research this distinction might not be useful 
or even valid (Ritchie, 2003: 24-25). Even if a social study is directed towards gaining 
insight into an existing problem, the collection and interpretation of evidence is based 
on certain theoretical assumptions, and the study can contribute to theory by providing 
greater understanding of the social world (Ritchie, 2003: 25). As such, social inquiry 
research is not absolutely theoretical or applied. 
 
When considering the purpose of this study, it can be argued that it is closer to applied 
research, in the sense that it aims to contribute to the understanding of a contemporary 
issue -development of AMR policies at the national level. However, at the same time, 
this study borrows from an existing theoretical framework (Kingdon’s MS theory of 
agenda-setting) to guide data collection and interpretation within a specific country 
case. Furthermore, this study goes on reflecting on the applicability of Kingdon’s theory 
under the specific peculiarities of the Mexican political context, and its usefulness in 
explaining agenda-setting for AMR at the national level. 
 
Finally, in order to understand the particular role of qualitative methods it is also 
convenient to consider the broader functions of social investigations (Ritchie, 2003). 
These can be classified as contextual (aiming to describe or explore what exists in the 
social worlds); explanatory (concerned with how and why phenomena occur); 
evaluative (aiming to elucidate how programmes or initiatives operate); and generative 
(concerned with generating new ideas, such as theories, strategies or actions). An 
initial part of this thesis plays a contextual function identifying which policies related to 
AMR exist or not, and identifying relevant actors on AMR policy. However, the main 
subject of this thesis –the determinants for agenda-setting for AMR– is closer to an 
explanatory function, as it aims to examine the reasons for which AMR reach the 
agenda and AMR policies are enacted.  Although there is debate as to whether social 
inquiry has the potential to truly detect causal relations or if it is merely speculative, 
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others argue that even so, qualitative research does have a role in identifying relevant 
influential factors and generating explanatory hypotheses (Ritchie, 2003: 28). These 
hypotheses can be tested on subsequent studies on AMR policymaking. Moreover, 
based on the identified influential factors in AMR agenda-setting, the present study 
draws lessons for Mexico, as well as for other countries, seeking to develop AMR 
policies.   
 
In conclusion, the use of a qualitative approach for this study is derived from the 
orientation of the research questions posed, which  aim to explore in depth and explain 
a phenomenon whose nature is highly complex, occurring in a real context, and in 
which an understanding of the perspectives and lived experiences of diverse social 
actors is of much relevance. As I mentioned before, policy analysis can make use of 
diverse theories, frameworks, research designs and data collection/ generation 
methods (Parsons, 1995; Walt, et al., 2008). In the following section I describe the 
research design of the present study, explaining the type of study conducted (a case 
study), and the methods (document analysis and individual interviews) for producing 
and analysing data. 
 
 
4.2 Research design: Case study 
 
The case study represents a common design in public policy analysis and in health 
policy analysis (Collier, 1993; Walt, et al., 2008; Yin, 2003) and has been used in 
agenda- setting studies (Kingdon, 1995). There is a fair amount of consensus in the 
literature pointing to the fact that case studies enable an intensive study of a complex 
social phenomenon in its natural context, aiming to answer broad questions about 
social processes and using multiple data collection methods. Nevertheless, there are 
multiple and conflicting definitions of what a case study is. While for some authors it is 
narrowly defined in relation to sample selection (involving a small number of naturally 
occurring phenomena), for other authors case studies represent a unique research 
design or research strategy (Green and Thorogood, 2004; Yin, 2003). The second 
understanding is used for the present study. A case study was chosen as an adequate 
strategy for the present investigation, based mainly on the scope or attributes that 
Robert Yin (2003) and Peter Swanborn (2010) describe for case studies.4 
                                                             
4
 Case studies can be pursued from positivist, post-positivist, constructivist or interpretative 
epistemological perspectives. The methodology proposed by these two authors (particularly Yin, 
who explicitly considers a preliminary theory prior to data collection, as well as the use of 
qualitative and quantitative research methods) has been identified by other authors as being 
predominantly deductive or testing oriented, and as such is based on post-positivist paradigms. 
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For Yin (2003: 13), a case study “is an empirical inquiry that investigates a 
contemporary phenomenon within its real life context, especially when the boundaries 
between the phenomenon and context are not clearly evident”. This deliberate 
emphasis on context5 (which differentiates this research strategy from others, such as 
a survey) is very relevant in policy analysis. As was mentioned before, public policies 
cannot be understood without understanding the social, economic, and political 
contexts and their interaction with policy contents, actors and processes (Walt and 
Gilson, 1994). According to Yin, the interaction between the phenomenon and the 
context can be used to refine a hypothesis for further scholarly inquiry (as in 
exploratory case studies), or to understand the role of context affecting causal 
relationships between the phenomena under study (as in explanatory case studies). In 
the present study, the contemporary phenomenon or ‘case’ is the agenda-setting 
process for AMR policies in Mexico, and the context is provided by health policy- 
making in Mexico.. 
 
According to Robert Yin (2003: 14), because in case studies phenomenon and context 
are difficult to distinguish, there are many variables of interest; consequently, case 
studies rely on multiple sources of evidence that need to converge in a triangulating 
fashion and benefit from theoretical propositions, either to develop or to test theory. 
Theory is used at the onset of the study to guide (‘operationalize’) research design and 
data collection; but it is also the ‘vehicle’ for generalizing the case study results6 (2003: 
33) through the process of analytic generalization. As was mentioned earlier in this 
chapter, the analysis of public policies requires multiple sources of evidence and is 
composed by a wide array of theories in order to grasp the different aspects in the 
complexity of policy-making. As such, a case study design was considered appropriate 
for the present study because it pays special attention to contextual conditions as well 
as to the experience of the actors, and considers the integration of multiple research 
sources and methods. Furthermore, this research strategy stresses the centrality of 
                                                                                                                                                                                  
They differ from case studies oriented towards providing a rich description of social phenomena, 
intending to capture its complexity and thus generating knowledge of the particular within the 
interpretative or social constructivist viewpoints; one of these qualitative case-study approaches 
is the one proposed by Stake (1995). According to this author, the researcher interacts with the 
case; the case is developed in a relationship between researchers and informants. 
Contrastingly, Yin’s post-positivist approach involves developing a defined protocol and pays 
special attention to validity and potential bias aspects. 
5
 Similarly Miles and Huberman (1994) define a ‘case’ as a phenomenon of some sort occurring 
in a bounded context. This context can be temporally or spatially defined, or refer to an episode 
or a process. 
6
 Yin (2003: 29) explains that rather than a formal or ‘grand’ theory, what is needed are 
theoretical propositions that are enough to provide a “blueprint”, a hypothetical story about why 
acts, events, thoughts, etc. occur.  
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theory (here, Kingdon’s MS theory) to shape research questions, the methodological 
framework, and for discussing results. 
 
Similar to Robert Yin, Peter Swanborn identifies case studies with intensive approach 
(contrary to an extensive approach such as a survey), aiming to answer the whats, 
whys, and hows of the social world. Swanborn (2010: 13) defines case study as the 
study of social phenomena or process that takes place within the boundaries of a social 
system (i.e. the case, such as individuals, groups, organizations, communities and 
countries), that is conducted in the case’s natural context and based on several data 
sources, particularly document analysis, interviews, and observations. Differently from 
Yin, for Swanborn, this type of empirical study begins with an initial broad question 
which can later evolve into more specific research questions guided by empirical 
findings. Although case studies use available theories from the beginning, for this 
author the research process “abstains from pre-fixed procedures of data collection and 
data analysis”; flexibility is needed for findings to be able to inform subsequent 
research steps (2010: 22). Finally, while Yin only considers the study of contemporary 
phenomena, Swanborn also contemplates undertaking retrospective case studies.  
 
Swanborn emphasises two aspects of case studies relevant to the present study: a) the 
relevance of processes; and b) its focus on a general phenomenon that manifested in 
one or few cases. With regard to the first concept, he underscores the relevance of 
case study strategy for ‘process-tracing’: the description and explanation of social 
processes that unfold between people, focusing on their values, perceptions, resources 
and decisions; or processes that unfold within and between social institutions. The 
descriptions, interpretations and explanations that diverse categories of participants in 
the social system attach to the social phenomenon under study, are a central focus of 
case studies according to this author. As such, the case study research strategy is 
relevant to the present study which aims to understand a policy process –i.e. agenda-
setting for AMR– taking into account the perceptions and explanations of different 
social actors and the role of institutions. With regard to the second concept that is 
relevant to the present study, Swanborn also emphasises that in case studies one 
should keep in mind that the researcher is interested in the general phenomenon more 
than in the case or ‘instance’, in which the phenomenon manifests itself (2010: 8). 
Accordingly, other expressions that the author uses to define case studies are “the 
study of a phenomenon or a process as it develops within one case” (2010: 9) or “the 
study of a social phenomenon in one, or only a few, of its manifestations” (2010: 22).  
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Depending on the phenomenon of interest, a case may be located at the micro-level 
(persons), at the meso-level (organizations, institutions), or at the macro-level 
(communities, nation-states). Swanborn explains that, at the macro-level, the 
predominant tradition is that of case studies in political science and economy (2010: 6), 
and is the level of analysis of the present study. In sum, in the present investigation, 
the wider phenomenon under study is the process of agenda-setting for national AMR 
policies; this phenomenon is studied as it develops or manifest within one instance, the 
case of Mexico,7 
 
As occurs with the multiple definitions of case study, there are diverse classifications 
which group case studies in accordance with their scope, purpose and design; some of 
these typologies are important to situate the present study, as I explain below. 
According to Yin (2003), a primary distinction occurs between single and multiple-case 
designs. Both types of case studies can be generalised to theory; however multiple-
case design has been regarded as being more robust. Yin advises that, given the 
analytic benefits, when choice and resources are available, multiple-case designs 
should be preferred. Nevertheless, there are several rationales for adopting a single-
case study design, like the one used in the present study. These include a critical case 
to test a theory, an extreme or unique case of a phenomenon, and when a longitudinal 
case is planned. This last rationale was relevant for the research design of the present 
study, which covers a 12-year period divided into two governmental administrations. 
Yin (2003: 42) explains that, by studying the same single case at two or more different 
points in time, the theory of interest allows us to see how certain conditions related to 
the social phenomenon under study change over time. This is further explained in 
section 4.3.  According to Sabatier (2007), the long term and longitudinal perspective is 
required to understand policy dynamics; this is, how agenda-setting and policy 
adoption changed over time change (Sabatier, 2007).  
 
In summary, the rationale for undertaking a case study has to do with the opportunity 
that this research strategy offers to study a complex phenomenon within its own 
context, from a contemporaneous and longitudinal perspective, using multiple methods 
and data sources, and incorporating theoretical propositions but yet with enough 
flexibility for data collection.  All these characteristics are relevant for analysing public 
policy processes, the focus of the present study.  
                                                             
7
 Gary Thomas (2011) also emphasizes the distinction between two parts of case studies: the 
subject of the study, which is the case itself; and the object, which is the analytical frame or 
theory through which the subject is viewed and which the subject illuminates and explicates. For 
this author, case studies can be classified by their purposes and the adopted approaches, 
distinguishing between theory-centred and illustrative studies; accordingly, the present study 
could be classified as theory-oriented 
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4.2.1 Case selection 
 
Case studies have been a common research design for health policy analyses of low 
and middle income countries; however, there is room for improvement in the way many 
of these studies have been conducted or reported (Gilson and Raphaely, 2008).  Walt 
et al. (2008) underline that the value or significance of case studies for health policy 
analysis increases with a careful case selection and when the purpose of the case 
study in terms of its contribution to knowledge is clarified. The following two questions 
(Walt, et al., 2008) are helpful to clarify the scope of a case study and its contribution to 
knowledge. First: What is it a case of? As has been explained above, the present study 
of AMR agenda-setting in Mexico is a case of AMR agenda setting at the national level. 
Second: Why is this case a useful one to study? The choice of Mexico to develop the 
case study was based on my previous knowledge of this country’s health policies and 
systems. Furthermore, because Mexico transited from a long period of policy stability 
and inaction on AMR, to a period of AMR agenda placement and policy action, this 
longitudinal study comprising two administrations allowed for better comprehension of 
AMR policy dynamics within one country, identifying, enabling and counteracting 
factors related to AMR agenda-setting and policy change over time.8 
 
4.2.2 Theoretical generalisation 
 
While case studies primarily allow us to reach conclusions about the unit of analysis, 
they can also illustrate a broader class of phenomena (Yin, 2003). In this sense, the 
present case study sheds light on a wider phenomenon –the process of agenda-setting 
for AMR– by analysing a single case –that of Mexico. Conclusions from the present 
study are discussed for this particular case, but also beyond the case itself.  
 
However, a common critique to case-study research is that it is not suitable for 
generalisation. With this regard, Yin (2003: 10) explains that given that cases are not 
‘samples’, “case studies, like experiments, are generalizable to theoretical propositions 
and not to populations or universes”. That is, during theoretical or analytical 
generalisation, the researcher attempts to link findings from a particular case to a 
theory of the phenomenon being studied. This theory, in turn, may have wider 
applicability than the particular studied case. There are two steps involved in the 
process of analytic generalisation, according to Yin (2010: 21). The first one involves a 
                                                             
8
 The longitudinal design of the present study comprising two periods is particularly relevant for 
explanatory case studies, as they allow to draw hypothesis  on the causal factors related to 
agenda placement (see section 4.3).  
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‘conceptual claim’ by which researchers state how their case study findings bear upon 
a pertinent theory or theoretical construct. These theories (which could be a series of 
hypotheses or even one hypothesis or proposition) are informed by the existing 
literature, i.e. are posed at a conceptual level, rather than that of the particular case. 
The second step involves applying the same theory, drawn hypothesis, or propositions 
to implicate other situations where similar events might occur. In this sense, the 
present case study allows to draw hypothesis or propositions on the factors influencing 
the process of AMR agenda-setting at the national level in Mexico, which can be used 
in future studies on AMR agenda setting in other countries.  
 
With regard to the present study, it draws from public policy theories in agenda-setting, 
(Kingdon’s MS), Findings from this case study on AMR policies in Mexico are linked to 
theory on agenda-setting (focusing on policy problems, alternatives, political context 
and entrepreneurs) to explain difficulties and opportunities for AMR agenda-setting. 
Findings from this case are discussed in the light of other cases from the literature, and 
can be applied to illuminate the wider social phenomenon of AMR agenda-setting and 
policy action at the national level.  
 
The generalizability of findings is facilitated by multiple-case study designs (Yin, 2003) 
and by the strategic selection of cases (Flyvbjerg, 2006). In fact, several authors 
underline the relevance of conducting comparative policy analysis studies (including 
similar, but also contrasting cases) in order to deepen the description and to facilitate 
hypothesis testing and theory building (Collier, 1993). In health policy analysis, cross-
country comparative studies aid to unscramble common from context-specific factors 
that affect the health policy-making process (Walt, et al., 2008). In this sense, the one-
country, single case study design presented here might pose a limitation. Nevertheless, 
Yin stresses that, for single case studies, generalizability is increased when they are 
supported by findings from other case studies, whether they are reported in the 
literature or are conducted after the first study (Yin, 2010: 22). Accordingly, findings on 
process of AMR agenda-setting that derived from the present longitudinal case study in 
Mexico are discussed together with findings from other cases reported in the literature. 
Furthermore, the single case-study presented here still makes a contribution to 
knowledge on AMR policies by offering a first case-study on the topic that can be used 
for future studies in other country contexts. Finally, Flyvbjerg describes that a common 
misunderstanding about case-study research is that general, theoretical (context-
independent) knowledge is more valuable than concrete, practical (context-dependent) 
knowledge. With this regard, he argues that concrete, context-dependent knowledge is 
valuable in itself and above the “vain search for predictive theories and universals” 
100 
 
(2006: 224). In this sense, the present study makes a contribution to knowledge by 
providing an in-depth account of the context-specific problems, policies and politics 
related to AMR in Mexico. 
 
4.3 The comparative approach in social sciences and policy 
research 
 
Comparison is considered as a fundamental tool in political and other social sciences: it 
strengthens the power of description, contributing to hypothesis testing, discovery of 
new hypotheses and to theory building (Collier, 1993: 105). Comparison can also 
contribute to inferences about causality (King, Keohane and Verba 2001). Within the 
disciplines of political science and policy analysis, the decision of analysing only a few 
cases derives from the complexity of the phenomenon under study (which requires a 
resource-intense research), as well as the uniqueness of instances of the phenomenon 
under consideration (Collier, 1993: 105). In social sciences, the label ‘comparative 
method’ refers to “the methodological issues that arise in the systematic analysis of a 
small number of cases, or a ´small N’” (Collier, 1993: 105).   
According to the classic author Arend Lijphart (1971), analysing only a few cases 
distances these studies from statistical (or large N), experimental, and case-study 
methods9, and implies the problem of having more rival explanations to assess than 
cases to observe; these characteristics determine the specificity of the comparative 
method. Aiming to solve these problems, Lijphart proposes to increase the number of 
cases (or units of observation). The number of cases can be increased by selecting 
new cases across space or across time, or both, as it is describe below (Lijphart 1971; 
King, Keohane and Verba 2001).  
In posterior work, Lijphart (1975) emphasised in the importance of selecting a small 
number of comparable cases. In this sense, the comparative method is now 
understood now as “a strategy for conducting research of naturally occurring 
phenomena in a way that controls for potential confounding variables through careful 
case selection […]” (Levy, 2008:10). According to Lijphart, “comparable cases are 
similar in a large number of important characteristics but dissimilar with regard to the 
variables between which a relationship is hypothesized” (1975:159). Comparable case 
strategies involve inter-case comparisons, and intra-case comparisons, (including 
longitudinal comparisons) (Levy, 2008). In longitudinal analysis, the different time 
                                                             
9
 Lijphart considers case-studies only as N=1 studies, a concept that diverges from Robert Yin 
(discussed on the preceding section), who considers both single- and multiple-case study 
designs.  
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periods under analysis (temporal units) are treated in the same way as spatial units 
(Bartolini 1993: 146). A longitudinal analysis of a single country has the advantage that 
a broad range of country-specific variables is held constant, which allows to better 
focus explanatory and explained variables (Lijphart, 1975). For the present study, this 
was the comparative approach used: two temporal units (corresponding to two 
presidential administrations) were studied and compared within the single-case 
longitudinal case study (AMR agenda setting in Mexico). This approach is further 
explained later on this section. 
4.3.1 The comparative approach in public policy and health policy analysis 
The comparative approach in political sciences research aims at explanations of 
political  phenomena by comparing them across systems, through time, or cross-
nationally (Pennings, Keman and Kleinnijenhuis 2006:20). However, in contrast to the 
ample interest in the comparative approach in reference to cross-spatial variance 
research, less attention has been dedicated to its application to cross-time variance 
(Bartolini 1993).  
A large body of research in public policy analysis has focused on differences and 
similarities in policy issues as well as the role of the comparative approach both within 
and between social units10. Within the field of health policy, comparative research has 
tended to focus on policy comparison and policy learning at the national or subnational 
level. This includes cross-national analysis on health policy and policy making 
(Immergut 1992; Marmor et al, 2005; Marmor and Wendt, 2012; Oliver et al, 2005). 
These comparative studies analyse political processes that shape policy-making and 
policy outputs; i.e., seek to explore and explain policy variation (John 2002). Within 
these studies, understanding the context-specific factors that affect policymaking in 
each setting is central.  
Another set of literature on policy analysis aims to explain policy dynamics, this is, 
policy stability and change along the time. Here understanding differences on the 
influence of social, economic and political processes along the time is central (John 
2002: 14). Within the field of health policy, examples of policy dynamics along the time 
are provided by Sabatier and Jenkins Smith (1993), analysing changes in the U.S. 
pollution control policies from one decade to the following one; and Uhlmann and 
Braun (2009) analysing policy stability and change in Swiss health care reforms. 
                                                             
10 
Journal of Comparative Policy Analysis: Research and Practice. At: 
http://www.tandfonline.com/action/journalInformation?show=aimsScope&journalCode=fcpa20#.
VoXBsuk5CM8. 
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The present study has its focus in policy dynamics; it uses a comparative approach, as 
it is explained below, analysing policy stability and change in two time-periods in 
Mexico. These two time periods relate to two governmental administrations; while 
many structural variables kept the same (e.g. economy, cultural, and bureaucracy 
related factors), other variables were different. Therefore, comparing these periods is 
useful to draw hypothesis on the factors that could explain the failure of AMR agenda-
setting in one period, and why progress was made in the following period. 
4.3.2 The comparative approach used in the present thesis.  
The present study is a case study of AMR agenda-setting in Mexico. According to Yin 
(2003), one of the reasons for selecting a single-case study (rather that a multiple-case 
design) is that is optimal for a longitudinal study, i.e., one that involves studying and 
comparing the same case at two or more different points in time. In a longitudinal case-
study design, the theory of interest (here, Kingdon’s theory) would shed light on how 
and why certain conditions and their underlying processes (here, AMR agenda-setting) 
change over time. Selected time intervals would reflect periods in which changes are 
expected to reveal themselves (here, two presidential administrations in Mexico). 
However, the single-observation design of single-case studies has been regarded as a 
limitation for generalization and to assess causal theory (Lijphart 1971, Yin 2003). 
Aiming to overcome this limitation, King, Keohane and Verba (2001) explain that it is 
possible –and desirable– to increase the number of observations from a single-case 
study in order to avoid the “Fundamental Problem of Causal Inference” in N=1 research 
problems: “[…] what may appear to be a single-case study […] may contain many 
potential observations, at different levels of analysis” (2001:208).  
King, Keohane and Verba (2001) explain that a qualitative single-observation design 
can be reformulated into one with more observations to be compared, in order to better 
sustain causal inference. One way of achieving this is by observing more units; this 
implies aiming to apply the same (or most of the) explanatory and dependent variables 
to new instances in which to observe the implications of a theory.  The main two ways 
to obtain more observable implications are 1) via variations across space (for example, 
seeking two or more similar units- i.e countries, cities, etc.); and 2) via variations 
across time (for example, one country, two different time periods) (2001:218). 
With regard with this second approach, the authors point out that it is possible to 
compare a social process in the same country in two different time periods, as done in 
this thesis. Period one of this thesis (presidential administration when AMR was not 
included in the agenda, and no AMR policy occurred) and period two (following 
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presidential administration, when AMR gained agenda status and a policy occurred) 
were compared to assess what changes occurred on the explanatory variables 
(problem recognition and definition, development of policy alternatives, political 
context, and activity of policy entrepreneurs).  
This approach (reformulating a single case study into one with more observations, via 
analysing variations of a social process across time) corresponds to what Bartolini 
(1993: 147-153) describes as diachronic or longitudinal comparative study, involving 
two different time periods determined by the data itself.  This approach also correlates 
to the ‘focused comparison’ research design proposed by Ragin (1991), in which the 
inclusion of cases, or units of observation, derives directly from the research question. 
With this regard, Ragin (1991) explains that the researcher might focus on the outcome 
of the dependent variable, choosing contrasting cases in order to better identify the 
independent and intervening variables:  “[O]ne might vary the outcome, choosing 
cases of both successes and failures in order to identify the conditions and variables 
that seem to account for differences in outcomes” (1991:79).  
By using this approach in the thesis, it was possible –within a single (conventionally 
labelled) case-study– to observe two separate instances of AMR agenda setting in 
Mexico, applying Kingdon’s theory.  In this way, the range of variation of the 
explanatory variables as well as the dependent variable was extended, providing 
additional leverage over causal inference (King, Keohane and Verba  2001: 218-21).  
One limitation of this diachronic comparative approach is the independence between 
the two observations across time, given the influence of events of an earlier time period 
on events of later time periods (Bartolini 1993; Collier 1993:117). However, according 
to King, Keohane and Verba (2001:222), unless the dependence is perfect (there are 
only predictable factors involved), “certain dependence between observations does not 
disqualify the observations as independent tests of a theory”. In the present study, 
dependence between the two periods is not perfect, as it considers: changes in the 
administration, which often bring along changes in the governmental priorities and 
governmental structures; as well as external factors that affect policymaking (in this 
study, for example, the influenza epidemic, and policy entrepreneur activity). 
In this sense, even if comparing two time periods within the single-case study (AMR 
agenda-setting in Mexico) does not allow causal inference, it can allow one to draw 
reasonable and plausible hypothesis (or testable propositions) about AMR policy 
determination and change in Mexico.  
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4.4 Selection of data collection and generation methods 
 
Policy analysis and case study research rely on multiple sources of evidence and 
multiple data collection methods. The use of multiple sources of evidence allows one to 
address a broader range of aspects related to the case (such as historical and 
attitudinal issues), but above all it allows for triangulation, or the convergence of lines of 
inquiry aiming to corroborate a fact or phenomenon (Yin, 2003: 96). 
 
There were two main sources of data for this thesis: documents (governmental 
documents and printed media) and interviews with stakeholders from the governmental 
and non-governmental sectors. Subsequently, document analysis, thematic analysis of 
interviews with key social actors, and media content analysis were undertaken. These 
data collection and analysis methods are commonly used when analysing agenda-
setting for public policies, and in case study research strategies (Baumgartner and 
Jones, 1993; Kingdon, 1995; Swanborn, 2010; Yin, 2003). 
 
Analysis of governmental printed and electronic material (complemented by the 
literature review described in chapter 2) was used to analyse the content of health 
policies in Mexico with regard to AMR. Furthermore, document  and literature reviews 
aided in addressing the research questions (i.e. factors related to agenda-setting) by 
providing a broad picture of the health policy context In Mexico, and by allowing me to 
identify both ‘visible’ and ‘hidden’ actors involved in medicines (and AMR) policies in 
the country, as well as potential interviewees.  
 
Semi-structured interviews were used to address the two research questions –factors 
related to agenda-setting during the 2000-2006 and 2006-2012 administrations, 
although most of them were used to analyse the first period. The interviews explored 
main medicine-related priorities in each interviewee organization, their perception 
regarding the issues of inadequate use of medicines and AMR and its possible 
solutions, as well as their participation (if any) in medicine policies in the country. 
 
Finally, media content analysis was used to analyse AMR agenda-setting during the 
second studied period, the 2006-2012 administration, addressing the second research 
question. Media content analysis was chosen as a method to gain insight into the 
political context and on the participation of diverse social actors during the policy 
formation process (regulation of antibiotic sales) given the logistical complications to 
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conduct interviews during this period. Furthermore, media analysis allowed me to 
understand how problems and solutions regarding AMR were publicly discussed.  
 
The relation between the objectives of the study, the posed research questions, as well 
as the conceptual framework and methods used is summarized in Appendix 2. Figure 
4.1 illustrates the integration of the different study components in the case study, over 
time. Data collection and analysis pertaining each of these methods are described in 
the following section. 
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Figure 4.1 Integration of study components 
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4.5 Document analysis 
 
Document analysis refers to the study of existing documents or written sources, such 
as newspapers, governmental reports, and others. Analysis can be pursued either to 
understand their substantive content or to illuminate other meanings, such as those 
revealed by their style and coverage (Ritchie, 2003: 35). The present study mainly 
used the first level of analysis, aiming to understand substantive content of health 
policy documents in relation to AMR, as well as to understand the health policy context 
(such as priorities stated by the Ministry of Health and the regulatory framework for 
medicines) and the actors involved in medicine-related policies. The collection and 
analysis of governmental documents is described below; the collection and analysis of 
printed media is described separately (section 4.6 media content analysis). 
 
4.5.1 Data collection 
 
Governmental documents were collected in three different moments (see Figure 4.1 
above). Initially, a first set of relevant documents was identified following the literature 
review and a consultation with experts in health systems and policies at the National 
Institute of Public Health (INSP) in Mexico. These documents pertained to the following 
two groups: 
 
1) Legislative and regulatory documents (health laws, regulations, decrees, and 
‘norms’ or standards). 
2) Ministry of Health (MOH) plans, programmes and policies. Proceedings of the 
National Health Council. 
 
An initial analysis of the first set of documents (undertaken between 2004 and 2005) 
allowed me to identify which ones were relevant for further analysis with regard to AMR 
policies, and also helped me identify key stakeholders to conduct interviews, as well as 
relevant interview topics.  
 
A second moment of document collection and analysis occurred concomitantly with the 
first round of interviews (during 2006). Some of the interviewees pointed to additional 
relevant documents, which were also included in the document analysis as part of the 
first studied period (2000-2006 administration). Additionally, other types of documents 
were also collected: these were organisational documents and ‘grey literature’, mainly 
on-line documents related to each of the identified stakeholders’ organizations 
(governmental and non-governmental), such as internal regulations, work plans, 
programme reports, etc. These documents were reviewed mainly to provide 
108 
 
‘background’ information, aiming to understand the stakeholders’ affiliation and role 
facing AMR policies in preparation for interviews –as is later explained– but were not 
included in the document analysis. 
 
The third moment of document collection occurred after the change of administration. 
Relevant plans, programmes and policies launched by the MOH during the 2006-2012 
administration were included in the document analysis as part of the second studied 
period in this study. The documents included in the document analysis are described in 
table 4.1. 
 
4.5.2 Data analysis 
 
The orientation of the document analysis was content analysis: the primary focus was 
on the substantive meaning of the data, and not on the language or structure of the text 
(as occurs in discourse or narrative analysis). In content analysis, themes are identified 
and attention is paid to the way the theme is treated or presented, and the frequency of 
its occurrence (Spencer, et al., 2003: 200). Furthermore, the content of documents is 
linked to their context (such as the characteristics of those who produced them). For 
the present study, diverse analyses were conducted: 
 
1- Current legislation and regulation were thoroughly reviewed in order to assess if 
and how the regulatory framework addressed the issues of AMR and the 
rational use of medicines. Similarly, organizational documents from the Ministry 
of Health (MOH) pertaining to different departments were reviewed in order to 
assess if and how AMR and the rational use of medicines were within their field 
of competence, i.e. if these issues were within their responsibility or area of 
jurisdiction. As all these documents were publicly available in electronic 
formats, first the ‘search’ tool was used to identify the following terms (in 
Spanish): antibiotics, antimicrobials, resistance, medicines, 
prescribe/prescription, dispensing, pharmacy and rational use. Sections of the 
documents in which these terms were identified were analysed in order to 
assess if they explicitly referenced elements of AMR and recommended 
strategies for the rational use of medicines. These elements are listed in Box 
2.1 and 2.2, which includes international recommendations on strategies to 
promote the rational use of antibiotics and to contain antimicrobial resistance.  
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Table 4.1 Governmental documents included in the document analysis of policies on 
antibiotic misuse and resistance  
 
First period of the study 
2000-2006 administration 
Second period of the study 
2006-2012 administration 
 General Health Law (GHL) ( Ley General de Salud) and its reforms 
 Regulation of Medical Supplies (Reglamento de Insumos para la Salud) 
 Internal Regulation of the Essential Medicines List Committee (Reglamento Interior de 
la Comisión Interinstitucional del Cuadro Básico de Insumos del Sector Salud) 
 Internal regulation and action programme of the  Federal Commission for Protection 
against Health Risks (Programa de acción COFEPRIS) 
 Catalogue of Mexican Official Standards , MOH (Normas Oficiales Mexicanas de la 
Secretaría de Salud) 
 National Health Programme NHP, 
2001-2006 and follow-up documents 
(Programa Nacional de Salud; Metas 
del Programa Nacional de Salud; 
Estrategia para la mejora en el abasto 
de medicamentos) 
 Health Quality Crusade Programme, 
2001-2006 (Programa de Acción 
Cruzada nacional por la calidad de los 
servicios de salud) 
 Medicines Policy, Health Protection 
System (Seguro Popular), 2006 
(Política de Medicamentos del 
Sistema de Protección Social en 
Salud) 
 Pharmacies Regulation, 2005 
(Suplemento para establecimientos 
dedicados a la venta y suministro de 
medicamentos y otros insumos para 
la salud, FEUM) 
 National Pharmaceutical Policy NPP, 
2004 and 2005 drafts (Hacia una 
Política Farmacéutica Integral para 
México)  
 Proceedings of the National Health 
Council (Consejo Nacional de Salud). 
 Archives of the Health Commission of 
the Legislature 
 National Health Programme NHP, 
2007-2012 (Programa Nacional de 
Salud) 
 Specific action plan to improve access 
to medicines, 2007-2012 (Programa 
de Acción Específico, 2007-2012. 
Mejora del Acceso de Medicamentos) 
 National Model for Hospital Pharmacy, 
2009 (Modelo Nacional de Farmacia 
Hospitalaria) 
 Bulletins and communications of the 
“Rational Use of Medicines” 
programme of the Health Quality 
Directorate (Programa SICalidad, 
Boletines, Instrucciones) 
 Agreement to determine guidelines for 
sales and dispensing of antibiotics, 
2010 ( Acuerdo por el que se 
determinan los lineamientos a los que 
estará sujeta la venta y dispensación 
de antibióticos) 
 COFEMER Documents, 2010 (Federal 
Commission for Regulatory 
Improvement. This bureau emits an ex 
ante analysis of any new proposed 
regulation, which includes an open 
public consultation in its website) 
 
Documents were classified as including or not elements relevant for AMR and 
rational use of medicines, and according to which elements were included. This 
analysis provided information as to the regulatory and institutional contexts in 
which health policies and programmes occur, an important feature of policy 
analysis (Spencer, et al., 2003: 201). This contextual information fed into the 
agenda-setting analysis (political context ‘stream’).  
 
2. In the case of the documents pertaining to the two National Health 
Programmes(for each period), the 2005 National Pharmaceutical Policy (NPP) , 
the 2010 Ministerial Agreement, and other health policy and program 
documents produced during each of the presidential administrations, analysis 
was oriented towards two different aspects: 
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a.  First, a similar analysis to the one described in point one above was 
performed, in order to assess if and how these policy documents 
addressed the issue of AMR (and compared them to international 
recommendations).  Additionally, attention was paid to the policy 
objectives and priorities mentioned in these documents. Data deriving 
from these documents were organized and reduced in thematic or 
descriptive summaries. The focus of this analysis was to assess which 
were the stated governmental health policy priorities during each of the 
studied periods (2000-2006 and 2006-2012 administrations), which 
health policy issues were receiving more attention and comparably, 
what was the prominence of AMR; also, to assess which AMR policy 
elements were addressed. This analysis provided relevant information 
on the political context ‘stream’.  
b. Second, these policy documents were reviewed in order to gain 
understanding on those who participated in the generation of the 
documents, as well as to understand how policy problems in relation to 
AMR and medicines use were defined, and what policies were 
considered as solutions. Following an interpretative approach, these 
governmental documents were read as providing insight into the 
perspectives of those who generated them, and the political process 
behind their production (O’Laughlin, 1998). Attention was paid to issues 
that were raised and issues that were omitted, participants that were 
included or excluded when producing these documents11, as well as the 
context in which these documents were produced. This analysis was 
performed in an iterative process with the conduction of interviews with 
stakeholders, to gain insight into the policy process for AMR and the 
stakeholders’ understanding of policy problems and solutions.  Similarly, 
a series of documents (19) posted in the COFEMER website by diverse 
stakeholders, as a reaction to the 2010 antibiotics sales regulation, was 
analysed to understand the position of diverse stakeholders vis-à-vis the 
regulation. This analysis provided relevant information on the political 
context, stakeholders involved, the development of policy alternatives, 
and problem definition ‘streams’. 
 
                                                             
11
 This, in reference to the processes and actors which, according to the WHO, should 
participate on the drafting of national pharmaceutical policies (WHO, 2001b). 
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Finally, a quantitative content analysis was performed in two series of 
documents. For this analysis I only focused on the occurrence of (mention, or 
allusion to) topics. First, archives from the Health Commissions in the 
Legislature (covering the 2000-2006 administration) were reviewed in order to 
assess the legislative ‘intensity’ with regard to medicine-related topics. These 
archives contain all the health policy initiatives discussed, passed and rejected 
as well as the minutes of debates concerning these initiatives. The number of 
reforms to the General Health Law was estimated, as well as the number of 
reforms that were incumbent to medicine and AMR policies. Second, 
proceedings of 25 meetings of the National Health Council (a board presided by 
the Minister of Health, where health policies are formulated), held from 2001 to 
2006, were reviewed. The frequency of medicine and AMR related issues, as 
well as the frequency of other health policy issues, were estimated. This 
analysis was performed in order to describe the priorities within the 
governmental agenda regarding pharmaceuticals, and to assess agenda 
placement for AMR versus other health related issues during the 2000-2006 
governmental administration. This analysis provided information on the political 
context ‘stream’.  
As I mentioned before, organizational data and grey literature from diverse sources 
(reports and bulletins available mainly in electronic format, institutional web pages) 
produced by the Ministry of Health as well as by non-governmental organizations, 
industry and professional bodies, were reviewed. The objective of the analysis was to 
understand more about medicine-related stakeholders and their possible role regarding 
AMR policies, to inform the creation of interview guidelines, and to contrast and 
complement the information that interviewees provided. 
 
Although document collection and analysis were performed entirely by the researcher, 
these processes –as well as the analysis results– were discussed and enriched by the 
commentaries of colleagues at the Mexican Institute of Public Health (INSP) in Mexico. 
This document analysis was later on incorporated into other analyses regarding 
pharmaceutical policies in Mexico, which were subsequently published (Dreser, et al., 
2008; Dreser, et al., 2011b; Leyva-Flores, et al., 2006; Wirtz, et al., 2013a). 
 
There are some drawbacks in using documents as primary data sources in policy 
analysis. As Green and Thorogood (2004: 168-169) explain, from a positivist approach, 
these include threats to reliability and validity. Regarding reliability, an important 
concern is the representativeness of records, which is related to selective deposit (not 
everything is recorded or published) and selective survival (not everything that is 
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recorded or published at one point remains available to be retrieved). For the present 
study, documents from the MOH and the legislature were analysed aiming to 
understand health policy priorities and what kind of attention was paid to AMR. 
However, official papers publicly available might not represent all relevant health policy 
documents; documents reflecting relevant health policy decisions might have been left 
out of the analysis12.. Finally, policy documents by themselves provide scarce 
information about the decision-making process that led to the policy or the role of 
groups or individuals in producing that document (Green and Thorogood, 2004: 169). 
However, for the present case study, document analysis was not the only source of 
data. As I explain below, interviews with diverse stakeholders allowed me to obtain 
relevant documents as well as information regarding the production of policy 
documents, such as the role and position of particular groups or individuals, and main 
controversies. Furthermore, some stakeholders provided me relevant documents that 
were not publicly available: this was the case particularly of various drafts of the 2005 
National Pharmaceutical Policy written prior to the final version that was released. 
Comparing these drafts with the final version provided important hints of topics that 
were included or excluded, or addressed differently –issues that were further explored 
in the interviews. 
 
 
4.6 Individual interviews 
 
As I discussed before, diverse authors have emphasized that the process of public 
policy-making is a complex phenomenon, with a variety of actors involved, and where 
no single perspective can provide a full account of the process. Understanding the 
diverse perspectives and actions of diverse actors related to the policy problem under 
study is central; therefore, individual interviews take on much relevance. As a matter of 
fact, for Kingdon (1995), interviews stand above any other data collection or generation 
method in the assessment of agenda-setting for public policies. When analysing public 
policy-making, interviews are undertaken with key informants inside and outside 
government; these key informants are ‘experts’ or part of ‘elite’ groups in any 
determined public policy arena, such as senior civil servants, managers, academics 
and representatives of professional groups; expert interviews provide a unique source 
of ‘inside’ information on the policy-making process (Dorussen, et al., 2005: 317). 
                                                             
12 Green and Thorogood (2004) explain that, by using qualitative approaches other than 
positivist traditions, this bias is less relevant as the documents that an organization 
deliberatively chooses to make public provide hints about the organization’s perspective 
regarding any given topic. 
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However, for some policy areas there are only few relevant experts to be interviewed, 
and not all experts are equally knowledgeable (Dorussen, et al., 2005). Furthermore, 
conducting expert or elite interviews involves some methodological challenges, as I will 
describe later on. 
 
Individual interviews were the second data collection method used for the present 
study. Individual interviews are one of the most widely used method in qualitative 
research, allowing a detailed investigation of people’s personal accounts (Green and 
Thorogood, 2004) of their own beliefs or motivations, but also regarding any given 
social phenomena. The type of interview chosen for this study was semi-structured, i.e. 
fairly structured questions, without response codes. This type of interview combines 
some of the opportunities offered by structured interviews and by informal interviews; 
this is effective when researching about complex topics13 (Bowling, 2002). Carrying out 
semi-structured interviews enables the researcher to structure data collection and set 
the agenda in terms of the topics covered, but, at the same, it keeps enough flexibility 
to alter interview sequences and maintains the focus broad enough to allow for 
emerging themes (Fontana and Frey, 1994; Green and Thorogood, 2004: 80; 
Varvasovszky and Brugha, 2000: 341). In this way, it is the interviewee’s response 
which determines the kind of information obtained about the pre-determined topics, as 
well as the time and relative importance granted to each topic (Green and Thorogood, 
2004: 80). 
 
4.6.1 Selection of participants 
 
Case studies allow us to understand a phenomenon, including a multiplicity of 
perspectives and rooted in a specific context; it is around context where the sample 
design of the case study is structured (Lewis, 2003: 52). For the present case study on 
the process of AMR agenda-setting in Mexico, the context was provided by the health 
policy arena in this country –including a wide array of actors, their perspectives and 
actions. Therefore, it became essential to understand which social actors were relevant 
within health and pharmaceutical policies in Mexico, and to identify key potential 
interviewees. Consequently, the selection of participants for this study followed a 
purposive (or purposeful) sampling: selected interviewees were those who were 
intended to generate appropriate data for the study (Green and Thorogood, 2004: 102). 
 
                                                             
13
 This kind of interview has been used in other health policy investigations in Mexico, for 
example, the research-policy connection study by Bronfman et al. (2003). 
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The identification of relevant individuals, groups, governmental and non-governmental 
organizations in the health policy arena in Mexico benefited from a stakeholder 
analysis; this analysis was carried out iteratively while conducting the literature review, 
revising documents and conducting interviews. Stakeholder analysis (also referred to 
as political mapping) is the process of collecting and systematically analysing 
information to understand the behaviours, intentions, interrelations, agendas and 
interests of relevant social actors, as well as the influence and resources they can bring 
to decision-making14 (Brugha and Varvasovszky, 2000; Reich, 1993; Roberts, et al., 
2004a; Varvasovszky and Brugha, 2000). During the process of identifying and 
mapping relevant actors for the present study, I did not intend to assess in-depth 
aspects such as the stakeholders’ values, power and resources; there are contested 
definitions of these aspects, and it is difficult to capture and measure them (Walt, et al., 
2008). Instead, the focus of the stakeholder analysis in the present study –and in much 
of the interviews– was to identify main individuals, groups and organizations related in 
some way to health and pharmaceutical policies, and more specifically related to AMR 
issues, and to understand their actions and perceptions about AMR and possible policy 
solutions. As it is customary in stakeholder analysis, the present study sought to map 
stakeholders’ interests in terms of their goals, responsibilities and strategies, and to set 
out their formal or informal connections with other relevant stakeholders (Varvasovszky 
and Brugha, 2000). 
 
For the first round of interviews (conducted during 2006) I developed a preliminary list 
of potential interviewees, informed by MS theory, and based on the literature review, 
document analysis, and interviews with key informants.  Following Kingdon’s MS, I 
aimed to identify actors deemed to be relevant for public policy agenda setting and 
policy alternative specification. This included high-level governmental appointees within 
the MOH, who have a prominent role on getting attention to problems and setting the 
governmental agenda; researchers and lower level MOH officials, whose major role is 
in generating policy alternatives; as well as interest groups related with the health 
sector (pharmaceutical industry and business, health care providers), which could 
affect both governmental agenda items, and the types of alternatives considered.  
Literature and document review provided hints about which were the relevant decision 
makers around health and pharmaceutical policies in Mexico, which groups could 
influence decision-making and groups not apparently involved in policy-making, but 
with expertise in AMR and the utilisation of medicines. Furthermore, I held informal 
                                                             
14
 The information generated by conducting stakeholder analyses is frequently used in 
prospective policy analysis to assess the feasibility of future policy directions; however, this is 
not the scope of the present study. 
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interviews with experts in health and pharmaceutical policies,15 who contributed to 
identifying key governmental and non-governmental actors as potential interviewees. In 
this way, informants were selected purposively, seeking to interview social actors 
involved (or with a potential to be involved) in AMR policies. The preliminary list of key 
informants fell into three broad categories, although, given the professional career and 
activities of some of the interviewees, there was some overlap (for example, academics 
that had had positions as governmental officials). The categories were: 
 
a) Governmental stakeholders directly involved in health and pharmaceutical 
policy-making: MOH officials, representatives of the Health Commission at 
the legislature. 
 
b) Interest groups, who might have exerted their influence on health and 
pharmaceutical policies, or who might otherwise be affected by them: 
representatives of the pharmaceutical industry and drugstores associations; 
representatives of medical and pharmaceutical professional associations: 
and consumer groups. 
 
c) Experts in health and pharmaceutical policies, and experts in AMR16 
(academics and specialists in universities, research institutes and health 
organizations); and representatives of international organizations related to 
medicine use and AMR. 
 
There was a deliberate bias on selecting a larger number of governmental 
interviewees, given two reasons. Firstly, given that the matter if inquiry was on public 
policy and governmental agenda-setting, a wide range of governmental actors were 
chosen to be interviewed. As Kingdon (1995) stresses, when aiming to ascertain which 
subjects occupy the time and attention of important government people; that is, what is 
on the governmental agenda, there is no substitute for asking them directly. Secondly, 
in the case of AMR agenda-setting for Mexico, there was not an obvious jurisdiction (or 
policy venue) for AMR policies. Rather, the document review and first interviews 
showed that diverse MOH offices could hold responsibility for this issue. Given this 
reason, a large number of interviewees were planned to cover all these MOH offices.  
                                                             
15
 From October 2005 to November 2006, I was invited as a visiting researcher to the Mexican 
National Institute of Public Health (INSP). From October 2005 to February 2006, the interview 
topic guide was designed, and pilot interviews were conducted. At INSP, Dr. René Leyva, Dr. 
Veronika Wirtz and Professor Michael Reich provided valuable feedback in identifying key 
stakeholders and relevant interview topics, as well as rich discussions around the pilot 
interviews. The rest of the interviews for this first period of the study were conducted between 
June and November 2006. Clearance from the Ethics Committee at INSP was obtained; the 
project was registered at INSP with the name “Análisis de políticas y prácticas farmacéuticas 
sobre el uso adecuado de antibióticos en México” (Analysis of pharmaceutical policies and 
practices related to antibiotic use in Mexico. Principal investigator: Dr. Veronika J. Wirtz, INSP 
2006-2009). 
16
 These actors corresponded to the ‘hidden participants’ in agenda-setting described by John 
Kingdon (1995). 
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The aim was to interview at least two people for every relevant organization or MOH 
department, so originally, around 40 interviews were planned. However, not all 
potential informants agreed to participate in the study; furthermore, as in policy analysis 
the identification of stakeholders is often a protracted process (Varvasovszky and 
Brugha, 2000), I was aware that important actors may emerge at a later stage of the 
fieldwork. For that reason, following the initial selection of relevant stakeholders, the 
“snowball sampling technique” was used, by which at the end of each interview, 
informants were asked to identify other stakeholders that could be somehow related to 
medicine use policies or AMR policies. The snowball approach allowed identifying 
information rich informants that were not previously listed, i.e. individuals 
knowledgeable or experienced with medicines policy-making. Snowball sampling 
provides and advantage on accessing hidden and hard to reach populations, including 
elites (Atkinson and Flint, 2001). For the present study, the snowball approach was 
useful to identify hidden participants (not previously identified by document review or 
experts opinion) such as lower level governmental officials involved in health policies; 
the snowball approach was also useful to reach elite respondents, namely high level 
MOH officials and pharmaceutical industry directives. It is important to mention here 
that snowball sampling has some drawbacks: given the similarity within social 
networks, this sampling approach might introduce a bias on identifying respondents 
toward people that know each other, or share certain viewpoints. In order to overcome 
this bias, it is recommended to begin with a set of informants as diverse as possible, 
which account for different ‘entry points’ or referral chains were used. For the present 
study, a set of interviewees were identified from the document review, and a referral 
chain began with these respondents. Another chain of interviewees began con 
stakeholders identified after consultation with experts. However, even when using this 
approach it is possible that ‘isolates’ would be ignored, this is, people   who are not 
connected to any network that the researcher has approached to (Atkinson and Flint, 
2001), The new identified stakeholders were added to the list of potential interviewees. 
Finally, 46 interviews were conducted from January to November 2006 (see Appendix 
3, interviewees list) which were included in the first period of the study: agenda-setting 
for AMR during the 2000-2006 administration. 
 
The second round of interviews was conducted from March 2007 to February 2008. 
These interviews were included in the second period of the study: agenda-setting for 
AMR during the 2007-2012 administration. However, these interviews proved to be 
very useful to inform on the previous period as well: because some of the interviewees 
occupied relevant (but different) positions during the two administrations, they were 
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able to offer accounts contrasting both administrations. The selection of interviewees 
for this second round was directed mainly to assessing medicine-related priorities and 
AMR agenda placement during the new administration. It sought to interview different 
informants but pertaining to the same governmental and non-governmental 
organizations that were included in the previous period; seven (7) interviews were 
conducted during this period. One informant interviewed in 2006 (as a university 
academic) was interviewed again in 2008, as a key MOH official during the 2006-2012 
administration, which was useful to contrast perspectives. 
 
Additionally, aiming to further understand the policy process that gave place to the 
innovative regulation of antibiotic sales in Chile (a case that is contrasted with the 
Mexican case in the discussion section), during 2009 four interviews were conducted 
with key informants from Chile. Two interviews were conducted face-to-face with health 
officials in Chile, and two academics were interviewed by telephone. Information 
derived from these interviews in Chile was incorporated later in a study on antibiotic 
policies in Latin American countries (Wirtz, et al., 2013a) Furthermore, personal 
communication with a public health official of the Brazilian regulatory agency ANVISA 
allowed to gain insight on the process of regulation of antibiotic sales in this country, 
which is described in the discussion chapter and has been incorporated in other 
studies (Dreser, et al., 2012; Santa-Ana-Tellez, et al., 2013). 
 
In total, 53 interviews –conducted between 2006 and 2008– were included in the case 
study of AMR policies in Mexico:  16 with Ministry of Health (MOH) officials, 1 with a 
member of the legislature; 12 with national academics, 7 with members or 
representatives of professional (medical and pharmaceutical) associations; 12 with 
representatives of the pharmaceutical industry and pharmacy associations; and 5 with 
members of international organizations (described in Appendix 3). 
 
As principal researcher, I conducted most of the interviews (36 in total). However, 17 
interviews were conducted by Dr. Veronika J. Wirtz and Dr. Kitty K. Corbett, both 
researchers at INSP with ample experience in elite interviewing and pharmaceutical 
policies. Dr. Wirtz and Dr. Corbett utilised in the interviews the same elements of the 
topic guide that I developed to be used in the rest of the interviews.17 These interviews 
were carried out during 2006, contemporaneously with others that I conducted; there 
was ample opportunity to discuss the progress of fieldwork amongst the three 
interviewers.  
                                                             
17
 In these interviews, an additional topic was explored (practices on antibiotic use and possible 
drivers for behavioural change) which were not included in the present analysis. 
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4.6.2 Data generation 
 
A general interview topic guide was used with all the interviewees (please see 
Appendix 4). However, the contents of this guide were adjusted for each interview: 
specific topics or questions were added or omitted in accordance with the institutional 
base or particular role of the interviewee (e.g. topics regarding the administration’s 
priorities were explored in-depth with MOH officials; the process of drafting the NPP 
document was explored with those who participated in it). The development of 
interview topic guides was informed by the research questions and the study 
conceptual framework (related to Kingdon’s MS theory); and by findings obtained in the 
literature and in the preliminary document review. 
 
Topics included in the general interview guide were:  
 
 Perceptions about medicine priorities and AMR placement in the health policy 
agenda  
 Main medicine-related priorities in each interviewee organization  
 Perceptions about AMR problems, possible solutions and their feasibility  
 Responsibilities of the respondent’s office on medicine use and on AMR  
 Interviewee participation in medicine policies in the country, including the 
development of the NPP 2005 document. Process of drafting the NPP and 
involved actors. 
 Role of research results and international recommendations in informing AMR 
policy-making 
 
Attention was paid to beginning the interview with very general questions, leaving more 
sensitive issues towards the middle or end and avoiding ‘leading’ or judgmental 
phrasing of questions. The first version of the interview topic guide was piloted in five 
interviews18 (4 MOH officials, 1 academic). Findings from pilot interviews were used to 
refine wording and improve the schedule of questions, as well as to assess and 
improve the researcher’s interviewing technique. When piloting the topic guide, I 
noticed that respondents understood differently the meaning of “medicine-related 
aspects or issues”, so it was difficult to explore their perceptions regarding which 
issues were higher on the health sector agenda. I decided therefore to begin each 
interview with a brief self-administered questionnaire (which took approximately 5 
minutes) that could provide a common language for all interviewees regarding 
medicine-related policy problems. This questionnaire was based on the categories of 
priorities for pharmaceutical policies developed by Rainhorn, et al. (1994) in a Delphi 
                                                             
18
 Given the richness of information provided, these five interviews were included in the final 
analysis. 
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survey. Later on in the interview, I returned to the questionnaire and asked the 
interviewees about their answers (please see question 3 and questionnaire at the end 
of Appendix 4). As the main purpose of the questionnaire was to facilitate the interview, 
no statistical analysis was carried out. 
 
With the exception of many of the interviews undertaken with academics, the majority 
of the interviews for the present study were conducted with political, professional and 
economic ‘elites’: policy makers, and representatives of professional associations and 
industry and business associations. ‘Elite’ interviewing implies that there is a clear 
social difference between the interviewer and the interviewee –being this last one more 
powerful– which is common in policy analysis. These interviews were a challenge, in 
terms of getting access to respondents in the first place, and second, in gaining 
openness by establishing enough trust and rapport. In this kind of interviews, there is a 
risk for the researcher of being patronized, and not getting personal assessments or 
accounts outside the ‘party line’ of the interviewee’s organization – obtaining at the end 
the same information that could have been obtained simply by documentary reviews 
(Green and Thorogood, 2004: 94; Mikecz, 2012; Welch, et al., 1999). Consequently, a 
series of steps were taken seeking to counteract the status imbalance between 
researcher and respondent. 
 
In order to gain access to stakeholders, an introductory letter was sent by a chief 
researcher of the Mexican National Institute of Public Health (INSP) where the 
academic nature of the study was emphasized19. Subsequently, I contacted (by 
telephone or by email) potential respondents to arrange interviews. Those who agreed 
to participate were sent in advance an information sheet and an informed consent form 
(more on the ethical issues regarding the research is described in section 4.4. below). 
Most of the contacted potential interviewees agreed to participate in the study; while 
some top-level governmental officials were not available for interview, they referred me 
to another person from the same governmental body that I could interview. While 
interviews with academics and those from professional associations were relatively 
quickly scheduled, interviews with governmental officials took several weeks to be 
scheduled, something expected when conducting elite interviews. As I mentioned 
before, document analysis was used to increase the researcher’s knowledge of the 
interviewee’s background and that of his/her organization, therefore enhancing the 
                                                             
19
 In order to prevent bias, in the introductory letter and on the information sheet, only the 
general topic of the study was mentioned. It stated that the research was about pharmaceutical 
policies –and not antibiotic policies– in order to assess if during the respondent’s discourse the 
topic of antibiotics arose spontaneously or not. 
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researcher’s position (Mikecz, 2012) and providing guidance on the specific topics to 
be addressed in the interview. 
 
All interviews were conducted in Spanish (my first language as well as the 
respondent’s), except for one interview conducted in English (with a representative of 
an international organization). The majority of interviews with Mexican stakeholders 
and academics were conducted face-to-face in the interviewees’ offices in Mexico City, 
which was their preferred space to talk. Other interviews were carried out in other 
Mexican cities where informants worked, and one was conducted by phone. Interviews 
with representatives of international organizations were conducted in Mexican cities, 
one in London, and one by telephone. Most interviews lasted around fifty minutes, 
although they went from half an hour to one and a half hours, depending on the issues 
raised by the respondent, as well as his/her availability. 
 
With prior authorization, all interviews were tape-recorded with simultaneous note 
taking. Only in one interview, the informant asked to turn-off the recorder during a 
fragment of the interview,  and in another few, informants asked to keep some issues 
‘off the record’; this happened during accounts in which actions of other groups of 
actors were criticized. In many interviews with MOH officials, the interview was 
interrupted by phone calls or by people coming into the interviewee’s office, and the 
recording was paused. In one interview conducted with a MOH official (COFEPRIS 
office), as well as in an interview with a representative of the pharmaceutical industry, a 
third person from those offices participated as observer; this was a condition put 
forward by the informants in order to agree to the interview. 
 
Throughout data collection, a fieldwork diary was maintained. In this diary, all the 
interviews scheduled together were registered, with notes derived from the analysis of 
documents that were relevant to the interview; after the interview was undertaken, 
particular conditions or difficulties when conducting the interviews were also recorded 
(in writing). Likewise, relevant documents and key informants listed by the interviewees 
were recorded for further inquiry. 
 
All the interview (audio) recordings were transcribed to Microsoft Word documents by 
two experienced transcribers at the INSP, with the exception of two transcripts: one 
case in which there were technical problems with the recording, and another in which 
the interview was conducted in English. In these cases the notes taken during the 
interview were expanded and transcribed by the researcher, and were included in the 
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analysis together with the rest of the transcripts. All transcripts were checked against 
the audio by the researcher. 
 
 
4.6.3 Data processing and analysis 
 
The transcripts of the five interviews conducted as part of the pilot study were imported 
to Atlas-Ti©, a qualitative research software that I have experience using. This software 
was used to aid the qualitative analysis of transcripts, which involved coding of the 
texts using an iterative thematic content analysis technique (Bernard, 2002; Bowling, 
2002). As with the document content analysis, the primary focus of thematic analysis 
was not language or the structure of talk, but the substantive meaning of data –derived 
from the description and interpretation of respondents’ views– aiming to illuminate a 
phenomenon. Coding refers to the process of labelling, grouping and conceptualising 
data sections, a process that emerges from the interaction of theory and data (Miles 
and Huberman, 1994: 249). Coding employed mainly a priori –deductive– codes 
(related to the questions in the topic guide and categories described in the conceptual 
framework). However, it was open to emergent (inductive) thematic codes that were 
created during coding and analysis (Crabtree and Miller, 1999), including those related 
to specific processes pertaining to individual respondents, as well as relevant 
contextual factors mentioned in the interviews. This early analysis informed an initial 
coding scheme, as well as subsequent data collection, as is customary in qualitative 
analysis. 
 
When further interviews were summed up, I found that even if coding and retrieval of 
passages of text for the thematic analysis were facilitated by the use of the software, 
data resulted to be over-fragmented and detached from the original transcripts. It was 
difficult therefore to understand and compare data both within individual interviews, and 
between groups of interviews. Consequently, I quitted using this software and used 
instead a matrix output on a Microsoft Excel sheet, as I explain below. 
 
The approach taken to analyse the whole data set (interview transcripts) was thematic 
content analysis, although many elements of framework analysis were incorporated as 
well. Thematic content analysis is a process by which common or recurrent ‘themes’ in 
respondents’ accounts are searched for and categorized. However, the present study 
sought to analyse data beyond the ‘emic’ summaries of respondents’ accounts, by 
providing a ‘thick’ description of the context under study and linking findings to theory 
(Green and Thorogood, 2004: 177-180) by means of ‘framework analysis’. Framework 
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analysis is a matrix-based analytic method, developed by the National Centre for Social 
Research in the United Kingdom (Ritchie and Spencer, 1994), to manage and analyse 
qualitative data explicitly oriented towards applied policy research. As such, this 
analysis method is distinguished from others, such as ‘grounded theory’ approaches, in 
terms that it is often linked to focused objectives and a structured topic guide. But the 
key difference is that throughout framework analysis, the integrity of individual 
respondents’ accounts is conserved (Green and Thorogood, 2004: 220); this aids in 
data interpretation, as I describe below. 
 
Following the steps described by Ritchie, et al., (2003), during the first phase I became 
familiar with the data. This involved reading all the transcripts while checking them 
against the recordings. Later on, a sample of the first set of interviews (involving a 
diversity of interviewer and interviewee categories) was reviewed to gain insight on the 
phenomena under study and the variety of perspectives involved, as well as to identify 
recurring and significant themes. In this process, key text segments in the electronic 
version of the transcripts were highlighted using different colours, identifying main 
themes related directly to the study’s conceptual framework (based on Kingdon’s 
theory, and retrieved in the topic guide), as well as emerging themes. Comments were 
inserted in the margins registering preliminary thoughts and interpretations (please see 
transcription coding example in Appendix 5). With this initial list of themes and 
subthemes an index (or coding scheme) was developed; this index was discussed with 
colleagues at INSP as well as with my advisory committee at LSHTM; however, as 
research progressed, some refinements had to be made which mainly involved making 
some subdivisions and collapsing some of the categories20 (please see the study 
themes index in Appendix 6). 
 
During the next phase, I applied the constructed codes to all the transcripts 
(‘indexing’21), following the same procedure described before. Later on, a thematic 
chart or matrix was created, using an Excel sheet. Here, data was reduced identifying 
cases (interviews) in rows, and themes and sub-themes in columns, trying to maintain 
the ‘voice’ of the participants by paraphrasing or transcribing  verbatim text fragments 
(translated into English); comments and interpretations were also included (in brackets 
and upper-case font to differentiate them from the informant’s voice). Furthermore, 
                                                             
20
 For example, ‘problem perception’ (more related to severity or proximity) and ‘problem 
framing’ (more related to causality) were initially separated codes; but given the frequent 
overlap in these codes on the same fragments of respondents’ accounts (such as when they 
referred to ‘problem populations’ involved) I decided to collapse them into one theme. 
21
 Ritchie et al. (2003: 224) explain that, in framework analysis, ‘indexing’ refers to identifying 
sections of the data in order to show what theme or concept is being mentioned; it is different 
from ‘coding’, which refers to assigning a more precisely defined label. 
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columns were added after each theme column to include original texts in Spanish, only 
for those rich or vivid accounts which were likely to be discussed or cited later with 
regard to specific findings. The finished matrix allowed for case-by-case data analysis 
and also analysis by theme. At the end of rows and columns, notes were introduced 
describing relationships between themes, data interpretation and relevant findings.  
During the analysis, I sought to characterise and contrast the informants’ 
understandings of AMR and their accounts on policy-making, both between and within 
different groups or categories of informants; for example, how governmental, non-
governmental and market-oriented informants defined and perceived AMR problems 
and solutions, and how these groups communicated with each other. Within each main 
theme in the thematic chart, I sought to identify evidence about AMR agenda 
placement, as well as factors that could have favoured or impeded AMR reaching the 
health policy agenda. These explanatory accounts were informed by theory on agenda- 
setting, and by continuously switching between the informants’ perspectives in their 
own terms (emic explanations) and the researcher’s perspectives (etic explanations); 
this process was facilitated by the thematic matrix. 
 
4.6.4 Rigour in analysis 
 
There is an ample debate on using the concepts of reliability and validity, developed in 
the natural sciences to assess the quality of qualitative research, which is based on 
different epistemological perspectives (Green and Thorogood, 2004; Lewis and Ritchie, 
2003; Mays and Pope, 2000). However, it has also been argued that, when used in 
their broader sense – reliability, meaning ‘sustainable’ and validity, meaning ‘well 
grounded’ - are notions that do have relevance for assessing the robustness and 
credibility of qualitative research (Lewis and Ritchie, 2003: 270); this is especially 
needed in research aiming to influence policy or practice. Along this same line, diverse 
authors have outlined a number of principles related to rigour in qualitative analysis 
(Green and Thorogood, 2004; Mays and Pope, 2000: 191-192). Some of these 
features are discussed in relation to the application and analysis of interviews for the 
present study. 
 
In order to maximise validity (i.e. the ‘truth’, ‘correctness’ or ‘plausibility’ of interpretation 
when analysing interviews) and avoid the charges of “anecdotalism”, common against 
qualitative research (Green and Thorogood, 2004: 192; Lewis and Ritchie, 2003), I was 
receptive to ‘deviant cases’ and disconfirming evidence when ‘testing’ theoretical 
propositions against findings (Bernard, 2002; Miles and Huberman, 1994). For 
example, even when accounts within one group of informants largely coincided and 
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supported propositions about factors hampering AMR agenda placement, if there was 
a testimony which differed –and contradicted emerging explanations– this was further 
explored and discussed. Additionally, I sought to provide enough context of the 
research setting and quotes, in order to clarify descriptions and interpretations. 
Although respondent validation would have provided a relevant validity check when 
interpreting interviews, this feedback with informants was not completed. Given the 
prolonged fieldwork and the frequent respondent turnover, only few informants were re-
contacted; this constitutes a limitation of the present study.  
 
Triangulation, the process of using multiple information sources and ‘readings’, is 
important to clarify meanings, verifying the repeatability of an observation or 
interpretation, and thus to ensure comprehensiveness and to deepen the 
understanding of a phenomenon. It was been argued that triangulation also has a role 
in the validation of findings, although there is controversy on this (Lewis and Ritchie, 
2003: 275; Mays and Pope, 2000). Triangulation can be obtained by comparing 
information by data source, by method, by researcher, by theory and data type. Along 
this line, the present study involved triangulation of sources: information from both 
documents and interviews, from different groups of interviewees, and collected at 
different points in time, which was compared to assess issues such as AMR agenda 
placement, problem perception, and the role of different stakeholders. Theory 
triangulations (analysing data from different theoretical perspectives) has also been 
recommended as a method of external validation, and is particularly relevant in 
empirical research of policy-making (Lewis and Ritchie, 2003: 276; Sabatier, 2007); 
however, it was not undertaken in this study.  
 
Regarding reliability –‘confirmability’ or ‘consistency’ are the related terms in qualitative 
research (Lewis and Ritchie, 2003)– attention was paid to ‘good practices’ in fieldwork 
(Green and Thorogood, 2004: 194) (keeping records and careful note-taking, checking 
transcriptions) and to analysing the whole data set. Because I was the only person 
involved in coding the interview, the concept of inter-rater reliability does not apply 
here. However, coding of the interviews as well as data interpretation was discussed 
amply with colleagues at INSP and at LSHTM;22 furthermore, results of the analysis of 
documents and interviews were presented in an international conference (Dreser, et 
al., 2009) which was an opportunity to receive feedback from experts in the field. 
 
                                                             
22
 Some of the interview transcripts were reviewed during the monthly Qualitative Analysis 
Workshop organized by Dr. Judith Green at LSHTM, during 2006. 
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As it was described throughout this section, interviewing as a research method places 
some limitations, which are further described in section 4.8 .  
 
4.7 Media analysis 
 
Media content analysis was the third method used in the present study. As pointed out 
in the previous chapter, the interest of conducting a media analysis as part of the 
present study was twofold: First, to analyse AMR agenda-setting during the second 
studied period (2006-2012 administration); and to gain insight on the participation of 
actors and the policy process that led to the adoption of a policy, the regulation of 
antibiotic sales, during this period. A key interest was the participation of diverse 
stakeholders and their position vis-à-vis the policy development during the second 
studied period. Second, media analysis was conducted to shed light on the potential 
effects of media framing on AMR problem definition and the overall policy process. 
These two aspects are, however, connected. 
 
Understanding the policy process through the media. Mass media outputs (such 
as newspaper reports or television programmes) offer a relevant source of data 
regarding health and health policy questions (Esmail, et al., 2010; Green and 
Thorogood, 2004: 161; Prosser, 2010; Wallack, et al., 1993). Furthermore, mass media 
outputs have being deemed as an important data source for agenda-setting studies. 
Baumgartner and Jones (1993) argue that in long term periods, media coverage 
indicators correspond to official concerns and can be used to describe both the degree 
to which a an issue is placed on the broad policy agenda, as well as the tone of elite 
understanding at a given time (1993: 50). Accordingly, with regard to the present study,  
media analysis allowed understanding the coverage of AMR-related topics (and thus, 
AMR agenda placement); as well as the participation of social actors on the policy 
process that led to regulation of antibiotic sales. Additionally, given the prolonged 
fieldwork for the present study, there were logistical difficulties in conducting more 
interviews to document the policy process (the Ethics Committee approval at INSP and 
LSHTM had expired, there were time and resource constraints for conducting and 
transcribing interviews); in this situation, mass media outputs provided a readily 
accessible source of information. 
 
Understanding media influence on the policy process. Mass media outputs have 
the potential to influence public perceptions and attitudes towards health; but also to 
influence public perceptions of health policy issues, political elite’s policy 
considerations and, eventually, the final policy product (Esmail, et al., 2010; Schön and 
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Rein, 1994; Wallack, et al., 1993). Media has been deemed an important influence in 
public and governmental agendas, by expanding and by framing issues (Kingdon, 
1995; Baumgartner and Jones, 1993; Entman, 1993 Accordingly, with regard to the 
present study, media analysis allowed understanding how problems and solutions 
regarding AMR were framed and publicly discussed during the second studied period; 
and, consequently, gaining insight on the potential effect of media framing on AMR 
problem definition, agenda setting, and the overall policy process.  
 
Media content analysis. Media content analysis focuses on the way in which issues 
are represented in the media (how they are ‘framed’, what messages they convey), and 
the frequency of their occurrence (Douglas Gould and Co., 2004; Green and 
Thorogood, 2004: 161). Therefore, it involves both quantitative and qualitative research 
approaches. The intensity of printed media coverage (e.g. number of articles on an 
issue as the total number of articles in a year) has commonly been used as an indicator 
of the relation between the mass media and the national agenda; but besides levels of 
attention, Baumgartner and Jones (1993) underscore the nature of that attention, as it 
sets the context for agenda access. This includes the general tone (positive or 
negative) of media articles on diverse public issues, as well as their concerns, such as 
the severity of the problem, its economic implications, or the actions that the 
government should or should not be taking (1993: 50-51). As such, media content 
analysis can be used within policy analysis to understand policy-making, but it can also 
be used to support advocacy efforts, by identifying opportunities in communication 
(Douglas Gould and Co., 2004). 
 
By looking directly at communication –via texts– media analysis sheds light on the 
ideas of those who produced them, as well as on social interaction. Compared to other 
methods such as interviews, media content analysis has the advantage of being 
unobtrusive: neither the sender nor the receiver of the messages is aware that he/she 
is being analysed, so there is little chance that the data will be influenced and 
confounded by the act of analysing them (Weber, 1990: 10). Media content analysis 
entails analysing media coverage during a set time-frame, aiming to answer questions 
such as the following ones formulated by Douglas Gould and Co. (2004: 1). 
 
 How do the media frame public discussion of an issue (by repeating various 
story elements, using common metaphors, quoting similar people, etc.)? 
 Who are the main spokespeople on a particular topic, and how are they being 
quoted? Are they mainly advocates, policy makers, academic experts, etc.? 
 How often are various spokespeople quoted and in what context? 
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 What topics are being covered, and what topics are being ignored? 
 Is a topic or organization front-page news, and if not, where in the paper is that 
topic or organization covered? 
 What messages are being used? 
 
4.7.1 Data collection 
 
For the second period of the study (2006-2012 administration), a media analysis was 
conducted covering the process of regulation of antibiotic sales and its follow-up. First, 
a systematic review of printed newspaper articles published between January 2009 
and December 2010 was conducted. A quantitative content analysis was performed to 
determine the frequency of topics and stakeholders that were covered; additionally, a 
qualitative content analysis was conducted to gain insight into stakeholder positions 
and actions in relation to the regulation. The study background, methods and results, in 
which other researchers participated, are described in detail in the article by Dreser, et 
al (2012),23 and are detailed below. Second, an on-line search engine of a major 
newspaper was used to retrieve articles addressing the regulation of antibiotic sales 
comprising the period between January 2011 and December 2012. 
 
For the systematic review, newspaper articles were retrieved using a specialized 
electronic media service24 which encompasses 18 national and regional newspapers, 
the most relevant ones in terms of copies sold, and representing a variety of political 
positions. This media service retrieves newspaper articles related to health and 
pharmaceutical issues, by using key words such as “medicines”, “antibiotics”, “Ministry 
of Health”, “pharmaceutical industry”, and “pharmacies”. All newspaper articles 
published between January 2009 and December 2010, retrieved by the media 
services, were manually screened in order to identify those that covered issues related 
to antibiotic use or antibiotic sales regulation; these were included in the study (322). 
The time period covers three stages of the policy process: 1) policy agenda-setting (01 
January 2009 to 24 March 2010, before the regulation was announced); 2) policy 
drafting (25 March 2010 to 24 August 2010, the period from the regulation 
                                                             
23
 I conceived this study, in which the following researchers also participated: Dr. Veronika 
Wirtz, Dr. Edna Vázquez, and Dr. Sandra Treviño, all researchers at the INSP at that time. The 
coding scheme for the quantitative content analysis was developed jointly by the research team; 
once the codebook was agreed upon, the codification of newspaper articles was performed by 
Dr. Vázquez under my supervision. The qualitative analysis of these notes –which describes the 
participation of stakeholders– and reporting of these results were conducted solely by me, 
although discussions on coding and interpretation were sustained with the other researchers. 
24
 Especialistas en Medios: http://www.emedios.com.mx/canifarma/.  
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announcement to the beginning of its implementation); and 3) policy implementation 
(25 August 2010 to 31 December 2010). 
 
As of 2011, it was no longer possible to use the specialized media service. 
Consequently, in order to provide follow-up on the public discussions regarding AMR 
policies and the regulation of antibiotic sales during the rest of the administration, a 
different media analysis was employed. This involved manual use of the on-line search 
engine of one of the most relevant national newspapers (El Universal25) to retrieve 
relevant articles published between January 2011 and December 2012. All the articles 
retrieved with the key word “antibiotics” were screened to identify those specifically 
related to the follow-up of the regulation of antibiotic sales and other discussions on 
AMR policies; these were included in the analysis. 
 
4.7.2 Data analysis 
 
All 322 articles were coded for the analysis (2009-2010). To develop the codebook, 
each author coded 20 articles identifying emerging themes through inductive 
reasoning. Those themes were then structured and sorted into subject categories and 
each of the defined codes. Seeking to improve reliability and validity, the codification 
was checked by using investigator triangulation with 20 randomly selected articles. 
Discrepancies were discussed and adjustments made to the codebook (please see 
Appendix 7). The rest of the articles were coded by one author using Atlas-Ti© 5.2 
software. In addition to the theme codebook, each article was coded according to 
stakeholders covered by the media: 1) government (executive); 2) congress 
(legislative); 3) pharmacies and outlet associations; 4) pharmaceutical industry; 5) 
medical and other professional associations; 6) civil society groups; 7) academic 
institutions; 8) journalists (in editorials and opinion columns); and 9) private sector other 
than the pharmaceutical industry. 
 
For the quantitative content analysis, first the frequency of thematic categories for each 
of the three time periods was calculated separately. If a thematic code was mentioned 
several times in the same article, it was counted only once. Second, stakeholder 
appearance was counted as the number of times a stakeholder was mentioned in a 
newspaper article. Additionally, the number of articles published by month was 
estimated. 
 
                                                             
25
 El Universal: http://www.eluniversal.com.mx 
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A qualitative thematic content analysis was undertaken in those notes in which a 
stakeholder code appeared; the objective was to understand the position and actions of 
stakeholders in relation to the new policy during each stage of the policy-making 
process. In order to gain understanding on the position of stakeholders vis-à-vis the 
regulation, only those articles in which the voice of stakeholders appeared, particularly 
quotes,  were analysed (and not the voice of journalists, except for editorials and 
opinion columns for which we considered journalists as another stakeholder group with 
its own voice. In order to gain insight into the actions taken by different actors, all 
articles which made reference to stakeholders (either in their own voice or that of 
journalists) were analysed. Similarly to what was described for the analysis of 
interviews, a matrix was elaborated in which newspaper articles were placed in rows. 
Relevant passages and interpretations were put in columns, which corresponded to the 
following themes: 
 
 Position (General statements about the regulation and its objectives,  
arguments against or supporting it) 
 Specific actions undertaken in relation to the new policy 
 
During the analysis, attention was paid to similarities and differences between actors 
within the same stakeholder group, and between different stakeholder groups. This 
same matrix was later expanded with the articles published between 2011 and 2012, 
which were retrieved by the manual search in the newspaper website. Discussions on 
coding and interpretation were sustained with the other researchers at INSP, who 
reviewed the thematic chart. 
 
The media content analysis undertaken as part of this case-study presents, however, 
some limitations, which are described in the following section.  . 
 
 
4.8. Methodological limitations of the present study 
 
The present study presents some limitations with regard to the overall design of the 
study, as well regarding the methods used (document analysis, individual interviews 
and media analysis), which are described below. 
 
Design of the study. The present study made use of methods valid for policy analysis 
(interviews, document and media analysis). However, a major limitation was that these 
methods were not used consistently in the two studied periods. During the first period, 
analysis was based on interviews and documents; AMR was so scarce on the news 
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media that a media analysis was discarded. However, during the second part of the 
study, due to logistical constraints only a limited number of interviews were conducted; 
analysis was based mainly on document analysis and media analysis; the latter 
method was favoured by the intense media coverage of the antibiotic regulation. This 
limited the discussion of results between the first and second period studied. 
 
Individual interviews. As it was mentioned earlier in this chapter, interviewing as a 
research method places some limitations.  Although interviewing allows gaining insight 
about people’s perceptions and lived experiences, respondent bias can occur as when 
the respondent gives a “socially desirable” or leaves out relevant information. 
Interviews take part in social interaction context, and they are influenced by that 
context (Fontana and Frey, 1994: 364). This is especially true when interviewing elites.  
When conducting interviews for the resent study (such as top decision makers at the 
MOH) it was difficult to move interviewees from speaking on behalf of their 
organisations, quoting official documents and “the party line”, to offering a personal 
assessment. This limitation was addressed, whenever it was possible, by interviewing 
different people within the same organization (for example: diverse respondents with 
different positions in the organisational hierarchy within one MOH office; or more than 
one academic from the same institution).  Additionally, a strategy that proved to be 
useful for obtaining richer information from top MOH officials was conducting some 
interviews after their administration had concluded; for instance, interviewing in 2007 
and 2008 health officials who held positions during the 2000-2006 administration.  
 
When conducting interviews, researcher bias can be introduced by an inadequate type 
of instrument and wording, or by an interviewer with flawed questioning techniques 
(Fontana and Frey, 1994: 364). Furthermore, being the present study conducted by 
only one researcher, the validity of findings depends greatly on the skills of the 
researcher what may lead to analytic bias, such as relying on pre-existing beliefs (Miles 
and Huberman, 1994). As has been described before, these possible sources of bias 
were addressed by getting training in qualitative analysis, by piloting the interview topic 
guide. During analysis, information derived from interviews was triangulated within the 
interviews dataset, and with information derived from the document analysis. When 
coding the interviews and developing interpretations, I built on validity checks by being 
receptive to negative evidence, looked at complete data, and discussed interviews 
coding and data interpretation with colleagues. Finally, although respondent validation 
would have provided a relevant validity check when interpreting interviews, this 
feedback with informants was only possible with only few informants.   
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Media content analysis. With regard to the media content analysis undertaken as part 
of this case-study there are some limitations. First, the analysis used a unique coding 
scheme (“issue-specific” instead of “generic” frames) which limits the ability to 
generalise and compare the results with other past and future cases (de Vreese, 2005). 
However, whenever possible, the coding scheme was discussed in relation to generic 
frames (Dreser, et al., 2012). Another limitation is that full media analysis (involving a 
large set of different newspapers) only covered a period of two calendar years (2009 
and 2010), a period of high coverage in which the issue of AMR rose into the agenda, 
and policy drafting and initial implementation occurred. For the rest of the period, due 
to financial constraints, media analysis was based on the review of only one major 
newspaper. Furthermore, the study excluded the analysis of electronic media (radio, 
television and internet) which are important in Mexico (Sánchez and Sivaraman, 2010), 
and might have reflected the views and actions of stakeholders differently from the 
printed media. Finally, as other authors have pointed out, we can describe the 
representation of issues and stakeholder participation in the media, but we can only 
infer their relation with the policy process (Esmail, et al., 2010). In sum, media analysis, 
allowed understanding media framing and public discussion of AMR and policy; as well 
as gaining insight stakeholder participation. However, the analysis of agenda setting for 
the second studied period would have benefited from conducting as well a larger set of 
interviews. As Kingdon ascertains, even if documents can provide insights on the policy 
process and agenda items, there is no substitute for conducting interviews. With regard 
to this limitation, even when no formal interviews were conducted during the process by 
which a policy was enacted in 2010, being an “insider” in the policy process 
(coordinating the drafting and dissemination of the INSP-AMIMC-APUA policy 
proposal) gave me the opportunity to have personal communication with several of the 
actors involved. In this manner, I was able to learn about their insights into the 
processes of agenda-setting, policy drafting and adoption. 
 
4.9 Position as researcher 
 
Gill Walt and her colleagues (2008) advice that we need to reflect on the positionality of 
researchers when conducting health policy analysis, given its implications for access to 
data and the construction of knowledge. To this regard, my connection with the 
Mexican National Institute of Public Health (INSP) is worth discussing. This is a 
research-oriented decentralized institute of the MOH. During the first period of the 
study, when most interviews were conducted, I contacted possible interviewees 
presenting myself as a LSHTM research student and a visiting researcher at INSP. 
When contacting health officials, an introductory letter was sent by a senior INSP 
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researcher. Being in close contact with researchers at INSP put me in the position of 
an ‘insider’; this facilitated the identification of relevant actors in the health and 
pharmaceutical policies arena, as well as gaining access to top decision makers in 
order to request interviews. However, even when access was attained, this did not 
always imply openness, as discussed before. This could relate (at least to a certain 
extent) to the complex relationship between INSP and the MOH, particularly regarding 
their independence, which might have affected the perception of the academic 
neutrality of this study. There were interviewees (from inside and outside the MOH) 
who, when criticizing a MOH programme, requested that I stop recording, or keep 
something ‘off the record’. Furthermore, being myself Mexican and being close to the 
national public health arena, favoured  a broad understanding of the cultural and  
political contexts in which policy-making occurs, as well as an understanding of jargon 
and an ability to read non-verbal cues. Yet ‘insiders’ have been accused of being 
inherently biased, as they do not have a critical distance from what they study, and 
carry with them a large number of assumptions, all of which might affect a 
comprehensive understanding of the policy process (Walt, et al., 2008; Welch, et al., 
1999). Aiming to address this limitation, during data collection and analysis, I sustained 
discussions with ‘outsiders’ –both researchers outside Mexico, as well as researchers 
in this country, but alien to the pharmaceutical policy arena. 
 
Moreover, during the second period of the study, my research team at INSP was 
involved in the policy-making process around the regulation of antibiotic sales. I 
participated in coordinating the drafting of the INSP-AMIMC-APUA policy brief on AMR 
(fragments of which were later on incorporated into the regulation document), and in 
some communications with decision makers. This put me in a position of being both 
participant and observer of the policy process. While this insider position allowed me to 
have a closer understanding of some parts of the policy process, it also jeopardized the 
neutrality of the analysis regarding the position and actions of diverse stakeholders. In 
order to minimize this risk, two researchers outside the pharmaceutical policy research 
team at INSP were involved in order to aid in the codification of newspaper notes 
(investigator triangulation, see (Dreser, et al., 2012), and discussions with other outside 
researchers were sustained when interpreting data and drawing conclusions. 
 
Finally, as Walt et al. (2008) assert, researchers linked to particular policy 
environments (as  is my case with the INSP and public health) will naturally be more 
concerned with developing policy relevant conclusions than new theoretical or 
methodological understanding, a critique that might well apply to the present study. 
Nevertheless, as I described in the discussion section, this study still contributes to the 
133 
 
advance of the incipient field of health policy analysis in low and middle income 
countries (Gilson and Raphaely, 2008) by applying a theoretical perspective in 
empirical research on a health policy issue. 
 
4.10 Ethical considerations 
 
Regarding the involvement of people in this study (in individual interviews), ethical 
approval was requested and obtained from the Mexican National Institute of Public 
Health (INSP) Ethics Committee (approval number 185) and from the LSHTM Ethics 
Committee (approval number 5034). 
 
Interviewees were fully informed about the nature of the study using information 
sheets; consent to be interviewed and audio-recorded was obtained in writing, through 
consent forms (please see Appendix 8). The information sheet included my name and 
contact details, the reason why the informant’s cooperation was requested, and how 
confidentiality would be maintained. I provided all interviewees with a presentation 
letter with the contact details of the Institution I was working with in Mexico. In these 
documents, the general theme of the study was mentioned without detailed 
explanations on its objectives, in order to prevent interviewees from creating 
perceptions before the interview, which could result in bias. All interviewees were told 
that they could interrupt their participation in the study at any time, and that they would 
have access to recordings and transcripts. 
 
In order to assure confidentiality of interview data, an ID code was assigned to each 
interview recording and transcript. Digital recordings and electronic versions of 
transcripts have been kept in password protected computers (and locked drawers, in 
the case of tapes and paper transcripts), and will be destroyed after conclusion of this 
thesis.  Transcripts had no signs of identification of participants (this information was 
deleted), and participant ID codes were used instead. The contents of the interview 
transcripts have been available only for those directly involved in the research 
(including my advisory committee at LSHTM and my research team at INSP). The list 
of participants in the study is presented in a manner that does not publicly disclose the 
identity of the participants.  
 
When specific quotations that were retrieved from the transcripts were presented to 
illustrate particular issues or views, the anonymity of the respondent was preserved; 
only the institutional base of the respondent has been cited. 
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5. RESULTS (I): POLICY INACTION ON ANTIMICROBIAL 
MISUSE AND RESISTANCE DURING THE 2000-2006 
ADMINISTRATION 
 
 
This first empirical chapter presents findings related to the first specific objective stated 
for the present study: To analyse the factors related to AMR agenda placement in 
Mexico during the 2001-2006 administration and the adoption of related policies, by 
focusing on problem definition and recognition, the political context, the development 
and perception of policy alternatives, and the role of policy entrepreneurs. The 
information presented was obtained from interviews conducted with stakeholders 
during 2006-2008, including government officials, NGOs, pharmaceutical-sector 
representatives, researchers and health professionals; their perceptions about AMR, 
AMR agenda status, and policy alternatives to deal with AMR were explored. 
Additionally, information derived from the analysis of official documents from the 
legislative and executive, as well as grey literature (see Table 4.2) is presented to 
describe health policy priorities in the country, AMR agenda status and background 
information of the stakeholders involved.1 
 
 
5.1 Political context 
 
After 70 years of hegemonic centre-right party rule, in 2000, a new conservative centre-
right party advocating free enterprise came to power: the National Action Party (PAN, 
by its Spanish initials), with Vicente Fox as president. At that time, Dr. Julio Frenk, a 
well-recognised public-health official and academic, was appointed Minister of Health. 
He was in office between December 1, 2000, and November 30, 2006 
 
As was described in the literature review chapter, during this administration, Mexico 
underwent an important health-system reform. The leadership of the Health Minister 
Julio Frenk was pivotal for the development of the reform that led to the adoption, in 
2003, of the subsidized insurance scheme  Seguro Popular (Popular Health Insurance; 
SP, by its Spanish initials) (Gómez-Dantés et al., 2015). The development of the SP 
was supported by evidence of out-of-pocket payments on health (including medicines) 
that led to further impoverishment and deeper inequity; it was recognised that assuring 
medicine availability and supply was key for the functioning of the new SP and 
                                                             
1
 Some of the findings described here have been published or presented before in: Leyva-
Flores, et al. 2006; Dreser, et al., 2008; and Dreser, et al., 2009. 
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sustaining the health-system reform (Nigenda, et al., 2003). Furthermore, one of the 
most pressing demands raised during the presidential campaigns was the problem of 
medicine stock-outs in public services, an issue that was reflected frequently on the 
mass media and later became, as stated in official documents, a “presidential priority”. 
Besides the policy developments around SP, another medicines related topic was 
highly discussed in the beginning of this administration: generic medicines.  A series of 
regulatory changes during 1997 and 1998 led to the expansion of the market for 
generic medicines, which faced opposition or the leading pharmaceutical industry 
associations; the conflict around this topic extended to the beginning of the new 2000-
2006 administration (Shadlen, 2009). In 2002, a MOH decree was introduced, by which 
public health services were bound to buy only generic medicines. The need to 
strengthen medicine management and supply within the SP, the presidential priority on 
guarantying the supply of medicines (decreasing stock-outs), and the conflict around 
generic medicines, led Health Minister Frenk to commission the development of a 
national pharmaceutical policy document (NPP). This is further explained in section 
5.3. 
 
The overall weight of medicines for the administration was stressed by a number of 
interviewees: 
 
“Within the health sector [...] the issue of medicines, it is a topic that I would say 
that has too much emphasis on politics” (MOH15). 
 
“Medicines, in this country, have been used as a political weapon”. (PHAR1) 
 
The relevance of medicines policies for this administration, and especially on improving 
the supply and access to high quality medicines, is revealed in many MOH documents, 
and by this discourse of Minister Julio Frenk in early 20032.  
 
“These are three major challenges we have to face in the National Health 
System: the challenge of quality, the challenge of equity and the challenge of 
financial protection. Precisely with this perspective is that the Ministry of Health 
has been given the task of designing and promoting a comprehensive 
pharmaceutical policy that responds to these three challenges. […] The 
objective is to guarantee universal access and rational consumption of high 
quality medicines for the entire population at a cost that Mexican society can 
afford. So here the key words are: access, rational consumption, high quality of 
medicines and fair prices. 
                                                             
2 Message from Dr. Julio Frenk Mora, Secretary of Health, at the opening of the symposium 
"Interchangeable Generic Drugs" organized by the General Health Council and the Mexican 
Academy of Surgery. March 18
th
, 2003. In: 
http://www.salud.gob.mx/unidades/dgcs/sala_noticias/discursos/2003-03-18-MEDICAMENTOS-
GENERICOS-INTERCAMBIABLES.htm 
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There are also all the policies in terms of procurement and supply, which are 
fundamental. The main claim made by citizens, and where the President of the 
Republic has given instructions to all holders of public health institutions, 
including the general managers of IMSS and ISSSTE and myself, is that we 
make visible improvements in the subject of the supply of medicines. 
 
Finally, the last great fusion that has to do with the quality of the provision of 
services, includes elements such as rational prescription based on scientific 
evidence, a very complex issue of therapeutic adherence and responsible self-
medication. As you can see, it is a policy that wants to include instruments 
around each of these links in the chain. 
 
Evidently, in a comprehensive pharmaceutical policy, one of the key elements is 
the production of generic medicines, which is one of the internationally proven 
means to improve medical care based on the quality, efficiency, supply and 
competitive price of medicines.” 
 
It is important to underline that while Minister Frenk mentioned the objective of 
achieving the rational use of medicines (by improving evidence-based prescription, 
patient’s adherence, and self-medication) achieving this objective was diluted along the 
administration, as it is described later in this chapter.  
 
5.1.1 The MOH agenda, jurisdictional borders, and perceived responsibility on 
AMR 
 
The National Health Programme (NHP) 2001-2006 (SSA, 2001) centred on improving 
equity, quality, and financial protection in health care, as well as strengthening the 
health system. To this end, the NHP document proposed ten strategies, some relating 
to medicines policy. The most important of these strategies was the creation of a new 
insurance scheme, the Seguro Popular (SP).  
 
Another NHP strategy consisted in strengthening MOH role in health systems 
stewardship. One of the related lines of action was the “reinforcement of national policy 
on access and rational use of medicines”, which included three components: ensuring 
medicine stocks in public services, improving use of quality generics, and elaborating 
standard-treatment guidelines (STG). Another line of action was strengthening the role 
of the MOH on protection against health risks. Consequently, a new regulatory agency 
was created: the Federal Commission for the Protection against Sanitary Risks 
(COFEPRIS, by its Spanish initials), which was charged with regulating the quality of 
medicines –together with numerous other responsibilities involving environmental 
hazards, food, pesticides and other chemical products, and around 200 more health 
hazards. Importantly, COFEPRIS was tasked by the Minister of Health to develop a 
national pharmaceutical policy towards the end of the administration. Finally, the NHP 
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document also proposed a strategy named the National Crusade for Health Care 
Quality which included, among other objectives, the promotion of STG and the 
certification of health services, health professionals and the universities dealing in their 
education. The strategy was assigned to the Health Quality Directorate (HQD). 
Improving medicines supply in health services was regarded as one of the five key 
commitments of the Crusade.  
 
It is important to mention that within the NHP there was a section which described the 
problem of inadequate use of antibiotics, both related to self-medication and to 
physician over-prescription. Nevertheless, it did not propose specific lines of action to 
address explicitly these problems (the action proposed was developing STG to improve 
overall prescription). Regarding antimicrobial resistance, the only action proposed was 
related to improving tuberculosis treatment. Importantly the NHP did not explicitly 
assigned responsibility on AMR to any office.  
 
Besides the creation of COFEPRIS other MOH offices were opened or re-arranged in 
order to better align their function with the NHP.  Among these were the National 
Centre for Technological Excellence in Health (CENETEC, by its acronym in Spanish), 
in charge of producing information to improve the management, assessment and use 
of health-related technologies, including medicines; this centre was assigned later on 
the task of developing STG. The Economic Analysis Office, as well as a National 
System for Health Information were created to support health policy decision-making. 
The Epidemiological Surveillance Centre, belonging to the General Directorate of 
Epidemiology, was reorganized: preventive programmes were developed for 
tuberculosis, vector-borne and zoonotic diseases, as well as health emergencies and 
disasters. This Centre also held the already existing Hospital Network for 
Epidemiological Surveillance (RHOVE), focused on the surveillance of nosocomial 
infection (including surveillance of antimicrobial resistance).   Additionally, the General 
Health Council (Consejo de Salubridad General) which depends directly on the 
President, continued with its responsibility of establishing health priorities, certifying 
medical units, and managing the Mexican national medicines list (Cuadro Básico y 
Catálogo de Insumos del Sector Salud).  
 
During President Fox administration, the general topic of medicines was high on the 
executive health agenda, as reflected on the Proceedings of National Health Council 
(the MOH board responsible for the formulation of health policies, composed by the all 
the state-level health ministers).  Medicines were discussed in 18/25 meetings held 
from 2001 to 2006 by the National Health Council. The main subjects addressed were 
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the of medicines in the public sector as an indicator of quality (12/25 meetings, which 
was described in the proceedings as a “Presidential priority”), and the management of 
medicines for the recently created SP. AMR was not mentioned as an agenda topic in 
itself, with antimicrobial resistance brought up exclusively in relation to medicines for 
AIDS and tuberculosis. 
 
Among the interviewees pertaining to different MOH offices, there was also a shared 
perception that improving medicines procurement and stock in public health services, 
as well as assuring the quality, safety and efficacy of medicines were the top priorities 
during the administration. Improving the prescription, dispensing and use of medicines 
was less often mentioned as a priority, while containing antimicrobial resistance was 
seldom recognized as a priority (see introductory questionnaire, Appendix 4). As 
described in these testimonies of MOH officials:  
“There was much controversy on the media about medicines stock-outs on 
public services. So one of the priorities when president Fox arrived was to 
improve the supply of medicines “(MOH5) 
“The issue of medicines has received a great deal of attention in the current 
administration, larger than on other occasions, manifesting this in both the 
investment made in medicines and in different initiatives, whether to define a 
policy, or to monitor the proper supply of medicines. It was established a whole 
system of measurement of the supply of medicines, of measuring the 
satisfaction of the population with the supply of the prescriptions and this has 
been very closely monitored, so much so that it is one of the indicators that the 
presidency itself follows” (MOH14) 
 
Among MOH interviewees, there was also fair consensus on the definition and causes 
of AMR, which was related to other two problems: self-medication (over-the-counter 
sales of antibiotics) and inadequate medical prescription. However, MOH interviewees 
did not reach consensus on the interventions required to address AMR at the national 
level or the implications of different policy alternatives. Even more, they were uncertain 
as to which MOH office was the competent authority to deal with policies or 
interventions aimed at improving medicine use and containing AMR. None of the 
offices recognised a direct responsibility in this area; many pointed in the direction of 
other offices.  
 
“Improving prescription? That is responsibility of the Ministry of Education.” 
(MOH8) 
 
“Rational use is not a domain of COFEPRIS. That is responsibility of another 
sub-ministry, Health Quality“(MOH3) 
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The Health Quality Directorate (HQD) recognised rational use of medicines and AMR 
as a shared responsibility between this office and COFEPRIS, with the latter office 
having the authority to regulate over-the-counter sales of antibiotics: 
 
“No, we don’t deal with pharmacies at all. We don´t have the authority that 
COFEPRIS has” (MOH7) 
 
The HQD recognized its responsibility on improving medical prescription, but adduced 
lack of resources as an impediment for executing such interventions, specifically the 
STGs recommended in the NHP and other pressing priorities. This office was almost 
fully dedicated to other endeavours, namely, measuring and improving medicine stocks 
in public-health services and supporting the National Crusade for Health Care Quality. 
 
“It is just lack of structural capacity, lack of attention and of budget to address all 
the problems that have to be fixed in a system […] Clinical guidelines, for 
example: we had money for one year to develop them. And then it was over […] 
And that was only the first step. Now imagine implementing it, that 50,000 
physicians use them. No, the challenge is not easy. “(MOH7). 
 
Similarly, a respondent in the Health Promotion and Prevention Directorate, admitted 
that they were not currently engaged on activities promoting the rational use of 
medicines in the population, although that would be part of a future agenda with 
COFEPRIS: 
 
“We have reestablished contact between this division and the COFEPRIS about 
four, five months ago, because we are looking at the common agenda and 
within the common agenda –between them in the part of health regulation, and 
us in health promotion– has emerged the issue of orientation and education of 
the consumer of medicines, and this is therefore within the agenda pending to 
be developed…”(MOH14) 
 
As for the COFEPRIS interviewees, they did not recognize their direct responsibility on 
rational use of medicines, explaining that the Comission was oriented to “involuntary 
risks”, thus their main activity was on regulation to assure quality of medicines, and 
pharmacovigilance.   
 
“The Federal Commission's [COFEPRIS] mission is basically to protect the 
population against involuntary risks to the person, what does this mean? That it 
is the will of the person to go with a doctor, who gives him a medical 
prescription, and it is the hundred percent willingness of the person to acquire 
or not to acquire the medication, to take it or not to take the medication. What is 
not the will of the person, is that the medication prescribed is of adequate  
quality, is efficient and safe; that is an act that the authority, in this case the 
Federal Commission has under its tutelage, being a guardianship of the public 
good that is health.” (MOH6) 
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 The contradictory views on interventions needed to promote rational medicines use 
and perception of responsibility on this matter is summarized in Table 5.1. 
 
Table 5.1: Perceptions of possible solutions and responsibilities among MOH 
interviewees 
 
Possible solutions to improve the use of 
medicines in general, and antibiotics in 
particular 
 
 
Perceived responsibility on addressing 
AMR 
Economic Analysis Office (EAO)  
 
 The main action is to improve access. 
Improving access, self-prescription is 
avoided. There has to be more control on 
medicines dispensing 
 The problem about inadequate 
prescribing is that there is not continuing 
medical education, guidelines, and there 
is excess promotion, especially in the 
private sector. This is related to absence 
of someone overseeing what physicians 
are prescribing, especially in the private 
sector. The solution is to have a third-
payer, the Seguro Popular or private 
health insurance to oversee prescriptions. 
The solution is to “institutionalize” doctors, 
to avoid them to be independent or 
autonomous actors. Regarding controlling 
excess marketing, "good practices" could 
be promoted. 
 
 EAO is not directly involved here, 
because these are "clinical issues" rather 
than economic topics. They do not know 
exactly who is developing interventions on 
AMR, and if there is an explicit policy on 
that issue.  
 EAO participated on the National 
Pharmaceutical Policy Proposal. 
 
Regulatory agency (COFEPRIS) 
 
 Antibiotic misuse comes from a problem 
of doctor-patient relationship, in part 
because of the patients demanding 
antibiotics. This problem should be 
addressed with educational campaigns 
directed both to physicians and patients 
 
 AMR is not within the competence of the 
regulatory agency, which is focused on 
assuring the quality and safety of 
medicines. The responsibility belongs to 
Health Quality Directorate. Educational 
campaigns have to be addressed by that 
office.   
 COFEPRIS participated on the National 
Pharmaceutical Policy Proposal. 
 
Health Quality Directorate (HQD) 
 
 The determinants of inappropriate use of 
medicines in the country are the deficient 
training in medical schools and 
institutions, the pressure of the 
pharmaceutical industry in promoting 
medicines, and the lack of a monitoring 
and feedback system to inform 
prescribing practices. 
 The responsibility is shared by 
COFEPRIS and this office. The HQD can 
influence policies, but COFEPRIS has the 
authority to regulate.  
 This office tried to implement STG to 
improve prescribing, but there was not 
enough financial resource to do so. 
 The office objective is to improve quality 
of services. However, given the 
President’s priorities on access to 
medicines, the main focus of HQD was to 
improve and monitor medicines stock in 
public health services. 
General Health Council (GHC) 
 
 Over-the counter sales of antibiotics could 
 
 The responsibility of the GHC on 
medicines is mainly related to integrating 
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be addressed with training more 
pharmacists and bringing them to work in 
pharmacies. Rational prescribing of 
antibiotics has to be promoted among 
physicians. 
the essential medicines list EDL (Cuadro 
básico) and defining policies on generic 
medicines. 
 Does not recognize their role in better 
connecting EDL with STG and medical 
training in order to promote RUM. 
 The responsibility of promoting STG and 
good prescribing practices belongs to 
each healthcare institution –IMSS has 
developed important interventions- and to 
medicine schools. 
 COFEPRIS should insist more on not 
allowing medicines sales without 
prescriptions, although it is difficult to deal 
with the private sector. COFEPRIS could 
also develop educational campaigns. 
 
 
 
5.1.2 The legislative agenda on health  
 
This period was characterised by active legislative work on health issues; while 82 
reforms to the General Health Law (GHL) were approved during the 2000-2006 
administration, only 26 reforms to the GHL were approved during the whole previous 
decade (1989-2000). The majority of the GHL reforms during the 2000-2006 
administration (16/82) were related to with the enactment of SP, as well as medicines 
issues.   The medicine-related topics debated in Congress revolved around the 
regulation of so-called “miracle products”, generics, counterfeit and non-bioequivalent 
medicines, subjects which were brought to the congressional agenda by the 
pharmaceutical industry and by physicians members of Congress. In the words of a 
Health Commission member:  
 
“Over the past years, the pharmaceutical industry has approached Congress to 
expose their proposals and opinions […] Topics such as ‘miracle medicines’ 
have been raised by senators who are specialised doctors, some of them 
cardiologists […], people who really know about this topic because of their 
experience…” (GOV1) 
 
According to this interviewee, rational use of medicines and AMR were not discussed 
by the commissions; AMR topics did not appear in any of the reports of the 
Congressional Health Commission hearings. 
 
To sum-up: President Fox administration was very active in promoting health-policy 
reforms under the leadership of Health Minister Julio Frenk, many of them related to 
medicines. This could have opened a ‘political window’ for medicine use and AMR to 
reach the health-policy agenda as well, but the political context was not conductive in 
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this regard. At the time, the competing issues on the executive agenda were the 
formulation and implementation of SP, and the National Crusade for Health Care 
Quality. Assuring the provision –not rational use- of medicines was at the heart of both 
initiatives. SP proved the most important public policy in that administration. One 
interviewee explained that during that administration, the MOH engaged in a “mono-
thematic” (MOH16) drive towards health reform and SP coverage. 
 
With regard to the responsibility on developing and implementing interventions directed 
to AMR, there was a clear fragmentation of responsibilities among the different MOH 
offices. Probably because many of these offices were recently re-organized, 
interviewees underlined a poor linkage among them. The responsibility of some 
elements pertaining to a national policy on AMR (see Boxes 2.1 and 2.2) were 
scattered between longstanding offices (GHC), and newly formed offices (COFEPRIS, 
CENETEC, HQD, EAO). 
 
As it is explained in the next section, during this administration there were groups 
undertaking actions or advocating for policies on the rational use of medicines and 
containing antimicrobial resistance. However, none of the interviewees within the 
government acknowledged these initiatives. In contrast, according to the testimony of 
one respondent (GOV1) the pharmaceutical industry was able to bring their own 
interests to the congressional agenda, especially regarding the regulation of generics, 
a topic that boosted during the Fox administration. As it was mentioned in Chapter 2, 
the pharmaceutical industry groups have a role as consultants in Congress3. The 
academic and professional organisations interested in promoting rational use of 
medicines and containing AMR had no direct channel of communication with either the 
legislative or the executive body. 
 
 
5.2 Problem recognition 
 
5.2.1 Problem identification  
The occurrence of inadequate use of antibiotics has been amply documented by 
researchers in Mexico, particularly during the late 1980s and early 1990s (Dreser, et 
                                                             
3
 An internal document of the pharmaceutical industry association CANIFAMA, states that this 
Association “is a body of consultation and collaboration with the State for the design and 
execution of policies, programs and instruments that facilitate the expansion of economic 
activity [...]. The most important function of the Health Affairs Committee is to be a link between 
the Pharmaceutical Industry and the Ministry of Health. This relationship occurs in several 
instances and levels of authority [...]”. CANIFARMA-Health Affairs Committee. Report 2000. In. 
http://www.canifarma.org.mx (accessed March, 2006). 
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al., 2008; Wirtz, et al., 2008). Nevertheless, as described by academics interviewed in 
the study, research on antibiotic use has been undertaken mostly as “biopsies” 
(ACAD4) to diagnose the situation in selected public and private health services, 
without however generating national data on antimicrobial consumption (ACAD2). 
Available findings on the health and economic impact of AMR have been minimal. As 
was described in chapter 2, research on antibiotic resistance has been reported in 
papers and conferences documenting specific cases such as hospital outbreaks and 
resistance levels in a particular health service. None of the MOH made reference to 
these research findings; only some interventions of antibiotic developed by the social 
security institution (IMSS) were mentioned, with regard to their experience on 
developing STG. During this administration, although monitoring systems were put in 
place to measure medicines stocks in public services, mechanisms to assess the use 
of medicines (for example, indicators to assess quality of prescription, or consumption 
levels) were not put in place. With regard to antimicrobial resistance, the General 
Directorate of Epidemiology implemented a hospital network for the surveillance of 
intra-hospital infections (the RHOVE network) which also collected information on 
antimicrobial resistance. However, at that time, as interviews explained, collected 
information was not used to provide feedback to prescribers, and was not publicly 
available.  
 
When explaining their views on the scope of the problem of AMR in the country, none 
of the interviewees made explicit references to indicators to measure the problem, nor 
to focusing events that could call their attention to the severity of the problem; very few 
made reference to research results.  The MOH interviewees recognized that the lack of 
indicators on AMR was a problem in itself: 
 “We don't have enough information in order to identify the magnitude of the 
problem and where it is more severe”.(MOH7) 
“I believe that the impact generated by non-optimal use of antibiotics is not yet 
documented. […] [With regard to antimicrobial resistance] this is an issue of 
health policy, a theme of rectory, where the MOH would have to generate 
evidence to exercise another type of regulation”.(MOH7) 
Similarly, academics also underlined the lack of indicators: 
“The indicators that are not measured end up not being a priority, I believe, 
within health systems or priorities within any ministry. And there are no, 
indicators have not been used to measure the adequacy of prescription or 
dispensing.”(ACAD2) 
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5.2.2 Problem definition 
 
Most interviewees recognised AMR as an important problem due to its consequences; 
health risks related with antimicrobial resistance and unnecessary expenses emerging 
as the most frequently cited effects, and adverse drug reactions lagging behind. 
Interestingly, despite the fact that the highly positioned problem of medicine stock-outs 
in public services may be in part a consequence of over-prescription, this relation was 
not recognized by interviewees. Overall, the severity of the problem of inappropriate 
use of medicines and AMR was stressed more frequently by academics and 
representatives of NGO’s, than by governmental officials and industry representatives. 
“[antimicrobial misuse and resistance] is a universal problem that has a terrible 
impact in our society, both economic and ecological, as well as in the patients’ 
health”. (ACAD4) 
 
For the majority of the respondents, AMR was a twofold problem residing in self-
medication and inadequate-prescription practices, which they associated, in turn, with 
other problems. The problem of inadequate prescribing was more emphasised by 
academics and representatives of medical associations.  In general, MOH respondents 
tended to overemphasise the problem of self-medication over the problem of 
inadequate prescribing of antimicrobials.  
“We still have a long way to go before medicines sales require a prescription 
[...]. I am very concerned in that sense, yes, with antibiotics; we are facing 
strong bacterial resistance problems” (MOH14) 
 
Self-medication with antibiotics. According to most of the interviewees, self-
medication stemmed from the insufficient health-insurance coverage, lack of 
enforcement of regulations, and from cultural aspects of a Mexican society accustomed 
to consuming antibiotics as “quick fixes” for health problems. With regard to lack of 
access to health-care, one interviewee explained: 
 
“Either you go to the doctor or go to the pharmacy. The truth is that it’s cheaper 
to go to the pharmacy because if you go to the doctor the consultation costs 
200 to 300 pesos. You don’t have enough even for the consult. The medication 
can cost you less, so you go directly or you ask the employee of the pharmacy” 
(PHAR3) 
 
Professional pharmaceutical associations explained self-medication as a problem 
deriving from the absence of professional pharmacists in pharmacies, as pharmacy 
clerks could not distinguish over-the-counter and prescription-only medicines (PROF1, 
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PROF 6, INDUS 1).The lax governmental regulation that allowed the over-the-counter 
sales of antibiotics was mentioned only by few respondents. According to this 
representative of the pharmaceutical industry, they are also to blame: 
 
”I think that industry also has a lot to do with it, because the industry does not 
care that the pharmacy is professionalized, because in any case the medicines 
are sold with or without a prescription,  they are sold freely, something that do 
not happen in other parts of the world. But also the Secretariat has turned a 
deaf ear here, because it is a way not to face the social and economic problems 
that it represents (INDUS1) 
 
According to two MOH interviewees (MOH3, MOH6), not enforcing the regulation of 
medicines sales only with prescription, was, in fact, a laissez-faire policy to facilitate 
access to medicines, given the lack of coverage of public insurance systems.  
 
“Why have not we done it? There is a problem that is clear: we have not yet 
been able to achieve universal coverage in health services; the popular 
insurance goes there, we will have, I hope that in 2010 –fingers crossed- we will 
attain that universal coverage. What happens with patients today? Today a 
person has two hundred pesos in the bag and has to make a decision: either I 
go to the doctor, I pay for the consultation and I run out of money for the 
medication; or I'm going to buy the medication."(MOH6) 
 
On the other hand, pharmacy owner associations, tended to minimize the problem of 
antibiotic sales without prescription, and their responsibility on it: “I was telling you, that 
in order to be objective, 95% of all antibiotics are dispensed with a prescription” 
(PHAR2). Similarly, other representative of a pharmacy owner association stated: 
“In any city in Mexico, if someone has a cold the first thing they will say to him is 
take an antibiotic ... it is very much a cultural issue” (PHAR1). 
 
Inadequate prescribing. Inadequate prescribing, in turn, was associated by 
interviewees with deficiencies in the education of physicians, although others underline 
cultural aspects as well: “It is the culture of each hospital and of each physician” 
(MOH5). The promotion of medicines by the pharmaceutical industry was recognized 
by many of the interviewees as a relevant factor that explained inadequate prescribing 
(MOH1, MOH7, MOH14). Interestingly, the pharmaceutical industry perceived that they 
had a key role in educating physicians: 
 
“What happens is that the pharmaceutical industry educates the doctors. The 
only way of staying current is through the pharmaceutical industry. [Company 
name] has over 30 projects right now, symposiums, Internet courses, distance 
learning courses, continuing education courses, to provide continual education, 
and not just about their products.” (INDUS2) 
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Interviewees from the MOH recognized the need to improve medical prescribing, and 
to strengthen physician education. However, this was deemed as a very difficult task, 
given the number of physicians and medical schools involved; the needed collaboration 
with the Ministry of Education, and the perception of opposition by medical 
professionals. In words of a HQD official: 
 
“The part that has to do with the training of the doctor involves the Ministry of 
Education, that is, it involves another area, and the universities. Initiating any 
change in the doctor's curriculum is really a Herculean task [...] Going into the 
curriculum implies putting 74 medical schools in the country into agreement […]. 
I think that the issues of prescription and improvement in the use of medicines 
reach a very delicate point,  that is the autonomy of medical practice, and that is 
one of the great barriers within health institutions, not only in Mexico, in all the 
world. Doctors reject much that their freedom of choice is restricted” (MOH4) 
 
Furthermore, MOH interviewees acknowledged that not enough attention was being 
devoted to AMR. They recognised that it was particularly difficult to find a solution 
because of the interdependence of AMR with other problems and the prevalence of 
conflicting priorities on the agenda, namely, enhancing access to quality generics and 
improving medicine stocks in public services. To summarise, government inaction 
regarding AMR was related to the complex situation of medicines in Mexico. In the 
words of a top MOH health official: 
 
Look, what is happening to us is the same that has happened to any other 
country in the world where the main discourse is coverage, and later the issue 
of quality begins to emerge; it is the natural evolution of the problem. I think that 
this has been the case of Mexico: firstly it is ‘let’s have the medicines´ and later 
it is ´let’s see how they can be used as God commands’. And the problem of 
medicines stock outs is so complex […]”.(MOH7) 
 
This same MOH official explains that the issue of AMR has indeed been mentioned in 
some meetings of the National Health Council, from two different perspectives: 
availability of antibiotics in the public sector, and nosocomial infections. The measures 
that have been developed to address these issues are improving medicines availability 
in general, and regarding nosocomial infections, it had to be addressed beginning with 
the most basic, promoting hand-washing, which hasn’t proved to be easy. So, given the 
situation of the Mexican health system, addressing the issue of the quality of 
prescription means a “level of sophistication” that has not been reached yet. However, 
he concluded, 
 
“We are plenty aware—and this is a topic that has been raised several times in 
the National Health Council—of the need to influence on the prescription 
patterns of physicians. But we haven´t had time, and I don´t think we will have 
time during this administration, to address this issue. I want to think that on the 
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next administration —having solved the issue of stock outs, or at least generally 
improved it—[…] naturally the next issue to be addressed will be the issue of 
medical prescription.” (MOH7) 
 
According to other MOH interviewees, the issues of rational use of medicines and AMR 
were raised sporadically in important policy meetings, but were not considered urgent.  
Some interviewees explained that AMR was not on the agenda because there has 
been no leadership to promote it; simply, “no one has put it forward” (MOH4). As this 
MOH official mentioned: “I think it has simply not been prioritized, right? It is not an 
issue that is high on the agenda, it is discussed, but it is not high on the agenda” 
(MOH14). Contrastingly, for some interviewees outside the government,  the 
absence of governmental initiatives to improve the use of antibiotics was related 
to corruption and lack of knowledge: 
 
“So there are political interests, there are economic interests and there is 
corruption, yes? And there is ignorance and, please, IGNORANCE in capital 
letters” (ACAD1) 
 
In general, AMR was perceived as a complex issue framed under two spheres: first, as 
a problem connected to circumstances intrinsic to the health system, such as limited 
access to health services and lack of mechanisms to regulate the private sector; 
second, as a problem pertaining to the national culture, or the individual realm, where 
people self-medicate regularly, and physicians treat patients with insufficient 
knowledge and inadequate prescription habits. Such a complex problem warranted 
complex solutions that were difficult to act upon. 
 
Although government and non-government actors recognised AMR as a problem, their 
perceptions differed with regard to its level of urgency. Non-government actors viewed 
AMR as an important problem requiring urgent governmental intervention, whereas 
government stakeholders saw it as relative minor problem compared to priorities such 
as the provision of medicines in the public sector. For some interviewees, these were 
mutually exclusive agenda items.  
 
Despite research in Mexico identifying AMR as a problem and most government 
interviewees acknowledging its existence, AMR was not perceived as a severe 
problem that had to be acted upon urgently. This can be attributed to various factors 
including the prevalence of competing items on the official health agenda, the absence 
of indicators, lack of feedback form previous programmes, absence of focussing events 
that may draw attention to the problem, and the perceived complexity of the nature of 
the problem and its possible solutions. 
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5.3 Development of policy proposals 
 
Inadequate use of medicines, particularly antibiotics, has been the object of various 
studies; however, researchers have focused considerably more on the occurrence of 
the problem in the public and private sectors than on interventions to combat it (Dreser, 
et al., 2008; Wirtz, et al., 2008). Exceptionally, in the late 80s and early 90s, the 
Mexican social security system (IMSS by its Spanish initials), the largest public-health 
security system at the time, implemented, evaluated and documented a series of 
educational and managerial interventions for improving antibiotic use in common health 
disorders such as acute respiratory infections and diarrhoeal diseases. Although the 
interventions were demonstrated to be successful in several publications (Guiscafre, et 
al., 1995 and 1998), the MOH did not adopt them to be implemented nation-wide. Two 
of the interviewees, who authored these investigations (ACAD4, ACAD5), recognized 
that they did advocate for these interventions to be adopted at IMSS, but not in other 
public or private services.  
 
Two main non-governmental groups were identified as performing activities aiming to 
gain awareness on the problem of AMR, or developing policy proposals.  In 1988, the 
NGO Health Action International-Mexico together with academics in various 
universities formed the National Committee for the Rational Use of Medicines aiming to 
improve the quality of education in therapeutics for health professionals (Vicencio 
Acevedo, 1999). HAI-Mexico (2000) and professional associations (CTFM, 1999) have 
demanded the government to provide patients and prescribers with independent, 
practical and reliable information on medicines. Nevertheless, as one interviewee of an 
NGO explained, gaining access to MOH officials proved to be very difficult: “They are 
like Gods” (ORG1). Thus, this organization was not actively involved in promoting their 
proposal to the MOH. Even more, despite an important momentum of activity during 
the 1990’s, afterwards the activities of such organizations subsided. 
 
During the 2000-2006 period, other groups developed actions on AMR. In particular, 
the Mexican chapter of the Alliance for the Prudent Use of Antibiotics (APUA), which is 
hosted by the Mexican Association for Infectious Diseases and Clinical Microbiology 
(AMIMC) organized annual workshops on antimicrobial resistance, directed to 
physicians; and also got involved in teaching about the use of antibiotics in some 
medical faculties. In 2001, APUA, AMIMC, the Pan American Health Organization 
(PAHO) and the Pan American Society for Infectious Diseases (API) organized an 
international symposium on antimicrobial resistance in Guadalajara, Mexico. It 
concluded with the “Guadalajara Declaration to Combat Antimicrobial Resistance in 
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Latin America”4 which involved key recommendations to improve antibiotic use.  Some 
of the interviewees that participated in this Declaration (ACAD7, ORG2) explained that 
there weren´t efforts to communicate it to decision makers in Mexico, besides inviting 
some MOH officials to the launch of the Declaration. And, in fact, none of the MOH 
interviewees knew about it.  During the following years, there were scarce efforts by 
these organizations to approach the MOH. According to a top researcher on 
antimicrobial resistance, this topic was not even relevant within public health research 
institutes: “They don’t care about a bunch of scientists talking about bugs” (ACAD8). 
When prompted about the role of PAHO on fostering AMR policies in Mexico, one 
respondent from this organization (ORG4) explained that, differently from other 
countries, Mexico did not need much support, as there was already an “excellent group 
of specialists” (referring to APUA-AMIMC). 
As was mentioned earlier, most interviewees related AMR with the problems of self-
medication and inadequate prescription. Accordingly, most of them were able to point 
to a number of possible solutions (for example, see Table 5.1). Rarely, however, they 
did cite studies on the situation in Mexico when discussing the effectiveness or 
feasibility of courses of action against AMR. Only interviewees from NGOs referred to 
the WHO initiatives on AMR, and only one referred explicitly to the Global Strategy for 
the Containment of Antimicrobial Resistance published in 2001. Not one of the MOH 
interviewees was aware of the WHO Global Strategy, or the measures it recommends 
for tackling AMR. MOH respondents explained that “tons” of documents arrived each 
day to their offices, and it was impossible to read everything (MOH3). Another MOH 
official, when recognizing that he was not aware of the Global Strategy on AMR, nor of 
policy initiatives on AMR developed by other groups in the country, explained: 
“Probably we are still very immature as a society; the influence over political agendas is 
very endogenous, or influenced by powerful interest groups” (MOH14). 
 
Interviewees were presented a list with some of the policy recommendations on AMR 
were asked for their opinion on the feasibility of implementing them in Mexico. With 
regard to enforce a prescription status for all antibiotics, all interviewees regarded this 
as a needed intervention;  however, MOH interviewees perceived that implementation 
was unfeasible in the sort term, given insufficient health insurance coverage in Mexico 
and the probable opposition of patients and pharmacies. Enforcing a prescription status 
for only some antibiotics seemed more viable to them. None of the interviewees made 
reference to the Chilean experience. Regulation of prescription (such as limiting 
                                                             
4
 APUA: Guadalajara Declaration to Combat Antimicrobial Resistance in Latin America. At: 
http://www.tufts.edu/tufts-test/med/apua/Chapters/Guad/guad_eng.html  
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prescription of some antibiotics only by infectious diseases specialists) was perceived 
as being likely opposed by doctors, and thus not feasible. Many interviewees pointed to 
educational interventions for physicians as a possible solution. However, as a key 
official interviewed from the Health Quality Directorate described, improvement of 
physician training and prescribing practices was a “Herculean task” (MOH4).Regarding 
the need to improve prescribing, another MOH informant explained: 
 
“We haven't found the way to do it. That is, even though the federal 
government, the health education institutions and the professional associations 
have sat down together, we haven’t found a way to sort it out”. (MOH9) 
 
 
5.3.1 Content and development of the national pharmaceutical policy proposal 
 
Towards the end of President Fox administration,  Health Minister Frenk commissioned 
the newly created regulatory agency, COFEPRIS, to develop a national pharmaceutical 
policy document (NPP). The agency convened a series of experts to participate in 
drafting the document; among them were mostly representatives from the main public-
health services and experts from the pharmaceutical industry, as well as members of 
some professional medical and pharmaceutical associations. No representatives from 
civil-society groups, academics, or public-health experts were included in the task. 
Some important MOH officials were also excluded from the process.  In the view of this 
interviewee from the health promotion office:  
 
“I did not participate in the elaboration of this document […] it clearly 
demonstrates the lack of participation of relevant groups; it is very directed 
towards the inside of the sector itself, with little gathering of opinion and 
information beyond the industry itself.” (MOH14). 
 
When asked about why public health researchers were not invited to participate on the 
elaboration of the NPP, one of the coordinators stated “because our work was not for 
public health, it was for medicines” (MOH6). 
 
According to some interviewees (MOH3, IDUS1) there was conflict among the 
participants about the document content. The first version of the NPP was circulated 
internally in 2004; rational use of medicines was one of the stated objectives of the 
document, and delineated strategies to improve prescription and dispensing.  
Subsequently, the leadership for developing the document was reassigned to the MOH 
Health Economics Unit, where the final version was drafted. In the final version, the 
objective of attaining rational use of medicines was omitted. Other relevant MOH 
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offices, such as Health Quality Directorate as well as the National Institute of Public 
Health (INSP by its Spanish initials) were assigned marginal roles that consisted mainly 
in providing comments on the final version. The finished NPP, named “Towards a 
comprehensive pharmaceutical policy for Mexico” (SSA, 2005), was disseminated only 
to a limited extent and was not launched officially. Overall, interviewees who 
participated in the formulation of the NPP document made scarce references to the 
WHO guidelines on how to develop and implement a national pharmaceutical policy 
(2001b), and coincided that the subject of rational use of medicines was only 
superficially addressed while drafting the document.  
 
In the NPP, there were not references to research on antimicrobial resistance or 
antimicrobial misuse, neither to interventions directed to address this problem.  
Nevertheless, antibiotic resistance was mentioned a number of times within the 
document, in relation to: a) the disposal of expired medicines (discarded antibiotics 
could generate resistance); b) medicines packages (that are not adjusted to treatment 
recommendations, and could affect treatment length, favouring resistance); c) 
inadequate prescription of antibiotics, favouring resistance; d) lack of patient adherence 
to VIH and tuberculosis treatment, leading to resistance. Nevertheless, none of the 
proposed strategies pointed specifically to improving the use of antimicrobials. With 
regard to improving prescription, the stated strategy was to include pharmaco-
economic information in STG and medical training (SSA, 2005:120-121). 
There was confusion among many interviewees on the scope of the document; while 
some informants perceived as a White Paper or even a “monograph” (Indus1); for other 
it was clearly an official policy.  The content of the NPP proposal is summarized in Box 
5.1 with regard to rational use of medicines and containment of antimicrobial 
resistance.5 
 
Box 5.1 Content of the national pharmaceutical policy proposal with regard to the 
rational use of medicines and containment of antimicrobial resistance 
 
The proposed new Mexican NPP presents an analysis of the epidemiological and 
pharmaceutical situation in the country as a base to promote changes in many areas. The 
three main objectives listed in the policy proposal are: assuring quality, security and efficacy of 
medicines; improving access and availability; and promoting innovation and competitiveness of 
the national pharmaceutical industry. 
 
The new NPP proposal does not include the rational use of medicines as an objective of the 
policy, neither proposes a mandated multidisciplinary national body to coordinate medicine use 
policies as it is internationally recommended. Nevertheless, some elements of policies towards 
the rational use of medicines are dispersedly addressed throughout the document, proposing 
interventions focused on improving prescription and dispensing, as well as consumers’ 
information on medicines.  
 
                                                             
5
 Part of the information presented in Box 5.1 has been published in: Leyva-Flores et al. 2006. 
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Within the document, the problem of rational prescribing is discussed in the section of access 
to medicines. In this way, the concept “rational” is explained only from a pharmacoeconomic 
perspective (cost-effectiveness) focusing in decreasing the costs of prescriptions. The 
proposed strategies are to further promote the use of generics among prescribers, and to 
include elements of pharmacoeconomy in the medical education curricula. 
 
In order to promote rational prescribing, new NPP draft proposes the development of standard 
treatment guidelines (STG) that include pharmacoeconomic information. The use of STG and 
EML in under and postgraduate education of health professionals to promote the rational use 
of medicines is overlooked. Similarly, the need for independent, practical and updated written 
information on medicines widely available for consumers, dispensers and prescribers –
particularly in the form of a national formulary related the EML and STG– is not discussed. 
 
Confusingly, the NPP draft analyses the problem of adequacy in medicines dispensing within 
the section of quality, efficacy and safety of medicines. In this way, the policy draft advocates a 
change in the training programs for pharmacy clerks and technicians in order to assure the 
maintenance of medicines safety. The document states that a prescription-only status for 
medicine sales had not been enforced given the need to ensure access to medicines in a 
context of insufficient health-care coverage. States that the regulation on sales, antibiotic sales 
included, would occur once SP insurance coverage increased and universal health coverage 
was attained 
 
Although the NPP document dedicates special sections to the regulation of certain medicines 
such as vitamins and pseudoephedrine, strategies towards improving the use of antibiotics and 
contain antibiotic resistance are omitted. The inclusion of these strategies within NPPs have 
been recommended by international organisations. 
 
The key concept of essential medicines is not central for the new Mexican NPP draft Contrary 
to this situation, for the new NPP the development and research of innovative medicines is 
defined as one of the main objectives. Along the document, it is stressed the fact that the 
epidemiological situation of Mexico demands more and better medicines. 
 
Finally, the new NPP draft document omits the use of internationally recommended indicators 
for monitoring and evaluating the NPP. 
 
 
Noteworthy, within the final document, the issue of rational use of medicines was 
largely disregarded.  Particularly, improving prescription was described as being out of 
the scope of the MOH and the NPP (See Figure 5.1, below). 
 
When asked why the document barely mentioned interventions to improve prescription 
practices (as recommended by the WHO), a key participant from COFEPRIS (MOH3) 
explained that prescribing “is not part of the pharmaceutical process” and the NPP 
document was intended to deal with medicines and the pharmaceutical process. As he 
further asserted: 
“Teaching doctors how to prescribe? No, that is not related to a pharmaceutical 
policy […] That is out of place. Because people at WHO sit down to write and 
they do not see how things are done in reality” (MOH3) 
 
 When prompted about why interventions on containing AMR were omitted, this same 
informant explained: “That’s another issue. It’s not pharmaceutical policy. It’s policy on 
how things have to be done in a hospital, not in a pharmacy […]” (MOH3) 
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Figure 5.1. Processes that pertain to the pharmaceutical policy. Reproduced and translated 
from: reference SSA 2005: 16.  
 
 
5.4 Policy entrepreneurs, and coupling of streams  
 
In the present study, no policy entrepreneurs on AMR were identified. AMR 
containment was backed by groups of academics and members of professional 
associations who did not engaged actively on pushing their views of the AMR problem 
or specific proposals outside their own groups; they had scarce interaction with policy-
makers. A tightly knit policy community did not emerge around the issue of AMR to 
push a single “pet” policy solution. On the contrary, little interaction took place among 
the infectious-disease specialists, academics and civil society groups in favour of 
achieving an AMR policy. 
 
The new government and the health policy reform implemented under the Fox 
administration opened a political window to bring medicines high on the agenda and for 
developing a national pharmaceutical policy. Nevertheless, there were no policy 
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entrepreneurs taking advantage of this open window to bring about the problem of 
AMR and ad- hoc policies. The formulation of the NPP was a missed opportunity to 
develop policies directed to deal with medicines use and AMR. 
 
The failure of this administration to discuss AMR policy alternatives in any significant 
manner may be explained by three factors connected to the generation and survival of 
ideas, the role of actors, and the health-policy-making process. To begin with, policy-
makers did not have data to recognise AMR as a problem, and there were many 
different understandings on this issue. Inappropriate antibiotic use was regarded as a 
complex issue, connected to many other problems, such as limited access to health 
services, lack of mechanisms to regulate the private sector, or cultural aspects.  While 
stakeholders had various ideas on how to deal with AMR, there was overall lack of 
information on the technical feasibility of the possible interventions, which may have 
resulted, in turn, from paucity in studies regarding medicine use in Mexico and 
unawareness of the relevant international recommendations on this matter. Given the 
fragmented national health-care system, policy solutions achieved by the IMSS were 
not disseminated to the rest of the system. Furthermore, some of the internationally 
recommended policy alternatives were considered to be hardly feasible due to lack of 
resources and the anticipated opposition of some groups. It was believed that 
physicians, pharmacists and the public at large would reject a regulation on prescribing 
and dispensing procedures. Finally, the AMR policy solutions “floating around”, as 
described by Kingdon, were not coupled to a pressing problem; in fact, policy solutions 
related to “limiting” medicine use were incompatible with the prevailing health policies 
directed to increase access to medicines. 
 
Concerning the health-policy-making process, the NPP was commissioned as a tool for 
improving the provision of medicines in the context of the newly adopted health reform. 
It was not the result of a planned process pursuing a comprehensive medicines policy 
with the open participation of a wide variety of actors. The objectives and content of the 
document reflect the concerns of the stakeholders who drafted it. The groups 
interested in improving medicine use and containing AMR (from inside and outside the 
government) were not included in the process.  
 
The MOH office that could had a leadership on promoting policies on rational use of 
medicines (Health Quality Directorate), was overwhelmed by the presidential priority of 
increasing medicines supply in public health services. Furthermore, the two offices in 
charge of drafting the document (COFEPRIS and the Economic Analysis Unit) believed 
that promoting rational use of medicines and containing antimicrobial resistance were 
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irrelevant to their jurisdictional attributions and exceeded what they perceived as the 
scope of a pharmaceutical policy. None of these governmental offices were in charge 
of implementing important AMR policy components, namely, integrating essential 
medicine lists, formulating standard-treatment guidelines, certifying hospitals, 
developing educational campaigns, or engage in antimicrobial resistance surveillance; 
relevant offices with those attributions did not participate on the NPP drafting, AMR 
was therefore “defined away” by the drawing of jurisdictional boundaries.  
 
 
5.5 Summary and conclusion 
 
According to Kingdon’s stream theory, problems are not addressed until they are 
recognised as such, policy solutions evolve sufficiently, and policy makers have a 
motive and an opportunity to adopt them. Policy windows for addressing a problem 
typically open when these three streams converge, and this generally occurs after a 
change in the problems stream or the politics stream, denominated by Kingdon a 
“problem window” or a “political window”. 
 
Why did AMR not reach the health policy agenda during the 2000-2006 administration 
in Mexico, and how that affected the adoption of related policies?? During the 2000-
2006 Fox administration, the new government and the health reform it promoted 
opened a political window for placing medicines high on the governmental agenda and 
for discussing policy alternatives that eventually crystallised into the NPP proposal in 
2005. This was favoured by the leadership of the Health Minister (Gómez-Dantés et al., 
2015). 
Is noteworthy that, contrary to the scarce participation of academics and public health 
experts on drafting the NPP, representatives from the pharmaceutical industry were 
fully engaged in the process; industry groups were regarded as “experts on 
pharmaceutical policy” (MOH6). The range of participants in the policy process 
(dominated by governmental and industry groups) could be related to longstanding 
tradition of State-centred and enclosed policy making in Mexico (Cabrero, 2000); but 
also to the increasing openness of policy-making to business groups during President 
Fox administration (Camp, 2012; Díez, 2006; Thacker 2012); and the experience of the 
well-organized pharmaceutical industry in influencing policy making (Shadlen, 20009). 
 
While the open politics window allowed medicine-related subjects to reach the decision 
agenda, especially with regard to improving access, policies dealing with use of 
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medicines and AMR did not prosper. AMR was not able to reach the decision agenda 
given the processes operating within each stream: lack of congruence among the 
perceptions of different stakeholder groups regarding the problem and policy solutions; 
no active policy entrepreneurs coupling problems with solutions; lack of governmental 
policy venues related to AMR; and an unfavourable political climate for regulating 
medicine use, given the demand from the population for increasing access to 
medicines and the commitment declared by the Minister of Health and the President to 
act upon it. In this way, the policy adopted largely disregarded contents related to 
improving medicines use and addressing AMR.  
However, during the following administration a window of opportunity opened for 
placing medicines use and AMR on the decision agenda. 
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6. RESULTS (II): A WINDOW OF OPPORTUNITY FOR 
ANTIBIOTIC MISUSE AND RESISTANCE POLICIES DURING 
THE 2006-2012 ADMINISTRATION 
 
 
This second empirical chapter presents findings related to second specific objective 
stated for the present study: To analyse the factors related to AMR agenda placement 
in Mexico during the 2007-2012 administration, by focusing on problem definition and 
recognition, the political context, the development and perception of policy alternatives, 
and the role of policy entrepreneurs. The information presented was obtained from 
interviews conducted with stakeholders during 2007-2008, the analysis of official 
documents from the legislative and executive, as well as MOH press releases, in which 
attention to AMR was explored. Additionally, this chapter describes the results an 
analysis of printed media covering the 2009-2012 period, which sought to further 
illuminate AMR agenda status, as well as the process of developing the regulation of 
antibiotic sales during this period.6 
 
 
6.1 Political context 
 
Newly elected President Felipe Calderón belonged to the same right-wing political 
party (PAN) as the previous administration. He was in office between December 1, 
2006, and November 30, 2012. President Calderón appointed José Angel Córdova, a 
physician and politician, as Minister of Health. 
 
The National Health Programme (NHP) 2007-2012 pursued similar objectives to those 
of the previous NHP, with the MOH still focusing its efforts on incrementing the Seguro 
Popular coverage. Additionally, the rise on obesity and overweight, as well as non-
communicable diseases (NCDs) documented by the 2006 National Health Survey, 
aided these topic to raise in the health policy agenda (see section 2.2.4). During this 
administration, a Presidential decree led to the creation of the National Council for the 
Prevention and Control of Non-communicable Diseases. One of its many 
responsibilities was to support the inclusion in the essential medicines list of medicines 
and medical supplies for NCDs.  
                                                             
6
 Some of the results of the analysis of printed media coverage (encompassing the 2009-2010 
period) have been presented in: Dreser, et al. (2011a) and Dreser, et al. (2012). A description of 
some aspects of the policy process presented in this chapter has been summarized in Zaidi, et 
al. (2014). 
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The NHP 2007-2012 pointed out that access to medicines remained a predominant 
demand from the population and a challenge for the health system. However, 
differently from the previous programme, the new NHP text included lines of action 
specifically on the use of medicines in two of its ten strategies, namely, prevention 
against sanitary risks (under the leadership of the regulatory agency, COFEPRIS) and 
implementation of a health care quality system named SICalidad (under the leadership 
of the Health-Quality Directorate). The first strategy specified the need to address the 
risks of self-medication, and proposed intensifying pharmacy inspections to ensure the 
sale of prescription-only medicines as specified. 
 
The second strategy (on health care quality), one central line of action was: “to design 
and implement a National Medicine Policy to promote the development of efficient 
models for medicine provision”. Furthermore, concerning the SICalidad system, the 
strategy proposed other lines of action: to promote evidence-based medicines and 
standard treatment guidelines (STG); prevent intra-hospital infections; generate 
projects for rational use of medicines at the sub-national/state level; and transform the 
functions of hospital pharmacies from administrative duties into professional patient-
oriented activities. 
 
Despite the inclusion of action lines on self-medication, STG and rational use of 
medicines, all of them intimately related to use of antibiotics, the new NHP document 
did not state the issue of AMR explicitly. Likewise, although one of the NHP strategies 
called for strengthening disease prevention and control, antimicrobial resistance was 
not accented in its own right; it was mentioned only marginally under other lines of 
action concerning tuberculosis and HIV/AIDS. Overall, improving antibiotic use and 
containing antimicrobial resistance were overlooked by the new NHP. 
 
Despite the fact that the NHP proposed the development of a National Medicine Policy, 
this was not achieved as a single-standing official document. With the customary 
turnover of officials following the election of a new government in Mexico, the 2005 
momentum for formulating an NPP document was diluted among the new MOH staff 
and priorities. Moreover, it became unclear which MOH office would take the 
leadership in organising the design of the National Pharmaceutical Policy (NPP). 
Responsibilities were assigned to different offices, and several official documents 
related to pharmaceutical policies were elaborated. 
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As early as February 2007 (only three months into rule), President Felipe Calderón 
announced the "Compromise to establish a national policy of sufficient, available and 
fair-priced medicines", undersigned by representatives of the public and private 
sectors. He recognised the pressing issues of insufficient medicines in public services 
and overpriced medicines in the private sector. Following this initiative, one year later, 
an inter-ministerial Coordinating Commission for Price Negotiations on Medicines and 
other Health Products was established with the objective of improving medicines 
supply in the public sector.7 
 
In the legislative field, pharmaceutical policies were also the subject of discussion. In 
2008, the Congress Competiveness Committee, with the participation of the MOH, the 
Ministry of the Economy and representatives from the pharmaceutical industry, 
organised a Forum to Advance the Competitiveness of the Pharmaceutical Sector in 
Mexico.8 At the Forum, NPP was described as having only a threefold objective on 
supply and access, quality and safety, and innovation. Medicine use was left aside. 
 
In 2007, as an upshot of the NHP and the aforementioned presidential “Compromise”, 
the MOH published a Specific Action Plan for Expanding Access to Medicines.9 While 
the Plan recognized four of the main NPP objectives, promotion of rational use of 
medicines included, the text indicated that its focus was set primarily on improving 
medicine supply and access. Regarding rational use of medicines, it merely announced 
the creation of an online information centre for medicines (which was not achieved) and 
the promotion of professional pharmacies in hospitals. The task of coordinating the 
design of a National Hospital Pharmacy Model,10 officially launched in 2009, was 
assigned to the General Directorate of Health Planning and Development (DGPLADES 
by its Spanish initials), with support from the Health Quality Directorate and the active 
participation of professional pharmaceutical associations. The model included a 
proposal for creating therapeutic committees to promote rational use of medicines in 
hospitals –which included developing antibiotic policies. 
 
With regard to the health care quality action lines proposed under the NHP, an 
interviewee from the Health Quality Directorate explained that time and resources for 
addressing use of medicines were freed up after the most pressing issues of SP 
                                                             
7
 “ACUERDO por el que se crea la Comisión Coordinadora para la Negociación de Precios de 
Medicamentos y otros Insumos para la Salud”. Diario Oficial de la Federación, February, 2008. 
8
 “Foro para impulsar la competitividad del sector farmacéutico en México”. Cámara de 
Diputados (Chamber of Representatives). November, 2008. 
9
 “Programa de Acción Específico 2007-2012: Mejora del Acceso a Medicamentos”, Ministry of 
Health, 2007. 
10
 “Modelo Nacional de Farmacia Hospitalaria”, Ministry of Health, 2009. 
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coverage and medicine provision were dealt with. This clarifies why the Calderón 
administration was able to consolidate the National Hospital Pharmacy Model and 
develop an extensive STG catalogue,11 both of which concentrated a great deal of 
effort. Furthermore, the Health Quality Directorate launched a Programme for Rational 
Use of Medicines oriented primarily to implement clinical pharmacies and therapeutic 
committees in hospitals. Despite these initiatives, the establishment of national or sub-
national bodies to coordinate policies on use of medicines and monitor their impact 
were not considered. The scope of the Programme did not include community 
pharmacies, primary-care facilities or actions targeting the population such as 
educational campaigns on rational use of medicines. In hospitals, monitoring under the 
Programme for Rational Use often consisted in documenting the mere existence of the 
therapeutic committees, not their actual functioning. Information indicating if and how 
hospitals developed antibiotic policies is unavailable; however, according to 
interviewees, the priority in hospitals has been strengthening pharmacy services, and 
collaboration needed to develop antibiotic policies (particularly involving laboratory 
facilities and infectious diseases specialists) is still a challenge. 
 
Lastly, with regard to the NHP strategy against health hazards, during the first years of 
the new administration, COFEPRIS devoted considerable effort not only to revising and 
renewing the national registry of medicines, but also to confiscating so-called “miracle 
products”, in line with its objectives on medicine quality assurance, an issue also 
supported by pharmaceutical industry associations. Regarding the regulation of 
prescription-only-medicine sales and public education on the risks of self-medication 
(lines of action also described on COFEPRIS Specific Action Programme12), no visible 
actions emerged until 2010 for reasons described in subsequent paragraphs. 
 
                                                             
11
 The impetus given to the formation of a National Catalogue of STG was unprecedented. A 
shared responsibility was assigned: the National Centre for Health Technology Excellence 
(CENETEC) was in charge of producing the STG; and the Health Quality Directorate was in 
charge of disseminating them. Up to 2011, more than 300 STG had been published; however, 
there were a number of barriers to implementation, including the limited validation of STG by 
medical associations (such as the infectious diseases association) and the lack of 
harmonization between STG and the essential medicines list. Furthermore, a mechanism to 
promote the use of STG for medical undergraduate training, continuing medical education and 
monitoring of prescribing practices within health services, was not established. These barriers 
might have affected STG legitimacy and had limited their utilization as input to improve 
prescription practices (Wirtz, et al. 2012). Furthermore, the drafting of the new STG for 
infectious diseases did not take into consideration local and updated information on 
antimicrobial resistance, as they were drafted based on evidence from national and international 
papers, and not in national reports on antibiotic resistance (personal communication, 
CENETEC). Thus, some of the STG warned about resistance rates for recommended antibiotics 
citing data of investigations conducted outside Mexico several years ago. These factors limited 
the potential relevance of STG to improve the prescription of antibiotics. 
12
 “Programa de Acción Específico 2007-2012. Comisión Federal para la Protección contra 
Riesgos Sanitarios”, Ministry of Health, 2009. 
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In summary, the political context for health policies provided somewhat of a continuum 
from the 2000-2006 Vicente Fox to the 2006-2012 Felipe Calderón administration. With 
the same political party in rule, improving access and the provision of medicines 
remained high on the governmental agenda. At the beginning of the Calderón 
administration, relevant policies were developed beyond the scope of the MOH and 
with direct backing from the president. However, while drafting a national 
pharmaceutical policy was listed as a core component of the 2007-2012 NHP, no 
agreement was reached on the formulation of a single all-inclusive policy document; 
instead, an array of governmental offices with different perspectives on NPP scope 
were charged with addressing disaggregated policy elements. 
 
In contrast with the high-level inter-ministerial commissions and legislative discussions 
dealing with the different aspects of improving access to medicines and stimulating 
innovation (like the ones organized by the Chamber of representatives) 13, the NPP 
objective of promoting rational use of medicines was delegated to diverse, scarcely 
interconnected MOH offices. Similarly to the previous administration, no national-level 
body was instituted to coordinate policies on use of medicines, in accordance with 
international recommendations, and responsibilities remained fragmented. 
Furthermore, the newly created Programme for Rational Use of Medicines mentioned 
above directed most of its actions to hospital settings, disregarding other dimensions of 
medicine use. 
 
Finally, it is important to mention that, in the last months of 2007, southern Mexico 
suffered severe floods during one of the worst natural disasters in the history of the 
country, leaving a toll of over 1,000,000 affected individuals.14 With floods recurring in 
2008, much of MOH’s attention was deviated by both disasters towards the prevention 
of cholera and other flood-related outbreaks. One of the interviewees, expert in 
antibiotic resistance and health official during this period, explained that, in fact, it was 
intended to develop and antibiotic resistance surveillance system during this 
administration within the MOH Epidemiological Surveillance Centre. However, this 
initiative was cancelled when epidemiological surveillance in relation to the 2007-2008 
floods (and posteriorly the 2009 influenza epidemic) became priorities. 
 
                                                             
13 “Foro para impulsar la competitividad del sector farmacéutico en México”. Cámara de 
Diputados (Chamber of Representatives). November, 2008 
14
 CNN. “Devastating floods prompt outbreak fears in Mexico”, in: 
http://web.archive.org/web/20071104102744/http:/www.cnn.com/2007/WORLD/americas/11/02/
mexico.floods.ap/index.html. 
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During the first half of the 2006-2012 administration, AMR was omitted from the 
governmental agenda for a number of reasons: the prevailing priorities were providing 
access to medicines, responding to health emergencies and NCDs. No changes 
occurred in terms of indicators or focal events that may have brought attention to the 
issues of antibiotic misuse and resistance; and no office or institution was designated 
to coordinate actions on use of medicines. 
 
However, unexpectedly, in 2009, a health crisis brought public and governmental 
attention to inappropriate use of antibiotics: the influenza A H1N1 pandemic. 
 
 
6.2 Problem recognition and definition 
 
In early April 2009, national health officials issued an epidemiological alert due to 
atypical and increasing cases of influenza. Confirmation of a new virus and initial 
uncertainty as to the nature of the disease -marked by a high case-fatality rate and 
rapid spread to other countries- triggered national and international concern. Within 
days, schools closed in Mexico City and the surrounding states and, by late April, all 
non-essential activities had been suspended, with social distancing measures 
sustained for two weeks (Sarti, et al., 2010). Flights to Mexico were cancelled by some 
countries and trade was halted by others. The WHO soon declared a public-health 
emergency of international concern, calling all countries to activate their pandemic 
preparedness plans, and by June, it had classified the outbreak as a pandemic. During 
these turbulent months, the evolution of the epidemic and Mexico’s response were kept 
under close scrutiny by the national and international media, with the MOH organising 
press conferences almost daily. 
 
As more information on the nature of the disease transpired, one question arose 
among journalists, the scientific community and the Mexican population at large: Why 
were the fatal cases of novel influenza disproportionally high among the Mexican 
population, albeit the extension of the virus across numerous countries?15 When Health 
Minister Córdova was asked this question during a press conference on May 6th, he 
answered that there was at least one “very convincing” factor: 
 
                                                             
15
 Alberto Aziz Nassif, “¿Cambiará la fotografía?”, El Universal, May 5
th
 2009, available at 
http://www.eluniversal.com.mx/editoriales/43963.html (accessed on September 9
th
, 2014); 
Ricardo Alemán “Morir de gripe” (Column “Itinerario Político”), El 
Universal, May 4
th
, 2009, available at http://www.eluniversal.com.mx/columnas/78006.html 
(accessed on June 21
st
, 2009). 
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Many people, especially between the ages of 20 and 50 years, do not seek 
medical care when they experience the first symptoms of an illness. Without 
hesitation, they self-medicate and ingest antibiotics or other medicines that 
should only be dispensed (…) with a prescription. This complicates their clinical 
condition.16 
 
This one single declaration attracted a great deal of public attention to the issue of self-
medication with antibiotics. Warnings against self-medication, particularly with 
antibiotics, and delayed medical care were reiterated throughout media declarations by 
medical associations and health officials as well as in governmental campaigns against 
influenza. Interestingly, in June, several media notes deliberated on the determinants 
of self-medication, discussing the issues of poor access to medical care and lax 
pharmacy regulations as underlying factors in the sale of medicines without 
prescription. Journalists interviewed academics, representatives of pharmacy 
associations and health officials regarding the lack of enforcement of the antibiotic-
sales regulation (Zuckerman, 2009).17 
 
In early October 2009, a new declaration from the Director of the National Institute of 
Respiratory Diseases was covered by the media. In his declaration, he confirmed that, 
while the majority of critically ill patients with influenza had indeed self-medicated with 
antibiotics, in many other cases, physicians had erroneously prescribed antibiotics to 
patients with influenza. This declaration was published by one the major newspapers in 
Mexico under the following piercing headline: “Antibiotics heighten the epidemic”.18 
 
Although this medical director publicly stressed the need to improve antibiotic 
prescribing, this theme had scarce resonance on the media. Similarly, media reporting 
on antibiotic use and its relation to bacterial resistance was infrequent around that time. 
 
                                                             
16
 Press conference. “Conferencia de prensa que ofrecieron José Ángel Córdova Villalobos, 
Secretario de Salud; Maki Esther Ortiz Domínguez, Subsecretaria de Innovación y Calidad de la 
Secretaría de Salud, y Directora General del DIF en la mañana del 6 de mayo”, Secretaría de 
Salud. May 6
th
, 2009, available at: http://www.presidencia.gob.mx/2009/05/conferenciade-
prensa-que-ofrecieron-jose-angel-cordova-villalobos-secretario-de-saludmaki-esther-ortiz-
dominguez-subsecretaria-de-innovacion-y-calidad-de-lasecretaria-de-salud-y-directora-general-
d/ (accessed on October 5
th
, 2009). 
17
 Listen also to: “Antonio Pascual Feria, presidente Anafarmex, habla de la situación de los 
medicamentos que se venden sin receta en farmacias”, W Radio, radio programme: “Hoy por 
Hoy” (audio interview, 15:26min), broadcasted on June 4
th
, 2009, available at 
http://www.wradio.com.mx/escucha/archivo_de_audio/antonio-pascual-feria-presidente-
anafarmex-habla-de-la-situacion-de-los-medicamentos-que-se-venden-sin-receta-en-
farmacias/20090604/oir/823359.aspx (accessed on July 25
th
, 2009); “Anahí Dreser, 
investigadora en ciencias médicas, habla de la automedicación” , W Radio, radio programme: 
“Hoy por Hoy” (audio interview, 19:04min), broadcasted on June 9
th
, 2009 available at 
http://www.wradio.com.mx/escucha/archivo_de_audio/anahi-dresser-investigadora-en-ciencias-
medicas-habla-de-la-automedicacion/20090609/oir/826058.aspx (accessed on July 25
th
, 2009). 
18
 Laura Toribio, “Antibióticos aumentan la epidemia”, Excélsior, October 8
th
, 2009, page 14. 
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On October 18, 2009, Health Minister José Ángel Córdova declared that, because the 
practice of self-medication in the influenza pandemic had “caused the death of many 
Mexicans”, he was initiating a process to ensure that “antibiotics for the respiratory 
tract” would be sold with prescription only. This declaration was covered by one 
newspaper under the headline “Because of influenza, antibiotics only with 
prescription”.19 
 
One month later, a top official from COFEPRIS, the agency tasked with controlling 
antibiotic sales in pharmacies, declared that the agency was revising all registered 
antibiotics (around 4,000) in order to “identify those related to health complications in 
influenza patients.”20 No further official declarations were made on the subject for some 
months, and there weren’t newspaper notes with this regard. It is probable that the 
media lost interest in the problem because it was reduced to only a limited set of 
antibiotics and COFEPRIS was already dealing with it. 
 
However, the declaration of Health Minister Córdova was perceived by some 
academics and medical associations as an opportunity to bring AMR to the 
governmental agenda and formulate an ad-hoc national policy. The circumstances are 
described below. 
 
6.3 Development of a policy proposal 
 
In October 2009, during its Annual Meeting in Guadalajara, the Mexican Association of 
Infectious Diseases and Clinical Microbiology (AMIMC by its Spanish initials) organised 
a meeting of experts to prioritise interventions towards two objectives: on one hand, to 
promote adequate antibiotic use and contain antimicrobial resistance in the human and 
veterinary health sectors; on the other, to recommend action lines to decision makers. 
The meeting was a response to two facts: first, the realisation that, almost ten years 
after the launch of its 2001 Guadalajara Declaration on Antimicrobial Resistance, none 
of the action lines proposed in the document had been implemented, and thus there 
was a need to reactivate the initiative; second, the recent public discussion and 
intention of action by the MOH regarding the perils of self-medication with antibiotics. 
 
Participants in the meeting of experts comprised not only researchers from the INSP, 
infectious-disease specialists and veterinarians, but also representatives from 
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 Nancy Narváez Cid, “Por influenza antibióticos sólo con receta”, Ovaciones, October 18
th
, 
2009, page 5. 
20
 Ángeles Cruz Martínez, “Seguros y eficaces antivirales próximos a caducar Cofepris”, La 
Jornada, November 5
th
, 2009, page 39. 
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academic institutions and hospitals throughout Mexico, the Alliance for the Prudent Use 
of Antibiotics (APUA), the World Organisation for Animal Health (OIE by its Spanish 
initials), and the pharmaceutical industry. Over the following few months, a sub-group 
of experts worked under the leadership of INSP, AMIMC and APUA to elaborate a 
consensus document that was ultimately endorsed by the principal medical and 
veterinary associations and institutions at the national level. The ensuing proposal, 
drafted as a policy brief,21 summarised the AMR situation in Mexico and enumerated 
the existing international recommendations on AMR and use of antibiotics. It called for 
seven priority actions to improve human/veterinary22 antimicrobial use and mitigate 
resistance in Mexico; the first involving the creation of a multidisciplinary advisory 
group on the use and regulation of antimicrobials (see Box 6.1). 
 
During the first quarter of 2010, printed and electronic versions of the proposal were 
sent to the head offices of the MOH (including COFEPRIS) and the Ministry of 
Agriculture. They were also submitted to the health and agriculture commissions of the 
Mexican legislature, and to various interest groups including professional, pharmacy 
and pharmaceutical industry associations. While press releases on the subject were 
run in major newspapers, the proposal was not mentioned at the time by journalists or 
health officials’ speeches. 
 
 
Box 6.1 Priority actions recommended in the INSP-AMIMC-APUA proposal for improving 
antibiotic use in Mexico, 2010 
 
1.- Creation of a multidisciplinary advisory group for antimicrobial use, regulation and 
licensure. 
2a.- Enforcement of national regulations requiring human and veterinary antibiotics to be 
dispensed only with prescription 
2b.- Stricter control of the critically important antibiotics 
3.- Establishment of national guidelines for the use of antibiotics for growth promotion and 
metaphylaxis in animals 
4.- Review of the licensure requirements for antimicrobial to safeguards antibiotics for 
human use 
5.- Creation of legal mechanisms to guarantee the quality, safety and efficacy of  human 
and veterinary antibiotics 
6.- Implementation of national surveillance systems for antibiotic usage and antimicrobial 
resistance 
7a.- Development of educational programs for pharmacists, physicians and veterinarians 
7b.- Development of public education campaigns through mass media 
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 Dreser, A., M.B. Zaidi, M.A. Peredo, 2010 (coordinators): Regulación y promoción del uso 
adecuado de antibióticos en México: Propuesta de lineamientos para la acción. Available at 
http://www.insp.mx/images/stories/Lineas/medicamentos/doc/acciones_antibioticos.pdf 
22
 There were some advances with regard to the strategies proposed for the veterinary sector; 
this aspect is not described here, but is explained elsewhere (Zaidi, et al., 2014). 
166 
 
6.4 A window of opportunity to develop policies on antibiotic use? 
 
On March 24, 2010, the President of the Mexican Red Cross was invited for the first 
time to participate in a National Health Council meeting. At a press conference after the 
meeting, without prior notice, he declared that, in a “historical voting”, the Council had 
decided to forbid the sale of antibiotics without prescription: “Beginning in April, there 
will be no more antibiotics without prescription, no more self-medication endangering 
the lives of Mexicans.”23 This declaration created an unprecedented public debate that 
gained prominence and space on the media over the following months. Press 
conferences and bulletins were organised by diverse stakeholders, while opinion 
columns in newspapers, discussion forums on the Internet, and special programmes on 
radio and television covered the enforcement process. 
 
The day after the declaration, COFEPRIS health officials confirmed that, in effect, the 
agency had developed such an initiative, and antibiotic sales would be regulated; 
however, not as soon as April, since pharmacy personnel needed to be trained and 
mechanisms installed to supervise pharmacies. Penalties faced by noncompliant 
pharmacies were also mentioned. Among the earliest statements on the subject were 
those of the largest independent-pharmacy association ANAFARMEX and the 
association of national pharmaceutical laboratories AMELAF requesting a deferral of 
the policy, under the argument that more time was needed to diffuse pertinent 
information among the population, to change the “Mexican self-medication culture”, and 
to warn the public of a possible “black market” of antibiotics and prescriptions.24 
 
Notoriously different from previous official pronouncements focusing on the influenza 
pandemic, this time, the topic of antimicrobial resistance came to light, with Health 
Minister José Ángel Córdova declaring that the decision to regulate antibiotic sales had 
been taken because “the practice of self-medication had generated antibiotic 
resistance, rendering antibiotics useless.”25 Notwithstanding the declared interest in 
antimicrobial resistance, the problem was linked to self-medication only, not to 
inappropriate prescribing practices. As the Health Minister explained in a press 
conference with the representatives of the association of pharmacies and distributors 
ANADIM: “Regulation is not just a whim: the Mexican population is becoming resistant 
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 Laura Toribio, “Anuncian venta de antibióticos sólo con receta”, Excélsior, March 25
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, 2010, 
page 22. 
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 Ruth Rodríguez, “Farmacias quieren prórroga en recetas”, El Universal, March 31
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, 2010, 
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to antibiotics as a consequence of self-medication” and quoted some of the figures on 
antimicrobial resistance stated on the INSP-AMIMC-APUA policy proposal.26 Even 
President Felipe Calderón was quoted supporting the regulation and mentioning the 
burden of antibiotic resistance policy.27 Other declarations by COFEPRIS officials and 
Health Minister Córdova included almost textual fragments of the policy proposal 
developed by INSP-AMIMC-APUA to explain the need for enforcing antibiotic sale 
regulations. Nevertheless, no official declaration and only a few newspaper notes 
referred explicitly to the tripartite policy proposal and its suggested lines of action. 
When during a press conference Health Minister Córdova was confronted with the 
argument that self-medication was a consequence of insufficient access to health care, 
and an antibiotic policy would therefore adversely affect the poorest families, he 
rebutted that, with the expanded coverage of the Seguro Popular, that argument was 
no longer valid (see footnote 21). 
 
Soon after its announcement, the policy was opened to public discussion on a 
governmental website of the Federal Commission of Regulatory Improvement 
(COFEMER, by its Spanish). COFEPRIS supported the regulation underlining the 
“risks of self-medication with antibiotics, which were evident during the influenza 
epidemic”. In total, 9 stakeholders sent communications against the regulation; these 
were:  representatives from the national pharmaceutical associations AMELAF and 
AMEGI (2); an international pharmaceutical company (GSK) (1); the association of 
independent pharmacy owners UNEFARM, and the associations of smaller pharmacy 
chains Farmapronto, Profarmex, and ANAFAR (4); the association of medicines 
distributors DIPROFAR (1); and the association of supermarkets and private outlets 
ANTAD (1). They argued that the regulation was incompatible with the current 
legislation; and that it imposed high costs to the private sector.  
 
Despite the arguments exposed in the public hearing, COFEMER approved the 
regulation with only minor changes, one of them delaying implementation for some 
months. In May 2010, the enforcement policy was officially enacted as a ministerial 
agreement, effective from August of the same year, under the title: Agreement on the 
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 “Versión estenográfica de la conferencia de prensa presidida por los doctores José Ángel 
Córdova Villalobos, Secretario de Salud Federal; Miguel Ángel Toscano Velasco, Comisionado 
Federal para la Protección contra Riesgos Sanitarios (COFEPRIS); y Miguel Ángel Salim Alle, 
Vicepresidente de la Asociación Nacional de Distribuidores de Medicamentos, A. C. (ANADIM), 
y Director General del Instituto de Seguridad Social del Estado de Guanajuato (ISSEG), 
realizada en el “Salón Las Joyas” del Hotel Fiesta Americana, de esta ciudad, posterior a la 
Asamblea General Ordinaria de dicha Asociación Nacional.” April 24
th
, 2010. 
27
 Press Release No. 271 “Antibióticos contendrán una advertencia sanitaria en sus etiquetas” 
Ministry of Health, June 30
th
, 2010, available at 
http://www.salud.gob.mx/ssa_app/noticias/datos/2010-06-30_4646.html (accessed on April 16
th
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Guidelines for Regulating the Sale and Dispensing of Antibiotics.28 The beginning of 
Agreement implementation was marked by a ceremony organised by COFEPRIS,29 
with an abundant presence of the media. Invited speakers were representatives of the 
pharmaceutical industry (CANIFARMA), medicines distributors and private outlets 
(ANTAD, the association of supermarkets, and ANADIM, representing large pharmacy 
chains) and an infectious diseases specialist –but none of the specialists that 
participated on the INSP-AMIMC-APUA proposal. The MOH press release that 
followed the ceremony, stated: 
 
“The decision to control the sale of antibiotics was taken after confirmation that 
more than half of the population self-medicates or stops treatment, which 
contributes to bacteria becoming resistant to these drugs, in addition to the 
adverse reactions produced, such as nausea, headache, tachycardia, 
hypotension, urticaria, erythema, skin rashes and others when given 
incorrectly.”30 
 
The Ministerial Agreement enforces the existing regulation of antibiotic sales with 
medical prescription only, as established under the General Health Law. Additionally, it 
requires all systemic antibiotic prescriptions to be registered and retained for one year 
in pharmacies, imposing high penalties for noncompliance, the rescission of business 
licenses included. Furthermore, the Ministerial Agreement includes some paragraphs 
indicating other requirements for prescription and dispensing. Particularly, it stresses 
that prescription can use generic or trade names of medicines; but if a prescription is 
written using a trade name, only that trade name can be sold. The enforcement policy 
for antibiotic sales applied to 2,000 medicines, roughly between one fourth and one-
fifth of all medicines commercially available in Mexico.  
 
The text of the published Ministerial Agreement incorporated several paragraphs from 
the INSP-AMIMC-APUA proposal, including a description of the problem of AMR in 
Mexico, and the AMR recommendations issued by the WHO. Nevertheless, it omitted 
information concerning inadequate medical prescription and use of antibiotics in food 
animals, and failed to cite the priority actions enumerated in the proposal. Likewise, the 
public information campaigns disseminated by COFEPRIS, which lasted only a few 
weeks, focused on the adverse health effects of self-medication with antibiotics, 
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 “ACUERDO por el que se determinan los lineamientos a los que estará sujeta la venta y 
dispensación de antibióticos”. Diario Oficial de la Federación, May 27
th
, 2010. 
29
 Press Release No. 364, “A partir de hoy, venta y dispensación de antibióticos sólo con receta 
médica” Ministry of Health, August 25
th
, 2010, available at 
http://portal.salud.gob.mx/redirector?tipo=0&n_seccion=Boletines&seccion=2010-08-
25_4749.html (accessed on April 16
th
, 2012). 
30 See previous footnote. 
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stressed the relevance of obtaining medical advice, and explained the new procedures 
established by the Ministerial Agreement, but provided little information on antibiotic 
use and on antibiotic resistance. 
 
6.4.1 Media Coverage of the policy process 
 
According to the analysis of the printed media coverage undertaken between January 
2009 and December 2010, the most notorious among stakeholder responses to the 
policy were the actions of pharmacy owners associations. Early on, an alliance called 
FADIF31 was built between some independent and chain pharmacy associations, 
medicine distributors and outlet organisations. This alliance, built as a common front to 
to negotiate medicines-related policies with health authorities, demanded the 
government to delay policy implementation and provide pharmacy information systems 
to facilitate the new dispensing procedures. They also organised frequent press 
conferences airing their views on the policy.  
 
Apart from that alliance, the media also reported the different strategies developed by 
independent pharmacy associations and associations of large pharmacy chains. 
Specifically, the independent-pharmacy association, ANAFARMEX, was the one that 
attained more media coverage. In their press conferences, they asked the government 
to provide loans for modernising small pharmacies, and publish a comprehensive 
database of all registered physicians in Mexico as a tool for detecting false 
prescriptions; even more, they asked the health commission in the legislature to 
establish a dialogue on the regulation of pharmacies. Another pharmacy association, 
UNEFARM, organised a protest in front of the COFEPRIS building, and sent a petition 
letter to the President contesting regulation. This association argued that, with the 
regulation, thousands of independent pharmacies could close, with a dramatic loss of 
direct and indirect jobs. 
 
On the other hand, large pharmacy chains developed a strategy to buffer the impact of 
regulation by setting up physician offices attached to their pharmacies to offer cheap or 
free medical consultations and prescriptions. This “business model” of “in-situ 
physicians” was recommended by a private consulting agency explicitly “to avoid 
economic drawbacks for pharmacies facing the new regulation”.32 The number of 
pharmacies with adjacent physician offices grew 130%, from 4,300 in 2010 to 10,000 in 
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 Karla Ponce, “Farmacias, la industria que debe reinventarse”, La Razón, September 21
st
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2012, with the average number of daily medical consultations provided by their 
physicians reaching 250,000 in 2012 (Pérez-Cuevas, et al., 2014). 
 
Actions from other stakeholders during the policy-drafting period received less media 
coverage. Medical professional associations and academics published open letters 
supporting the enforcement policy for antibiotic sales, but also demanding a 
comprehensive strategy to contain antibiotic resistance and improve use of antibiotics, 
prescription practices included. Except for a few media declarations, no apparent 
actions were taken by patients, civil society groups, or national/international 
pharmaceutical companies. Congress, the legislative body in Mexico, manifested 
individual reactions towards the antibiotics policy, rather than a solid position, for 
example, through its Health Commission. While legislators of the ruling political party, 
PAN, stated their support for the policy on the media, members of the centrist PRI and 
left-wing PRD parties stressed the adverse health and economic effects of policy on 
the population, who would now be “forced to pay a doctor”, given the limited availability 
and deficient quality of public-health services. Some legislators in Congress attempted 
to promote an initiative to revoke the policy on the grounds that it was “a restrictive 
measure inconsistent with the kind of health policy needed in a country facing a 
political, economic and social crisis”; that it would trigger a black market of antibiotics.33 
Other members of Congress proposed a law reform involving harsher punishment for 
those using false prescriptions, among other strategies to intervene with the 
enforcement policy. They also demanded the executive branch of the government to 
develop information campaigns and to perform an independent evaluation of policy 
impact. Towards the end of 2010, members of Congress from the opposing parties 
organised an initiative requiring the MOH to amend the Agreement, given the logistical 
difficulties that retaining medical prescriptions would cause for both patients and 
pharmacies. None of these initiatives succeeded. 
 
With regard to media coverage and public discussions, the most prominent aspects of 
antibiotic use addressed by the news media during the policy-drafting period and first 
months of implementation (March-December 2010) were the following: the 
development of the policy itself and its objectives (29% of newspaper reports); self-
medication (13%); and the adverse economic impact of the policy (12%). Self-
medication and antibiotic resistance, frequently mentioned with regard to each other, 
were used as arguments to support the policy. Rational use of medicines, medical 
prescribing practices, and health systems were mentioned much less frequently. 
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 Elena Michel, “PRD pide posponer la receta obligatoria”, El Universal, April 5
th
, 2010, 
available at http://www.eluniversal.com.mx/nacion/176755.html (accessed on May 15
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The preponderance of these themes in the news media relates to the stakeholders 
whose voices were most frequently replicated. Overall, the MOH –particularly 
COFEPRIS– dominated media coverage with 35% of newspaper reports. Their 
declarations focused on justifying the policy and providing counter-arguments to 
critiques, for instance, by explaining that access to medical services was guaranteed 
as a result of increased SP coverage. Second ranked were pharmacies and outlet 
associations, primarily ANAFARMEX, accounting for 23% of news reports. The media 
presented their position as predominantly against the enforcement policy on antibiotic-
sales regulations, alleging economic losses and logistical difficulties for pharmacies as 
well as negative health and economic effects, especially for the poor populations with 
scarce access to health care. Editorials and opinion columns, representing 9% of the 
notes, considered the regulation appropriate, recognising the conflict between the 
problems of self-medication and antimicrobial resistance on one side and the problems 
of limited access and low quality of public medical services, on the other. The voices of 
academic institutions and medical associations, comprising 9% and 6% of reports, 
respectively, were more salient during the early stages of policy development, 
highlighting antimicrobial resistance and adverse drug reactions as serious public 
health problems. At the same time, they stressed the need for an integrated action plan 
to improve medical prescribing, increase public awareness regarding prudent use of 
antibiotics, and professionalise pharmacies. Declarations of other groups were much 
less frequently covered on newspaper notes: legislators (6%), civil society groups (5%), 
pharmaceutical industry (4%) and other private enterprises (3%). See Appendix 9. 
 
Stakeholder participation in the development of the enforcement policy on antibiotics 
and media coverage of the process was largely polarised. On one side was the MOH 
as chief supporter of the policy dominating media coverage. The main argument in 
favour of regulating antibiotics was the problem of self-medication discussed initially in 
relation to the influenza pandemic and later to antimicrobial resistance. Policy drafting 
was largely an enclosed process assigned first to the regulatory agency, COFEPRIS, 
and then to the National Health Council. No advisory groups were formed with relevant 
stakeholders to inform policy drafting. The participation of other actors in the policy 
process consisted mainly of letters and petitions to the government as well as opinions 
reflected on the media. On the other side of the polarised debate were pharmacy and 
medicine-outlet associations. As leaders of the opposition, these groups contended 
that the enforcement policy would exert a negative health and economic impact on the 
population, given the limited access to medical care; diminish their own revenues; and 
impose logistical difficulties. They also argued that regulation would trigger corruption, 
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specifically, a black market of antibiotics and prescriptions. With their views reflected 
abundantly on the media through press round-ups, these groups developed strategies 
to delay implementation, and created pharmacy clinics offering cheap or free medical 
consultation. 
 
Contrasting with the declarations of pharmacy and outlet associations, which abounded 
on the media during the entire period of policy drafting and early months of 
implementation, the statements of medical and academic organisations fizzled out over 
the policy process. The INSP-AMIMC-APUA group concentrated their efforts on 
drafting the policy proposal and organising its initial dissemination, with far less time 
devoted to maintaining a continuous dialogue with decision makers and key 
stakeholders, establishing an effective deliberative process, or communicating with the 
media. This was due in part to their inexperience in policy advocacy and social 
communication, and in part to the tightly enclosed policy process headed by 
COFEPRIS. 
 
The participation and views of other actors, such as legislative bodies, consumers and 
patient associations, in the policy process were allegedly  tangential to the polarised 
policy debate, as their views were very scarcely reported by the media  The role of 
medical associations and academic institutions was outstanding in the development 
and communication of a policy proposal, but their arguments scarcely impacted media 
coverage or the final policy product as regards the need for developing a 
comprehensive strategy to combat antibiotic resistance in human and animal health as 
well as the importance of improving the quality of medical prescription. Nonetheless, 
their policy proposal was able to reach decision makers, as parts of it were 
incorporated into official declarations and the Ministerial Agreement on regulation. 
Their proposal may have thus influenced the shift in the way the problem was framed 
by public debate: from an issue centred on influenza patients who self-medicated with 
antibiotics, to one centred on self-medication with antibiotics resulting in antibiotic 
resistance. 
 
Along the policy process, although the voice of citizens was scarcely reflected within 
the printed media articles, various on-line newspapers organized discussion forums 
with regard to the regulation of antibiotic sales. An analysis of one discussion forum34 
retrieved 395 commentaries between March 25 and December 31, 2010.  Out of these, 
184 (47%) were against the regulation, 162 (41%) were neutral or non-classifiable, and 
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only 49 (12%) were supportive of the regulation (Dreser, et al., 2011a). Some 
examples of the entries are: 
 
“We don't believe that this regulation is for the well-being of the 
population…they only care about giving more profits to the physicians.” 
27/09/10 
 
“If they already took the decision of not selling medicines without prescriptions, 
they also have to put good doctors in public clinics opened the 24 hours, so that 
we can obtain prescriptions without our pockets being so damaged”. 31/03/10 
 
“I only want to know if medicines for diabetes and high blood pressure neither 
will be sold without prescription, because we people with diabetes already know 
which medicines we have to take.” 30/08/10 
 
These quotes illustrate some of the citizen’s concerns with the new regulation35 
 
Media coverage of the policy process was high, peaking with the start of policy 
implementation in August 2010, and declining thereafter. In the following months, few 
newspaper reports and media declarations occurred on the subject, most of them 
dealing with the impact of the policy. One year after implementation, the MOH revealed 
that a 20% drop in antibiotic sales had been attained, and the independent-pharmacy 
associations underlined the economic losses pharmacies were facing, in part, as a 
result of the antibiotic policy. Public discussions on the Ministerial Agreement and AMR 
resumed briefly on two occasions, as described below. 
 
The first occasion was on April 7th, 2011, when the WHO dedicated the World Health 
Day to the theme of Antimicrobial Resistance and introduced a six-point policy package 
to combat its spread. That day, a ceremony was organised in the presidential residency 
with the attendance not only of health officials and representatives of the Legislature’s 
Health Commissions, the Pan-American Health Organization (PAHO) and medical 
associations, but also of the media. During the ceremony, the PAHO representative 
underlined the threat posed by antimicrobial resistance and recognised the headway 
that Mexico had made in regulating antibiotic sales. However, he also stressed the 
need to develop and implement a wide-ranging national plan on AMR. Contrastingly, 
President Felipe Calderón focused his speech on acknowledging the work of the health 
workers, and elaborated on the achievements of his administration regarding health-
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 These concerns may be explained, in part, by the lack of a previous educational campaign. 
As misunderstandings about antibiotics are common (e.g. people mistake Aspirin and cold-and 
cough medications for antibiotics) (Gonzales, et al., 2012) people were worried that the 
regulation would include all medicines, including over-the-counter medicines. 
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care coverage. He welcomed only briefly the exhortation from the WHO to combat 
antimicrobial resistance, and declared the following: 
 
Precisely, in Mexico, we have worked in a coordinated manner and have 
advanced in the global strategy for overcoming drug resistance. It was a 
difficult step, yes, but we took it. In Mexico, antibiotics are not –and will 
not– be dispensed without a medical prescription. We will make special 
efforts to achieve a culture of truly responsible and appropriate use of 
antibiotics to avoid running out of defences for fighting disease.36  
 
Health Minister Córdova explained that inadequate use of antibiotics became 
particularly evident during the 2009 influenza pandemic, “and this motivated, among 
other factors, the re-emergence in Mexico of the strategy to combat antimicrobial 
resistance presented by the WHO”. He further explained that, apart from sales 
regulation, the “strategy” in Mexico included health promotion initiatives and training 
activities for pharmacies. Minister Córdova concluded, however, that Mexico still 
needed “to combat customs of self-medication and inadequate medical-prescription 
practices not based on scientific evidence.” 
 
Media coverage of the ceremony underlined the same aspects raised by the President 
and the Minister of Health: Mexico has already acted upon antimicrobial resistance. 
Interestingly, during the rest of the administration, there were no more declarations or 
further evidence of the additional efforts that the president announced would be taken 
to change the culture, or customs, of inappropriate antibiotic use. 
 
Finally, the Ministerial Agreement on antibiotic sales was again publicly -but briefly- 
discussed in October 2011, when a state court judge declared the Agreement as 
unconstitutional, arguing that it was not adequately justified and undermined free trade. 
The sentence followed a motion filed by two pharmacy owners against the Agreement. 
The MOH lodged appeals against the sentence, arguing the protection of the 
population’s health, and the sentence was ultimately overturned by the Supreme Court 
of Justice.37 
 
It is important to mention that the rest of the 2006-2012 President Calderón 
administration was marked by social instability set off by the “drug war” (the armed 
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 Office of the President, “Diversas intervenciones en la ceremonia conmemorativa del día 
mundial de la salud 2011” (Discourses on World’s Health Day ceremony), April 7
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 2011, 
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conflict among rival drug cartels and against the Mexican government forces), and by 
economic contraction linked to the 2009 global recession and the deployment of 
emergency measures against the influenza epidemic (ECLAC, 2010: 173). The 
administration was heavily criticised for its perceived inefficacy in dealing with the drug 
war and the high death toll resulting from its battle against the cartels. It was also 
reproached for its perceived “overreaction” in responding to the influenza epidemic.38 It 
is very likely that this context limited the array of policy problems under consideration 
by the executive, including those that could imply criticism of public health care 
services.  
 
 
6.5 Summary and conclusion 
 
Why did AMR reach the health policy agenda during the 2006-2012 administration in 
Mexico, and how that affected the adoption of related policies? During the 2006-2012 
Felipe Calderón administration, an important window of opportunity for placing AMR on 
the governmental agenda opened as a result of a change in the problem stream. In 
Kingdon’s terms, a problem window arose and called for solutions. Despite the lack of 
indicators drawing attention to the problem of AMR, the crisis caused by the 2009 
influenza pandemic, specifically, the occurrence of influenza-related deaths caused by 
self-medication with antibiotics, posited self-medication with antibiotics as a problem in 
itself, a status that was confirmed by public statements from the Minister of Health. 
Once the problem was defined as such, a viable solution came forth: the enforcement 
policy for regulating antibiotic sales. Attempts by other groups at redefining the problem 
to include other facets of inappropriate antibiotic use, particularly inadequate 
prescribing practices, in hopes of obtaining a more comprehensive policy solution had 
minimal impact on the media policy debate and the final policy product. This may be 
related to the fact that policy-making occurred in a context of national crisis, as 
discussed below.  
With regard to the confluence of the policy stream, the problem window provided an 
opportunity to push for “pet” solutions: the MOH drove the regulation of medicine sales, 
while medical and academic associations pressed for actions on AMR. Although, in 
Kingdon’s terms, the former had been “floating around” as a policy alternative for years, 
it was considered impracticable by policy makers. It began to appear feasible during 
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 “Tras la epidemia originada en México, Influenza AH1N1 costó 0.7% del PIB: Córdova”, El 
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the Calderón administration when SP extended health-care coverage, guaranteeing 
access to medical services and medicines, and thereby neutralising the main argument 
raised against regulation. It had become evident that pharmacy regulation was failing to 
prevent self-medication with antibiotics, and this favoured the serious consideration of 
a policy alternative involving stricter regulation. Additionally, the policy proposal 
developed by INSP-AMIMC-APUA and communicated to decision makers aided in 
coupling problems to solutions; even more, it helped to legitimise a policy solution that 
had –to a large extent– already been chosen, but was likely to face opposition. 
Coupling a visible problem with a legitimate solution undoubtedly increased the 
chances for AMR to rise on the governmental agenda. 
 
Finally, regarding the politics stream, despite the opposition of some interest groups, 
there were not severe constraints to action, i.e. to adopt the policy to regulate antibiotic 
sales. Pharmaceutical business groups, through the Federal Commission for 
Regulatory Improvement (COFEMER) were able raise their voices opposing to the new 
regulation, but they were not able to withdraw it.   The influenza pandemic alongside 
the health, social and economic crisis in Mexico induced the government to take action 
to ensure that the Mexican population would never again be exposed to these risks. 
Convergence of the three streams therefore allowed AMR to reach the decisional 
agenda, and regulation of antibiotic sales to be enacted. 
 
However, a number of factors prevented the window of opportunity from opening39 wide 
enough to permit the discussion and development of a comprehensive national policy 
on AMR. The first of these factors related to governmental processes: the drawing of 
jurisdictional boundaries. On the positive side, however, the NHP 2007-2012 
recognised self-medication as a health hazard, governmental officials publicly 
expressed their intention to act on the problem, and COFEPRIS was assigned 
responsibility for action, all of which facilitated the confluence of streams towards the 
achievement of an AMR policy. Although no steps appeared to be taken in this 
direction until 2009, the recognition of self-medication with antibiotics as a problem and 
its incorporation into the governmental agenda created an institutional venue for action 
and paved the way for policy development. However, the scope of the policy solution 
was narrowed down to the jurisdictional bounds of COFEPRIS. In the absence of an 
institutional body to coordinate policies on adequate use of medicines, COFEPRIS was 
unable to interact with other MOH offices in pursuit of an overarching policy. 
                                                             
39 Kingdon MS does not make reference to this concept. In the discussion chapter, I argue that 
that institutional arrangements limit the opening of windows. Other authors (Mannheimer, et al. 
2007) had previously made reference to open, half-open and half-shut policy windows.  
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Furthermore, the enclosed character of the policy process prevented non-MOH actors 
from participating in policy drafting, and possibly contributed to the narrow focus of the 
policy product. 
 
Apart from institutional restrictions, three other factors in the politics stream contributed 
to the tight window of opportunity for discussing and developing a comprehensive 
national policy on AMR: a decision-making context immersed in a national crisis; the 
participation of interest groups in the policy process; and media framing. 
 
Despite attempts by some groups to redefine the problem with the view of achieving a 
broader policy solution including other facets of inappropriate antibiotic use, 
particularly, inadequate prescribing practices, health officials confined the problem to 
self-medication. Again, this may have been the result of a policy-making context 
entangled in a national crisis that placed the government under enormous pressure to 
act quickly on the basis of practicable solutions. In this context, the idea of plunging 
into a wider problem requiring systemic changes in the provision of health services was 
probably viewed as politically unviable.  
 
With regard to stakeholder participation, the recognition that pharmacy regulation was 
part of the problem –and part of the solution as well– affected the interests of 
pharmacies and derived in their active participation. This was particularly clear in the 
case of independent pharmacies that had no medical offices offering antibiotic 
prescriptions and lacked the means to mitigate their financial losses. Independent-
pharmacy associations acted as pressure groups to influence public opinion and policy 
development. They also took advantage of the open policy window to promote their 
own agenda, namely, protecting the interests of small businesses vis-à-vis the growing 
number of large pharmacy chains. While their actions did not influence the final policy 
product, they succeeded in using the media to raise their negative view of the policy 
and shape the public debate. As it was discussed in the previous chapter, stakeholder 
participation reflects the semi-opened, government-centred process of policy-making in 
Mexico. This system is characterized by the scarcity of well-defined channels of 
communication between researchers and decision-makers; but also by an increasing 
access of organized business to the policy-making process (Cansino, 2012; Camp, 
2012; Díez, 2006; Thacker 2012). Given their longstanding lobbying experience and 
strong organization (such as in the commercial chambers) and their relation to political 
elites, business groups in Mexico had been able to block the enactment of health 
policies that affect their interests (Shadlen, 2009; Barquera, et al. 2013) 
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Finally, media framing of the policy process may have also contributed to the reduced 
window of opportunity for discussing and developing a comprehensive national policy 
on AMR. Although the policy process gained wide media coverage, the focus was 
consistently placed on the problems of policy development, with minimal attention 
drawn to its objectives and its relation to public-health issues, except for the problem of 
self-medication. The dominant themes in media debates mirrored the voices of the two 
major stakeholders: on one hand, the MOH defended the policy by citing the dangers 
of self-medication; on the other, pharmacy associations opposed it, citing its economic 
impact and issues of corruption. Besides reflecting the interests and resources of the 
two main stakeholders, the dominant themes were subject to journalistic conventions 
characterised by what is known as “episodic framing” of social issues and the tendency 
to report health news in Latin America under a frame of political conflict (Waisbord 
2010). These divergent frames -the problem of self-medication versus the economic 
impact of regulation- were scarcely addressed by the media on the common ground of 
a wider public debate concerning rational use of medicines and pharmaceutical policy. 
Because framing emphasises some aspects of the issues at the expense of others, 
narrowly focused and polarised media coverage was not conductive to a public 
discussion on AMR. The absence of debate on the relationship between the policy and 
promoting rational use of medicines, improving the quality of services provided in 
pharmacies, and addressing the global public-health threat posed by antimicrobial 
resistance was in fact a missed opportunity to engage in an in-depth discussion on 
pharmaceutical policies and the development of a national strategy on antibiotic use. 
 
Concerning the implementation and evaluation of the regulation, surveillance systems 
for antimicrobial usage, critical to measure its impact, were not established. Similarly, 
failure to set up mechanisms that allow analysing the valuable information contained in 
retained prescriptions forfeited a clear opportunity to understand which were the 
frequent problems underlying antibiotic prescription, and to develop interventions 
accordingly (Zaidi, et al., 2014). During the first year of implementation only, 
COFEPRIS carried out assessments of the impact of the regulation on antibiotic sales. 
The agency concluded initially that a 35% reduction had been attained, but later 
revised the figure to 20%. It also reported that 85% of pharmacies were compliant with 
the regulation.40 Contrastingly, an independent evaluation indicated that, two years 
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 “Disminuye 20% la venta de antibióticos en México, por control con receta médica: SSA”, La 
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after implementation, antibiotic consumption had decreased by only 12% (Santa-Ana-
Tellez, et al., 2013). This decrement was smaller than expected, given that self-
medication with antibiotics was estimated at around 40% of total antibiotic 
consumption, and a similar regulation implemented in Chile in 1999 yielded a steeper 
drop in consumption amounting to 30%. The modest effect of the regulation may be 
explained, at least in part, by the fact that, since the beginning of enforcement, many 
pharmacies began to operate in-store medical clinics. With the number of these retail 
clinics increasing almost 200%, by 2012, they represented circa 15% of all ambulatory 
medical consultations in Mexico. A study found that the average number of prescribed 
medicines per encounter was larger in these clinics than in other private or public 
services (Pérez-Cuevas, et al., 2014), which may indicate antibiotic over-prescription. 
 
It is well known that once a policy window opens, it does not stay open long. As John 
Kingdon (1995: 169) puts it:  “An idea’s time comes, but it also passes.” While antibiotic 
problems and policies were able to reach the decisional agenda, the window closed 
rapidly for the following reasons: firstly, the enactment of the Ministerial Agreement was 
followed by a perception that the problem, narrowly defined as self-medication with 
antibiotics, had been dealt with, a perception reinforced by declarations from health 
officials and media coverage. Secondly, policy discussions and enactment were closely 
associated with the influenza pandemic; consequently, as the health crisis faded away, 
so did the related interest in its policy solutions. Problem definition and the crisis 
context favoured the opening of the policy window, but they also caused its rapid 
closure, especially when subsequent crisis (pertaining to the national economy and 
security) surmounted the governmental agenda. Even when some groups acted as 
policy entrepreneurs seeking to redefine the problem and aiming for spillovers of the 
policy momentum to impact on adjacent areas, namely, rational-use-of-medicine and 
comprehensive AMR policies, this was not fully attained. Finally, the last declarations of 
the Health Minister and the President portraying the problem of AMR in the country as 
related to the culture and customs of antibiotic use were probably not conductive for 
this issue to be considered on the decisional agenda for the rest of the administration.  
 
For the time being, curtains are down –again– for AMR policies. 
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7. DISCUSSION 
 
 
This long-term analysis of policy-making allowed shedding light on the policy dynamics 
around AMR in Mexico, including a period of stability and policy inaction, and a short 
period of conflict and policy change. In the following pages, I first contrast these 
periods using John Kingdon’s three-stream theory of agenda-setting, in order to explain 
certain factors that affected the development of policies for the appropriate use of 
antibiotics and containment of antibiotic resistance in Mexico. Secondly, I discuss the 
results of this study in the light of other studies1 on agenda- setting and policy 
development for antibiotic use and resistance.  
 
The chapter goes on to discuss the applicability Kingdon’s theory under the specific 
peculiarities of the Mexican political context, and its usefulness in this this study to 
explaining agenda-setting for AMR at the national level.  Finally, based on the results of 
this study and those found in the literature, I draw lessons for health reformers in 
Mexico, aiming to promote the adoption of further AMR policies; furthermore, I provide 
lessons for health reformers in other countries who seek to learn from Mexico’s 
experiences in adopting national AMR policies. 
 
 
7.1 Barriers and opportunities for action on AMR in Mexico 
 
Data were drawn from official documents and records of the executive and legislative 
branches, and from interviews held with decision makers. The ensuing analyses 
indicate that, during the 2000-2006 Vicente Fox administration, the problem of AMR 
was not high on the health-policy agenda. It was kept off the decisional agenda as a 
result of the processes operating within each of Kingdon’s streams and the absence of 
active policy entrepreneurs promoting its consideration. 
 
Information derived from interviews with health officials, from MOH documents and 
from an analysis of printed media indicates that significant changes occurred during the 
2006-2012 Felipe Calderón administration. A major change in the problem stream, 
coupled with favourable factors in the policy and politics streams as well as the active 
participation of policy entrepreneurs, created a window of opportunity for moving AMR 
onto the health-policy agenda. 
                                                             
1
 A previous examination of the cases of Chile, Brazil and India described here was presented 
in Dreser, et al., 2012; Wirtz, et al., 2013; Santa-Ana, et al., 2013. 
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Table 7.1 summarises the key factors –related to each of Kingdon’s streams and the 
role of policy entrepreneurs– that hindered policy change during the 2000-2006 
administration, and facilitated agenda placement and policy development on AMR 
during the 2006-2012 administration. These factors are described below in the light of 
Kingdon’s theoretical framework, as well as other social- and political-science works 
analysing why some issues receive governmental attention while others do not. 
 
Table 7.1 Key factors related to policy inaction and action on antibiotic use and 
resistance in Mexico, 2000-2012 
   
2000-2006 Vicente Fox 
administration 
2006-2012 Felipe Calderón 
administration 
Problem 
recognition 
and definition 
 Low problem visibility. Difficulties in 
measuring and assessing the problem 
of AMR; 
 Poor understanding of problem 
determinants, given its complexity; 
 Framing of the problem in cultural or 
structural spheres, or in the realm of 
individual behaviour and professional 
expertise (not within the scope of 
governmental action). 
 The health crisis linked to the 2009 
influenza pandemic brought visibility 
to the problem of AMR –but 
particularly to self-medication with 
antibiotics; 
 Health Minister José Ángel Córdova 
and other top-level health officials 
described self-medication with 
antibiotics and antibiotic resistance as 
serious problems. They framed AMR 
as a health risk, which legitimised 
governmental action on it; 
 Discussions around the regulation of 
antibiotic sales received ample media 
coverage; 
 High problem visibility and its new 
framing opened the window of 
opportunity for AMR to reach the 
heath policy agenda. 
 
Development 
and 
perception of 
policy 
alternatives  
 Scarce knowledge of recommended 
interventions to address AMR; 
 Limited intervention research on 
medicine use, and scarce evidence 
on contextually specific interventions 
to address AMR; 
 Anticipation of rejection by patients, 
pharmacies and physicians for some 
interventions; 
 Insufficient access to medicines and 
health care seen as a major obstacle 
to enforce regulations on antibiotic 
sales; 
 Enclosed policy process to draft the 
National Pharmaceutical Policy 
(NPP), with AMR-related specialists 
excluded. 
 Increasing coverage of new insurance 
system (Seguro Popular ) facilitated 
policy alternative of stricter regulation 
of antibiotic sales to be seriously 
considered; 
 The regulation of antibiotic sales was 
one of the priorities for action 
recommended in a policy proposal 
developed and promoted by a group 
of policy entrepreneurs on AMR; 
 The policy process to draft the 
Agreement on antibiotic sales was 
enclosed; however, information from 
the policy proposal promoted by 
policy entrepreneurs was used for 
policy drafting. 
Political 
context 
 No clear institutional responsibility or 
accountability regarding policies for 
medicine use or AMR; 
 Competing issues on the agenda: 
fostering health reform and improving 
medicine stocks in public services; 
 Lack of powerful constituencies 
supporting policy change. 
 An institutional body (COFEPRIS) 
had been previously designated to 
control medicine sales; 
 The crisis context in Mexico resulting 
from the influenza A H1N1 pandemic 
placed the Mexican government 
under close scrutiny and compelled it 
to take action. However, action was 
restricted to sales regulation (not a 
comprehensive policy) given the 
narrow scope of problem definition, 
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the jurisdictional boundaries of 
COFEPRIS and the urgency to 
respond to the crisis situation; 
 Independent-pharmacy associations 
opposed the policy; however, there 
was no opposition from other powerful 
groups (health professionals, the 
pharmaceutical industry, and large 
pharmacy chains). 
 
Role of policy 
entrepreneurs 
 Fragmented group of specialists 
advocating for AMR policies within 
their own area of expertise did not 
actively engage as policy 
entrepreneurs and approach decision 
makers. 
 
 Groups of academics and 
professionals worked together 
developing and promoting a policy 
proposal to address AMR, and 
actively communicated it to decision 
makers. 
 
7.1.1 Problem recognition and definition 
 
Why was the problem of AMR not on the radar of decision makers during the first 
period, but gained the attention of governmental officials during the second period? 
According to Kingdon’s theory, the answer lies in two factors: the means by which 
officials learned about the problem (visibility and recognition), and the ways in which 
issues or conditions become framed and defined as problems (Kingdon, 1995: 197). 
 
During the first period, AMR had low visibility: indicators were not available to assess 
the problem, nor focusing events which could have drawn attention to AMR (in contrast 
with the problem of insufficient medicine stocks in public-health services). Kingdon 
argues that it helps when a problem is countable: “The countable problem sometimes 
acquires a power of its own that is unmatched by problems that are not countable”, 
such as the “soft” areas pertaining to quality (Kingdon, 1995: 93). While academics and 
members of professional associations interviewed perceived AMR as a very important 
problem, decision makers interviewed lacked the information required to assess its 
scope or severity.  
 
Additionally, AMR was ‘framed away’ of the scope of health and pharmacuetical 
policies. Some interviewees both in and outside the government perceived AMR as a 
complex problem related either to the cultural or structural spheres, or to the realm of 
individual behaviour, where it is difficult to identify determinants and responsibilities 
and, consequently, to act on problems. Following Deborah Stone’s causal stories 
(1989: 282) given unclear understanding on AMR causes and consequently difficulties 
in attributing blame for a problem and responsibility for its solution, AMR was kept off 
the realm of governmental action. On these same lines, Kingdon (1995) and 
Baumgartner and Jones (1993) affirm that social issues and conditions are not always 
recognised as public policy problems (i.e. within the scope of governmental action) 
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and, hence, do not automatically generate policy actions. According to Baumgartner 
and Jones (1993:27 “Before a problem is likely to attract the attention of government 
officials, there must be an image, or an understanding, that connects the problem to a 
possible governmental solution”.  Furthermore, the way a policy problem is defined 
determines to a great extent how and if it will be acted upon. Definition also has strong 
implications for determining which groups have the competence to make decisions on it 
.According to the results presented, the need for a governmental response to AMR was 
not obvious during the first period. 
 
Many interviewees perceived AMR more as an issue to be addressed through 
professional expertise: “It is a policy on how things have to be done in a hospital”, or a 
policy “on improving the doctors’ education”, rather than through governmental action 
or legal norms, such as a comprehensive pharmaceutical policy and a legal framework 
for use of medicines. This limited understanding of AMR may explain, on one hand, 
why it was not discussed as a problem amenable to a governmental response and, on 
the other, why a governmental body was not designated to address it. Furthermore, the 
perceived complexity of the AMR issue –together with lack of mobilisation– may have 
also influenced the AMR agenda status during this period. William Gormley (1983) 
succinctly asserts that highly complex issues detached from any important conflict are 
likely to remain far from the public agenda. 
 
Contrastingly, during the second period of the study, covering the 2006-2012 
administration, AMR gained unprecedented visibility when the 2009 novel influenza 
deaths were linked to self-medication with antibiotics. This relationship became a 
strong symbolic reference which, reinforced by media declarations from the Health 
Minister and other top health officials, brought visibility and a new understanding to the 
problem of AMR. The official declarations on antibiotic use together with the rising 
influenza death toll and images of severely ill patients were reproduced on the media 
during the first months of the new administration, causing self-medication with 
antibiotics to be publicly perceived as an important problem. Subsequently, figures 
pushed by specialists on the national rates of antibiotic resistance for common 
pathogens began to be used by health officials and media reports, reinforcing the 
severity of the AMR problem. The image of this public-health problem slowly shifted 
from one centred on self-medication to one integrating antibiotic resistance as well. 
Nevertheless, MOH officials reinforced the view of AMR as a problem of self-
medication, and not medical prescription, which influenced the content of the policy 
output. 
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Within the crisis context, self-medication with antibiotics (and later antibiotic resistance) 
was framed by government officials as a health risk for the population. Importantly, as a 
result of interventions from other actors and journalists, the risk stopped being related 
exclusively to a ‘culture of self-medication’, and was connected to a deficient pharmacy 
regulation as well. This new and arguably simpler understanding of the problems was 
indisputably within the scope of a governmental solution. In other words, even if no 
changes occurred within the issue of AMR itself, its image switched from a medical 
issue to that of a public problem amenable to a governmental solution, allowing it to 
rise on the health-policy agenda. As Deborah Stone (1989) stresses, policy-making is 
strongly influenced by changes in the definition of which conditions are subject to 
governmental response. With regard to the studied case in Mexico, in the midst of the 
influenza crisis the cause of deaths was attributed to self-medication with antibiotics; 
and, at a certain point, blame was attributed to the lax regulation of pharmacies, which 
underlined governmental responsibility. In this way, causal ideas related to self-
medication with antibiotics, brought the issue of antibiotic use to the realm of 
governmental action. This underlines the relevance of the problems stream to open a 
window of opportunity to place AMR on the governmental agenda. 
 
By comparing the studied periods, it can be concluded that a crisis was a necessary 
factor for AMR to gain visibility as a problem. However, the influenza crisis was not 
enough on its own; the response of Health Minister José Ángel Córdova, and the 
advocacy of external experts helped critically, as is further explained below. 
 
 
7.1.2 Development and perception of policy alternatives 
 
Why was regulation of antibiotic sales not considered as a viable policy alternative 
during the first period, but emerged largely as the only policy alternative considered for 
AMR during the second period? According to Kingdon, there are two sets of answers to 
explain alternative specification: one related to the role of specialists, or ‘hidden 
participants’, developing proposals; the other, to a selection process within the policy 
stream. 
 
Potential alternatives (proposals or solutions) for public-policy consideration are 
generated in communities of specialists. With regard to the AMR topic in Mexico, these 
specialists belonged to two main groups: public-health researchers and infectious-
disease physicians (with the punctual collaboration of members of some international 
organisations) and formed a very loosely knit policy community on AMR. Interestingly, 
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other potential participants in the development of relevant policy proposals, including 
career bureaucrats in the MOH and legislative figures such as congressional staffers, 
do not play a part in the case of AMR in Mexico. Throughout the years, specialists in 
AMR had stressed its relevance, calling for interventions to improve antibiotic use, 
namely, education for patients and providers, surveillance of resistance, and regulation 
of medicine sales and advertising, echoing international recommendations. However, 
these ideas circulated more in academic than in policy forums. Establishing 
relationships between specialists and decision-makers with regard to AMR was 
exceptional, even though these inter-personal relationships have been regarded as an 
important factor for research uptake in Mexico and in other settings (Oliver, et al., 2014; 
Trostle, et al., 1999). Furthermore, given the scarce research on interventions for 
improving use of medicines in Mexico (and much of it circumscribed to prescribing 
practices in the IMSS social security system), there was limited evidence on context-
specific ways of addressing AMR. Consequently, during the first period, most decision 
makers were largely unaware of nationally or internationally promoted interventions for 
improving antibiotic use and containing resistance. They were uncertain about the 
priority levels and feasibility of such interventions in Mexico, perceived their 
implementation as complex, and were concerned about the resources required for their 
execution. The enforcement of regulation on the sale of prescription-only medicines, 
including antibiotics, was an idea discussed sporadically among decision makers, but 
perceived as unfeasible. 
 
Although a policy window opened during this period to draft a new National 
Pharmaceutical Policy (NPP) during this period, specialists related to AMR and use of 
medicines were not invited to participate, and these themes were, for the most part, left 
aside from the policy document. This may be related to the very understanding of what 
subjects a NPP comprised (an understanding that largely excluded use of medicines). 
However, it may have also resulted from the tradition of top-down and exclusionary-
style policy-making customary in Mexico, which generally excludes representatives of 
the academia, professional associations and consumers, but favours the participation 
of business groups (Cansino, 2012; Camp, 2012; Díez, 2006; Thacker 2012). 
Particularly, the organized pharmaceutical industry has an ample opportunity of 
influencing pharmaceutical policies, given their formal roles as consultants to the MOH, 
and political context that favour their participation as consultants (González-Casanova, 
1985; Shadlen, 2009). As such, they were able to participate in NPP drafting, and 
reflected their views in the final document. 
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Within the policy stream, potential alternatives are narrowed down to the few ones that 
will actually receive attention. This selection occurs related to some “survival criteria”, 
which include technical feasibility, congruence with predominant values, anticipation of 
future constraints, including budget, public and specialist acceptability, as well as 
politician receptivity (Kingdon, 1995: 200). Although decision makers and stakeholders 
interviewed for this research delineated some of the required actions to address AMR, 
they perceived that some of these interventions were likely to be rejected by patients, 
pharmacies and physicians. For governmental officials, implementing these 
interventions (particularly restricting antibiotic sales only with prescription, and 
controlling prescribing) may have constituted a political risk that they were unwilling to 
take. Insufficient access to medicines and health care was perceived as a major 
obstacle to enforcing regulations on antibiotic sales, and thus perceived as an 
unfeasible policy alternative. 
 
Differently from the previous period studied, during the 2006-2012 administration, there 
were two relevant factors that facilitated the consideration of antibiotic sales regulation 
as a policy alternative to address AMR, namely, increasing health insurance coverage, 
and diffusion of a policy proposal with priority lines of action to address AMR in Mexico. 
Firstly, the enforcement of a sales regulation for prescription-only medicines was 
perceived more feasible, as the increase in health coverage by SP guaranteed access 
to medical services and medicines, overturning the main argument against regulation. 
Regulation was clearly stated as an intended line of action in the National Health 
Programme (NHP), and considered as a strategy of protection against health / sanitary 
risks under the leadership of COFEPRIS. There had been no visible actions in this 
regard before 2010; however, the visibility that the issue of self-medication gained 
within the 2009 influenza crisis favoured serious consideration of this policy alternative, 
placing antibiotic sales under stricter regulation. Secondly, differently from the first 
period, in which groups of public health academics and infectious-disease specialists 
worked fairly disconnectedly supporting diverse policy alternatives on AMR, during 
2010, they were able to collaborate and to agree on a comprehensive policy proposal 
to address AMR in Mexico, and communicate it to decision makers. The document 
listed seven priority actions, among which was the regulation of antibiotic sales. 
Although this group of specialists was not involved later in the drafting of the Ministerial 
Agreement on antibiotic sales, fragments of their policy proposal were retaken by 
declarations from health officials and included in the final policy product, specifically, 
the Ministerial Agreement. It is impossible to conclude with available data whether the 
policy proposal (particularly figures and arguments regarding antimicrobial resistance) 
was used by governmental officials only to justify or to gain legitimacy for a policy 
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alternative already decided upon2, or whether it was useful –at least– to persuade 
decision makers of the need to regulate all antibiotic sales, not some of them, as they 
declared initially. 
 
Why weren’t the rest of the priority actions pointed out by specialists seriously 
considered by health officials as policy alternatives to address AMR? No direct 
evidence (as from interviews) was obtained under the study to answer this question. 
However, two sets of explanations could be considered: one is related to the fact that 
the problem was predominantly defined in connection with self-medication and over-
the-counter sales of antibiotics, thus calling for solutions only in these areas; the other 
may be related to the ´recombination’ of policy ideas, as worded by Kingdon. Following 
on from Lindblom’s incremental approach to policy-making (1980), Kingdon (1995: 201) 
suggests that the coupling of already familiar elements (‘recombination’) is more 
important than the appearance of totally new elements (‘mutation’). In the case of 
policy alternatives for AMR in Mexico, the proposal of enforcing regulation on antibiotic 
sales was ‘recombined’ with the (stated) governmental line of action of stricter 
regulations for pharmacies; while the rest of the proposed actions –such as the 
creation of a multidisciplinary advisory group for antimicrobial regulation and licensure, 
and the development of a national surveillance system for antibiotic usage– were 
wholly new elements not considered before by that administration. Similarly, Oliver   
(Oliver, 2006) affirms that, despite consensus on the severity of a public health problem 
and the appropriateness of governmental action, it is incrementalism (rather that 
comprehensive reforms) what predominates in almost every area of public health 
policy. This author explains that major causes of inclementalism and inaction in health 
policy is typically are decision maker’s time and information constraints which favour 
that they build in existing programmes and policies, the institutional design which 
disperses capacity for policy development,  concentrated interests (for example, in the 
industry) as well as fiscal constraints in the government. These factors may have 
influenced the consideration of policies to address emerging issue of AMR. 
 
7.1.3 Political context 
 
John Kingdon explains that, independently of problem recognition or the development 
of policy proposals, circumstances in the political sphere flow according to their own 
dynamics, and act as powerful agenda setters. Political factors considered by Kingdon 
are swings in the national mood (not addressed in this study), the balance of organised 
                                                             
2
 This could relate to a ‘strategic’ model of research utilization, according to Weiss’ (1979) 
description. 
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political forces (including interest group pressure) and changes in the administration 
(comprising turnover of key personnel and questions of jurisdiction). These factors 
involve ‘visible’ participants in the process: the administration itself (president and high-
level appointees), members of the legislature, the media and representatives of interest 
groups. With regard to the present study, what political factors acted as constraints for 
policy change on AMR during the first period, but favoured policy action during the 
second period? Further down, changes of administration, jurisdictional borders and 
interest group activity are discussed to respond to this question. 
 
Governmental turnover and competing issues on the agenda. During the 2000-2006 
administration, a new political party, PAN, came to power. The new administration had 
a very clear health-policy agenda: to foster a health sector reform, in which improving 
access to and the quality of health care were key preoccupations. Those two priorities 
were strongly linked to improving medicine stocks in public-health services. Improving 
medicine use and AMR were kept off the agenda by these competing priorities. The 
development of the NPP document during this period was very much oriented to 
improving access to medicines in a context of health system reform, whereas use of 
medicines was largely disregarded in this policy initiative. As Kingdon explains, there is 
a limit on the capacity of the system to process a multitude of agenda items. Even 
when a problem is recognised as such, there is an available solution and there are no 
political barriers to action, “bigger” agenda items press down “smaller” agenda items in 
the pipeline (Kingdon, 1995: 184). Furthermore, the new administration did not bring 
any ‘visible’ actors pushing the AMR issue. As Kingdon further explains (p. 199), “the 
chances of a subject rising on the governmental agenda are enhanced if that subject is 
pushed by participants in the visible cluster, and dampened if it is neglected by these 
participants”. 
 
During the 2000-2006 period, health system reform and the Seguro Popular  start-up 
were the subjects dominating the agenda. However, during the 2006-2012 Felipe 
Calderón administration, the stability given by the same political party in power, the 
steady implementation of the reform and the increasing health-care coverage gave 
more space for “smaller” subjects to be considered by health officials. This space 
allowed decision makers to pay attention to the previously relegated issue of medicine 
use, and to indicate some lines of action in this regard. There were important 
developments concerning the preparation of treatment guidelines and the promotion of 
professional pharmaceutical services in hospitals; however, up to 2010 there had been 
no evidence of concrete action with regard to other strategies on medicine use relevant 
to AMR, particularly on regulating antibiotic sales. The crisis context resulting from the 
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2009 influenza A H1N1 pandemic placed the problem of self-medication with antibiotics 
on top of the health-policy agenda. This happened following the Health Minister José 
Ángel Córdova declarations underlining the severe implications of self-medicating with 
antibiotics, declarations that were supported later by President Calderón and received 
ample media coverage. It is unlikely that without these elements, the issue of antibiotic 
use would have reached the agenda. As John Kingdon stresses, the administration 
(the president and his appointees) is a powerful agenda setter: regarding the roles of 
various participants, in agenda-setting, a top-down model prevails (1995: 199). 
 
The strenuous response (even criticised as overreaching by some actors) by the 
Mexican government to the 2006 influenza pandemic –which extended to the 
regulation of antibiotic sales– can be understood in terms of the international scrutiny in 
which the country was attributed the worldwide spread of the so-called “Mexican flu”. 
But two additional factors at the national level have been pinpointed to explain the 
governmental response. Firstly, the epidemic –and subsequent media coverage– 
“unveiled” the prevalent weakness of public health-care institutions (specifically 
problems on access and quality) as well as the lack of credibility in them (González 
González, et al., 2011). Public discussion of these issues probably derived in the need 
for the MOH to demonstrate its capability and leadership, and triggered policy action. 
Secondly, the response to the epidemic has been regarded as a “political weapon”: in 
early 2009, when the epidemic began, Mexico was in the midst of preparing for the 
federal elections to be held later that year. These elections were crucial, as they would 
constitute an indicator of voting trends for the 2012 presidential elections. Because the 
2006 presidential election was won by the ruling party’s candidate only by a minimum 
margin over the left-wing party, the new administration sought to enhance its legitimacy 
through a policy of stricter national security. This context may have influenced the strict 
response to the influenza epidemic (González González, et al., 2011: 123). With 
available data from this study, it is impossible to discern whether the MOH intention to 
regulate antibiotic sales derived solely from the need to respond to internal and 
external pressures to act on the subjacent causes of the influenza epidemic’s impact, 
or whether the health minister had a previous interest in AMR. 
 
Jurisdictional boundaries. During the 2000-2006 administration, one of the factors 
preventing AMR from reaching the agenda was the drawing of jurisdictional 
boundaries. Similarly to some aspects of Kingdon’s theory, Baumgartner and Jones 
(1993) propose that agendas result from an interplay of policy images and institutional 
venues. As mentioned in a previous chapter, policy image is how a policy problem is 
understood or defined, and policy venues are the institutional locations or groups in 
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society that have the authority to make decisions concerning a given issue: the 
“jurisdiction”, using Kingdon’s term. During the first period studied, there was no clear 
institutional venue for policies aiming to improve medicines to be discussed. In a way, 
the issue may be seen as having a shared policy venue: it could simultaneously be 
subject to the jurisdiction of several institutions, such as offices related with quality of 
health care, regulation of pharmacies, medicine procurement, and epidemiological 
surveillance. However, health officials pertaining to these offices did not recognise their 
full responsibility (or priority) in addressing AMR. In other words, there was no clear 
institutional responsibility or accountability on policies for use of medicines or AMR. 
According to Baumgartner and Jones (1993: 33), the lack of a defined policy venue can 
be explained “because the problems are new and societal responses to them have not 
become routinized, because there are many possible solutions but no clearly superior 
ones, or because problems are extremely complex and pose many contradictory or 
unrelated questions, each of which may interest different groups of people”. All these 
factors may have determined the lack of policy venue for AMR, underlining the 
relevance of international recommendations to create a specific and independent 
governmental body to address use of medicines and AMR policies. 
 
During the 2006-2012 administration, the same situation of a lack of institutional venue 
for use of medicines and AMR policies remained. Nevertheless, within the NHP, the 
responsibility of enforcing regulations on medicine sales was assigned explicitly to 
COFEPRIS. Consequently, the existence of a defined policy venue facilitated the 
consideration of regulated antibiotic sales as the preferred policy alternative to address 
AMR during 2010. However, at the same time, the designation of this policy venue may 
have limited the consideration of other policy alternatives, as discussed later on this 
section. 
 
Interest group activity. During the 2000-2006 administration, AMR kept limited to a 
specialised agenda, and did not permeate the larger health agenda. This may be 
related to the fact that the issue had neither “natural” nor powerful constituencies 
behind it in the politics stream and thus failed to gain attention without the support of 
such advocates. In this regard, only a small group of public health officials and 
infectious diseases specialists were interested in promoting AMR policies. However, for 
patients, physicians, pharmacies, the pharmacy industry and the government probably 
it was not evident that they would be better off with AMR policies (particularly, limiting 
use of antibiotics); consequently, they had no incentives to support them. The contrary 
–i.e., supporting policies to increase access to antibiotics and other medicines– may 
have been true. Furthermore, the costs of implementing AMR policies fall in 
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concentrated interests, particularly retail pharmacies (impact on antibiotic sales) and 
physicians (restricting their practice). It is well known that lack of support for a policy 
proposal and perceived opposition by interest groups are important factors that may 
cause policy advocates to back off. Expanding further on this, Kingdon (1995: 152) 
explains that governmental inertia is driven by both the building of a clientele in favour 
of an existing programme (or as in this case, interest favouring by the lack of 
programmes), and the absence of a strong constituency favouring change to 
counteract the inertia; both elements may explain governmental inertia on AMR. 
 
Regarding stakeholder activity, I found no evidence (neither from governmental nor 
from interest’ group sources) that an interest group explicitly sought to exclude AMR 
from the policy agenda. However, it was interesting that the representatives of 
pharmacy associations and pharmaceutical industry groups, tended to describe 
antibiotic misuse more as an issue of culture or poor education than an issue of lax 
regulation; and representatives of pharmacies associations minimized the figures of 
antibiotic sales without medical prescription. As was described earlier, Cobb and 
Howard-Ross (1997) Bachrach and Baratz (1962), argue that major reason that issues 
are excluded from the agenda (known as agenda denial, or non-decision-making) is 
that they are deliberately suppressed from agendas or prevented from being matters of 
decision because they directly threaten the interests of a given group. These authors 
distinguish non-decision-making from the ‘negative’ aspects of decision-making related 
to anticipated reactions: public officials will avoid raising issues likely to provoke a 
strenuous reaction by deciding not to decide. In other words, the perception of intense 
opposition to a proposal is an important reason for not pushing for it. In this regard, 
some health officials interviewed in this study anticipated the negative reactions likely 
to occur if some policy alternatives to address AMR were to be implemented (for 
example, physicians against control of their prescribing practices; and pharmacies, the 
pharmaceutical industry and patients against enforcement of regulations on antibiotic 
sales). Nevertheless, with the available data it is impossible to conclude whether the 
actions of interest groups (i.e., organised political forces) were directly or indirectly a 
major influence excluding AMR from the policy agenda during this first studied period. 
 
With regard to the second period analysed (the 2006-2012 administration), the public 
discussion regarding the regulation of antibiotic sales was an opportunity to analyse the 
actual position taken by diverse stakeholders vis-à-vis the regulation. Somehow 
expectedly, independent-pharmacy associations emerged as key opponents to the 
regulation as their interests –medicine sales– were threatened. 
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Interestingly, although the policy typology may be defined as regulatory (establishing 
limits in private activity in the public interest), given its impact on pharmacy revenues –
and, arguably, on patients’ expenditures in health care– antibiotic sales regulation was 
actually a redistributive policy. Furthermore, the policy costs were concentrated in well-
organised groups (the pharmacy associations) which rapidly mobilised against the 
policy, while there were no clear beneficiaries of the policy change which could 
mobilise political support. It is well known that redistributive policies generate a higher 
level of controversy and participant mobilisation than regulatory ones, which explains 
the wide public debate that broke out when the Agreement was announced. However 
not all industry groups reacted equally: there was no opposition from large pharmacy 
chains, which could buffer the regulation impact hiring in-situ physicians, nor from the 
pharmaceutical industry, which presumably could benefit from new physicians’ 
prescriptions instead of people buying generics over the counter. There was no 
straightforward opposition from other relevant groups, such as health professionals 
(some associations even manifested their support), nor from patient associations or 
organised consumer groups, despite the fact that media-based discussion forums 
reflected a predominance of negative perceptions of the regulation. Finally, the position 
of members of the legislature was divided. According to Kingdon, interest-group activity 
can affect the agenda by seeking to include agenda items or to influence the 
alternatives considered by policy makers; but, more frequently, they seek to block the 
consideration of policy proposals they do not prefer, which was the case of the 
independent-pharmacy associations in Mexico. Apart from the opposition of some 
groups, other powerful groups refrained from mobilising or were supportive, which 
favoured the regulatory change. 
 
7.1.4 Policy entrepreneurs 
 
According to Kingdon’s theory, changes in either the problem or the politics stream can 
open a window of opportunity for an issue to reach the governmental agenda; but for 
issues to reach the decisional agenda and for policies to be developed, the coupling of 
the three streams is needed. Policy entrepreneurs are essential for stream coupling. 
They are generally willing to invest their resources to promote policies they favour, 
motivated by their frank concern about a given problem, their pursuit of self-serving 
benefits, or others. However, in order to have an effective role, their activity must 
precede high agenda status or enactment. Policy entrepreneurs ‘soften-up’ the system 
by highlighting indicators that give visibility to problems, pushing for one kind of 
problem definition, and promoting certain policy alternatives or their ‘pet’ solutions. By 
developing their ideas and proposals in advance, they can be ready to surface and 
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push for them when the window opens, and then coupling of the three streams takes 
place. With regard to the present study, what were the differences in the policy 
entrepreneurs’ activity on AMR in the first versus the second period? 
 
During the 2000-2006 administration, I found no evidence of policy communities or 
individuals acting as entrepreneurs; that is, actively seeking to promote their ideas on 
policy problems or policy alternatives related to AMR. There were, however, advocates 
for AMR policies (specialists in infectious diseases, health-care quality, and public 
health) organising meetings and disseminating their ideas in very specialised forums. 
For the most part, these groups of specialists worked disconnectedly, rather than as a 
tight policy community; they did not actively engage as policy entrepreneurs pushing 
their ideas in policy forums or in the media. Kingdon emphasises that specialists (i.e., 
hidden participants) are not agenda setters, but can influence alternative specification. 
However, it is not clear if, during the first administration, these specialists were even 
able to agree on and promote specific policy alternatives. During this period, an NPP 
document was developed, providing an important opportunity to introduce aspects 
related to AMR; however, according to the interviews, the specialists were not 
considered to participate in NPP formulation, as discussed before. In addition, the 
specialists (particularly infectious-disease and public health specialist, the most 
important promoters of AMR policies) were largely unaware of this policy development, 
and of their possible role on it. 
 
Differently from the first period, during the 2006-2012 administration, there were key 
policy entrepreneurs for AMR policies. Firstly, the role of Health Minister José Ángel 
Córdova was arguably that of an entrepreneur, linking the specific problem of self-
medication with antibiotics to the solution of regulating the sales of these medicines 
(although I found no evidence of previous activity by the Minister promoting antibiotic 
policies). Secondly, following the Minister Córdova declarations, groups of academics 
and professionals joined to work together developing and actively promoting a policy 
proposal to address AMR in the country. They acted as policy entrepreneurs coupling 
the three streams: they took advantage of the attention paid to the problem of use of 
antibiotics and the favourable political context in order to push for a policy solution, a 
comprehensive policy on AMR. Besides pushing their ‘pet’ proposal among decision 
makers, this newly formed group (maybe more a loose network than a cohesive policy 
community) aimed to redefine the problem: from one centred on self-medication alone, 
to one centred on inappropriate use of antibiotics. This new definition included other 
aspects such as inadequate medical prescribing and use of antibiotics in animals, as 
well as the related problem of antimicrobial resistance. 
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Consequent to this broader problem definition, as part of their communication with 
decision makers and with the media, these entrepreneurs called for a wider-ranging 
policy solution including the establishment of a national committee on AMR. Following 
the policy-proposal dissemination, declarations of health officials and media coverage 
did incorporate antimicrobial resistance as a central issue, using data and arguments 
exposed in the policy proposal. Therefore, presumably, the actions of the 
entrepreneurs were able to change the problem definition to a certain extent, from self-
medication alone to antibiotic resistance. However, they were unable to influence the 
policy problem solution, as it was still directed to only regulating antibiotic sales. With 
the available data, it is impossible to explain the reasons for this, but at least two 
factors can be considered. Firstly, an issue of timing: the specialists’ proposal was 
circulated in a very short-time frame, so there was not enough time to soften-up the 
system; and it probably came up too late, when policy decisions had already been 
taken. Secondly, factors related to the political context may play a key role in explaining 
why the new problem definition was not accompanied by a change in the consideration 
of other policy alternatives, as is discussed below. 
 
7.1.5 Constraints to comprehensive governmental action on AMR 
 
During the second period studied, relevant changes in each of the Kingdon model 
streams −as well as their confluence− opened a window of opportunity for AMR to 
move onto the governmental agenda. While this opportunity allowed enacting a 
regulation on antibiotic sales, it did not attain the development of other strategies, nor a 
national AMR policy. This may be related to the initial narrow scope of problem 
definition (focused almost exclusively on self-medication). However, key factors on the 
politics stream (political institutions, jurisdictional boundaries, stakeholder and media 
involvement, as well as the crisis context itself) may also explain why the window of 
opportunity for AMR did not open enough (or closed too soon) for a national policy on 
AMR to be developed. 
 
Stakeholder participation. The open policy window was an opportunity for diverse 
stakeholders to use the policy process to push attention to problems and solutions on 
matters of interest to them. The participation of two stakeholders –MOH and 
independent pharmacies associations– was most notorious, dominating the public 
debate. While the MOH stressed the risks of self-medication and actively promoted the 
regulation of antibiotic sales, pharmacy associations sought to delay policy 
implementation, and used the media to highlight the problems faced by independent 
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pharmacies and to stress the negative consequences (economic impact and 
corruption) of the sales regulation. Within this saturated context of problems and 
solutions, the participation and views of other groups were less noticeable. Among 
these, stands out the role of the group organised by INSP-AMIMC-APUA, which aimed 
to function as policy entrepreneur seeking to reframe the understanding of the policy 
problem and to influence policy formation, as has been described before. Kingdon 
(1995: 204) explains that, because open windows are small and scarce, they attract a 
number of problems (or new problem definitions) and policy proposals, overloading the 
system. Therefore, in this moment the investment of enough resources by stakeholders 
is fundamental for their preferred problems and proposals to be acted upon, or to being 
drifted away from the policy process. With this regard, the MOH and pharmacy 
associations had an active participation during the whole policy process, investing their 
resources to widely display their views on the media. Contrastingly, the network 
organised by INSP-AMIMC-APUA lacked experience and resources for policy 
advocacy, and only participated during the earlier months of the policy process, which 
caused that their understandings on the policy problems and solutions did not gain 
much visibility. 
 
Institutions and jurisdictional boundaries. The dominant role of the MOH in this 
process should be understood in the context of the “semi-open” political system in 
Mexico, in which policy-making derives from a strong statist tradition. Despite the 
democratic transition, neither governmental institutions nor actors are oriented to an 
open and plural policy process; hence, agenda-setting (as well as other stages of 
policy-making) continues to be a highly endogenous process (Cabrero Mendoza, 
2000). Although Kingdon’s theory is based on a well-established democracy, he 
reflects on the views of the new institutionalism to stress that the government is at least 
(and under certain conditions) somewhat autonomous. In other words, rather than only 
reacting to public opinion or interest groups, government may generate its own agenda 
through its own processes, and its interaction with the public may involve mainly 
mobilising support (1995: 230). In the case of agenda-setting for AMR in Mexico during 
the 2006-2012 period, an inside-access agenda model may have prevailed. 
 
Although later on in the process there were efforts to change the policy image from an 
issue of self-medication by influenza patients, to the wider problem of antimicrobial 
resistance, the policy venue did not change. COFEPRIS has a clear role in protection 
against health and sanitary risks, attributed by the General Health Law: medicine and 
pharmacy regulation as well as risk communication are within its jurisdiction. 
Nevertheless, other key aspects relevant for addressing AMR, such as health-care 
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quality, medical prescription, health promotion and antibiotic-resistance surveillance, 
are not within the competence of this agency. Furthermore, at the time of the policy 
discussion, COFEPRIS was relatively new, and apparently had not established clear 
coordination with other health offices with competence on those topics. Finally, 
although the NHP listed actions for improving use of medicines, no overarching 
governmental body was created for use of medicines; so, in practice, these actions 
were implemented largely dissociated one from the other. 
 
As John Kingdon explains, the first consequence of system fragmentation is policy 
fragmentation (1995: 119). The policy process on AMR was thus circumscribed to the 
jurisdictional boundaries and responsibilities of COFEPRIS, with scarce participation of 
other stakeholders, and the final policy product implied a single action that distanced 
much from a comprehensive national AMR strategy. The designation of COFEPRIS as 
a policy venue for AMR may have imposed constraints on the policy-making process, 
as well as on the policy outcomes. As Baumgartner and Jones explain, once a 
definable institutional structure is responsible for policy-making, that structure limits 
access to the policy process (1993: 7). Similarly, Kingdon (1995: 230) affirms that 
institutions, such as governmental forms and procedures, constitute important 
constraints on policy-making, rendering some policy outcomes possible and others 
unlikely. 
 
It is important to underline that, although the definition of the policy problem eventually 
shifted to include antimicrobial resistance, the subject was still largely discussed by 
decision makers and the media as related mainly to self-medication, not to medical 
prescribing. As Reich suggest (1983), despite efforts to change or widen the 
understanding of problems, problem definitions become frozen in bureaucracies  and 
consequently the responsibility over such problems remains unchanged as well. 
Additionally, there was probably an interest of governmental officials to maintain the 
problem definition away from the more contentious issues related to prescription (and 
therefore maintain their envisaged policy solution and responsible administrative body, 
COFEPRIS), as described below. With this regard, Baumgartner and Jones (1993: 6) 
underline that interest groups have a major stake in establishing a “monopoly” on the 
political understanding of any given policy, as well as the institutional arrangement that 
reinforces that understanding. In this case, the same may apply to the government. 
 
Given that the final policy product, the Ministerial Agreement, only involved a stricter 
enforcement of a regulation already in place that fell within the jurisdiction of a 
government department (COFEPRIS) which already had policy competence in that 
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field, at the end, the 2010 Mexican policy on AMR represented more a form of 
incrementalism than a radical change. As it was mentioned before, bounded rationality, 
fragmented political institutions, resistance from concentrated interests, as well as 
fiscal constraints (Oliver, 2006: 195) lead decision makers to adopt incremental policy 
changes rather than comprehensive reforms, when facing public-health problems. In 
the Mexican case, fragmented political institutions may have been a very important 
factor determining the scope of the policy alternatives considered and the one decided 
upon. 
 
Media coverage during the policy process. The potential of the media to influence 
public perceptions of health-policy issues, the political elite’s policy considerations, and, 
eventually, the final policy product has been well recognised (Esmail, et al., 2010; 
Wallack, et al., 1993). The media can shape public opinion of health-policy issues by 
framing them; that is, by emphasising particular aspects of an issue, thus influencing 
how problems are defined and which policy alternatives are considered to address 
them. Although Kingdon´s studies (1995) found that the media did not have a critical 
and independent effect on the governmental agenda, they may still be important in 
other ways, such as magnifying or shaping an issue that originated somewhere else, or 
affecting some of the participants through public opinion. In this way, the media act 
both as a participant and as an observer of the policy process. 
 
Elite stakeholders elicit their power to reflect their views on the media, whether to 
reinforce status quo or to force direction of a new policy; but the media can also 
provide a voice to less powerful actors, which opens a space for media advocacy in 
public health (Wallack, et al., 1993). However, the role of the media in policymaking is 
affected by the political system (Buse, et al., 2005: 76). In Mexico, together with the 
democratic transition, the media has attained a status relatively independent of 
governmental control, but also increasingly beholden to commercial interests (Lawson, 
2002) ; this may explain the extensive coverage of MOH and the pharmacy 
associations’ voices, in comparison with other groups, and thus its overall influence of 
these groups on public discussion around antibiotics regulation. However, despite the 
strong opposing voice of pharmacy associations on media coverage, its effect on the 
policy process appears to be have limited. This suggests that the influence of other 
political factors (in this case the statist tradition of policymaking in Mexico, in which the 
MOH has an outstanding role) may outweigh media framing effects on policy-making, 
as other studies have pointed up (Esmail, et al., 2010). 
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With regard to Mexico, during 2009, columns and editorials in the printed media as well 
as some radio and television programmes reflected upon the official declarations 
connecting self-medication with influenza deaths, and questioned why the current 
regulation on medicine sales was not enforced. These arguments may have aided a 
change in the public debate framing of self-medication: from a problem attributed only 
to individual behaviour to one concerning governmental responsibility. It is probable 
that this framing change pointing to the need of governmental intervention aided 
regulation of antibiotic sales to reach the decisional agenda. 
 
During 2010, the ample media coverage of the antibiotic regulation in Mexico aided the 
problems of self-medication with antibiotics and antibiotic resistance to gain visibility. 
Additionally, media framing may potentially have influenced the policy alternatives 
considered by decision makers. Even if media coverage aided AMR to gain visibility, 
media framing may have also shaped the public debate away from an integrated 
approach on AMR that addressed issues such as antibiotic prescription and 
surveillance both in human and animal medicines. The main divergent frames used in 
media coverage (problem of self-medication versus the economic impact of regulation) 
put aside a wider public debate on rational use of medicines, quality of care and 
pharmaceutical policy. This represented a missed opportunity to publicly discuss the 
development of a national strategy on use of antibiotics (Dreser, et al., 2012). However, 
as other authors have indicated (Esmail, et al., 2010), even if the results of a media 
analysis can describe how policy problems and solutions were framed, we can only 
infer the potential effects of it on the policy process. 
 
Policy-making in a crisis context. As mentioned before, the 2009 influenza pandemic 
and the subsequent declarations of health officials linking influenza death to self-
medication with antibiotics, gave unexpected visibility to the subjects of antibiotic use 
and regulation. At the same time, the national crisis context placed the government 
under enormous pressure to act, calling for short-term and implementable solutions, 
rather than to engage in a process of policy deliberation or developing systemic 
changes. The prevailing narrow problem definition focused primarily on self-medication 
was coupled to a narrow problem solution, the regulation of antibiotic sales, favouring 
the enactment of a limited Ministerial Agreement, but not the discussion and 
development of a national AMR strategy. 
 
John Kingdon has pointed out the relevance of crisis to act as focusing events capable 
of opening problem windows and favour policy change. However, not all crisis episodes 
inevitably drive policy change; this depends largely on the causal ideas behind the 
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crises (Stone, 1989). Additionally, crises by themselves are not sufficient to drive policy 
change, if there are no perceived viable solutions, a favourable political climate, and 
policy entrepreneurs taking advantage of the crisis momentum. Schwartz and 
MacConell (2009), based on discussions on the politics of crisis management (Boin, et 
al., 2005), reinforce the understanding of the complexities of agenda-setting and policy 
change in a crisis context. In the wake of a crisis, they affirm, policy makers are forced 
in two directions: “They need to offer some ‘learning’ commitment to ensure that never 
again will society be exposed to the same risks, but they also need to offer 
reassurance that existing frameworks are essentially robust. This tension between 
reformism and conservatism in the aftermath of a crisis is both an enabler and a 
constraint for policy change after the crisis.” (Schwartz and McConnell, 2009: 93). In 
the case of the influenza pandemic, enacting antibiotic sales regulation was probably a 
viable policy solution within the crisis context, given the perceived risk of self-
medicating with antibiotics. However, even when later governmental officials raised the 
issue of antimicrobial resistance, health professionals pointed to inadequate 
prescribing practices and advocates called for a comprehensive AMR strategy, 
discussions on the functioning of health services and the quality of medical prescription 
were –reassuringly– left aside of official declarations and of the final policy product. 
This political interest in reassuring the adequacy of medical services may have been an 
additional factor determining why the crisis context was not conductive to a wide-
ranging policy change to address AMR. 
 
Finally, within this crisis context, the policy window closed rapidly and antibiotic 
problems and policies lost their agenda status. This was related to the following factors: 
firstly, with the enactment of the Ministerial Agreement on antibiotic sales regulation, 
there was the perception that the problem (as understood and defended by 
government officials: self-medication with antibiotics) had been taken care of and, 
consequently, decision makers could turn their attention to other problems. And indeed, 
towards the end of the administration, the executive was being severely criticised for its 
response to the influenza epidemic, and was facing an economic contraction as well as 
the insecurity crisis set off by the drug war. This political climate was not favourable to 
introduce further changes in the system. Furthermore, the dominance of these high-
politics issues contributed as well to the fading of the low-politics issue of antibiotics 
regulation. Secondly, changes in the conditions that gave rise to the problem also 
caused its loss of agenda status. Given that the policy discussion and enactment on 
antibiotics was closely associated to the influenza pandemic, when this health crisis 
waned, so did the interest in the policy solutions related thereto. Thirdly, external policy 
entrepreneurs did not sustain their efforts (such as communication with decision 
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makers and efficient use of the media) to maintain AMR on the public and political 
agenda. As such, the opportunity window closed and the problem, as understood and 
advanced by health professionals and academics (i.e., improving use of antibiotics, 
including prescription, and containing AMR) remained largely unaddressed. 
 
It can be concluded that, during the 2006-2012 administration, the following factors 
were key to enable use of antibiotics reaching the health-policy agenda: the health 
crisis context, the response of Health Minister Córdova (emphasising the connection 
between the influenza crisis and the issue of self-medication with antibiotics), and the 
existence of a governmental body, COFEPRIS, specifically in charge of regulating 
medicine sales. However, these same factors acted as constraints for policy-making, 
narrowing the array of participants and policy solutions to be considered. 
Consequently, only an incremental policy change, rather than a comprehensive 
national AMR policy, was pursued. 
 
 
7.2 How does the health-policy agenda-setting for AMR in Mexico 
compare with other countries? 
 
In this section, I will discuss the constraints and opportunities to place AMR on the 
Mexican health-policy agenda identified in the present case-study, in the light of  (a) 
efforts to place AMR on the global agenda; (b) other country-level experiences where 
AMR has reached the national health-policy agenda; and (c) country-level experiences 
concerning other health policy problems that have been kept off the decisional agenda, 
or have not attained public-health action. 
 
Since 1998, the WHO has urged member countries to promote appropriate use of 
antimicrobials and to contain the global public-health threat caused by antimicrobial 
resistance. In 2001, the organisation launched its Global Strategy for Containment of 
Antimicrobial Resistance. The Strategy suggested a range of interventions to be 
organised under the umbrella of national health and medicine policies. However, as 
other authors have pointed out before, few –mainly high-income– countries have 
developed national strategies to promote appropriate use of antibiotic. It has been 
suggested that the WHO Strategy has not fully attained its objectives of either raising 
awareness among policy makers and the public, or prompting governments to pursue 
the recommended policy changes (Leung, et al., 2011; WHO, 2012). The international 
response to AMR has been described as vague, and it has been recognised that 
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existing knowledge has failed to be translated into concrete action (Cars and Nordberg, 
2005). 
 
One of the suggested reasons behind the WHO Strategy failure to spark national and 
global responses was that its official launch coincided with the attacks of September 
11, 2001 in the United States, and consequently, any momentum was lost in the 
following turmoil (Chatterjee and Fleck, 2011). However, other arguments are linked to 
the understanding of the problem itself. Some authors have pointed to the failure of 
international initiatives to define or to frame the problem of AMR in a way that is 
conductive to place this issue on the political agenda and to elicit governmental action. 
To begin with, antimicrobial resistance has been considered as a “faceless threat” in 
the sense that it is not of itself a disease entity, making it unknown for people outside 
the medical field (Cars and Nordberg, 2005). On the other hand is the issue of AMR 
framing within global health agendas. In some countries, the problem of antibiotic 
resistance was at first closely related to the problem of intra-hospital infections, such 
that the public understanding of the issue was narrowed down to cleanliness; and this, 
in turn, has been the only focus of some governmental policies (Nerlich and James, 
2009). Furthermore, other efforts to raise the public profile of AMR and get it on the 
governmental agenda may have been counterproductive. Aiming to stimulate the 
discussion of policy alternatives and arguing against oversimplified problem definition 
and responses, more recently, antibiotic resistance has been reframed by using the 
“post-antibiotic apocalypse” metaphor. It has been argued that, while this political 
framing device is capable of alerting politicians to a severe problem that needs urgent 
attention, it also evokes negative emotions. The apocalypse is usually seen as 
something that is inevitable, against which one cannot do anything; thus, the use of this 
metaphor may have stifled behavioural and policy change (Nerlich and James, 2009). 
 
Besides the aspects discussed above with regard to the difficulties that AMR 
recognition and framing place for eliciting national and global responses, another 
aspect to take into consideration is the potential conflict implicit in actions directed to 
promote rational medicines use (see Box 2.4). But differently from other health 
problems (for example, alcoholism or malaria) in which policy solutions undoubtedly 
benefit both individual patients and the community, the problem of AMR may represent 
in itself a dilemma between the short-term individual care of patients and the longer-
term global population health3. Public policies directed to reduce use of antibiotics (and 
                                                             
3
 Importantly, access to antibiotics is needed to contain infectious diseases and antibiotic 
resistance, while excess is the main driver of resistance; on the other hand, excess or overuse 
also contributes to the problem of antibiotic access, by depleting antibiotics stockpiles in health 
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therefore contain antibiotic resistance) face the need to balance the best interest of the 
individual patient with the global need for sustainable access and use of antibiotics. 
This dilemma mirrors what has been termed the “tragedy of the commons” (Baquero 
and Campos, 2003) bringing uncertainty to AMR policy solutions and therefore 
hampering policy change. In practice, the apparent short-term advantages of use of 
antibiotics for patients (which could be life-saving), health-care providers and medicine 
distributors seem to have overweighed concerns about future consequences on 
antibiotic resistance (Cars and Nordberg, 2005; Laxminarayan, et al., 2013). On these 
same lines, globally, important efforts to improve access to medicines may also have 
deviated attention to efforts to improve (and limit) medicines use, which is a key 
component of AMR policies. A clear example of this is the Millennium Development 
Goals, the majority of which include, to a greater or lesser extent, increasing access to 
medicines. Even more, as a response to the emergence during the last decades of new 
global health treats (including AIDS, pandemic influenza, and bioterrorism) national 
governments are increasingly incentivising the regulatory approval and building 
stockpiles of medicines  to treat these diseases (Avery, 2004; Elbe, et al., 2014). As 
such, presently is not only the pharmaceutical industry that has pushed consumers and 
governments to acquiring more medicines; but it is also governments that are 
contributing to the pharmaceuticalization of society (Elbe, et al., 2014). Within this 
global context that stresses the development, acquisition and access to medicines, 
restricting the use of antibiotics may be a rather dissonant discourse. 
 
Other documented factors that hinder the development of national AMR policies and 
interventions to improve use of medicines are related to the weaknesses of health 
systems: insufficient human resources and information systems, and weak 
governance. Among them are the high transaction cost associated with the 
bureaucracy of regulating and monitoring antimicrobial use, as well as its potential 
conflict with clinical freedom (Smith and Coast, 2002). Other health-system-related 
factors are the insufficient microbiology laboratory facilities and information networks 
that lead to a paucity of antimicrobial-resistance-surveillance data and, consequently, 
to a poor understanding of the scale of the problem, hampering an effective response 
(Leung, et al., 2011; Smith and Coast, 2002). Additionally, authors have also pointed to 
the lack of commitment or political will to develop AMR policies and interventions for 
improving use of medicines. These issues have not been prioritised by national 
governments due to a poor understanding of the problems, the complexities of 
                                                                                                                                                                                  
services and by rendering antibiotics useless because of resistance. In this “access and excess 
dilemma” rational use of antibiotics is central challenge (Laxminarayan, et al., 2013: 15). 
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stakeholder coordination, and the perceived priority of improving access to medicines 
(Gasman, 1995; Leung, et al., 2011; Ventura, 2008). 
 
The studies described before shed light on some of the factors related to the difficulties 
for placing AMR on the global health agenda, as well as some of the factors that 
obstruct translating global initiatives into national action. Many of these factors coincide 
with the findings of this study in Mexico, explaining the low agenda status and policy 
inaction on AMR: low problem visibility and problem framing not conductive to 
governmental action; uncertainty about the technical feasibility and acceptability of 
recommended policy solutions; and governmental policies and institutions that favour 
improved access to medicines over improved use of medicines. Nevertheless, there is 
scarce information available that allows, on one hand, understanding in depth the 
policy-making process –particularly the processes, context and actors involved in 
agenda-setting– for AMR in low- and middle-income countries; and, on the other, 
comparison with the present study in Mexico. Antibiotic policies developed in Chile 
(1999), Peru (2007), Brazil and India (2010) are worth considering.4 Even if the 
available literature does not provide thick descriptions of these policy processes, it is 
possible to identify some factors related to agenda-setting and the subsequent policy 
development in these countries, both in contexts of “politics as usual” (Chile and Peru) 
and in crisis contexts (Brazil and India). 
 
In the case of Chile, it was a group of infectious-disease specialists who began to call 
attention to the problem of AMR. Worried about the evidence drawn from national and 
regional studies regarding the rise in consumption of antibiotics in the 1990s, and the 
resulting levels of resistance, they began to discuss policy alternatives to improve use 
of antibiotics. In 1998, the Pan American Conference on Antimicrobial Resistance in 
the Americas. organised by the PAHO and the Pan American Association of Infectious 
                                                             
4 The case of South Korea is worth mentioning as well. In 2000, a health-care reform was 
introduced to separate drug prescribing by physicians from dispensing by pharmacists. In 2001, 
a new payment system was introduced to correct inefficiencies in health-care delivery by the 
prevailing fee-for-service system. While these reforms were not focused on AMR, they did have 
a positive impact in reducing antibiotic over-prescription. Kwon and Reich (2005) explain that 
even if the financial incentives for prescribing had been recognized for a long time, policy 
change had not been possible given the influence of physicians and pharmacists. However, the 
change of government and the new president’s keen interest in health policy open a window of 
opportunity for reform. Democratization and the movement to a more pluralistic political context 
favoured the participation and support for reforms by civic groups, which succeeded in quickly 
setting the reform agenda, despite the opposition of powerful stakeholders. These reforms 
reached the agenda not by events in the problem stream (there were not major shifts in health 
care indicators) but rather by changes in the political context. Civil groups (mainly progressive 
academics) served as policy entrepreneurs, pushing the presidents of the Korean Medical 
Association and the Korean Pharmaceutical Association to the table, and helping formulating 
the content of the reforms (Kwon and Reich, 2005). 
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Diseases, recommended key actions to improve antibiotic use. The conference 
provided new impetuous to the work of infectious-disease specialists, who then 
approached health officials of the Chilean MOH. A steering committee was organised, 
which took the lead in developing and implementing enforcement measures prohibiting 
antibiotic sales without medical prescription in 1999 (Bavestrello and Cabello, 2011; 
Wirtz, et al., 2013a). Enforcement was accompanied by information campaigns 
directed to the public and the involvement of pharmacies. One key factor that facilitated 
the regulatory changes was the previous experience (1995) of the Chilean MOH 
medicine agency in regulating the sales of benzodiazepines only with medical 
prescription (Interview 1, Chile). Shortly after the regulatory change on antibiotics was 
introduced, antibiotic consumption decreased sharply, circa 30%. However, two years 
after the introduction of the regulation, consumption slowly began to increase. This 
reverse of the initial impact has been related to the lack of further monitoring of 
antibiotic consumption, and the subsequent lack of reinforcement of the regulation and 
informative campaigns (Bavestrello and Cabello, 2011; Wirtz, et al., 2013a). As one 
interviewee from the Chilean MOH explained about the relevance of monitoring to 
recognize problems with antibiotic consumption: “If we don’t measure it, then it doesn’t 
exist” (Interview 2, Chile).  
 
The Chilean process for agenda-setting on AMR differs substantially from that in 
Mexico in various aspects. Firstly, attention to the problem of AMR was not sparked by 
a crisis, but by available indicators on antibiotic consumption and antibiotic resistance. 
Infectious-disease specialists acted as policy entrepreneurs calling the attention of 
health officials to these problems and to policy alternatives recommended by the PAHO 
at the Pan American Conference. The feasibility and serious consideration of the policy 
alternative of regulating antibiotic sales only with medical prescription by the Chilean 
MOH was further facilitated by a positive previous experience in regulating 
benzodiazepine sales. AMR was thus able to reach the health-policy agenda and a 
policy was developed. 
 
The case of the development of antibiotic policies in Peru is similar to Chile and 
different from Mexico in the sense that it was not triggered by a crisis. In the Peruvian 
case, the role of international agencies was central for governmental action on AMR. In 
2005, the South American Infectious Disease Initiative – SAIDI, organised by USAID, 
PAHO, APUA and other international organisations, began a regional initiative in Peru, 
Bolivia and Paraguay, offering technical support to local organisations in order to 
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improve use of antibiotics.5 SAIDI, in cooperation with national and local organisations 
in Peru (among them, diverse offices at the MOH, and the Health Action International-
HAI group), developed an assessment on use of antibiotics, and began an intervention 
in 2007 in the Peruvian district of Callao. The intervention was comprehensive, 
involving local physicians and hospitals, a social responsibility campaign with local 
pharmacies, as well as a social marketing campaign and activities for community 
mobilisation. The development of the SAIDI initiative in Peru was facilitated by three 
relevant contextual factors: an already very active civil society organisation advocating 
on medicine policy issues (the national branch of the NGO HAI-Health Action 
International); the National Medicine Policy enacted in 2004, including rational use of 
medicines as one of its objectives; and the existence of an office within the MOH 
specifically devoted to promoting rational use of medicines. Despite the success of 
implementing interventions within the SAIDI initiative, institutionalising and scaling-up 
these interventions remain a challenge (Meza, 2011). The Peruvian policy process on 
AMR diverges sharply from the experience in Mexico in terms of the crucial roles of 
international agencies and national civil society organisations. 
 
In contrast to the previous cases discussed, in India and Brazil, AMR gained visibility 
as a policy problem and was able to reach the health-policy agenda interconnected 
with antimicrobial-resistance-related health crises, which were widely covered by the 
media (Dreser, et al., 2012). 
 
In India, infectious-disease specialists had been flagging for some time the urgent need 
for stricter guidelines on antibiotic prescriptions and policies in order to contain 
antimicrobial resistance (Chatterjee and Fleck, 2011; Lakshmi, 2008). During 2010, 
international attention turned to a novel type of resistance linked to the New Delhi 
metallo-beta-lactamase 1 (NDM-1) enzyme. Firstly identified in 2009 in a Swedish 
medical tourist who had returned from New Delhi, by 2010, the resistant NDM-1 
bacteria has spread across India, Pakistan and the United Kingdom. Experts were 
particularly concerned because many strains of commonly encountered bacteria 
containing this enzyme appeared to be resistant to all known antibiotics, and warned 
that other medical tourists might be at risk. The Indian government and physicians 
reacted with anger at these warnings and at the very naming of the enzyme (“New 
Delhi”), arguing that it unfairly ruined the reputation of the country’s health system and 
its booming medical tourism industry (Shah, 2012). The NDM-1 spread and its 
                                                             
5
 See South American Infectious Disease Initiative http://www.usaidsaidi.org/. A more detailed 
account of this initiative is presented in the case study by Anya Levy and Michael Reich 
“Changing the use of antibiotics in Peru”, in Roberts and Reich (2011: 279-286). 
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surrounding controversy were followed by intense media coverage and public debate in 
India, all of which finally pressed the Indian government into action to address AMR 
(Shetty, 2011). In 2011, the Indian government published the National Policy for 
Containment of Antimicrobial Resistance. The policy included, among other 
interventions, educational programs for physicians and the banning of over-the-counter 
antibiotic sales, as well as registering antibiotic prescriptions in pharmacies. However, 
soon after, pharmacy associations showed their opposition and staged a strike; they 
argued that the policy would cause inaccessibility to medicines in rural areas, would 
push people to use the black market, and would inflict loss of revenues and extra 
administrative chores to pharmacies6 (Easton, 2011). Finally, the government decided 
to put this regulation on hold indefinitely arguing it was not implementable, particularly 
due to concerns over access to antibiotics in remote rural areas (Ghafur, et al., 2013; 
Shah, 2012).7 Furthermore, it has been suggested that the policy was nothing more 
than a “gesture”; it had little chance of being implemented as, in India, health policy is 
implemented at the state level, not the federal level (Shah, 2012). In 2012, a high-level 
meeting in Chennai with the participation of medical associations, the WHO and the 
Medical Council of India gave new impetuous to the development of the policy; the 
“Chennai Declaration” was launched, proposing a 5-year strategy to control antibiotic 
resistance (Ghafur, et al., 2013). 
 
In the case of Brazil, the National Health Surveillance Agency (ANVISA, by its 
Portuguese initials) had been discussing the need to improve the control of antibiotic 
sales since 2009. However, it was the spread of the multi-resistant KPC bacteria 
(Klebsiella pneumoniae carbapenemase) and related deaths from hospital infections 
during 2010 –also followed widely by the media– which speeded up the regulation 
process (Dreser, et al., 2012). ANVISA Resolution RDC 44/2010 was implemented in 
November 2010, establishing that antibiotics were to be sold by prescription only and 
retained in pharmacies. The resolution was supported mainly by medical groups, but 
faced the opposition of pharmacy and commerce associations. Arguing the social 
impact of the regulation, namely, insufficient infrastructure of public medical services 
and scarce access for the poorest populations, as well as the risk of triggering a 
                                                             
6 “Regulating Over-the-Counter Antibiotic Sales: What Will "Schedule HX" Mean for India?” Alice 
Easton, A.  August 2
nd
, 2011. 
https://www.cddep.org/blog/posts/regulating_over_the_counter_antibiotic_sales_what_will_
schedule_hx_mean_india/ (accessed August 19th, 2014.) 
7
 See also: “Govt holds antibiotic policy, not to restrict access to drugs”, Daily News and 
Analysis (India), October 3
rd
, 2011 http://www.dnaindia.com/health/report-govt-holds-antibiotic-
policy-not-to-restrict-access-to-drugs-1594660 (accessed August 19
th
, 2014). A previous 
attempt to restrict the sale of certain medicines only with prescription or by trained pharmacists 
was opposed by druggists who responded with a boycott and a national strike (Shiva, 1985). 
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parallel black market of antibiotics, these associations conducted actions seeking the 
postponement or withdrawal of the resolution. Some of the arguments exposed and 
reflected upon by the media were: “What will happen to a child who is burning in fever 
with tonsillitis or an intestinal infection, but lives in a distant community, where a 
physician is available only once a week? […] Infections can’t wait!”; or “Leaving people 
without treatment […] is, to say the least, to deny them access to health”.8 
Nevertheless, the resolution was implemented. According to a study, antibiotic 
consumption in the private sector had decreased by nearly 24% within two years 
(Santa-Ana-Tellez, et al., 2013). However, following anecdotal reports of problems in 
the verification of pharmacy compliance with the resolution, a stricter regulation was 
introduced in April 2013, incorporating antibiotics into the ANVISA national system for 
management of controlled substances. 
 
There were similarities in the processes of agenda-setting and policy development for 
AMR in Mexico, India and Brazil. Salient among them is the relevance of focusing 
events (for instance, the spread of influenza, NDM-1 and KPC) to give visibility to 
antibiotic use and resistance, and to open a window of opportunity for placing the issue 
on the health-policy agenda.9 In addition to problem visibility, however, other factors 
aided the health crises to spur the development of AMR policies: previous efforts in the 
policy stream led by infectious-disease specialists and medicine regulatory agencies; a 
political context conductive to governmental action, which can be determined, at least 
in part, by extensive media coverage; and international pressure. Taken together, the 
contemporaneous policy processes in Mexico, India and Brazil also indicate that a 
perceived health crisis and pressure for action can lead to a knee-jerk governmental 
response which, in the cases of Mexico and Brazil, concluded with a narrow problem 
definition and a narrow policy response directed only to antibiotic sales. Urgency for 
action can also lead to policy processes with scant involvement of stakeholders and 
insufficient analysis of implementation feasibility.  Leung and colleagues (2011) point 
out that the scarce action on AMR at the national level tends to be taken forward by 
individual programmes and institutions; however, these efforts are fragmented and not 
comprehensive. Similarly, they conclude that though sensational individual events, 
                                                             
8
 “Entidades dizem que novas regras para antibióticos restringem o acesso da população à 
saúde” Jornal Na Net, November 28
th
 2010, available at: 
http://www.jornalnanet.com.br/noticias/1698/entidades-dizem-que-novas-regras-para-
antibioticos-restringem-o-acesso-da-populacao-a-saude (accessed on August 19
th
, 2014). 
9
 This was also the case in France. The rapid spread and hyper-endemic occurrence of MRSA 
(Methicillin-resistant Staphylococcus aureus) observed in hospitals, together with benchmarking 
data demonstrating the high consumption of antibiotics in France amongst other European 
countries, raised awareness on AMR. After a consultative process involving health professionals 
in human and animal health from the public and private sectors, a national plan of action to 
control antibiotic resistance was drafted (WHO, 2012; Aubry-Damon, et al., 2000). 
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such as the NDM-1 spread, were able to attract attention to AMR, these events have 
not been able to prioritise governmental attention to the wider threat of antimicrobial 
resistance, and the need for sustained containment efforts. 
 
Interestingly, stakeholder participation during policy development in Mexico, India and 
Brazil was similar: while medical and infectious-disease associations were supportive 
of the policies, pharmacy associations appeared as important opponents. The 
arguments exposed against regulating antibiotic sales by these last groups were 
surprisingly alike in the three countries: restricted access to life-saving medicines; 
boost of the medicine black market; and an adverse economic and administrative 
impact on pharmacies. Taken together, these cases also show that an apparently 
technical issue –for instance, regulating antibiotic sales– can be very politically 
sensitive because economic interests are affected and because of its relation to wider 
complex societal issues such as the functioning of health systems. Indeed, besides 
being a central component of health systems, medicines serve multiple social, 
psychological and political functions; these material and symbolic functions render 
medicines a potentially powerful issue in public debate (Reich, 1987: 45). This 
underlines the need to discuss antibiotic policies within the common framework of a 
pharmaceutical policy, and to mobilise political support from the beginning of policy 
development (Dreser, et al., 2012). 
 
Together with the second period analysed in this study in Mexico, the cases of Chile, 
Peru, Brazil and India allow describing the actors, processes and contexts in which 
AMR did arrive to the national health-policy agenda. However, no country-level-policy 
studies are available providing thick descriptions of the factors that have prevented 
AMR from reaching the health-policy agenda, which would allow comparison with this 
study in Mexico. Nonetheless, valuable examples of governmental inaction for other 
health-related-policy problems may shed light on the factors related to inaction on AMR 
in Mexico, which are set out in more detail below. 
 
In a study on policy-making for injuries in central and Eastern Europe, McKee et al. 
(2000) identify the factors that have inhibited policy development on this topic. Among 
these factors were the low visibility of injuries as a health problem given insufficient 
data to identify the burden of disease they constitute, as well as the insufficient 
capacity of public-health authorities to assess the scope of the problem and to develop 
strategies to address them. Other identified factors were uncertainty and fragmentation 
regarding the responsibility of the policy problem; no tradition of intersectoral working; 
lack of related non-governmental organisations (which in other countries had been 
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central for placing the topic on the health-policy agenda); and the null role of 
international donors, which centred efforts on health-care reform. These factors on 
public-health (in)action are similar to those found in the first part of this study in Mexico, 
and can be related to weaknesses in each of Kingdon’s streams: visibility (problems), 
public-health capacity (policy alternatives),  ownership and intersectoral action 
(politics), as well as the lack of entrepreneurs advocating for policy change. 
 
During the second period analysed in this study, it was a health crisis that caused the 
problem, politics and policy streams to converge and to open a window of opportunity 
for AMR.  Even when the policy window allowed a regulation on antibiotic sales to be 
passed, it did not allow a comprehensive national policy on AMR to be developed. As 
Schwartz and McConnell (2009) demonstrate, crises do attract attention to problems, 
but are not sufficient factors to elicit policy change: the political context is crucial. In 
their comparative study, the authors analyse how a health crisis resulting from a safety 
problem in drinking water in Walkerton, Canada, led to regulatory changes, while the 
disaster caused by the collapse of a banquet hall in Jerusalem, in Israel, did not. The 
authors conclude that, despite the fact that recommendations for governmental action 
on these two disasters received broad public support, the political context and 
stakeholder participation were quite different. One relevant aspect was related to the 
locus, or policy venue, of administrative authority: policy changes in the Jerusalem 
case were less feasible because they required a radical administrative creation, 
contrary to the Walkerton case, which only involved a form of administrative 
incrementalism. While in Canada there was a sustained action of an organised group 
of citizens advocating for policy change and using the media to ensure that water-
reform issues stayed on the political agenda, this did not happen in Jerusalem. Finally, 
in the Jerusalem case, the dominance of high politics, the threat of terrorist attacks, 
and a system overloaded with crisis, did not allow more than a very short issue 
attention, in which policy solutions were not able to be discussed and developed. 
 
There were some similarities in the agenda-setting processes within the crisis contexts 
of Jerusalem and Mexico. While building safety and antibiotic use gained visibility with 
the crises, the complexities related with the need to create an administrative body to 
address these issues, the insufficient efforts of policy entrepreneurs and the 
concurrence of other crises prevented these issues from being maintained on the 
governmental agenda and ad hoc policies from being developed. As Schwartz and 
McConnell conclude with regard to building reforms in the Jerusalem case: rather than 
‘‘an idea whose time had come,’’ the prospect of developing a national antibiotic policy 
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in Mexico was “more akin to an idea that got lost in the ether of national politics” (2009: 
108). 
 
 
7.3 Applicability of Kingdon’s theory for the case study, and limitations of 
the study 
 
This long-term analysis of agenda setting for AMR in Mexico coincides with 
Baumgartner and Jones’ characterization of policy agendas: a long period of stability 
and policy inaction, which is punctuated by a short period of conflict and policy change. 
The structural elements of Kingdon’s MS theory were used as independent variables to 
explain both when the issue of AMR was denied a position on the agenda (first period 
studied) and when the issue gained agenda status and a policy change occurred 
(second period studied). In this way, by using KIngdons’ MS, it was possible to 
understand the process of agenda setting for AMR in Mexico; this theory proved to be 
useful to explain why the issue of AMR was not able to reach the policy agenda during 
the first studied period, as well as to explain why a policy window opened during the 
second studied period. 
 
However, with regard to the second period studied, using MS theory only offered a 
limited insight in explaining the policy outputs, i.e. the policies that were adopted as a 
result of agenda-setting. This limitation on using MS for explaining agendas and policy 
change has been raised before by other authors (Hewlett, et al. 2013; Capano, 2009), 
as described in Chapter 3 in this thesis. 
An important issue that was raised up in the present study is that, despite the fact that 
AMR was able to reach the public and policy agenda, the outcome, was a narrow-
focused regulation, which was –largely– already decided upon. In fact, John Kingdon 
(1995: 176) asserts that, once policy window opens, the outcomes can be quite 
unpredictable. In open windows, the system is often overloaded with an unmanageable 
multitude of problems and alternatives. In this situation, some problems and 
alternatives will drift away, leaving a set behind that is more manageable. As was 
discussed in section 7.1.5, given the initial problem definition (focused in self-
medication) and the crisis context, most probably the ‘manageable’ choice was 
regulating antibiotic sales, but not acting upon medical prescribing practices, for 
example. But an alternative view can be that the institutional design of policy-making in 
Mexico did not allow the window to open widely: in the AMR case, the state-centred 
processes limited the participation and impact of other actors in the policy process, 
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particularly of that of the INSP-AMIMC-APUA group; the media favoured the coverage 
of governmental voices; jurisdictional borders confined decision making to a closed 
governmental group. Within this constrained policy process, few problems and policy 
solutions can be included in the agenda, thus limiting the possible outputs.  
 
The state-centred political system in Mexico could have caused only a narrow window 
to be opened. Even though Kingdon does not refer to wide or narrow windows, he 
recognises the importance of institutions and (to a certain extent) governmental 
autonomy on constraining policy-making. Governmental forms and procedures, he 
asserts, make some outputs possible, while others unlikely (1995: 229-230). Similarly 
other authors have stressed in impact of institutions in mediating the impact of ideas 
(Béland, 2015), or as acting as veto points to block policy proposals, especially in 
settings different than the American liberal democracy in which MS theory was based 
(Powers et al, 2015). 
 
Findings of the present study suggest that the relevance of institutions in constraining 
agenda-setting and policy outputs could be more important in non-liberal-democracies, 
like the Mexican system. Institutions such as legal systems and bureaucracies 
structure policy decisions, constrain how decision makers behave, and favour the 
participation of some groups above others. This aspect has to be considered when 
applying the MS theoretical framework to statist or less plural settings. To explore 
these aspects more in-depth, the present study could have benefited of including 
insights of institutional approaches on policy determination. An in-depth comparative 
study, for example, between agenda-setting on AMR in Mexico and in India, would 
have also provided more understanding of the relative role of that idea, interests, and 
institutions have in forming agendas. 
 
Other authors have argued before that, because Kingdon’s theory is largely based on 
assumptions –such as the openness of the political system– that coincide with 
American pluralism, its applicability in other governance systems can be questioned 
(Sabatier, 2007). Similarly, Enrique Cabrero (2000) warns against a non-critical 
application of perspectives proposed by the traditional American school of policy 
sciences to culturally and politically different environments, as in the case of Mexico. 
This author underscores that policy sciences derive from open and plural democratic 
contexts of policy-making, and follow a pluralist perspective. But policy-making in 
Mexico derives from an authoritarian and statist tradition of policy-making; and, even if 
immersed in the dynamics of democratic transition, weak participation persists. 
However, Walt, et al., (2008) affirm that much of the theory from policy analysis in high-
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income countries still has resonance for health and developing countries, and can be 
used to inform research in those areas. Transferring such concepts, though, needs to 
be undertaken with caution; it is necessary to contextualise the health-policy 
environment in order to understand the challenges to methodology and theory. 
Regarding the application of the MS theoretical framework in the present study, 
references to the political traditions of policy-making in Mexico were provided when 
discussing the study results, in order to contextualise the health-policy environment in 
this country. For example, Kingdon underlines the major impact that high governmental 
appointees have to set the agenda, which was also found in this case study in Mexico; 
but differently from what Kingdon discusses, the role of the legislative in the case 
presented here seems much minor, which can be explained by the particularities of the 
Mexican political system centred in the executive. The institutional constraints 
mentioned before is other aspect to consider when applying Kingdon’s theory in non-
liberal-democracies. 
 
Finally, with regard to the theoretical framework used, Kingdon’s MS, despite some 
critiques, has been acknowledged as a synthetic (John, 2002) or comprehensive 
approach of policy-making which addresses the broad set of factors traditionally 
deemed important in public policy-making (Sabatier, 2007). However, theoretical 
frameworks are based on a set of simplifying presuppositions aiming to understand the 
extreme complexity of public policy-making; as such, while they indicate to the 
researcher a number of factors which are likely to be critically important, they leave 
other factors aside. Consequently, Sabatier (2007) advises to be aware of applying 
several different theoretical perspectives in empirical research. With this respect, a 
limitation of the present study is that it is based only on Kingdon’s MS theory, and did 
not contrast the results in the light of two different theoretical perspectives. 
 
Other frameworks propose that the adoption of specific policies is not only function of 
internal determinants (extensively addressed in the present study), but also results 
from a process of innovation and communication between one political setting and 
another, which allows policies to be built on what has occurred elsewhere (aspects 
scarcely attended in this study). Indeed, in a world of heightened globalisation and 
global health policies, the role of international actors, policy transfer and learning from 
abroad are of much relevance. Along these lines, Parkhurst and Vulimiri (2013) 
underscore that applying policy transfer theories may provide additional understanding 
on individual country decision-making as well as the grade in which global 
recommendations are adopted. This approach of policy transfer may have 
complemented well the present study, aiding to respond the following questions related 
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to agenda-setting for AMR at the national level: How have global initiatives on AMR 
such as WHO’s Global Strategy for Containment of Antimicrobial Resistance influenced 
national agendas on AMR? How may experiences on AMR policies in one country 
affect adoption of similar policies in other countries? 
 
Finally, as other authors have pointed before, there are some practical issues when 
applying Kingdon’s MS to an empirical study. One of them is that events in the policy 
process can exist in more than one stream (Shroff et al, 2015.115), as there is not 
complete independence among streams.  For example, in the first period studied as 
part of this thesis, the development of the NPP proposal was analysed both in the 
politics and policies streams. Secondly, events in the policy process can be classified 
in different way by different authors. While in this thesis I analysed the WHO 
recommendations as part of the policy process, Shroff et al. (2015) analysed global 
policies as part of the political context.  
 
Limitations of the study.  
Some limitations of this study should be considered with regard to the study design and 
the methods employed. The methodological limitations are discussed in detail in 
section 4.8.  
 
The single-case and longitudinal approach that this study follows is well suited to study 
the rise and fall of issues from the public agenda. It allows assessing the slow changes 
in the understanding of issues, policy contents, and the mobilisation of participants in 
the policy process, as well as the occurrence of focusing events that prompt a sudden 
shift in attention paid to a certain issue. However, it has been recognised that this 
approach has drawbacks in terms of generalizability and comparability (Baumgartner 
and Jones, 1993: 47; Yin, 2003). A multiple-case study would have brought more 
understanding on policy variation and a better insight into the determinants of AMR 
policy formation. Alternatively, adopting a comparative approach based on two different 
health policies in Mexico: a policy problem that was able to quickly escalate the health 
agenda and be enacted as a comprehensive national law (tobacco policy) in contrast to 
the problem of AMR, would have shed more light on the specific issue characteristics, 
policy solutions and participants in the policy process that acted as facilitators or 
constraints for policy change. A comparative analysis of the Mexican case on AMR 
policies with other countries would have provided more insight into the political-context 
factors that may act as determinants for the AMR agenda status and policy formation. 
Nevertheless, this study still provides a thick description of the policy process in 
Mexico. By reformulating the single case study into one with two observations 
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belonging to two time periods (diachronic or longitudinal comparative study) (Bartolini, 
1993) it was possible to analyze policy variation or dynamics across time. By using this 
approach in the thesis, it was possible –within a single (conventionally labelled) case-
study– to observe two separate instances of AMR agenda setting in Mexico, applying 
Kingdon’s theory.  In this way, the range of variation of the explanatory variables as 
well as the dependent variable was extended (King, Keohane and Verba  2001: 218-
21). As such, the present study allowed to draw a series of propositions on the factors 
influencing the process of AMR agenda-setting at the national level in Mexico, which 
can be used in future studies on AMR agenda setting in other countries.  
 
7.4 Lessons learnt: setting the agenda for AMR 
 
It has been stressed that policy analysis plays an important role not only in 
understanding past policy failures and successes, but also in planning for future policy 
development (Walt, et al., 2008). Research results are important for advancing the 
health policy agenda and influencing policy outputs and outcomes in both developed 
and developing countries (Grindle and Thomas, 1991: 141; Walt and Gilson, 1994: 
366). 
 
The present longitudinal case-study in Mexico aimed to generate understanding, by 
applying a policy-analysis approach, of the potential factors influencing policy inaction 
and policy change with regard to antimicrobial misuse and resistance (AMR) at the 
national level. By additionally discussing these findings on the light of others reported 
from other countries, some lesson can be drawn for stakeholders in Mexico and in 
other countries aiming to move forward the issue of AMR in governmental agendas to 
favour the adoption of related policies. 
 
Despite efforts to place AMR on the global health-policy agenda and the promotion of 
global strategies and policy ‘packages’ to address these issues, there is still much 
room for eliciting political action in low- and middle-income countries. As most health 
issues, AMR is seen as a low-politics issue and, hence, does not tend to attract the 
attention of decision makers. However, as the described cases demonstrate, windows 
of opportunity can open –both in “politics as usual” and in crisis contexts– to place 
AMR on the governmental agenda. Therefore, it is possible for health professionals, 
academics, civil society organisations and health officials to advance the health-policy 
agenda on AMR, firstly, by moving ahead factors related to agenda-setting in each of 
the three streams; secondly, by taking a policy entrepreneur role, actively seeking to 
couple these streams. 
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(a) Facilitate AMR visibility and understanding as a public problem. Theorists 
on agenda-setting underscore that for a problem to elicit a response, it must be 
made visible to those with the power to initiate action. Furthermore, because 
problems get attention based on how they are framed or defined by participants 
who compete for attention, it is fundamental to redefine AMR in a way that is 
amenable to a governmental solution. Therefore, it is necessary to change the 
public and governmental perceptions regarding the severity of the AMR 
problem, emphasise that it can potentially affect the entire population, and 
stress the government’s responsibility in its solution. 
 
 In order to attain problem visibility, surveillance systems for antibiotic 
use and resistance should be strengthened in a way that its results allow 
decision makers to assess the scope of the problem. In Mexico –as in 
other countries– antibiotic-resistance surveillance is largely undertaken 
in a piecemeal fashion; diverse systems report their own results, mostly 
in biomedical scientific papers or in infectious-disease-specialist 
meetings. Consequently, antibiotic resistance tends to be reduced to a 
“natural” or scientific issue, not clearly identified as a public-health risk, 
and consequently kept distant from governmental action. The recent 
report, “Antibiotic Resistance Threats in the United States, 2013” (CDC, 
2013) is a valuable example of how data on antimicrobial resistance can 
be reported to demonstrate that it is a “serious threat” for the country, 
indicating the “catastrophic consequences of inaction”, as well as proven 
public-health strategies to address it. The report summarises the 
disease burden, death toll and associated costs (topics largely 
disregarded by research and surveillance in Mexico), in a manner that is 
attractive and understandable for the media, the public, and decision 
makers. Additionally, there are opportunities to improve the surveillance 
of antibiotic consumption. Recent efforts to document national (Wirtz, et 
al., 2010) and hospital trends (Rodríguez-Ganen and Asbun-Bojalil, 
2012) on antibiotic consumption IN Mexico should be complemented 
with routine monitoring of indicators and benchmarking data on antibiotic 
consumption in all health services. Creating and communicating 
evidence-based information on antibiotic consumption patterns is 
needed in order to raise the visibility of inadequate antibiotic utilisation 
as a public-health problem (see below). Further evidence on antibiotic-
related adverse drug events (Linder, 2008) at the national level (an 
216 
 
issue scarcely addressed by health officials or in the news media) is 
needed as well for the issue of antibiotic misuse (particularly over-use) 
to be perceived as a problem in itself.  
 
 As other authors have pointed before (Parkhurst and Vulimiri, 2013), 
health-policy agendas are not set only through evaluations of burden or 
distribution of the disease, neither evidence on problems and potential 
solutions speak for themselves: an adequate framing process is 
necessary to facilitate policy attention. Antibiotic resistance is a complex 
issue difficult to understand as a policy problem in itself. In Mexico, as in 
other countries, this topic has been related to intra-hospital infections 
and, consequently, interventions have been focused on preventing 
antibiotic-resistance transmission. However, there is ample consensus 
that the primary goal to contain this problem should be avoiding the 
emergence of resistance. Given that the use of antibiotics is the single 
most important factor leading to antibiotic resistance around the world, 
national strategies to ensure the appropriate and rational use of existing 
antibiotics are of upmost relevance (Smith and Coast, 2002). 
 
However, the concept of antibiotic misuse (which includes practices like 
self-medication and inadequate prescription) is not easy to grasp. As the 
present study shows, the concept tends to be related with individual or 
cultural practices, frames that are not conductive to governmental 
intervention. Consequently, it may be necessary to reframe antibiotic 
misuse as an issue related to “public policy failure”; this is, a condition 
that stems from government sources or is at least amenable to such 
solutions (Baumgartner and Jones, 1993: 27). 
 
In Mexico, the public discussion on self-medication with antibiotics 
during 2009 and 2010 was able to shift the problem understanding from 
only a cultural practice to a problem related to the failure in pharmacy 
regulation and the insufficient access to health care. Once pharmacy 
regulation has been at least partially addressed in Mexico, there will still 
be room to discuss the structural causes of inadequate medical 
prescribing, and to reframe the problem stressing the need for more 
categorical governmental action with this regard, such as undergraduate 
education and prescription auditing. The potential of using metaphors 
and strategic issue framing to shape health agendas and to shift support 
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for determined health policies has been suggested before (Barry, et al., 
2009; Geneau, et al., 2010; Parkhurst and Vulimiri, 2013). There are 
examples empirically demonstrating how public-health advocates can 
deliberatively redefine policy issues, and how the change in policy-
debate framing has favoured health-policy change (Breton, et al., 2008; 
Vittal Katikireddi, et al., 2014). 
 
 Efforts directed to enhance the visibility and understanding of AMR as a 
public problem may be supported by sensitising the public and actively 
involving the news media. There is an opportunity for improving media 
reporting on issues of antibiotic resistance, antibiotic use and 
pharmaceutical policies in Latin America and other middle-income 
countries. The scarcity of in-depth reporting on these topics has been 
related to the limited availability of specialised journalism and 
independent information sources (Sánchez and Sivaraman, 2010). 
Aiming to overcome these limitations, the South American Infectious 
Disease Initiative - SAIDI has worked with the news media in three 
countries, achieving an improvement in the quantity and quality of 
coverage of these themes; this experience is worth replicating in other 
countries (Sánchez and Sivaraman, 2010). The experience in Mexico 
showed that even if the voices of governmental and business-related 
groups were favoured in media coverage, the views of other groups also 
achieved visibility in the media. Consequently, medical and public-health 
professionals advocating for AMR policies have an opportunity to 
improve their capability of interacting with the media, which may 
contribute to reframing the policy debate on AMR, as well as to 
developing a more informed policy process (Dreser, et al., 2012).  
 
(b) Foster research development and evidence uptake to inform context-
specific policy alternatives for addressing AMR. As has been discussed 
earlier, research and action regarding AMR in Mexico has largely been 
conducted from a biomedical perspective. Much less operative research in this 
field has been conducted, especially that directed to the determinants of 
antibiotic misuse, and interventions directed to address this problem. There is 
much room for enhancing research on AMR from a health-system and policy 
perspective, which is necessary to guide decisions on policy alternatives 
according to evidence regarding cost-effectiveness, technical feasibility and 
support for interventions to improve use of antibiotics. Furthermore, generating 
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evidence on interventions to improve use of antibiotics and other medicines is 
of upmost relevance for current efforts in Mexico striving to raise the quality and 
safety of health services, as well as for this and other countries undertaking 
health-system reforms that imply increasing access to medicines through 
universal health coverage. 
 
Health-policy decision makers should be sensitised about this linkage. Indeed, 
inappropriate use of medicines, including overuse of antibiotics, are among the 
top causes of waste of scarce health system resources that threaten the 
sustainability of universal health-coverage schemes (Wagner, et al., 2014). It is 
important, therefore, to move research and action on AMR from its usual venue 
in infectious-disease forums, and bring it into health-system forums. Indeed, the 
WHO (2012: 93) has underlined the need to strengthen the collaboration 
between those involved in promoting the rational use of medicines, and those 
involved in infectious diseases prevention and control. In addition, a much more 
systemic thinking on AMR problems and solutions is needed. This system-wide 
approach centres on the use of antibiotics (rather than in the spread of 
antimicrobial resistance) involving related actors and structures ‒health care 
facilities and providers, dispensers, patients, and governments (Nordberg, et 
al., 2005; WHO, 2012: 35); but also should stress the relation between the use 
of antibiotics and each of the health-system “building blocks”: human resources 
for health, health-information systems, financing, etc. (Bigdeli, et al., 2013). 
Addressing the potentially conflictive objectives of improving access to 
medicines and attaining their rational use is a key issue to be considered.  
 
Importantly, research, diffusion and softening up of policy alternatives to 
address AMR have to be undertaken before a new policy window opens. The 
country-level cases of Mexico and other countries underline the constraints that 
a crisis context imposes on policy-making and, consequently, the need to 
advance the agenda before a crisis is recognised. In the process of softening 
up policy alternatives, it would be relevant to tie the understanding of proposed 
strategies with policies or programmes already in place (the recombination of 
new and already familiar policy elements, which has been mentioned before). 
Kingdon (1995: 80) points out that politicians, apprehensive about not fully 
understanding the unanticipated consequences of radically new policies or 
programmes, are sometimes reluctant to take big steps. Consequently, those 
who advocate for major policy changes often benefit from pushing for one small 
part at a time, in order to gradually attain the desired policy change. 
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Finally, the work developed by the INSP-AMIMC-APUA group in Mexico, as 
well as the experiences in Chile, Peru and India, underline the capacity of 
multidisciplinary groups in advocating for AMR policies. At the same time, these 
experiences stress the need for these groups to engage in a long-term 
deliberative process with decision makers (Lomas, et al., 2005), in order to 
inform policy development. In conclusion, there are opportunities for AMR 
advocates to disseminate evidence on the burden placed by AMR and on its 
policy solutions, to reframe the public debate, and to take an entrepreneur role 
by identifying and creating political opportunities to advance the health-policy 
agenda on AMR. To attain this, policy advocates should be prepared to get fully 
involved in a process of argumentation and persuasion (Parkhurst and Vulimiri, 
2013) with other health-policy participants. The recent capacity-building 
initiatives to improve advocacy for AMR in Africa are worth reviewing in-depth 
(Joshi, et al., 2011). 
 
(c) Considering the political dimension of public-health policy. John Kingdon 
warns that the politics stream flows along separately of the other two, quite 
independently of what other actors may be doing with relation to bringing 
attention to selected problems or preferred policy alternatives. Nevertheless, 
the political context and the involvement of highly visible governmental and 
interest group participants have a powerful effect on agendas. Diverse authors 
have drawn the attention to the relevance of taking into consideration the 
political dimension when analysing public-health policy both retrospectively and 
prospectively, as for policy advocacy (Bernier and Clavier, 2011; Oliver, 2006; 
Walt and Gilson, 1994). Furthermore, given the social relevance of medicines, 
the potential conflict between public and private medicine-related actors, 
concentrated political costs in well-organised and powerful groups (the 
pharmaceutical industry and medicines commercialisation sector) and the 
amount of expenditures medicines signify for health systems, among other 
factors, formulating and implementing pharmaceutical policies are profoundly 
political processes (Reich, 1995b, 2002). And indeed, as some of the national-
level studies on AMR policies discussed here point out, an apparently technical 
issue such as enforcing the regulation of antibiotic sales can be politically very 
sensitive, given the diverse interests and the social and economic importance of 
the issues involved. 
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 With regard to interest group pressure, during the first period of the 
Mexican study, some of the MOH interviewees perceived that AMR may 
face opposition from prescribers (if their prescribing freedom was going 
to be limited), or from the pharmaceutical sector and the public (if 
antibiotics sales were going to be regulated). This perceived opposition 
may have backed policy inaction on AMR. During the second period of 
this study in Mexico, the opposition of some interest groups (pharmacy 
associations) vis-à-vis antibiotic sales regulation was manifest, as it was 
in the cases of Brazil and India, making use of practically the same 
arguments. From this, an important lesson can be drawn for other 
countries considering enforcing antibiotic sales regulation: active 
opposition by some stakeholders should be expected, particularly 
arguing the adverse health and economic impact on the population. 
AMR policy advocates should be prepared to counteract these 
arguments,(in the same way that there has been learning of strategies 
and arguments deployed by the tobacco and food industries national 
public health policies affecting their interests are attempted (Brownell 
and Warner, 2009) and to identify ways of working with opponents, 
before regulation is introduced. 
 
Emphasising the potentially severe adverse drug events related to 
antibiotic use and, therefore, the need for medical supervision of 
antibiotic treatment, may be used as a counter argument against those 
opposing sales regulation. It may be worth replicating the experience of 
Peru and, to a certain extent, Chile involving pharmacies, specifically the 
manner in which these countries publicised the professionalism and 
social responsibility of pharmacies in complying with the regulation and 
promoting rational use of antibiotics. None of the national-level cases 
discussed allow analysing in depth the position of organised medical 
groups with regard to strategies focused on improving medical 
prescription. However, the favourable declarations of some medical 
associations with this regard in Mexico indicate that it may be important 
to involve them as active AMR policy supporters. Nevertheless, as 
political contexts vary from country to country, AMR policy advocates 
may benefit from analysing relevant political conditions in each country, 
and from shaping major political factors in favour of AMR policies; for 
example, by means of mobilising or de-mobilising certain groups. For 
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this, Political Mapping (Reich, 2002) or stakeholder analysis methods 
are of much relevance. 
 
Finally, as has been pointed out before, in order to improve the political 
feasibility of pharmaceutical policies, it is important to identify political 
allies susceptible of supporting agenda placement, and maintain their 
support throughout the processes of policy formulation and 
implementation (WHO, 2001b). The need of stronger political leadership 
and commitment for AMR policies, including the involvement of highly 
visible actors, is becoming evident in other contexts. This can be 
illustrated by the recent declarations of Prime Minister Cameron in the 
United Kingdom.10 However, as has been argued in this study, political 
commitment is only one of many other factors that could influence AMR 
agenda status. 
 
 Another important lesson that can be drawn from the experiences of 
Mexico, Brazil and India is that, even if governmental action focuses on 
a single problem and a single intervention (for example, enforcement of 
sales regulation to avoid self-medication), other medicine-related issues 
will soon arise in public debate. These issues include access to health 
care and medicines (very sensitive issues for the population), the quality 
of medical services, and pharmacy regulation. These concerns highlight 
the need to publicly discuss and formulate AMR policies, not in an 
isolated manner, but within the common framework of national health 
and pharmaceutical policies (Dreser, et al., 2012). Similarly, it is 
necessary to engage, in the early moments of the policy process, the 
multiplicity of governmental and non-governmental actors related to 
medicine policy and quality of care. 
 
Given the array of actors and offices involved in policy responses to face 
AMR as well as the linkage of these policies with other health-system 
components, AMR responses cannot be led solely from infectious-
disease-oriented venues or medicine regulatory agencies (as was the 
case in Mexico). AMR policies should be owned by a governmental 
organisation or institution oriented to the quality use of medicines, with 
                                                             
10
 Press release, “Prime Minister warns of global threat of antibiotic resistance” UK’s 
Department of Health and Prime Minister's Office, July 2
nd
, 2014, available at: 
https://www.gov.uk/government/news/prime-minister-warns-of-global-threat-of-antibiotic-
resistance (accessed on August 23 2014). 
222 
 
sufficient capacity to design and implement programmes that 
incorporate the variety of strategies needed to address AMR, as well 
with sufficient capacity for intra-sectorial and inter-sectorial coordination. 
These recommendations on a system-wide approach on AMR and clear 
designation of responsibility to an institutional body have previously 
been proposed (Holloway and van Dijk, 2011; WHO, 2012), and are 
stressed by the findings of the present study. 
 
223 
 
8. SUMMARY AND CONCLUSIONS 
 
 
Worldwide, the inappropriate use of medicines is contributing to the increase of 
adverse clinical outcomes, unnecessary expenditures by consumers, and a heavy 
economic burden to health-care systems.   The misuse of antibiotics is of particular 
concern, because it triggers the spread of antimicrobial resistance, which poses a 
major threat to public health. In 1998, the World Health Assembly Organization urged 
member States to advance practices to contain antimicrobial resistance and to promote 
appropriate antibiotic use in health care facilities and in the community, by improving 
prescribing, dispensing, information, surveillance and legislation. Over the years, 
similar policy recommendations have been stressed by the World Health Organization 
and a number of other international organizations. Overall, the progress has been slow; 
few low- and middle-income countries have fully incorporated strategies to address 
antibiotic misuse and resistance (AMR) into their national health and pharmaceutical 
policies. It has been concluded that political commitment on AMR has been scarce, 
and that AMR has not been prioritized by national governments. Nevertheless there is 
a paucity of research on the reasons behind that lack of prioritization, and on factors 
that affect the development and adoption of antibiotic policies at the national level. The 
present study addresses this gap by applying a policy-analysis approach to understand 
the determinants of policy inaction and policy change with regard to AMR, focusing on 
the case of Mexico. 
The main argument in the present thesis is that policy action (and inaction) on AMR 
can be understood  –at least in part– by understanding whether AMR is on the policy 
agenda and the factors that affect AMR agenda-setting. The aim of this study was, 
consequently, to explain the process of AMR agenda-setting (AMR) in Mexico, and 
how that affected the adoption of related policies.  
 
The present study looked at events between 2001 and 2012, which cover two periods 
of government (2000-2006 and 2006-2012 presidential administrations). The study 
used Kingdon’s multiple streams (MS) theory of agenda-setting to guide the analysis, 
explaining both when the issue of AMR was denied a position on the agenda (first 
period studied) and when the issue gained agenda status and a policy change 
occurred (second period studied). The longitudinal case-study undertaken, involving 
two governmental administrations, proved to be useful to understand how conditions 
related to problem recognition, policy alternatives, policy entrepreneur activity and 
political events changed over time, and affected agendas differently.   
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John Kingdon’s theoretical framework on agenda setting, although largely applied in 
developed countries and liberal democracies, has scarcely been applied in low- and 
middle income countries or statist regimes like the one in Mexico; and has not been 
used before specifically to understand AMR agenda setting. In the present study, the 
application of Kingdon’s MS theory proved to be useful to explain both the lack of 
agenda status and how a policy window was opened to bring AMR to the decision 
agenda and trigger a policy change. Nevertheless, using MS provided less insight the 
scope or nature of the policy change (i.e. which policy was adopted as a result). This 
could be related to a limitation of MS theory itself on explaining windows outputs, as 
Kingdon underlines (1995: 177) but also to the MS application within the Mexican 
political system.   
 
The main empirical findings of the present study were summarized within the two 
results chapters concerning agenda-setting for AMR in Mexico during the President 
Fox 2000-2006 administration, and the President Calderón 2006-2012 administration. 
Below, these empirical findings are synthesized to answer the study’s two research 
sub-questions following the study conceptual framework.  
 
1. Why did AMR not reach the health policy agenda during the 2000-2006 
administration in Mexico, and how that affected the adoption of related 
policies? 
Processes within each of Kindon’s streams acted as impeding factors that prevented a 
window of opportunity opening to place AMR on the policy agenda. 
 
With regard to the problem stream, there were two relevant aspects: the recognition of 
AMR as a problem (and its nature, such as severity) and the definition (or framing) of 
such problem. Most interviewees were aware about the problems of antibiotic misuse 
(self-medication and inadequate prescription) and antibiotic resistance; the economic 
impact and adverse drug reactions related to antibiotic misuse were less recognized. 
While academics and NGOs stressed the relevance of AMR as a problem, 
governmental officials alluded to the lack of indicators with which assess it, and 
perceived it as a secondary issue in relation to the priority problem in the 
administration: improving access to medicines. In addition, during this period there 
were not focussing events that may draw attention to the problem. There were neither 
efforts to link AMR to a more visible problem or to a policy solution, such as evidence 
on medicines stock outs, out-of-pocket expending on medicines and the 
implementation of the Seguro Popular (SP), which had an important momentum during 
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president Fox administration. Besides the scarce visibility of AMR and the fact that it 
was not recognized as a severe problem nor as a priority, the way in which the problem 
was defined and framed also prevented it to gain agenda status. The majority of 
respondents perceived antibiotic misuse as a complex issue, connected to difficulties 
intrinsic to the health system (particularly limited access to health services); to the 
national culture (self-medication) or to the individual realm (prescription habits difficult 
to change). AMR was not defined with regard to public policy failures (such as the 
failure to auditing prescribing or regulating antibiotic sales).  Understood as such, for 
these respondents there were not obvious or straightforward solutions to address AMR. 
 
With regard to the policy stream, two factors outstand: the lack of clarity on the policy 
alternatives available and their feasibility; and the absence of policy entrepreneurs 
promoting these policies. Research in Mexico has disregarded operative research on 
interventions to improve antibiotic use and contain antibiotic resistance that could 
inform policy-makers about the available options to address AMR. Additionally, MOH 
officials had, in general, scarce awareness of international policy recommendations on 
AMR, and lack of knowledge of the Global Strategy for the Containment of 
Antimicrobial Resistance published in 2001.  AMR containment was backed by a 
loosely knit community composed mainly by infectious-disease specialists and public 
health researchers who, however, did not adopt the role of policy entrepreneurs. 
Information on antibiotic resistance was shared in medical and academic forums, but 
not in health policy forums, and there was scarce interaction between these specialists 
and policy-makers. Even when a national pharmaceutical policy proposal (NPP) was 
developed by the MOH, AMR was not considered an issue to be included, and thus 
infectious-diseases and public health specialists were not invited to participate.  In 
exploring the perception of policy options to address AMR, interviewees highlighted 
obstacles rather than enablers, namely scarcity of resources to implement programs 
(such as standard treatment guidelines), perception of opposition of physicians if 
limiting or auditing antibiotics prescription was attempted, difficulties  training 
physicians, and the impossibility to regulate antibiotics sales only with prescription 
when universal health coverage has not been attained. As enforcing restrictions on 
antibiotics sales or antibiotic prescription had not been attempted, there was no 
evidence of frontal opposition to these strategies; nevertheless, many of the MOH 
interviewees anticipated the opposition of involved groups (particularly medical doctors) 
which could denote the power of this group to restrict agenda items. 
 
Finally, regarding events in the political stream, two main factors emerge as relevant 
to explain the low agenda status of AMR; namely, competing issues on the agenda 
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and the drawing of jurisdictional boundaries. First, within the implementation of the SP 
–the most relevant social policy during President Fox administration, which had been 
intensely promoted by the newly appointed Minister of Health Frenk– improving 
access to medicines was a priority; according to MOH interviewees, much of their 
activity was directed towards that initiative. Even for freshly implemented National 
Crusade for Health Care Quality, improving medicines stocks and supply in health 
services (and not improving medicines prescribing or dispending) was a priority. This 
is not a surprise, given that medicines are a visible output of health services, and 
often legitimize them. But moreover, in Mexico, improving medicines supply was 
commitment made during the presidential campaign; and out-of-pocket expenses on 
medicines was a key justification for (or was the problem attached to) the policy 
proposal that led to the creation of the SP. In the legislature, health policy topics 
discussed were those brought by the executive; but also those raised up by the 
pharmaceutical industry, which has a formal role as consultant to the legislature. This 
contrast with the absence of permanent channels of communication between health 
commissions in the legislature and academics or specialists, which could have risen 
up the issue of AMR. A second relevant factor in the problems stream is that 
improving medicines utilisation and containing antibiotic resistance was not explicitly 
assigned by regulations and programmes at that time to a specific governmental 
office, Furthermore, the majority of MOH interviewees did not perceive addressing 
AMR as a direct responsibility pertaining to their offices.  These factors acted as 
institutional constraints to trigger action on promoting medicines use and address 
AMR.  
 
Conclusively, during this period impeding factors within each of Kingdon’s streams, and 
the absence of policy entrepreneur activity, prevented AMR reaching the agenda. 
Borrowing from Baumgartner and Jones’ punctuated equilibrium theory, the policy 
image on AMR was not conductive to political action, and there was not a clear policy 
venue to deal with this issue.  Even in when the new administration and health policy 
reform opened a ‘political window’ to develop a NPP, this open window was a lost 
opportunity to advocate for AMR proposals. At the end, the absence of individual 
agents actively pushing proposals on AMR, competing agenda items, and the 
entrenched institutions and interests favoured the status quo; that is, policy inaction on 
AMR. These factors explain policy stability regarding AMR during the 2000-2006 
presidential administration.  
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2. Why did AMR reach the health policy agenda during the 2006-2012 
administration in Mexico, and how that affected the adoption of related 
policies? 
 
During this period, the national health crisis posed by the 2009 influenza pandemic 
opened an unpredictable ‘problem window’. Favourable processes on the policies and 
politics stream enabled the three streams to converge, which brought AMR to the 
policy agenda; however, this streams convergence did not allow the formation of a 
comprehensive national policy on AMR. 
 
With regard to the problems stream, the problem of antibiotic misuse (but particularly 
self-medication with these medicines) gained visibility when it was related to 
inadequate treatment and death among influenza patients. Later on, the sales of 
antibiotics without prescription, and laxity in the regulation of pharmacies emerged in 
the public discussion. Although the AMR problem itself or related indicators did not 
change at all, there was an important shift on causal ideas regarding AMR; that is, a 
change in the problem’s framing or image, which was reflected on the media. The 
relation between inadequate antibiotics use, insufficient regulation and patient deaths 
acted as a strong symbolic device, which opened a problem window. This open 
window, in a crisis context, called for readily implementable solutions from the policy 
stream.  
 
Given the crisis context and the initial problem definition (i.e. self-medication with 
antibiotics, which was underlined by governmental health officials, in dismiss of 
inadequate medical prescription) the regulation of antibiotic sales became a reasonable 
solution. However, this narrow problem-solution duo (self-medication as a problem, 
antibiotics sales regulations as solution) was challenged by two groups. Pharmacy 
owners association emerged as leading opponents to the policy, alluding to its adverse 
economic effect of the sector and on the population, themes with ample coverage on 
media coverage. On the other hand, a network of specialists did take advantage of the 
open window (differently from the previous administration) to push their proposal on 
AMR. They sought to reframe the problem to include inadequate use (both in human 
an animal sectors) and antibiotic resistance, calling for a more comprehensive strategy 
as solution; these themes were less covered by the media. While, consequently, health 
officials did incorporate (in public speeches and official documents) antibiotic 
resistance as part of the problem for which the new regulation was being introduced, 
this did not imply an important change in the solution already chosen; probably, it just 
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reinforced it. Inadequate medical prescribing, a problem raised up by medical and 
public health specialist, was largely left aside the policy debate; this could be related to 
an anticipation of opposition, or because it was contrary to an important message 
disseminated by MOH during the pandemic: to seek medical care.   
 
There were favourable factors on the politics stream that facilitated the consideration of 
regulating antibiotic sales. Although this solution was politically unacceptable during the 
previous administration given the insufficient coverage of health services for the 
population, it was now acceptable given the SP implementation. Furthermore, this 
solution was favoured because the stricter regulation of medicines sales was already 
contemplated by the National Health Programme, and there was an institutional venue 
(COFEPRIS, the MOH regulatory agency) designated to implement it. Despite the 
opposition of vested interests (pharmacy owners) to the regulation, probably other 
factors (national and international pressure to act upon the influenza pandemic) had 
more weight in advancing the regulation. 
 
Conclusively, during this period, the unexpected problem window opened by the 
influenza crisis, the role of the Health Minister and policy entrepreneurs defining the 
problem and promoting solutions, as well as a favourable political context were 
conductive for AMR to reach the public and policy agenda. Despite the open window, 
the initial problem definition, the crisis context that called for rapid solutions and the 
assignation of responsibility to the regulatory agency COFEPRIS (whose realm of 
action is not medicines utilisation, and drafted the policy in an enclosed process) 
resulted in a narrow-focused regulation (an incremental change), and not in the 
consideration and formation of a comprehensive national policy on AMR. The policy 
process reflected the predominant role of the state in health policymaking in Mexico, 
the capacity of ideas and individual agency to spark policy action, the role of the media 
in expanding issues, and the constraints imposed by institutions to health policy-
making. 
 
Lessons learnt 
 
Based on the results from this study and findings from the literature, some lessons can 
be drawn for Mexico and for other countries seeking to develop AMR policies. 
There is scarce literature providing thick descriptions on the agenda-setting processes 
with regard antibiotic use and resistance that could provide empirical findings to 
compare with the present study. Nevertheless, experiences on the promotion of 
rational use of medicines (described in the literature review chapter) as well as the 
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country-level experience on agenda-setting and AMR policies examined in the 
discussion chapter, allowed to identify some key factors on AMR policy determination 
that could be helpful for policy advocates. Key factors related to agenda-setting have 
been found within each of Kingdon’s streams, and the activity of policy entrepreneurs: 
 
Problems streams: 
 Challenges: Low problem visibility, and scarce data to assess its severity; 
framing of the problem away from the scope of governmental action. 
 Opportunities: Crisis that, directly or indirectly, call the attention to AMR. Media 
coverage that reinforces AMR as a public policy problem. 
 
Policies stream: 
 Challenges: Insufficient information regarding context-specific policy 
alternatives, including cost-effectiveness, technical feasibility and support on 
interventions to improve use of antibiotics. Scarce communication between 
researchers and advocates on AMR with decision-makers. 
 Opportunities: Persistent activity of policy entrepreneurs, promoting in advance 
their policy proposals. Strengthening of policy communities. 
 
Politics stream: 
 Challenges: Competing issues on the policy agenda; absence of a clear 
institutional venue for AMR. Opposition of powerful stakeholders. 
 Opportunities: Involvement of highly visible social actors. 
 
An important lesson derived from this study is that, given the nature of the problem and 
solutions implicit on AMR policies, opportunity windows to advance such policies are 
likely to be scarce. This is particularly true in low- and middle-income countries, in 
which much of policy effort are directed to improving access to medicines and not 
improving their use (Falkenberg and Tomson, 2000; Kanji, 1992; LSHTM/KIT, 1989; 
Reich, 1987, 1994, 1995b; Summers, 2004; WHO, 1988, 1997). Crisis can, 
nevertheless, open unexpected windows of opportunity to bring AMR into the agenda. 
However, to take advantage of them, policy advocates should be prepared in advance, 
‘softening-up’ the system with persistence and argumentation. Evidence on problems 
and potential solutions do not speak for themselves; as such, data on antimicrobial 
resistance or WHO policy recommendations are not enough to place AMR on the 
agenda. Policy advocates should be aware and could benefit from:   
a) Facilitate AMR visibility and understanding as a public problem 
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b) Foster research development and evidence uptake to inform context-specific 
policy alternatives for addressing AMR 
c) Considering the political dimension of public-health policy 
 
Finally, it is important to underline that this single-case study has drawbacks in terms of 
generalizability and comparability of its findings. A multiple country- case study would 
bring more understanding on policy variation and a better insight into the determinants 
of AMR agenda-setting and policy formation. Even so, this study allowed drawing 
testable propositions on AMR policy determination and changing in Mexico. Future 
research on agenda-setting for AMR could benefit for exploring, in other settings, the 
relevant factors found on this study.  
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APPENDIX 1: Publications and presentations derived 
from this thesis 
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APPENDIX 2: Research objectives, questions and methods 
 
Aim Theoretical framework Research design 
The aim of this study is to explain the process of agenda-setting for the appropriate use of 
antibiotics and containment of antimicrobial resistance (AMR) in Mexico, and how that affected 
the adoption of related policies.  
 
Multiple Streams theory on 
agenda setting 
(J. Kingdon, 1984) 
Case study 
   Longitudinal, single case, explanatory (Yin, 2003) 
  
Specific objectives Research questions Dimensions in conceptual 
framework 
Methods of data collection and analysis 
1. To analyse the factors related to AMR agenda 
placement in Mexico during the 2000-2006 
administration, and the adoption of related 
policies, by focusing on problem definition and 
recognition, the political context, the 
development and perception of policy 
alternatives, and the role of policy entrepreneurs. 
 
1) Why did AMR not reach the health policy 
agenda during the 2000-2006 administration 
in Mexico, and how that affected the 
adoption of related policies?? 
 
 
Problem definition and 
recognition (Problems stream) 
 
Development and perception 
of policy alternatives (Policies 
stream) 
 
Political context (politics 
stream)  
 
Role of policy entrepreneurs 
 
Policy windows  
 
Policy adoption 
Documents (official documents from the legislative 
and executive; ‘grey’ literature about stakeholders) 
Interviews with stakeholders 
 
Content and thematic analysis 
2. To analyse the factors related to AMR agenda 
placement in Mexico during the 2006-2012 
administration, and the adoption of related 
policies, by focusing on problem definition and 
recognition, the political context, the 
development and perception of policy 
alternatives, and the role of policy entrepreneurs. 
 
 
2) Why did AMR reach the health policy agenda 
during the 2006-2012 administration in 
Mexico, and how that affected the adoption 
of related policies? 
 
Documents (official documents form the legislative 
and executive; ‘grey’ literature about stakeholders) 
Interviews with stakeholders 
Media documents (newspaper articles)  
 
Content and thematic analysis  
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APPENDIX 3: Interviewees list 
 
 
Round 1: January - November 2006 
(2000-2006 administration) 
Group # 
 
Identifier 
Code 
 
Interviewee profile and institutional affiliation 
 
Government 1  MOH1+ Ministry of Health official, Health Economics Unit 
2  MOH2+ Ministry of Health official, Health Economics Unit 
3  MOH3+ Ministry of Health official, COFEPRIS 
4  MOH4+ Ministry of Health official, Health Quality 
5  MOH5 General Health Council 
6  MOH6 Ministry of Health official, COFEPRIS 
7  MOH7 Ministry of Health official, Health Quality 
8  MOH8 General Health Council 
9  MOH9 Ministry of Health official, Health Promotion 
10  MOH10 Ministry of Health official, COFEPRIS 
11  MOH11 Ministry of Health (retired) 
12  MOH13 Ministry of Health official, COFEPRIS 
13  MOH14 Ministry of Health official, Health Promotion 
14  GOV1 Health Commission, Legislative 
Academics 15  ACAD1+ Pharmacist, University 
16  ACAD3 Infectious diseases researcher, IMSS 
17  ACAD4 Infectious diseases researcher / Professional 
association AMIMC 
18  ACAD5 Health systems researcher, IMSS 
19  ACAD6 Pharmacist, University 
20  ACAD7 Infectious diseases researcher, hospital  / 
Professional association AMIMC 
21  ACAD8 Infectious diseases researcher , INSP 
22  ACAD9 Health systems researcher, INSP 
23  ACAD10* Pharmacist, University 
24  ACAD11* Pharmacist, University 
25  ACAD12* 
(**) 
Infectious diseases researcher, University /  
MOH Epidemiological Surveillance 
26  ACAD13* Pharmacist, University 
Health 
professionals 
27  PROF1 Pharmacist, Pharmaceutical association 
28  PROF4* Pharmacist, hospital 
29  PROF5* Infectious diseases specialist, hospital 
30  PROF6* Pharmacists, Pharmaceutical association 
31  PROF7 Infectious diseases specialist / Professional 
association AMIMC 
Pharmaceutical 
industry 
32  INDUS1 Pharmaceutical industry association 
33  INDUS2 Pharmaceutical industry association 
34  INDUS3* Representative pharmaceutical company 
35  INDUS4* Representative pharmaceutical company 
36  INDUS5* Representative pharmaceutical company 
37  INDUS6* Pharmaceutical industry association 
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38  INDUS7* Representative pharmaceutical company 
39  INDUS8* Representative pharmaceutical company 
Pharmacies and 
distributors 
40  PHAR1* Representative, pharmacy association 
41  PHAR2* Representative, pharmacy  association 
42  PHAR3* Medicines distributor company 
43  PHAR4* Medicines distributor company 
Non-
governmental 
organisations 
44  ORG1 Physician, NGO Health Action International 
45  ORG2 Physician, NGO Salud y Fármacos 
46  ORG3 Infectious diseases specialist, NGO Alliance for 
the prudent use of antibiotics 
 
Round 2 (March  2007- February 2008) 
(2006-2012 administration) 
Health 
professionals 
47 PROF2 Infectious diseases specialist / Professional 
association AMIMC 
48 PROF3 Infectious diseases specialist / Professional 
association AMIMC 
Government 49 MOH15 Ministry of Health, COFEPRIS 
50 MOH16 Ministry of Health official, Health Quality 
51 MOH17 Ministry of Health official, Health Quality 
Non-
governmental 
organisations 
52 ORG4 Infectious diseases specialist, Pan American 
Health Organization 
53 ORG5 Public health researcher, World Health 
Organization 
 
(+) These interviews formed part of the pilot study. 
(*) These interviews were conducted by Dr. Kitty Corbett and Dr. Veronika Wirtz, 
researchers at the Mexican National Institute of Public Health.   
(**) This informant was interviewed again in 2008, as a MOH official during the 2006-
2012 administration. 
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APPENDIX 4: General interview topic guide 
 
I. General information  
1. Can you tell me what is your profession, your position, and which are your main 
responsibilities? 
 
II. Medicines on the health sector agenda 
2.   Which do you think is the relevance of medicines within the actual health sector 
agenda? Why? 
a) Has there been much change on the relevance of this issue on the last years / 
in comparison with the previous administration ? If yes, why has that change 
taken place? 
 
3. Of the different aspects regarding medicines (including production, procurement, 
commercialisation, regulation, information, use...) what do you think are the major 
problems that are being addressed by the health sector?  
a) Why do you think these particular problems are the ones receiving attention? 
How have they come to be considered top issues? 
b) Explore answers on the introductory questionnaire (see at the end of this 
appendix). 
 
4. What are the major problems related to medicines that you and others on this office 
are paying attention to? 
a) How and why these issues became a priority? 
b) What are the strategies or programmes that are being developed to tackle this 
problem? 
 
III. Appropriate use of medicines, antibiotics and antibiotic resistance 
 
5. What is your opinion on the issue of inappropriate use of medicines (prescription, 
dispensing and patient use) in Mexico? 
a) What is the scope of inappropriate use of antibiotics and the problem of 
antibiotic resistance in Mexico? 
 
6. What do you think are the factors that determine the inappropriate use of antibiotics? 
7. Can something be done about these factors? Which are, in your opinion, the main 
strategies to improve the use of antibiotics? 
8. Whose responsibility is to promote the appropriate use of antibiotics and contain 
antibiotic resistance? 
9. During the time that you have worked in this office, has there been any initiative to 
develop a strategy or programme to promote the adequate use of antibiotics? Can you 
comment on this?  
a) Are you aware of any person or group promoting aiming to raise awareness 
about antibiotic misuse and resistance or strategies to address this issue? 
10. Do you know WHO/PAHO recommendations to improve the use of antibiotics and 
contain antibiotic resistance? How have they been incorporated on the work you 
develop in this office?  
11. What do you think is the relevance and feasibility of the following alternatives that 
could be considered to improve antibiotic use? 
(Different strategies are mentioned according to the interviewee background and 
position, e.g.: regulation of antibiotics sales only with medical prescription, professional 
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dispensing, medical education, training of pharmacy employees, consumer’s 
information, antibiotic surveillance in hospitals, etc.) 
 
IV. Linking between research antibiotic use and resistance and policy formulation (For 
key informants on the academic field.) 
12. How have the research results obtained by you and your colleagues been 
communicated to the Ministry of Health? 
a) Do you think they have been taken into account for the formulation of 
pharmaceutical policies? Please comment on this. 
b) What are the factors that favour or impede the linking between research 
developed by you and policy formulation? 
 
13. Recently, a new national pharmaceutical policy has been published, titled “Hacia 
una política farmacéutica integral para México, SSA-COFEPRIS 2005”.  
a) Do you know this document? Did you participate somehow on it?  
b) What is your opinion on this document? 
 
V. Formulation of the new national pharmaceutical policy draft (only for key informants 
which participated on the development of the document).  
14. Recently, a new national pharmaceutical policy has been published, titled “Hacia 
una política farmacéutica integral para México, SSA-COFEPRIS 2005”. About this 
document, 
a) Where and when did the initiative come from? 
15. Which was your (and the people you work with) participation in the process   of 
development of the document? 
16. Could you describe which was the process by which this document was 
developed? 
a) Who participated on the process?  
17. How were WHO guidelines on national pharmaceutical policies taken or not into 
account during this process? 
18. What were the discussions around improving prescribing and dispensing, or 
promoting the rational use of medicines?  
 a) Was antibiotic misuse and resistance a topic discussed? How? 
19. What do you think is the objective of the document?  
a) Are these objectives been accomplish? 
b) What do you think is the future of this document?  
 
VI. Identification or other informants 
 
20. Which organizations (within and outside the government) do you think should be 
involved on the design and implementation of an intervention focussed on improving 
the use of antibiotics on Mexico? 
 
 21. Could you mention the name of people that are involved on the topic of antibiotic 
use and resistance in Mexico that I might be interested on talking to?  
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Introductory questionnaire 
 
Within the actual health sector agenda, which priority do you think is being given to the 
following aspects regarding medicines? 
(1= Less priority, 5= Greater priority) 
 
a) Formulate and implement a National Pharmaceutical Policy   1  2  3  4  5 
b) Improve medicines procurement and stock in public health services 
          1  2  3  4  5 
c) Assure the quality, safety and efficacy of medicines   1  2  3  4  5 
d) Achieve equitable access to medicines     1  2  3  4  5 
e) Improve the prescription, dispensing and use of medicines  1  2  3  4  5 
f) Improve the use of antibiotics and contain antibiotic resistance 1  2  3  4  5 
g) Achieve greater innovation, research and development of medicines  1  2  3  4  5 
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APPENDIX 5: Thematic matrix and transcription indexing example 
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APPENDIX 6: Study index with themes and subthemes 
(for interviews) 
 
MAIN THEMES AND SUB-
THEMES 
INCLUDED CONCEPTS 
AMR problem recognition and definition 
Problem evidence How aware were stakeholders about the issue of AMR in Mexico?   How 
do they become aware of this issue? What were the available indicators? 
Focusing events? 
Problem perception and framing How do they frame this issue? Causal ideas? Blame? Do they define it as 
a problem? Severity, novelty, proximity, specificity, significance?  
Problem populations involved (individuals/ government/ industry…) 
Possible solutions and 
responsibility 
Did they perceive a need to address this problem? Possible solutions, 
and responsibility (ownership, jurisdictional control) 
AMR Policy alternatives 
Perception of policy alternatives Did stakeholders know international policy recommendations on AMR? 
Which was their position on different policy alternatives regarding AMR 
and the reasons for this.     Experience of previous policies implemented 
to address this problem. Budgetary considerations. Proposed solutions 
for AMR seen as technically, economically and politically viable? Would 
they support them? 
Policy formation (NPP) How was the process of developing the NPP? Who participated and who 
did not? Which alternatives regarding AMR were discussed? 
Connection between  research / 
international recommendations 
and AMR policies 
How did researchers on medicines use and AMR communicate their 
findings to decision-makers? Did decision-makers recognize research 
findings or international recommendations as an input of policy-making 
(raising awareness about AMR or about its solutions)? 
Political Context 
AMR placement in health policy 
agenda  
What were the issues higher on the health policy agenda, and the 
reasons for this. Perceived agenda placement for AMR, and the reasons 
for it. 
Competing issues on the health policy agenda 
AMR in own organizational 
agenda 
How relevant was this problem within they own agenda?  Competing 
issues on their organizational agenda. 
Responsibility of medicines use 
and AMR policies 
Did stakeholders perceive AMR and medicines use as within the 
competence of their organization? Who, do stakeholders perceive, holds 
responsibility for addressing these issues? Governmental jurisdiction.  
Interest group activity What were the interests / position of organized political forces regarding 
AMR? Stakeholders’ perceptions, and accounts on present of past 
experiences of own / other organizations advocating for / opposing 
policies on AMR and medicines use. 
Role of policy entrepreneurs 
Role of policy entrepreneurs Did informants recognize their role as policy entrepreneurs investing time 
and resources to promote AMR policies? Did they have access to policy-
makers? Did they acknowledge other individuals or groups taking this 
role? Did decision-makers make reference to individuals or groups 
advocating for AMR policies?  
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APPENDIX 7: Media analysis codebook 
 
Thematic category Description of the category and subcategories included 
Self-medication 
(SM) 
Purchase and use of prescription-only-medicines, including antibiotics, 
without medical prescription. Subcategories: i) SM to treat viral 
infections (influenza, other respiratory or gastro-intestinal infections); ii) 
causes and scope of SM; iii) solutions to the problem of SM, including 
the new policy to enforce sales regulation.  
Bacterial resistance 
(BR) 
Microbial or bacterial resistance. Subcategories: i) causes and scope, 
including relation to self-medication and prescription ii) solutions, ii) 
using BR as an argument to support the new policy to enforce 
regulation on antibiotic sales.  
Prescription (PM) Medical PM of antibiotics. Subcategories: i) unjustified PM of antibiotics 
(for instance, for influenza and other respiratory diseases) ii) perception 
of low quality of PM; iii) need to train physicians and improve their PM 
of antibiotics 
Economic impact 
(EI) 
Direct and indirect EI resulting from the enforcement policy. 
Subcategories: i) EI in the private sector such as pharmacies and the 
pharmaceutical industry; ii) EI in the population.  
Corruption (CO) Corruption in the pharmaceutical sector derived from the enforcement 
policy. Subcategories: i) Black market of counterfeit medicines; ii) Black 
market of prescriptions; iii) CO in the process of pharmacy supervision; 
iv) physicians involved in CO. 
Regulation (RE) Regulation and policies related to the sales of antibiotics in Mexico. 
Subcategories: i) Legislative framework and lack of enforcement; ii) 
processes of drafting and  implementing the enforcement policy; iii) 
need to develop an impact evaluation of the enforcement policy; iv) 
objective of the enforcement policy; v) need to disseminate information 
about the enforcement policy.  
Health System (HS) Functioning of the Mexican health system in relation to antibiotic use or 
the enforcement policy. Subcategories: i) problems of the HS; ii) impact 
of the enforcement policy on the health services provided in the HS; iii) 
access to health services for the population without health insurance. 
Rational use of 
medicines (RUM) 
Rational use of medicines in the national and international context. 
Subcategories: i) International guidelines on RUM; ii) recommendations 
to achieve RUM in Mexico; iii) causes and consequences of 
inappropriate use of antibiotics, including adverse reactions (but 
excluding references related solely to self-medication). 
Pharmacies (PH) Functioning of pharmacies in relation to antibiotic use or the 
enforcement policy. Subcategories: i) Operation of PH, ii) quality of 
services provided by pharmacy staff, and training of pharmacy staff; iii) 
position of pharmacy associations towards the enforcement policy; iv) 
demand of the pharmacy associations owners towards the government.  
Reproduced from: Dreser, et al. (2012): Regulation of antibiotic sales in Mexico: an analysis of 
printed media coverage and stakeholder participation. BMC Public Health 12:1051. 
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APPENDIX 8: Information and consent forms 
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APPENDIX 9: Results of media coverage analysis 
(Reproduced from Dreser, et. al, 2012) 
 
 
Figure 1 
Monthly coverage on antibiotic use and regulation in Mexican printed media, and main 
policy milestones 2009-2010.  
Source: Dreser, A., Vázquez-Vélez, E., Treviño, S. and Wirtz, V.J. (2012). Regulation of antibiotic sales in 
Mexico: an analysis of printed media coverage and stakeholder participation. BMC Public Health, 12, 1051 
 
 
 
 
 
Figure 2 
Theme categories covered by the printed media by stage of the policy process. 
Source: Dreser, A., Vázquez-Vélez, E., Treviño, S. and Wirtz, V.J. (2012). Regulation of antibiotic sales in 
Mexico: an analysis of printed media coverage and stakeholder participation. BMC Public Health, 12, 1051 
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Figure 3 
Printed media coverage of stakeholders by policy stage. 
Source: Dreser, A., Vázquez-Vélez, E., Treviño, S. and Wirtz, V.J. (2012). Regulation of antibiotic sales in 
Mexico: an analysis of printed media coverage and stakeholder participation. BMC Public Health, 12, 1051 
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